0001410578-24-00121610-Q Quoin Pharmaceuticals, Ltd. 20240808202408081601281601291601290 0001410578-24-001216 10-Q 69 20240630 20240808 20240808 Quoin Pharmaceuticals, Ltd. 0001671502 2834 000000000 L3 10-Q 34 001-37846 241188034 23 HATA'AS STREET KFAR SABA L3 44425 97299741444 23 HATA'AS STREET KFAR SABA L3 44425 Cellect Biotechnology Ltd. 20160721 Cellect Biomed Ltd. 20160406 10-Q 1 qnrx-20240630x10q.htm 10-Q
http://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerM
-12-312024Q2falsehttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMember397997039799700.00083001.6725000http://fasb.org/us-
gaap/2024#RelatedPartyMemberhttp://fasb.org/us-
gaap/2024#RelatedPartyMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberhttp://fasb.org/srt/2024#OfficerMemberl
03-070001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-06-300001671502us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-06-300001671502us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300001671502us-gaap:FairValueMeasurementsRecurringMember2024-06-300001671502us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001671502us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USTreasuryBillSecuritiesMember2023-12-310001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001671502us-
gaap:FairValueMeasurementsRecurringMember2023-12-310001671502dei:AdrMemberqnrx:PublicOffering2024Member2024-03-072024-03-070001671502us-gaap:CommonStockMember2024-
01-012024-03-310001671502dei:AdrMember2024-01-012024-03-310001671502us-gaap:CommonStockMember2023-01-012023-03-310001671502dei:AdrMember2023-01-012023-03-
310001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-01-012021-12-3100016715022023-11-082023-11-080001671502us-
gaap:RetainedEarningsMember2024-06-300001671502us-gaap:AdditionalPaidInCapitalMember2024-06-300001671502us-gaap:RetainedEarningsMember2024-03-310001671502us-
gaap:AdditionalPaidInCapitalMember2024-03-3100016715022024-03-310001671502us-gaap:RetainedEarningsMember2023-12-310001671502us-gaap:AdditionalPaidInCapitalMember2023-12-
310001671502us-gaap:TreasuryStockCommonMember2023-06-300001671502us-gaap:RetainedEarningsMember2023-06-300001671502us-gaap:AdditionalPaidInCapitalMember2023-06-
300001671502us-gaap:TreasuryStockCommonMember2023-03-310001671502us-gaap:RetainedEarningsMember2023-03-310001671502us-gaap:AdditionalPaidInCapitalMember2023-03-
3100016715022023-03-310001671502us-gaap:TreasuryStockCommonMember2022-12-310001671502us-gaap:RetainedEarningsMember2022-12-310001671502us-
gaap:AdditionalPaidInCapitalMember2022-12-310001671502qnrx:CommonWarrantsMember2024-01-012024-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2024-01-
012024-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2023-01-012023-12-
310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2023-12-310001671502qnrx:CommonWarrantsMemberdei:AdrMember2024-01-012024-06-
300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2024-01-012024-06-300001671502qnrx:TherapeuticsInc.Memberus-
gaap:ResearchAndDevelopmentArrangementMember2024-04-012024-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2024-04-012024-06-
300001671502qnrx:SchoolOfPharmacyAtUccMemberus-gaap:ResearchAndDevelopmentArrangementMember2024-04-012024-06-300001671502qnrx:TherapeuticsInc.Memberus-
gaap:ResearchAndDevelopmentArrangementMember2024-01-012024-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2024-01-012024-06-
300001671502qnrx:SchoolOfPharmacyAtUccMemberus-gaap:ResearchAndDevelopmentArrangementMember2024-01-012024-06-300001671502qnrx:TherapeuticsInc.Memberus-
gaap:ResearchAndDevelopmentArrangementMember2023-04-012023-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2023-04-012023-06-
300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-06-300001671502qnrx:SclerodermaMemberus-
gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-06-300001671502qnrx:Ms.CarterMember2024-04-012024-06-300001671502qnrx:Dr.MyersMember2024-04-012024-06-
300001671502qnrx:Ms.CarterMember2023-04-012023-06-300001671502qnrx:Dr.MyersMember2023-04-012023-06-300001671502qnrx:Ms.CarterMember2023-01-012023-06-
300001671502qnrx:Dr.MyersMember2023-01-012023-06-300001671502qnrx:Ms.CarterMember2024-06-300001671502qnrx:Dr.MyersMember2024-06-
300001671502qnrx:SalaryAndOtherCompensationMember2024-06-300001671502qnrx:SalaryAndOtherCompensationMember2023-12-310001671502us-gaap:RetainedEarningsMember2024-
04-012024-06-300001671502us-gaap:RetainedEarningsMember2024-01-012024-03-310001671502us-gaap:RetainedEarningsMember2023-04-012023-06-300001671502us-
gaap:RetainedEarningsMember2023-01-012023-03-310001671502qnrx:Convertiblenotes2020Member2024-06-300001671502qnrx:Convertiblenotes2020Member2023-12-
310001671502qnrx:Convertiblenotes2020Member2024-04-012024-06-300001671502qnrx:Convertiblenotes2020Member2023-04-012023-06-
300001671502qnrx:Convertiblenotes2020Member2023-01-012023-06-300001671502us-gaap:LicensingAgreementsMember2024-06-300001671502us-gaap:LicensingAgreementsMember2023-
12-310001671502dei:AdrMember2024-01-012024-06-300001671502dei:AdrMember2023-04-012023-06-300001671502dei:AdrMember2023-01-012023-06-300001671502us-
gaap:CommonStockMember2024-06-300001671502us-gaap:CommonStockMember2024-03-310001671502dei:AdrMember2024-03-310001671502us-gaap:CommonStockMember2023-12-
310001671502us-gaap:CommonStockMember2023-06-300001671502dei:AdrMember2023-06-300001671502us-gaap:CommonStockMember2023-03-310001671502dei:AdrMember2023-03-
310001671502us-gaap:CommonStockMember2022-12-310001671502dei:AdrMember2022-12-310001671502dei:AdrMember2024-06-300001671502dei:AdrMember2023-12-
310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2024-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2024-06-
300001671502srt:MinimumMemberqnrx:PriorWarrantsMember2024-06-300001671502srt:MaximumMemberqnrx:PriorWarrantsMember2024-06-
300001671502qnrx:PriorWarrantsMember2024-03-0700016715022023-06-300001671502qnrx:SkinvisibleLicenseAgreementMember2019-10-310001671502us-
gaap:EmployeeStockOptionMemberdei:AdrMember2024-04-012024-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2024-04-012024-06-300001671502us-
gaap:EmployeeStockOptionMemberdei:AdrMember2024-01-012024-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2024-01-012024-06-300001671502us-
gaap:EmployeeStockOptionMemberdei:AdrMember2023-04-012023-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2023-04-012023-06-300001671502us-
gaap:EmployeeStockOptionMemberdei:AdrMember2023-01-012023-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2023-01-012023-06-300001671502us-
gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001671502us-
gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001671502us-
gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001671502us-
gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001671502us-
gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100016715022024-01-012024-03-310001671502us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001671502us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016715022023-01-012023-03-310001671502us-gaap:CommonStockMember2024-04-012024-06-
300001671502dei:AdrMember2024-04-012024-06-3000016715022023-07-182023-07-180001671502qnrx:SchoolOfPharmacyAtUccMemberus-
gaap:ResearchAndDevelopmentArrangementMember2024-06-102024-06-1000016715022023-04-012023-06-300001671502qnrx:Ms.CarterMember2024-01-012024-06-
300001671502qnrx:Dr.MyersMember2024-01-012024-06-300001671502srt:MinimumMember2023-07-1800016715022023-07-
180001671502qnrx:SeriesEWarrantsAmericanDepositarySharesMemberqnrx:PublicOffering2024Member2024-03-
070001671502qnrx:SeriesDWarrantsAmericanDepositarySharesMemberqnrx:PublicOffering2024Member2024-03-070001671502dei:AdrMember2023-11-0800016715022023-11-
0800016715022023-01-012023-06-300001671502qnrx:PreFundedWarrantsMemberdei:AdrMember2024-01-012024-06-300001671502qnrx:AlumniPurchaseAgreementMember2024-01-
25000167150220 24-06-300001671502qnrx:Convertiblenotes2020Member2024-01-012024-06-300001671502qnrx:Convertiblenotes2020Member2023-01-012023-12-3100016715022022-01-012022-12-
310001671502qnrx:Convertiblenotes2020Member2022-01-012022-12-310001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-12-
310001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-
05-310001671502qnrx:NethertonSyndromeMemberqnrx:ConsultingAgreementMember2021-11-
300001671502qnrx:SeriesWarrantsAmericanDepositaryShares2024Memberqnrx:PublicOffering2024Member2024-03-
070001671502qnrx:PreFundedWarrants2024Memberqnrx:PublicOffering2024Member2024-03-
070001671502qnrx:SeriesWarrantsAmericanDepositaryShares2024Memberqnrx:PublicOffering2024Member2024-03-072024-03-
070001671502qnrx:SeriesEWarrantsAmericanDepositarySharesMemberqnrx:PublicOffering2024Member2024-03-072024-03-
070001671502qnrx:SeriesDWarrantsAmericanDepositarySharesMemberqnrx:PublicOffering2024Member2024-03-072024-03-
070001671502qnrx:PriorWarrantsMemberqnrx:PublicOffering2023Member2024-03-072024-03-070001671502qnrx:PriorWarrantsMemberqnrx:PublicOffering2022Member2024-03-072024-03-
070001671502qnrx:PreFundedWarrants2024Memberqnrx:PublicOffering2024Member2024-03-072024-03-070001671502qnrx:PreFundedWarrantsMemberdei:AdrMember2024-06-
300001671502qnrx:SkinvisibleLicenseAgreementMember2019-10-012019-10-310001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2020-11-012020-11-
300001671502qnrx:PublicOffering2024Member2024-03-072024-03-070001671502us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000016715022024-06-3000016715022023-12-
3100016715022024-04-012024-06-300001671502us-gaap:CommonStockMember2024-08-070001671502dei:AdrMember2024-08-0700016715022024-01-012024-06-
30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesqnrx:itemqnrx:agreementiso4217:EURqnrx:segmentTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, DC 20549â€‹FORM 10-Qâ€‹(Mark One)â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended June 30, 2024â€‹ORâ€‹â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from _____ to _____â€‹Commission file number: 001-37846â€‹QUOIN PHARMACEUTICALS LTD.(Exact name of registrant as specified in its charter)â€‹â€‹â€‹State of IsraelÂ Â Â Â 92-2593104(State or other jurisdiction ofâ€‹(I.R.S. Employerincorporation or organization)â€‹Identification No.)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹42127 Pleasant Forest CourtÂ Â Â Â â€‹Ashburn, VAâ€‹20148-7349(Address of principal executive offices)â€‹(Zip Code)â€‹(703) 980-4182(Registrantâ€™s telephone number, including area code)â€‹N/A(Former name, former address and former fiscal year, if changed since last report)â€‹Securities registered pursuant to Section 12(b) of the Act:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Title of each classÂ Â Â Â Trading Symbol(s)Â Â Â Â Name of each exchange on which registeredAmerican Depositary Shares, each representing one (1) Ordinary Shares, no par value per shareâ€‹QNRXâ€‹The Nasdaq Stock Market LLCOrdinary Shares, no par value per share*â€‹â€‹â€‹N/A*Not for trading, but only in connection with the registration of the American Depositary Shares (â€œADSsâ€) pursuant to requirements of the Securities and Exchange Commission.â€‹Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜â€‹Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜â€‹Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜’Emerging growth companyâ˜â€‹â€‹â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜â€‹Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’â€‹As of August 7, 2024, the registrant had 3,979,970 ordinary shares, no par value per share, outstanding, and 3,979,970 ADSs outstanding (assuming all ordinary shares are represented by ADSs), with each ADS representing one (1) ordinary share.â€‹â€‹â€‹â€‹â€‹ Table of ContentsQUOIN PHARMACEUTICALS LTD.INDEXÂ PageCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS1Â Â PART I-FINANCIAL INFORMATION3Â â€‹Item 1. Financial Statements.3Â â€‹Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.18Â â€‹Item 3. Quantitative and Qualitative Disclosures About Market Risk.29Â â€‹Item 4. Controls and Procedures.29Â â€‹PART II-OTHER INFORMATION30Â â€‹Item 1. Legal Proceedings.30Â â€‹Item 1A. Risk Factors.30Â â€‹Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.31Â â€‹Item 3. Defaults Upon Senior Securities.31Â â€‹Item 4. Mine Safety Disclosures.31Â â€‹Item 5. Other Information.31Â â€‹Item 6. Exhibits.32Â â€‹SIGNATURES33â€‹â€‹â€‹ Table of ContentsGENERAL INFORMATIONUnless otherwise indicated or the context otherwise requires, all references in this Quarterly Report on Form 10-Q (the â€œQuarterly Reportâ€) to the terms â€œQuoin,â€ â€œQuoin Ltd.,â€ the â€œCompany,â€ â€œus,â€ â€œweâ€, â€œourâ€ and the â€œRegistrantâ€ refer to Quoin Pharmaceuticals Ltd., an Israeli company, and its consolidated subsidiaries. In this Quarterly Report, the U.S. Securities and Exchange Commission is referred to as the â€œSECâ€, the Securities Act of 1933, as amended, is referred to as the â€œSecurities Actâ€ and the Securities Exchange Act of 1934, as amended, is referred to as the â€œExchange Act.â€CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSAND SUMMARY OF RISK FACTORSCertain information included in this Quarterly Report may be deemed to be â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by the use of forward-looking terminology such as â€œmay,â€ â€œwill,â€ â€œexpect,â€ â€œanticipate,â€ â€œestimate,â€ â€œcontinue,â€ â€œbelieve,â€ â€œshould,â€ â€œintend,â€ â€œprojectâ€ or other similar words, but are not the only way these statements are identified.These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:â—our limited operating history and the difficulties encountered by a small developing company;â—our history of losses and need for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;â—our lack of revenue generated from product sales since inception, and potential inability to be profitable;â—uncertainties of cash flows and inability to meet working capital needs;â—our ability to obtain regulatory approvals;â—our ability to generate favorable pre-clinical and clinical trial results;â—our ability to identify and develop potential product candidates;â—additional costs or delays associated with unsuccessful clinical trials;â—the inability to predict the timing of revenue from sales of a future product;â—the extensive regulatory requirements and future developmental and regulatory challenges we will still face even if we obtain approval for a product candidate;â—our ability to obtain or maintain orphan drug designation or data exclusivity for our product candidates;â—our ability to obtain Orphan Disease and Rare Pediatric Disease designations for our product candidates;1 Table of Contentsâ—the potential oversight of programs or product candidates that may be more profitable or more successful;â—our manufacturing processes may not be validated and our methodology may not be accepted by the scientific community;â—the ability to conduct clinical trials, because of difficulties enrolling

patients or other reasons;â—the requirements of being a publicly traded company may strain our resources;â—potential adverse effects resulting from failure to maintain effective internal controls;â—our ability to comply with the applicable continued listing requirements of Nasdaq;â—the potential negative impact on our securities price and trading volume if securities or industry analysts do not publish reports about us or if they adversely change their recommendations about our business;â—failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our ADSs;â—the potential volatility of the market price for our ADSs;â—the potential dilution of our shareholdersâ€™ potential ownership due to future issuances of share capital;â—the requirement for holders of ADSs to act through the depositary to exercise their rights;â—the potential limitations on ADS holders with respect to the transfer of their ADSs;â—the risks of securities class action litigation; andâ—other risks and uncertainties, including those listed under described in Part I â€“ Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 (â€œForm 10-Kâ€), as well as our subsequent reports filed with the SECYou are urged to carefully review and consider the various disclosures made throughout this Quarterly Report which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.You should not put undue reliance on any forward-looking statements. Although the forward-looking statements in this Quarterly Report are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.â€‹2 Table of ContentsPART I â€“ FINANCIAL INFORMATIONItem 1. Financial Statements.QUOIN PHARMACEUTICALSÂ LTD.Condensed Consolidated Balance Sheetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹Â (Unaudited)Â â€‹ASSETSâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Current assets:Â â€‹Â Â Â â€‹Â Â Cash and cash equivalentsâ€‹$ 2,845,126â€‹$ 2,401,198Investmentsâ€‹â€‹ 9,725,463â€‹â€‹ 8,293,663Prepaid expenses and other current assetsâ€‹Â 650,696â€‹Â 591,034Total current assetsâ€‹Â 13,221,285â€‹Â 11,285,895â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹Prepaid expenses - long termâ€‹â€‹300,000â€‹â€‹300,000Intangible assets, netâ€‹Â 533,334â€‹Â 583,334Total assetsâ€‹$ 14,054,619â€‹$ 12,169,229â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹LIABILITIES AND SHAREHOLDERSâ€™ EQUITYâ€‹Â Â Â â€‹Â Â Â Current liabilities:â€‹Â Â Â â€‹Â Â Â Accounts payableâ€‹$ 819,674â€‹$ 526,523Accrued expensesâ€‹Â 1,386,625â€‹Â 1,308,706Accrued interest and financing expenseâ€‹Â 1,146,251â€‹Â 1,146,251Due to officers - short termâ€‹Â 600,000â€‹Â 600,000Total current liabilitiesâ€‹Â 3,952,550â€‹Â 3,581,480â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹Due to officers - long termâ€‹â€‹ 2,623,733â€‹â€‹ 2,923,733Total liabilitiesâ€‹$ 6,576,283â€‹$ 6,505,213â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commitments and contingenciesâ€‹Â Â Â â€‹Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹Shareholdersâ€™ equity:â€‹Â Â Â â€‹Â Â Â Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized at â€‹$ â€”â€‹$ â€”June 30, 2024 and December 31, 2023, respectively - 3,979,970 (3,979,970 ADS's) ordinary shares issued and outstanding at June 30, 2024 and 987,220 (987,220 ADS's) at December 31, 2023â€‹Â â€‹â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Additional paid in capitalâ€‹Â 57,982,969â€‹Â 51,867,336Accumulated deficitâ€‹Â (50,504,633)â€‹Â (46,203,320)Total shareholders' equityâ€‹Â 7,478,336â€‹Â 5,664,016â€‹â€‹â€‹ â€‹â€‹â€‹ â€‹Total liabilities and shareholders' equityâ€‹$ 14,054,619â€‹$ 12,169,229â€‹The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statementsâ€‹3 Table of ContentsQUOIN PHARMACEUTICALSÂ LTD.Condensed Consolidated Statements of Operations (Unaudited)â€‹Three months ended JuneÂ 30,Â Â Â Â Â Six months ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Operating expensesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â

believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.Warrants:The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Companyâ€™s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Companyâ€™s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated its warrants outstanding to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.Investments:Investments as of June 30, 2024 and December 31, 2023 consist of U.S. Treasury Bills and Notes, which are classified as trading securities, totaling $9.7 million and $8.3 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Companyâ€™s U.S. Treasury Bills and Notes held on June 30, 2024 have maturities within one year from the balance sheet date. As of June 30, 2024, the carrying value of the Companyâ€™s U.S. Treasury Bills and Notes approximates their fair value due to their short-term maturities.Long-lived assets:Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10Â years.The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:â—Significant changes in the manner of the Companyâ€™s use of the acquired assets or the strategy for its overall business,9 Table of Contentsâ—Significant underperformance relative to expected historical or projected development milestones,â—Significant negative regulatory or economic trends, andâ—Significant technological changes which could render the platform technology obsolete.The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2024 and 2023, there were no impairment indicators which required an impairment loss measurement.Research and development:Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.Stock based compensation:The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.Since the Company has a limited history of trading as a public company, the Companyâ€™s expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.Fair value of financial instruments:The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (â€œASC Topic 820â€). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.â€‹10 Table of ContentsEarnings (loss) per share:The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, other than unexercised prefunded warrants as described below, potential common shares are excluded if their effect is anti-dilutive.For the three and six months ended June 30, 2024, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 8,988,346 ADS and outstanding stock options to purchase 278,011 ADS, and for the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS, respectively, as their inclusion in the denominator would be anti-dilutive. For the three and six months ended June 30, 2024 basic and diluted net earnings (loss) per share included 1,069,750 ADS issuable with respect to unexercised prefunded warrants (See NoteÂ 13).NOTE 4 â€“ ACCRUED INTEREST AND FINANCING EXPENSEOn October 2, 2020, Quoin Inc. issued promissory notes (the â€œ2020 Notesâ€) to certain investors (â€œ2020 Noteholdersâ€). The 2020 Notes were mandatorily convertible into 432 ADSs, subject to adjustment and were converted in 2021. The ADSs issued to the 2020 Noteholders did not include accrued interest. Two of the five 2020 Noteholders received their amount due during the year ended December 31, 2022 and the Companyâ€™s estimate of the liability to the remaining three 2020 Noteholders was estimated to be $1,146,000 as of June 30, 2024 and December 31, 2023.There was no interest expense recognized in both the three and six month periods ended June 30, 2024 and 2023.NOTEÂ 5Â - FAIR VALUE OF FINANCIAL INSTRUMENTSThe Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs.In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.â€‹11 Table of ContentsThe following table presents the Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2024 and December 31, 2023:â€‹â€‹â€‹

to this agreement in the three and six months ended June 30, 2024.Performance milestones and RoyaltiesSee NoteÂ 9 for asset and in-licensed technology commitments.NOTEÂ 13Â â€“ SHAREHOLDERSâ€™ EQUITYAlumni Equity Line and Purchase AgreementOn January 25, 2024, the Company entered into a purchase agreement (the â€œAlumni Purchase Agreementâ€) with Alumni Capital LP (â€œAlumniâ€). Pursuant to the Alumni Purchase Agreement, the Company has the right to sell to Alumni up to $8,000,000 (the â€œCommitment Amountâ€) of newly issued ordinary shares that are represented by ADS, subject to certain conditions and limitations, from time to time during the term of the Alumni Purchase Agreement.The Company does not have the right to commence any sales of ordinary shares represented by ADSs to Alumni under the Alumni Purchase Agreement until the date, which the Company refers to as the Commencement Date, that all of the conditions set forth in the Alumni Purchase Agreement have been satisfied, including that the registration statement the Company agreed to file with the SEC pursuant to the Alumni Purchase Agreement is declared effective by the SEC, and the Companyâ€™s shareholders have approved of the issuance of ADSs under the Alumni Purchase Agreement, which approval was obtained on April 5, 2024. From and after the Commencement Date, the Company may, from time to time and at the Companyâ€™s sole discretion for a period of three months, which the Company at its sole discretion may increase by an additional three months (such period, including any extension, the â€œCommitment Periodâ€), on any business day that the Company may select, direct Alumni to purchase ordinary shares represented by ADSs. The purchase price for the ordinary shares represented by ADSs the Company may sell to Alumni will be based upon formulas set forth in the Alumni Purchase Agreement based on the then current market price of the ADSs as computed under the Alumni Purchase Agreement and will depend on the type of purchase notice the Company submits to Alumni from time to time. There is no upper limit on the price per share that Alumni could be obligated to pay for the ADSs under the Alumni Purchase Agreement; provided, however at no time can the purchase price be below a floor price of $1.00 per share (subject to adjustment). The Company agreed to issue purchase notices for an aggregate of at least $4,000,000 of the Commitment Amount prior to the end of the Commitment Period.As consideration for Alumniâ€™s irrevocable commitment to purchase ADSs under the Alumni Purchase Agreement, the Company agreed to issue to Alumni, at the times set forth in the Alumni Purchase Agreement beginning with the trading day after the Commencement Date, a number of ADSs with a value at the time of issuance not to exceed $240,000 in the aggregate (the â€œCommitment Securitiesâ€). The Company may pay cash in lieu of issuing all or any portion of the Commitment Securities.15 Table of ContentsPublic Offering On March 7, 2024, (the â€œ2024 Closing Dateâ€) the Company completed an offering (the â€œ2024 Offeringâ€) of the following securities (i) 811,250 ordinary shares represented by ADSs, (ii) 4,062,500 Series D warrants (the â€œSeries D Warrantsâ€) to purchase 4,062,500 ordinary shares represented by ADSs, (iii) 4,062,500 Series E warrants (the â€œSeries E Warrantsâ€ and together with the Series D Warrants, the â€œ2024 Warrantsâ€) to purchase 4,062,500 ordinary shares represented by ADSs, and (iv) 3,251,250 pre-funded warrants (the â€œ2024 Pre-Funded Warrantsâ€) to purchase 3,251,250 ordinary shares represented by ADSs for aggregate gross proceeds of approximately $6.5 million, resulting in net proceeds of approximately $5.5 million, after deducting the placement agentâ€™s fees and offering expenses paid by the Company. Each ADS (or 2024 Pre-Funded Warrant to purchase one ADS in lieu thereof) was sold together with a Series D Warrant to purchase one ADS and a Series E Warrant to purchase one ADS. The ADSs and accompanying 2024 Warrants were sold at a combined public offering price of $1.60 and the 2024 Pre-Funded Warrants and accompanying 2024 Warrants were sold at a combined public offering price of $1.5999, which is equal to the combined purchase price per ADS and accompanying 2024 Warrants, minus the exercise price of each 2024 Pre-Funded Warrant of $0.0001. The Series D and Series E warrants have an exercise price of $1.60 per share, were exercisable immediately following the 2024 Closing Date and expire in two years and five years, respectively, from the closing of the 2024 Offering. As of June 30, 2024, 2,181,500 2024 Pre-Funded Warrants have been exercised and are included in issued and outstanding ADSs. In connection with the 2024 Offering, the Company entered into a Securities Purchase Agreement (the â€œ2024 Purchase Agreementâ€) dated March 4, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the ADSs, 2024 Pre-Funded Warrants and 2024 Warrants sold in the 2024 Offering. Pursuant to the terms of the 2024 Purchase Agreement, the Company agreed, subject to certain exceptions, (i) to not enter into variable rate financings for a period of 180 days following the closing of the 2024 Offering, and (ii) to not enter into any equity financings for 90 days from closing of the 2024 Offering.On March 7, 2024, the Company also entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 638,834 ADSs, 207,499 of which were warrants issued in the Companyâ€™s 2022 public offering and 431,335 of which were warrants issued in the Companyâ€™s 2023 public offering (collectively, the â€œPrior Warrantsâ€) to, among other things, reduce the exercise price of such Prior Warrants to $1.60 and to extend the current expiration date of the Prior Warrants until March 7, 2029. The incremental fair value of the modified warrants was approximately $209,000, which was accounted for as an offering expense in connection with the 2024 Offering.WarrantsThe following table summarizes warrant activities during the six months ended June 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â

effective by the SEC, and our shareholders have approved of the issuance of ADSs under the Alumni Purchase Agreement, which approval was obtained on April 5, 2024.From and after the Commencement Date, we may, from time to time and at our sole discretion for a period of three months, which we at our sole discretion may increase by an additional three months (such period, including any extension, the â€œCommitment Periodâ€), on any business day that we select, direct Alumni to purchase ordinary shares represented by ADSs. The purchase price for the ordinary shares represented by ADSs we may sell to Alumni will be based upon formulas set forth in the Alumni Purchase Agreement based on the then current market price of the ADSs as computed under the Alumni Purchase Agreement and will depend on the type of purchase notice we submit to Alumni from time to time. There is no upper limit on the price per share that Alumni could be obligated to pay for the ADSs under the Alumni Purchase Agreement; provided, however at no time can the purchase price be below a floor price of $1.00 per share (subject to adjustment). We agreed to issue purchase notices for an aggregate of at least $4,000,000 of the Commitment Amount prior to the end of the Commitment Period.As consideration for Alumniâ€™s irrevocable commitment to purchase ADSs under the Alumni Purchase Agreement, we agreed to issue to Alumni, at the times set forth in the Alumni Purchase Agreement beginning with the trading day after the Commencement Date, a number of ADSs with a value at the time of issuance not to exceed $240,000 in the aggregate (the â€œCommitment Securitiesâ€). The ADSs to be issued will be valued at the average of the closing prices of the ADSs on Nasdaq for the five trading days immediately prior to the date such ADSs are issued. We may pay cash in lieu of issuing all or any portion of the Commitment Securities.In connection with the 2024 Offering, we agreed not to sell any ADS to Alumni under the Alumni Purchase agreement for a period of 180 days from the 2024 Closing Date.Nasdaq ListingOn April 29, 2024, we received a letter from the Listing Qualifications staff (the â€œStaffâ€) of The Nasdaq Stock Market, LLC (â€œNasdaqâ€) notifying us that the closing bid price per ADS of the Company was below the required minimum of $1.00 for a period of 31 consecutive business days and that we did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of our ADSs and the ADSs will continue to trade on The Nasdaq Capital Market under the symbol â€œQNRX.â€Pursuant to Nasdaq Rule 5810(c)(3)(A), we have a period of one hundred eighty (180) calendar days, or until October 28, 2024 (the â€œCompliance Periodâ€), to regain compliance with Nasdaqâ€™s minimum bid price requirement. Compliance may be achieved without further action if the closing bid price of our ADSs is at or above $1.00 for a minimum of ten consecutive business days at any time during the Compliance Period, in which case Nasdaq will notify us if it determines we are in compliance and the matter will be closed; however Nasdaq may require the closing bid price to equal or to exceed the $1.00 minimum bid price requirement for more than 10 consecutive business days before determining that a company complies. In the event we do not regain compliance by October 28, 2024, we may be eligible for an additional 180 calendar day grace period. To qualify, we will be required to meet the continued listing requirement for market value of publicly held ADSs and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. We intend to actively monitor the bid price of our ADS and will consider available options to regain compliance with the Nasdaq listing requirements.21 Table of ContentsComponents of Our Results of OperationsOperating ExpensesOur current operating expenses consist of two components - research and development expenses, and general and administrative expenses.Research and Development ExpensesResearch and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. We utilize outside consultants and third parties to conduct the majority of our research and development, under the supervision of our management team.Future research and development expenses may include:â—employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses, share-based compensation, overhead related expenses and travel related expenses for our research and development personnel;â—expenses incurred under agreements with CROs, as well as consultants that support the implementation of the clinical studies described above;â—manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;â—formulation, research and development expenses related to QRX003; and other product candidates we may choose to develop; andâ—costs for sponsored research.Research and development activities will continue to be central to our business plan. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to be significant over the next several years as personnel and compensation costs increase and we conduct late-stage clinical studies and prepare to seek regulatory approval for QRX003 and any other future product candidate.The duration, costs and timing of clinical trials of QRX003 and any other future product candidate will depend on a variety of factors that include, but are not limited to:â—the number of trials required for approval;â—the per patient trial costs;â—the number of patients that participate in the trials;â—the number of sites included in the trials;â—the countries in which the trial is conducted;â—the length of time required to enroll eligible patients;â—the number of doses that patients receive;22 Table of Contentsâ—the drop-out or discontinuation rates of patients;â—the potential additional safety monitoring or other studies requested by regulatory agencies;â—the duration of patient follow-up;â—the timing and receipt of regulatory approvals; andâ—the efficacy and safety profile of our product candidates.General and Administrative ExpensesGeneral and administrative expenses consist primarily of compensation and employee related expenses including non-cash stock-based compensation, professional fees and other corporate expenses.We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities. These increases will likely include compensation and employee-related expenses including stock-based compensation, increased costs related to the potential hiring of personnel, travel costs and fees to outside consultants, lawyers and accountants.Other Expenses (income)Other expenses (income) consist primarily of interest income and unrealized loss (gain) on investments.â€‹Results of Operations â€” Three months ended June 30, 2024 compared to the three months ended June 30, 2023The following table sets forth our results of operations for the three months ended June 30, 2024, compared to the three months ended JuneÂ 30, 2023:â€‹â€‹â€‹

also requires that we make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.27 Table of ContentsIn November 2020, Quoin Inc. entered into a Master Service Agreement with Therapeutics Inc. for the management of the preclinical and clinical development of QRX003 for Netherton Syndrome. The initial term of the agreement was three years with automatic one year extensions, and the agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. An additional work order was entered into in December 2022 for a second QRX003 clinical study at an expected estimated cost of approximately $830,000. For the three and six months ended June 30, 2024 and 2023, we incurred research and development expenses under these agreements of approximately $162,000 and $650,000, and $360,000 and $959,000, respectively.In November 2021, we entered into a research agreement with Queensland University of Technology (â€œQUTâ€) for a pre-clinical research program for the development of a product to treat Netherton Syndrome of approximately $250,000. In May 2022, we entered into a second research agreement with QUT for the development of a product to treat Scleroderma of approximately $610,000. Each agreement remains in place until the completion of the research program. For the three and six months ended June 30, 2024 we did not incur any costs related to these agreements. For the three and six months ended June 30, 2023, we incurred research and development costs related to these agreements of approximately $138,000 and $276,000 respectively.On June 10, 2024, we entered into a research agreement with The School of Pharmacy at UCC. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. Under the terms of the agreement, based on the achievement of certain milestones, we will fund up to approximately â‚¬567,000 ($608,000) plus VAT over an anticipated 2-1/2 year period to support UCC research program to investigate the development of a number of topical rapamycin formulations for future development as potential treatments for several rare and orphan diseases. Following completion of the research program, we will have the option to advance the clinical development of rapamycin formulations developed by UCC. Â For the three and six months ended June 30, 2024 we did not incur any costs related to this agreement.Critical Accounting EstimatesThere have been no material changes to our critical accounting estimates from the information provided in Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ included in our Annual Report on Form 10-K for the year ended December 31, 2023.28 Table of ContentsItem 3. Quantitative and Qualitative Disclosures About Market Risk.We are a smaller reporting company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) and are not required to provide the information otherwise required under this Item 3.Item 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresWe maintain disclosure controls and procedures, which are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation, as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15e under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingDuring the quarter ended June 30, 2024, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹29 Table of ContentsPART II â€“ OTHER INFORMATIONItem 1. Legal Proceedings.From time to time, we may become involved in legal or administrative proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us.Item 1A. Risk Factors.Except as set forth below, there have been no material changes in our risk factors from the risks previously reported in Part 1, Item 1A, â€œRisk Factorsâ€ of our Form 10-K. You should carefully consider the factors discussed in Form 10-K, which could materially affect our business, financial condition or future results. The risks described in our Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our ADSs.Our ADSs are listed on the Nasdaq Capital Market, which imposes, among other requirements, a minimum bid requirement.On April 29, 2024, we received a deficiency letter from the Listing Qualifications Department of the Nasdaq notifying us that for the preceding 31 consecutive business days (March 14, 2024 through April 26, 2024), our ADSs did not maintain a minimum closing bid price of $1.00 (â€œMinimum Bid Price Requirementâ€) per ADS as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a compliance period of 180 calendar days, or until October 28, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved automatically and without further action if the closing bid price of our ADSs is at or above $1.00 for a minimum of ten consecutive business days at any time during the 180-day compliance period, in which case, in its discretion, Nasdaq will notify the Company of its compliance and the matter will be closed. If, however, we do not achieve compliance with the Minimum Bid Price Requirement by October 28, 2024, we may be eligible for additional time to comply. In order to be eligible for such additional time, we will be required to meet the continued listing requirement for market value of publicly held ADSs and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period. We intend to actively monitor the bid price of our ADSs and will consider available options to regain compliance with the Nasdaq listing requirements. If we cannot regain compliance with the Minimum Bid Price Requirement or if we otherwise fail to meet any of Nasdaqâ€™s listing standards, our ADSs will be subject to delisting. If that were to occur, our ADSs would be subject to rules that impose additional sales practice requirements on broker-dealers who sell our securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our ADSs. This would adversely affect the ability of investors to trade our ADSs and would adversely affect the value of our ADSs. Delisting from Nasdaq would cause us to pursue eligibility for trading of our ADSs on other markets or exchanges, or on an over-the-counter market. In such case, our stockholdersâ€™ ability to trade or obtain quotations of the market value of our ADSs would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of these securities. There can be no assurance that our ADSs, if delisted from the Nasdaq, would be listed on a national securities exchange, a national quotation service or the over-the-counter markets. Delisting from the Nasdaq could also result in negative publicity, adversely affect the market liquidity of our ADSs, decrease securities analystsâ€™ coverage of us or diminish investor, supplier and employee confidence. 30 Table of ContentsThe delisting of our ADSs from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future, or at all. Such a delisting would likely have a negative effect on the price of our ADSs and would impair your ability to sell or purchase our ADSs when you wish to do so. Further, if our ADSs were to be delisted from Nasdaq, our ADSs would cease to be recognized as a covered security, and we would be subject to additional regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we take to restore our compliance with the Nasdaq Minimum Bid Price Requirement would stabilize the market price or improve the liquidity of our ADSs, prevent our ADSs from falling below the Nasdaq minimum bid price required for continued listing again or prevent future non-compliance with other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholdersâ€™ equity or market values of our ADSs, our ADSs could be delisted.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.None.Item 3. Defaults Upon Senior Securities.None.Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.During the second quarter of 2024, none of our directors or executive officers adopted or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as each term is defined in Item 408(a) of Registration S-K).â€‹31 Table of ContentsItem 6. Exhibits.The following exhibits are included in this Form 10-Q or incorporated herein by reference:Exhibit No.Â Â Â Â Exhibit Description3.1â€‹Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on February 28, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on February 8, 2022).3.2â€‹Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on April 12, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).3.3â€‹Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on November 3, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on September 21, 2022).3.4â€‹Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on October 26, 2023 (incorporated by reference to Annex A included in the proxy statement filed with the SEC on September 12, 2023).31.1*â€‹Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 193431.2*â€‹Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 193432.1*â€‹Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 135032.2*â€‹Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350101*â€‹Information formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Shareholdersâ€™ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.104*â€‹Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)*Filed herewithâ€‹â€‹â€‹32 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹Quoin Pharmaceuticals Ltd.â€‹â€‹â€‹August 8, 2024By:/s/ Gordon DunnName: Gordon DunnTitle: Chief Financial Officerâ€‹â€‹â€‹33 EX-31.1 2 qnrx-20240630xex31d1.htm EX-31.1 Exhibit 31.1CERTIFICATION PURSUANT TORULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Dr. Michael Myers, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the â€œregistrantâ€);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹/s/ Dr. Michael Myersâ€‹Name: Dr. Michael Myersâ€‹Title: Chief Executive Officerâ€‹Date: August 8, 2024â€‹â€‹ EX-31.2 3 qnrx-20240630xex31d2.htm EX-31.2 Exhibit 31.2CERTIFICATION PURSUANT TORULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Gordon Dunn, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the â€œregistrantâ€);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹/s/ Gordon Dunnâ€‹Name: Gordon Dunnâ€‹Title: Chief Financial Officerâ€‹Date: August 8, 2024â€‹â€‹ EX-32.1 4 qnrx-20240630xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the â€œCompanyâ€) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.â€‹/s/ Dr. Michael Myersâ€‹Name: Dr. Michael Myersâ€‹Title: Chief Executive Officerâ€‹Date: August 8, 2024â€‹â€‹The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§ 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. EX-32.2 5 qnrx-20240630xex32d2.htm EX-32.2 Exhibit 32.2CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the â€œCompanyâ€) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as

amended; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.â€‹/s/ Gordon Dunnâ€‹Name: Gordon Dunnâ€‹Title: Chief Financial Officerâ€‹Date: August 8, 2024â€‹â€‹The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§ 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. EX-101.SCH 6 qnrx-20240630.xsd EX-101.SCH 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - PREPAID EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - PREPAID EXPENSES (Details) - Calc 2 link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - STOCK BASED COMPENSATION - Stock-based activities (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - SHAREHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - ORGANIZATION AND BUSINESS link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - PREPAID EXPENSES link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - IN-LICENSED TECHNOLOGY link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - PREPAID EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - LICENSE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 qnrx-20240630_cal.xml EX-101.CAL EX-101.DEF 8 qnrx-20240630_def.xml EX-101.DEF EX-101.LAB 9 qnrx-20240630_lab.xml EX-101.LAB Document and Entity Information Entity Addresses [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock [Member] Ordinary shares ADR [Member] ADSs Loss per ADS Entity Addresses [Line Items] Document and Entity Information Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address State Or Province Entity Address, City or Town Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(g) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Amendment Flag Entity Central Index Key Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash balance Investments Investments Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Prepaid Expense, Noncurrent Prepaid expenses - long term Long-term portion Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Interest Payable Accrued interest and financing expense Other Liabilities, Current Less: Short-term portion Due to officers - short term Other Liability, Current, Related Party, Type [Extensible Enumeration] Other liability, current, related party, type extensible enumeration Liabilities, Current Total current liabilities Other Liabilities, Noncurrent Long-term portion Due to officers - long term Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration] Other liability, noncurrent, related party, type extensible enumeration Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Common Stock, Value, Issued Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized at June 30, 2024 and December 31, 2023, respectively - 3,979,970 (3,979,970 ADS's) ordinary shares issued and outstanding at June 30, 2024 and 987,220 (987,220 ADS's) at December 31, 2023 Additional Paid in Capital Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of year Balance at beginning of year Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Common Stock, Par or Stated Value Per Share Ordinary shares, par value Common Stock, Shares Authorized Ordinary shares, shares authorized Common Stock, Shares, Issued Ordinary shares, shares issued Common Stock, Shares, Outstanding Balance at ending of year (in shares) Balance at beginning of year (in shares) Ordinary shares, shares outstanding Condensed Consolidated Statements of Operations (Unaudited) Operating Expenses [Abstract] Operating expenses Selling, General and Administrative Expense General and administrative Research and Development Expense Research and development Operating Costs and Expenses Total operating expenses Other (income) and expenses Unrealized Gain (Loss) on Derivatives Unrealized loss Amount of realized and accrued interest income from investment. Realized and Accrued Interest Income Realized and accrued interest income Nonoperating Income (Expense) Total other income Net loss Net loss Earnings Per Share, Basic and Diluted [Abstract] Loss per ADS Earnings Per Share, Basic Basic Earnings Per Share, Diluted Fully-diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of ADS's outstanding Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Diluted Fully-diluted Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Equity Components [Axis] Equity Component [Domain] Treasury Stock Common [Member] Treasury Stock Additional Paid-in Capital [Member] Additional Paid In Capital Retained Earnings [Member] Accumulated Deficit Stock Issued During Period, Value, New Issues Issuance of ADS's, pre-funded warrants and warrants, net Stock Issued During Period, Shares, New Issues Issuance of ADS's, pre-funded warrants and warrants, net (in shares) Amount of increase in additional paid in capital (APIC) resulting from the exercise of warrants. Adjustments to Additional Paid in Capital, Warrants Exercised Exercise of pre-funded warrants Number of pre-funded warrants that are exercised during the current period. Stock Issued During Period, Shares, Exercise of Warrants Exercise of pre-funded warrants (in shares) Amount of increase in additional paid in capital (APIC) resulting from reversal of the accrued offering expenses associated with the issuance of warrants. Adjustments to Additional Paid in Capital, Reversal Of Accrued Offering Costs Reversal of accrued offering expenses APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock based compensation Condensed Consolidated Statements of Cash Flows (unaudited) Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows used in operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Share-based Payment Arrangement, Noncash Expense Stock based compensation Amortization of Intangible Assets Amortization of intangibles Unrealized Gain (Loss) on Investments Unrealized gain and accrued interest on investments Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Accounts Payable and Accrued Expenses Increase in accounts payable and accrued expenses Increase (Decrease) in Prepaid Expense Decrease (increase) in prepaid expenses & other assets Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows used in investing activities: Payments to Acquire Investments Purchase of investments Proceeds from Sale, Maturity and Collection of Investments Proceeds from maturity of investments Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows provided by financing activities: Repayments of Related Party Debt Payment of amounts due to officers Non-bearing interest indebtedness The net cash inflow from the additional capital contribution to the entity. Net Proceeds from Issuance of Common Stock Proceeds from sale of equity securities, net Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net change in cash and cash equivalents: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Supplemental Cash Flow Information [Abstract] Supplemental information - Non cash items: Amount of offering expenses associated with warrant modification. Offering Expenses Associated with Warrant Modification Offering expenses associated with warrant modification ORGANIZATION AND BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] ORGANIZATION AND BUSINESS No definition available. LIQUIDITY RISKS AND OTHER UNCERTAINTIES Substantial Doubt about Going Concern [Text Block] LIQUIDITY RISKS AND OTHER UNCERTAINTIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ACCRUED INTEREST AND FINANCING EXPENSE The entire disclosure pertaining to accrued interest and financing expense. Accrued Interest and Financing Expense[Text Block] ACCRUED INTEREST AND FINANCING EXPENSE FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS STOCK BASED COMPENSATION Share-based Payment Arrangement [Text Block] STOCK BASED COMPENSATION PREPAID EXPENSES The entire disclosure for current prepaid expenses. Prepaid Expense Disclosure Text Block PREPAID EXPENSES ACCRUED EXPENSES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] ACCRUED EXPENSES IN-LICENSED TECHNOLOGY Asset Acquisition [Text Block] IN-LICENSED TECHNOLOGY INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Commitments Disclosure [Text Block] RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS SHAREHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SHAREHOLDERS' EQUITY CONTINGENCIES Contingencies Disclosure [Text Block] CONTINGENCIES No definition available. LICENSE AGREEMENTS The entire disclosure for license agreements. License Agreements [Disclosure Text Block] LICENSE AGREEMENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation: Use of Estimates, Policy [Policy Text Block] Use of estimates: Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents: Disclosure of accounting policy for warrants. Warrants Policy [Policy Text Block] Warrants: Investment, Policy [Policy Text Block] Investments: Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-lived assets: Research and Development Expense, Policy [Policy Text Block] Research and development: Share-based Payment Arrangement [Policy Text Block] Stock based compensation: Fair Value Measurement, Policy [Policy Text Block] Fair value of financial instruments: Earnings Per Share, Policy [Policy Text Block] Earnings (loss) per share: Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring basis Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock-based activities Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Related Party Transactions [Table Text Block] Schedule of amounts due to officers Tabular disclosure of warrant activities. Summary Of Warrant Activities [Table Text Block] Schedule of warrant activities Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Subsidiary, Sale of Stock [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Number of Operating Segments Number of operating segments Represents the number of shares represented for one American depositary share. Number of Shares Represented for One American Depositary Share Number of shares represented for one ADS Percentage of entity's shares owned. Shares Owned, Percentage Shares owned (as a percent) Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Number of ordinary shares for each American Depositary Shares. Number of Ordinary Shares for American Depositary Shares Number of ordinary shares for ADS Debt Securities, Trading, and Equity Securities, FV-NI U.S. Treasury Bills Duration of investments maturity term. Investments Maturity Term Maturity term Finite-Lived Intangible Asset, Useful Life Intangible assets, useful life Goodwill and Intangible Asset Impairment Impairment loss measurement Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] This member represents outstanding warrants. Outstanding Warrants [Member] Outstanding warrants Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to pre-funded warrants. Pre Funded Warrants [Member] Pre-Funded Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of prefunded warrants. Incremental Common Shares Attributable to Dilutive Effect of Pre Funded Warrants Unexercised prefunded warrants Schedule of Long-term Debt Instruments [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Debt Convertible Notes issued in 2020. Convertible notes 2020 Convertible Notes Warrants, Common Stock. Convertible Notes Warrants, Common Stock Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ACCRUED INTEREST AND FINANCING EXPENSE[Line Items] ACCRUED INTEREST AND FINANCING EXPENSE Stock Issued During Period, Shares, Conversion of Convertible Securities Shares issued

upon conversion Represents the number of noteholders who received consideration. Convertible Notes Payable, Number of Noteholders Who Received Consideration Number of notes holders who received consideration Represents the number of noteholders. Convertible Notes Payable, Number of Noteholders Total number of notes holders Represents the number of remaining noteholders who received consideration. Convertible Notes Payable, Number Of Remaining Noteholders Receive Consideration Number of remaining noteholders Interest Expense, Debt, Excluding Amortization Interest expense Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Financial Instrument [Axis] Financial Instruments [Domain] US Treasury Bill Securities [Member] US Treasury Bills Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS Warrants and Rights Outstanding Warrant liability Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the amended and restated equity incentive Plan (the "Amended Plan"). Amended Plan [Member] Amended plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] STOCK BASED COMPENSATION Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage of ordinary shares reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Number of ordinary shares reserved for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] ADSs Underlying Warrants ADS Underlying Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options outstanding at end of period Number of options outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Terminated (in shares) Forfeited/Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Per Share Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period Outstanding at beginning of the period Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Terminated (in dollars per share) Forfeited/Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable options (in years) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development Research and Development Expense General and Administrative Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] STOCK BASED COMPENSATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value of outstanding options Share-based Payment Arrangement, Expense Stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized stock compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period Amount of asset related to research and development costs paid in advance that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research And Development Costs Prepaid R&D costs Prepaid Insurance Prepaid insurance Other Prepaid Expense, Current Prepaid expense Deferred Offering Costs Deferred offering costs Prepaid Expense Total Prepaid Expense, Current Less: Short-term portion Carrying value as of the balance sheet date of obligations incurred through that date and payable for research contract expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research Contract Expense Current Research contract expenses Accrued Salaries, Current Payroll Accrued Payroll Taxes, Current Payroll taxes Accrued Professional Fees, Current Professional fees Other Accrued Liabilities, Current Other expenses Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] This member stands for skinvisible license agreement. Skinvisible License Agreement [Member] Skinvisible Licensing agreement Asset Acquisition [Line Items] IN-LICENSED TECHNOLOGY Asset Acquisition, Consideration Transferred License Fee Represents the percentage of revenues to be paid under asset acquisition. Asset Acquisition, Percentage of Revenues to be Paid Percentage of revenues to be paid Asset Acquisition, Contingent Consideration, Liability Amount of payment to be made Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] Technology license - Skinvisible Finite-Lived Intangible Assets [Line Items] INTANGIBLE ASSETS Finite-Lived Intangible Assets, Gross Total cost Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Net Net book value Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Expected amortization expense Finite-Lived Intangible Asset, Expected Amortization, Year One 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four 2027 Finite Lived Intangible Assets Amortization After Year Four Finite Lived Intangible Assets Amortization After Year Four Thereafter Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Represents the information pertaining to Dr. Myers. Dr. Myers [Member] Dr. Myers Represents the information pertaining to Ms. Carter. Ms. Carter [Member] Ms. Carter Related Party Transaction [Line Items] RELATED PARTY TRANSACTIONS Other Liability, Related Party, Type [Extensible Enumeration] Related Party Transaction, Due from (to) Related Party (Deprecated 2023) Outstanding indebtedness The amount of monthly payment to related party. Payment to Related Party Per Month Monthly payment amount Related Party Transaction [Axis] Related Party Transaction [Domain] Represents information pertaining to salary and other compensation due to officers. Salary And Other Compensation [Member] Salaries and other compensation Other Liabilities Total Long-term Purchase Commitment [Table] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Research and Development Arrangement [Member] Research and consulting agreement Represents consulting agreement. Consulting Agreement [Member] Consulting agreements Counterparty Name [Axis] Counterparty Name [Domain] Represents Netherton Syndrome. Netherton Syndrome [Member] Netherton Syndrome Represents information pertaining to Therapeutics Inc. Therapeutics Inc. [Member] Therapeutics Inc. Represents information pertaining to Scleroderma. Scleroderma [Member] Scleroderma Represents information relating to the school of pharmacy at UCC. The School Of Pharmacy At UCC [Member] The School of Pharmacy at UCC Long-term Purchase Commitment [Line Items] RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Period of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Initial Term Initial term Period of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Written Termination Notice Written termination notice period The aggregate amount of fee per consulting or service agreement. Consulting or Service Agreement, Agreed Amount Total amount of agreement The maximum liability for the entity in relation to the funding for the research agreement entered into. Research Agreement, Maximum Funding Amount Maximum funding amount Long-Term Purchase Commitment, Period Commitment period Schedule of Stock by Class [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to Alumni Purchase Agreement. Alumni Purchase Agreement [Member] Alumni Purchase Agreement Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to public offering 2022. Public Offering 2022 [Member] Public Offering 2022 Represents information pertaining to public offering 2023. Public Offering 2023 [Member] Public Offering 2023 Represents information pertaining to 2024 public offering. Public Offering 2024 [Member] Public Offering 2024 Maximum [Member] Maximum Information pertaining to warrant amendments member. Warrant Amendments [Member] Warrant Amendments Represents information pertaining to prior warrants. Prior Warrants [Member] Prior Warrants Represents information pertaining to Series D Warrants represented by American Depositary Shares. Series D Warrants American Depositary Shares [Member] Series D Warrants Represents information pertaining to Series E Warrants represented by American Depositary Shares. Series E Warrants American Depositary Shares [Member] Series E Warrants Represents information pertaining to 2024 pre-funded warrants. Pre-Funded Warrants 2024 [Member] 2024 Pre-Funded Warrants Represents information pertaining to 2024 Series Warrants combined of Series D and Series E represented by American Depositary Shares. Series Warrants American Depositary Shares 2024 [Member] 2024 Warrants Equity, Class of Treasury Stock [Line Items] SHAREHOLDERS' EQUITY The cash inflow associated with the amount received from entity's offering of stock to the public net of issuance costs. Net Proceeds From Issuance Public Offering After Issuance Costs Net proceeds from offering Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants, exercise price of warrants (in dollars per share) The amount of cash inflow associated with aggregate gross proceeds from offering. Aggregate Gross Proceeds from Issuance Offering Aggregate gross proceeds Class of Warrant or Right, Number of Securities Called by Warrants or Rights Shares warrants may purchase Warrants Not Settleable in Cash, Fair Value Disclosure Incremental fair value Number of warrants or rights exercised as of reporting date. Class of Warrant or Right, Exercised Number of warrants or rights exercised Number of warrants issued during the period. Class Of Warrant Or Right Issued Warrants issued (in shares) The maximum commitment amount related to right to sell newly issued ordinary shares that are represented by ADS. Maximum Commitment Amount Commitment amount The minimum commitment amount for which purchase notices agreed to be issued. Minimum Commitment Amount For Which Purchase Notices Agreed To Be Issued Minimum commitment amount The floor price per share. Floor Price Floor price The maximum value of commitment securities that can be issued at the times set forth under the agreement. Maximum Commitment Securities Value At Times Set Forth Under The Agreement Maximum commitment securities value Number of ordinary shares for each American Depositary Shares. Number Of Ordinary Shares For Each American Depositary Shares Number of ordinary shares for each ADS The combined public offering price. Combined Public Offering Price Combined public offering price Maturity term of class of warrants or rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Maturity Term Warrant maturity term Represents the threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering. Threshold Period for Not to Enter Into an Agreement to Effect a Variable Rate Transaction, After the Closing Date of the Offering Threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering Represents the threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering Threshold Period for Not to Issue, Enter Into Any Agreement to Issue or Announce the Issuance or Proposed Issuance of Any ADSs, After the Closing Date of the Offering Threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering Common Warrants [Member] Common Warrants [Member] Common Warrants Class of Stock [Line Items] SHAREHOLDERS' EQUITY Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Number of new license and supply agreements entered during the period. Number Of License And Supply Agreements Entered Number of license and supply agreements entered Royalty Income, Nonoperating Royalty revenues EX-101.PRE 10 qnrx-20240630_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 07, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Jun. 30, 2024 Â Entity File Number 001-37846 Â Entity Registrant Name QUOIN PHARMACEUTICALS LTD. Â Entity Incorporation, State or Country Code L3 Â Entity Tax Identification Number 92-2593104 Â Entity Address, Address Line One 42127 Pleasant Forest Court Â Entity Address State Or Province VA Â Entity Address, City or Town Ashburn Â Entity Address, Postal Zip Code 20148 Â City Area Code 703 Â Local Phone Number 980-4182 Â Title of 12(g) Security American Depositary Shares Â Trading Symbol QNRX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Current Fiscal Year End Date --12-31 Â Amendment Flag false Â Entity Central Index Key 0001671502 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Ordinary shares Â Â Document and Entity Information Â Â Entity Common Stock, Shares Outstanding Â 3,979,970 ADSs Â Â Document and Entity Information Â Â Entity Common Stock, Shares Outstanding Â 3,979,970 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityAddressesLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units

exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(g) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection g + Details Name: dei_Security12gTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 2,845,126 $ 2,401,198 Investments 9,725,463 8,293,663 Prepaid expenses and other current assets 650,696 591,034 Total current assets 13,221,285 11,285,895 Prepaid expenses - long term 300,000 300,000 Intangible assets, net 533,334 583,334 Total assets 14,054,619 12,169,229 Current liabilities: Â Â Accounts payable 819,674 526,523 Accrued expenses 1,386,625 1,308,706 Accrued interest and financing expense 1,146,251 1,146,251 Due to officers - short term $ 600,000 $ 600,000 Other liability, current, related party, type extensible enumeration srt:OfficerMember srt:OfficerMember Total current liabilities $ 3,952,550 $ 3,581,480 Due to officers - long term $ 2,623,733 $ 2,923,733 Other liability, noncurrent, related party, type extensible enumeration srt:OfficerMember srt:OfficerMember Total liabilities $ 6,576,283 $ 6,505,213 Commitments and contingencies Shareholders' equity: Â Â Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized at June 30, 2024 and December 31, 2023, respectively - 3,979,970 (3,979,970 ADS's) ordinary shares issued and outstanding at June 30, 2024 and 987,220 (987,220 ADS's) at December 31, 2023 0 0 Additional paid in capital 57,982,969 51,867,336 Accumulated deficit (50,504,633) (46,203,320) Total shareholders' equity 7,478,336 5,664,016 Total liabilities and shareholders' equity $ 14,054,619 $ 12,169,229 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-

1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference

7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other and noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Ordinary shares, par value $ 0 $ 0 Ordinary shares, shares authorized 100,000,000 100,000,000 Ordinary shares, shares issued 3,979,970 987,220 Ordinary shares, shares outstanding 3,979,970 987,220 ADSs Â Â Ordinary shares, shares issued 3,979,970 987,220 Ordinary shares, shares outstanding 3,979,970 987,220 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses Â Â Â Â General and administrative $ 1,617,769 $ 1,634,960 $ 3,233,221 $ 3,318,777 Research and development 519,349 625,104 1,362,181 1,716,837 Total operating expenses 2,137,118 2,260,064 4,595,402 5,035,614 Other (income) and expenses Â Â Â Â Unrealized loss 2,177 34,472 8,686 14,045 Realized and accrued interest income (165,262) (187,589) (302,775) (339,643) Total other income (163,085) (153,117) (294,089) (325,598) Net loss $ (1,974,033) $ (2,106,947) $ (4,301,313) $ (4,710,016) Loss per ADS Â Â Â Â Loss per ADS Â Â Â Â Basic $ (0.39) $ (2.13) $ (1.20) $ (5.79) Fully-diluted $ (0.39) $ (2.13) $ (1.20) $ (5.79) Weighted average number of ADS's outstanding Â Â Â Â Basic 5,049,720 987,220 3,576,506 813,187 Fully-diluted 5,049,720 987,220 3,576,506 813,187 X - DefinitionAmount of realized and accrued interest income from investment. + ReferencesNo definition available. + Details Name: qnrx_RealizedAndAccruedInterestIncome Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -

Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses,

Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A + Details Name: us-gaap_UnrealizedGainLossOnDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) Ordinary shares Treasury Stock Additional Paid In Capital Accumulated Deficit ADSs Total Balance at beginning of year at Dec. 31, 2022 Â $ (2,932,000) $ 47,855,521 $ (37,516,747) Â $ 7,406,774 Balance at beginning of year (in shares) at Dec. 31, 2022 403,887 Â Â Â 403,887 Â Net loss Â Â Â (2,603,069) Â (2,603,069) Issuance of ADS's, pre-funded warrants and warrants, net Â Â 5,849,266 Â Â 5,849,266 Issuance of ADS's, pre-funded warrants and warrants, net (in shares) 583,333 Â Â Â 583,333 Â Stock based compensation Â Â 261,472 Â Â 261,472 Balance at end of year at Mar. 31, 2023 Â (2,932,000) 53,966,259 (40,119,816) Â 10,914,443 Balance at ending of year (in shares) at Mar. 31, 2023 987,220 Â Â Â 987,220 Â Balance at beginning of year at Dec. 31, 2022 Â (2,932,000) 47,855,521 (37,516,747) Â 7,406,774 Balance at beginning of year (in shares) at Dec. 31, 2022 403,887 Â Â Â 403,887 Â Net loss Â Â Â Â (4,710,016) Balance at end of year at Jun. 30, 2023 Â (2,932,000) 54,230,635 (42,226,763) Â 9,071,872 Balance at ending of year (in shares) at Jun. 30, 2023 987,220 Â Â Â 987,220 Â Balance at beginning of year at Mar. 31, 2023 Â (2,932,000) 53,966,259 (40,119,816) Â 10,914,443 Balance at beginning of year (in shares) at Mar. 31, 2023 987,220 Â Â Â 987,220 Â Net loss Â Â Â (2,106,947) Â (2,106,947) Stock based compensation Â Â 264,376 Â Â 264,376 Balance at end of year at Jun. 30, 2023 Â $ (2,932,000) 54,230,635 (42,226,763) Â 9,071,872 Balance at ending of year (in shares) at Jun. 30, 2023 987,220 Â Â Â 987,220 Â Balance at beginning of year at Dec. 31, 2023 Â Â 51,867,336 (46,203,320) Â $ 5,664,016 Balance at beginning of year (in shares) at Dec. 31, 2023 987,220 Â Â Â 987,220 987,220 Net loss Â Â Â (2,327,280) Â $ (2,327,280) Issuance of ADS's, pre-funded warrants and warrants, net Â Â 5,482,472 Â Â 5,482,472 Issuance of ADS's, pre-funded warrants and warrants, net (in shares) 2,808,750 Â Â Â 2,808,750 Â Stock based compensation Â Â 306,314 Â Â 306,314 Balance at end of year at Mar. 31, 2024 Â Â 57,656,122 (48,530,600) Â 9,125,522 Balance at ending of year (in shares) at Mar. 31, 2024 3,795,970 Â Â Â 3,795,970 Â Balance at beginning of year at Dec. 31, 2023 Â Â 51,867,336 (46,203,320) Â $ 5,664,016 Balance at beginning of year (in shares) at Dec. 31, 2023 987,220 Â Â Â 987,220 987,220 Net loss Â Â Â Â Â $ (4,301,313) Balance at end of year at Jun. 30, 2024 Â Â 57,982,969 (50,504,633) Â $ 7,478,336 Balance at ending of year (in shares) at Jun. 30, 2024 3,979,970 Â Â Â 3,979,970 3,979,970 Balance at beginning of year at Mar. 31, 2024 Â Â 57,656,122 (48,530,600) Â $ 9,125,522 Balance at beginning of year (in shares) at Mar. 31, 2024 3,795,970 Â Â Â 3,795,970 Â Net loss Â Â Â (1,974,033) Â (1,974,033) Exercise of pre-funded warrants Â Â 18 Â Â 18 Exercise of pre-funded warrants (in shares) 184,000 Â Â Â 184,000 Â Reversal of accrued offering expenses Â Â 13,707 Â Â 13,707 Stock based compensation Â Â 313,122 Â Â 313,122 Balance at end of year at Jun. 30, 2024 Â Â $ 57,982,969 $ (50,504,633) Â $ 7,478,336 Balance at ending of year (in shares) at Jun. 30, 2024 3,979,970 Â Â Â 3,979,970 3,979,970 X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from reversal of the accrued offering expenses associated with the issuance of warrants. + ReferencesNo definition available. + Details Name: qnrx_AdjustmentsToAdditionalPaidInCapitalReversalOfAccruedOfferingCosts Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the exercise of warrants. + ReferencesNo definition available. + Details Name: qnrx_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of pre-funded warrants that are exercised during the current period. + ReferencesNo definition available. + Details Name: qnrx_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows used in operating activities: Â Â Net loss $ (4,301,313) $ (4,710,016) Stock based compensation 619,436 525,848 Amortization of intangibles 50,000 52,022 Unrealized gain and accrued interest on investments (121,026) (230,755) Changes in assets and liabilities: Â Â Increase in accounts payable and accrued expenses 371,070 761,283 Decrease (increase) in prepaid expenses & other assets (59,662) 282,358 Net cash used in operating activities (3,441,495) (3,319,260) Cash flows used in investing activities: Â Â Purchase of investments (9,649,774) (13,491,505) Proceeds from maturity of investments 8,339,000 13,035,000 Net cash used in investing activities (1,310,774) (456,505) Cash flows provided by financing activities: Â Â Payment of amounts due to officers (300,000) (175,000) Proceeds from sale of equity securities, net 5,496,197 5,849,266 Net cash provided by financing activities 5,196,197 5,674,266 Net change in cash and cash equivalents: 443,928 1,898,501 Cash and cash equivalents - beginning of period 2,401,198 2,860,628 Cash and cash equivalents - end of period 2,845,126 4,759,129 Supplemental information - Non cash items: Â Â Offering expenses associated with warrant modification $ 209,225 $ 238,231 X - DefinitionThe net cash inflow from the additional capital contribution to the entity. + ReferencesNo definition available. + Details Name: qnrx_NetProceedsFromIssuanceOfCommonStock Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of offering expenses associated with warrant modification. + ReferencesNo definition available. + Details Name: qnrx_OfferingExpensesAssociatedWithWarrantModification Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-

3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ORGANIZATION AND BUSINESS 6 Months Ended Jun. 30, 2024 ORGANIZATION AND BUSINESS Â ORGANIZATION AND BUSINESS NOTEÂ 1Â â€“ ORGANIZATION AND BUSINESSQuoin Pharmaceuticals Ltd. (â€œQuoin Ltd.,â€ or the â€œCompanyâ€), formerly known as Cellect Biotechnology Ltd. (â€œCellectâ€), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (â€œQuoin Inc.â€). Quoin Inc. was incorporated in Delaware on March 5, 2018. On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the â€œMergerâ€). Immediately after completion of the Merger, Cellect changed its name to â€œQuoin Pharmaceuticals Ltd.â€The Company is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Companyâ€™s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Companyâ€™s first lead product, QRX003, is a topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed InvisicareÂ® technology, is under development as a potential treatment for Netherton Syndrome (â€œNSâ€), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (â€œU.S.â€) under an open Investigational New Drug (â€œINDâ€) application with the Food and Drug Administration (â€œFDAâ€). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (â€œRDEBâ€). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (â€œQUTâ€), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma , and with University College Cork (â€œUCCâ€) for the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. To date, no products have been commercialized and no revenue has been generated. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LIQUIDITY RISKS AND OTHER UNCERTAINTIES 6 Months Ended Jun. 30, 2024 LIQUIDITY RISKS AND OTHER UNCERTAINTIES Â LIQUIDITY RISKS AND OTHER UNCERTAINTIES NOTEÂ 2Â - LIQUIDITY RISKS AND OTHER UNCERTAINTIESThe unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (â€œU.S. GAAPâ€), which contemplates continuation of the Company as a going concern. The Company has incurred net losses every year since inception and has an accumulated deficit of approximately $50.5 million at June 30, 2024. The Company has a limited operating history and has historically funded its operations through debt and equity financings. The Company incurred net losses of approximately $4.3 million, and negative cash flows from operations of $3.4 million for the six months ended June 30, 2024. At June 30, 2024, the Company had cash and cash equivalents balances totaling $2.8 million and investments of $9.7 million. The Company has determined that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these unaudited condensed consolidated financial statements.Additional financing will still be required to complete the research and development of the Companyâ€™s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Companyâ€™s business, results of operations and financial condition.Other risks and uncertainties:The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements.The Companyâ€™s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Companyâ€™s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.There can be no assurance that the Companyâ€™s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed.The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Companyâ€™s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug product for clinical development.On April 29, 2024, the Company received a letter from the Listing Qualifications staff (the â€œStaffâ€) of The Nasdaq Stock Market, LLC (â€œNasdaqâ€) notifying the Company that the closing bid price per ADS of the Company was below the required minimum of $1.00 for a period of 31 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Companyâ€™s ADSs and the ADSs will continue to trade on The Nasdaq Capital Market under the symbol â€œQNRX.â€Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until October 28, 2024 (the â€œCompliance Periodâ€), to regain compliance with Nasdaqâ€™s minimum bid price requirement. Compliance may be achieved without further action if the closing bid price of the Companyâ€™s ADS is at or above $1.00 for a minimum of ten consecutive business days at any time during the Compliance Period, in which case Nasdaq will notify the Company if it determines it is in compliance and the matter will be closed; however Nasdaq may require the closing bid price to equal or to exceed the $1.00 minimum bid price requirement for more than 10 consecutive business days before determining that a company complies. In the event the Company does not regain compliance by October 28, 2024, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held ADSs and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. The Company intends to actively monitor the bid price of its ADS and will consider available options to regain compliance with the Nasdaq listing requirements. X - ReferencesNo definition available. + Details Name: qnrx_SubstantialDoubtAboutGoingConcernAbstract Namespace Prefix: qnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Jun. 30, 2024 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTEÂ 3Â - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of Presentation:The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2023 and for the year then ended which are included in the Companyâ€™s Annual Report on Form 10- K, filed with the SEC on March 14, 2024. The Company operates in one segment.Effective July 18, 2023, the ratio of American Depositary Shares (â€œADSsâ€) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12

reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. Except as specifically provided, ADSs and related option and warrant information presented in these unaudited condensed consolidated financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes.Use of estimates:The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.Cash and cash equivalents:The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.Warrants:The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Companyâ€™s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Companyâ€™s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated its warrants outstanding to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.Investments:Investments as of June 30, 2024 and December 31, 2023 consist of U.S. Treasury Bills and Notes, which are classified as trading securities, totaling $9.7 million and $8.3 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Companyâ€™s U.S. Treasury Bills and Notes held on June 30, 2024 have maturities within one year from the balance sheet date. As of June 30, 2024, the carrying value of the Companyâ€™s U.S. Treasury Bills and Notes approximates their fair value due to their short-term maturities.Long-lived assets:Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10Â years.The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:â—Significant changes in the manner of the Companyâ€™s use of the acquired assets or the strategy for its overall business,â—Significant underperformance relative to expected historical or projected development milestones,â—Significant negative regulatory or economic trends, andâ—Significant technological changes which could render the platform technology obsolete.The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2024 and 2023, there were no impairment indicators which required an impairment loss measurement.Research and development:Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.Stock based compensation:The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.Since the Company has a limited history of trading as a public company, the Companyâ€™s expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.Fair value of financial instruments:The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (â€œASC Topic 820â€). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.â€‹Earnings (loss) per share:The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, other than unexercised prefunded warrants as described below, potential common shares are excluded if their effect is anti-dilutive.For the three and six months ended June 30, 2024, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 8,988,346 ADS and outstanding stock options to purchase 278,011 ADS, and for the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS, respectively, as their inclusion in the denominator would be anti-dilutive. For the three and six months ended June 30, 2024 basic and diluted net earnings (loss) per share included 1,069,750 ADS issuable with respect to unexercised prefunded warrants (See NoteÂ 13). X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED INTEREST AND FINANCING EXPENSE 6 Months Ended Jun. 30, 2024 ACCRUED INTEREST AND FINANCING EXPENSE Â ACCRUED INTEREST AND FINANCING EXPENSE NOTE 4 â€“ ACCRUED INTEREST AND FINANCING EXPENSEOn October 2, 2020, Quoin Inc. issued promissory notes (the â€œ2020 Notesâ€) to certain investors (â€œ2020 Noteholdersâ€). The 2020 Notes were mandatorily convertible into 432 ADSs, subject to adjustment and were converted in 2021. The ADSs issued to the 2020 Noteholders did not include accrued interest. Two of the five 2020 Noteholders received their amount due during the year ended December 31, 2022 and the Companyâ€™s estimate of the liability to the remaining three 2020 Noteholders was estimated to be $1,146,000 as of June 30, 2024 and December 31, 2023.There was no interest expense recognized in both the three and six month periods ended June 30, 2024 and 2023. X - DefinitionThe entire disclosure pertaining to accrued interest and financing expense. + ReferencesNo definition available. + Details Name: qnrx_AccruedInterestAndFinancingExpenseTextBlock Namespace Prefix: qnrx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE OF FINANCIAL INSTRUMENTS 6 Months Ended Jun. 30, 2024 FAIR VALUE OF FINANCIAL INSTRUMENTS Â FAIR VALUE OF FINANCIAL INSTRUMENTS NOTEÂ 5Â - FAIR VALUE OF FINANCIAL INSTRUMENTSThe Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs.In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.â€‹The following table presents the Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2024 and December 31, 2023:â€‹â€‹â€‹

Plan:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â â€‹Â Â Â Â Â WeightedÂ Â Â Â Weightedâ€‹â€‹â€‹â€‹Averageâ€‹Averageâ€‹â€‹ADSÂ Underlyingâ€‹Exerciseâ€‹Contractualâ€‹â€‹Optionsâ€‹Priceâ€‹Te
at December 31, 2023Â 278,011â€‹$ 25.34Â 9.68GrantedÂ â€”â€‹â€‹ â€”Â â€‹Forfeited/CancelledÂ â€”â€‹â€‹ â€”Â â€‹Outstanding at June 30, 2024Â 278,011â€‹$ 25.34Â 9.18â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exercisable options at June 30, 2024Â 14,228â€‹$ 210.00Â 7.83â€‹The intrinsic value of outstanding options at June 30, 2024 was $0.Stock based compensation expense was approximately $313,000 ($68,000 included in research and development expense and $245,000 included in general and administrative expenses) in the three months ended June 30, 2024 and approximately $619,000 ($118,000 included in research and development expense and $501,000 included in general and administrative expenses) in the six months ended June 30, 2024Stock based compensation expense was approximately 264,000 ($34,000 included in research and development expense and $230,000 included in general and administrative expenses) in the three months ended June 30, 2023 and approximately $526,000 ($69,000 included in research and development expense and $457,000 included in general and administrative expenses) in the six months ended June 30, 2023At June 30, 2024, the total unrecognized compensation expense related to non-vested options was approximately $2.4 million and is expected to be recognized over the remaining weighted average service period of approximately 3.25 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PREPAID EXPENSES 6 Months Ended Jun. 30, 2024 PREPAID EXPENSES Â PREPAID EXPENSES NOTEÂ 7Â â€“ PREPAID EXPENSESPrepaid expenses are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Prepaid R&D costsâ€‹$ 649,241â€‹$ 447,979Prepaid insuranceâ€‹Â 159,746â€‹Â 401,972Prepaid expenseâ€‹Â 33,605â€‹Â 8,500Deferred offering costs (note 13)â€‹â€‹ 108,104â€‹â€‹ 32,583Totalâ€‹$ 950,696â€‹$ 891,034Less: Short-term portionâ€‹â€‹ (650,696)â€‹â€‹ (591,034)Long-term portionâ€‹$ 300,000â€‹$ 300,000â€‹ X - DefinitionThe entire disclosure for current prepaid expenses. + ReferencesNo definition available. + Details Name: qnrx_PrepaidExpenseDisclosureTextBlock Namespace Prefix: qnrx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED EXPENSES 6 Months Ended Jun. 30, 2024 ACCRUED EXPENSES Â ACCRUED EXPENSES NOTEÂ 8Â - ACCRUED EXPENSESAccrued expenses are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Research contract expenses (note 12)â€‹â€‹$ 550,391â€‹$ 358,287Payroll (note 11)â€‹Â 611,843â€‹Â 804,156Payroll taxes (note 11)â€‹Â 90,781â€‹Â 93,989Professional feesâ€‹Â 97,622â€‹Â 50,534Other expensesâ€‹Â 35,988â€‹Â 1,740Totalâ€‹$ 1,386,625â€‹$ 1,308,706â€‹ X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 IN-LICENSED TECHNOLOGY 6 Months Ended Jun. 30, 2024 IN-LICENSED TECHNOLOGY Â IN-LICENSED TECHNOLOGY NOTEÂ 9Â â€“ IN-LICENSED TECHNOLOGYSkinvisible:In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the â€œLicense Agreementâ€) with Skinvisible Pharmaceuticals, Inc. (â€œSkinvisibleâ€), under which Skinvisible granted the Company an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. The Company made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the â€œLicense Feeâ€). In addition, the Company agreed to pay Skinvisible a single digit royalty percentage of the Companyâ€™s net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. The Company also agreed to pay Skinvisible 25% of any revenues the Company receives as royalties in the event that the Company sublicenses any licensed products to a third party. The License Agreement also requires that the Company make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder. There were no milestone or royalty obligations due at June 30, 2024 and December 31, 2023.â€‹ X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INTANGIBLE ASSETS 6 Months Ended Jun. 30, 2024 INTANGIBLE ASSETS Â INTANGIBLE ASSETS NOTEÂ 10Â - INTANGIBLE ASSETSIntangible assets are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Technology license â€“ Skinvisibleâ€‹$ 1,000,000â€‹$ 1,000,000Total costâ€‹Â 1,000,000â€‹Â 1,000,000Accumulated amortizationâ€‹Â (466,666)â€‹Â (416,666)Net book valueâ€‹$ 533,334â€‹$ 583,334â€‹The Company recorded amortization expense of approximately $25,000 and $26,000 in the three months ended June 30, 2024 and 2023, respectively. The Company recorded amortization expense of approximately $50,000 and $52,000 in the six months ended June 30, 2024 and 2023, respectively. The annual amortization expense expected to be recorded for existing intangible assets for the years 2024 through 2027, and thereafter, is approximately $50,000, $100,000, $100,000, $100,000 and $183,000, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS 6 Months Ended Jun. 30, 2024 RELATED PARTY TRANSACTIONS Â RELATED PARTY TRANSACTIONS â€‹NOTEÂ 11Â - RELATED PARTY TRANSACTIONSEmployment Agreements and Due to Officers/Founders:Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid by Dr. Myers and Ms. Carter to third parties on behalf of Quoin Inc., were not paid by Quoin Inc. to Dr. Myers and Ms. Carter, and were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to repay the above-described non-interest-bearing indebtedness. The Company repaid $75,000 and $75,000 of such indebtedness to Dr. Myers and $75,000 and $0 to Ms. Carter in the three months ended June 30, 2024 and 2023, respectively. The Company repaid $150,000 and $150,000 of such indebtedness to Dr. Myers and $150,000 and $25,000 to Ms. Carter in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, approximately $1.8 million and $1.4 million of such indebtedness was outstanding to Dr. Myers and Ms. Carter, respectively.Amounts due to officers at June 30, 2024 and December 31, 2023 consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â March 31,Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Salaries and other compensationâ€‹$ 3,223,733Â $ 3,523,733Totalâ€‹$ 3,223,733Â $ 3,523,733Less: Short-term portionâ€‹Â (600,000)Â â€‹ (600,000)Long-term portionâ€‹$ 2,623,733â€‹$ 2,923,733â€‹Interest Payable:See Note 4 for interest payable on the 2020 Notes. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS 6 Months Ended Jun. 30, 2024 RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS NOTEÂ 12Â â€“ RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTSResearch agreementsIn November 2020, Quoin Inc. entered into a Master Service Agreement with Therapeutics Inc. for the management of the preclinical and clinical development of QRX003 for Netherton Syndrome. The initial term of the agreement was three years with automatic one year extensions, and the agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90Â days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million. An additional work order was entered into in December 2022 for a second QRX003 clinical study at an expected estimated cost of approximately $830,000. For the three and six months ended June 30, 2024 and 2023, the Company incurred a research and development expense under these agreements of approximately $162,000 and $650,000 and 360,000 and $959,000 respectively.In November 2021, the Company entered into a research agreement with Queensland University of Technology (QUT) for a pre-clinical research program for the development of a product to treat Netherton Syndrome of approximately $250,000. In May 2022, the Company entered into a second research agreement with QUT for the development of a product to treat Scleroderma of approximately $610,000. Each agreement remains in place until the completion of the research program, which in each case was initially anticipated to be 18 months from execution. For the three and Â six months ended June 30, 2024 the Company did not incur any costs related to these agreements. For the three and six months ended June 30, 2023, the Company incurred research and development costs related to these agreements of approximately $138,000 and $276,000 respectively.On June 10, 2024, the Company signed a research agreement with The School of Pharmacy at UCC. The scope of the agreement encompasses the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. Under the terms of the agreement, based on the achievement of certain milestones, the Company will fund up to approximately â‚¬567,000 ($608,000) plus VAT over an anticipated 2-1/2 year period to support UCC research program to investigate the development of a number of topical rapamycin formulations for future development as potential treatments for several rare and orphan diseases. Following completion of the research program, the Company will have the option to advance the clinical development of rapamycin formulations developed by UCC. The Company incurred no costs related to this agreement in the three and six months ended June 30, 2024.Performance milestones and RoyaltiesSee NoteÂ 9 for asset and in-licensed technology commitments. X - DefinitionThe entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHAREHOLDERS' EQUITY 6 Months Ended Jun. 30, 2024 SHAREHOLDERS' EQUITY Â SHAREHOLDERS' EQUITY NOTEÂ 13Â â€“ SHAREHOLDERSâ€™ EQUITYAlumni Equity Line and Purchase AgreementOn January 25, 2024, the Company entered into a purchase agreement (the â€œAlumni Purchase Agreementâ€) with Alumni Capital LP (â€œAlumniâ€). Pursuant to the Alumni Purchase Agreement, the Company has the right to sell to Alumni up to $8,000,000 (the â€œCommitment Amountâ€) of newly issued ordinary shares that are represented by ADS, subject to certain conditions and limitations, from time to time during the term of the Alumni Purchase Agreement.The Company does not have the right to commence any sales of ordinary shares represented by ADSs to Alumni under the Alumni Purchase Agreement until the date, which the Company refers to as the Commencement Date, that all of the conditions set forth in the Alumni Purchase Agreement have been satisfied, including that the registration statement the Company agreed to file with

the SEC pursuant to the Alumni Purchase Agreement is declared effective by the SEC, and the Companyâ€™s shareholders have approved of the issuance of ADSs under the Alumni Purchase Agreement, which approval was obtained on April 5, 2024. From and after the Commencement Date, the Company may, from time to time and at the Companyâ€™s sole discretion for a period of three months, which the Company at its sole discretion may increase by an additional three months (such period, including any extension, the â€œCommitment Periodâ€), on any business day that the Company may select, direct Alumni to purchase ordinary shares represented by ADSs. The purchase price for the ordinary shares represented by ADSs the Company may sell to Alumni will be based upon formulas set forth in the Alumni Purchase Agreement based on the then current market price of the ADSs as computed under the Alumni Purchase Agreement and will depend on the type of purchase notice the Company submits to Alumni from time to time. There is no upper limit on the price per share that Alumni could be obligated to pay for the ADSs under the Alumni Purchase Agreement; provided, however at no time can the purchase price be below a floor price of $1.00 per share (subject to adjustment). The Company agreed to issue purchase notices for an aggregate of at least $4,000,000 of the Commitment Amount prior to the end of the Commitment Period.As consideration for Alumniâ€™s irrevocable commitment to purchase ADSs under the Alumni Purchase Agreement, the Company agreed to issue to Alumni, at the times set forth in the Alumni Purchase Agreement beginning with the trading day after the Commencement Date, a number of ADSs with a value at the time of issuance not to exceed $240,000 in the aggregate (the â€œCommitment Securitiesâ€). The Company may pay cash in lieu of issuing all or any portion of the Commitment Securities.Public Offering On March 7, 2024, (the â€œ2024 Closing Dateâ€) the Company completed an offering (the â€œ2024 Offeringâ€) of the following securities (i) 811,250 ordinary shares represented by ADSs, (ii) 4,062,500 Series D warrants (the â€œSeries D Warrantsâ€) to purchase 4,062,500 ordinary shares represented by ADSs, (iii) 4,062,500 Series E warrants (the â€œSeries E Warrantsâ€ and together with the Series D Warrants, the â€œ2024 Warrantsâ€) to purchase 4,062,500 ordinary shares represented by ADSs, and (iv) 3,251,250 pre-funded warrants (the â€œ2024 Pre-Funded Warrantsâ€) to purchase 3,251,250 ordinary shares represented by ADSs for aggregate gross proceeds of approximately $6.5 million, resulting in net proceeds of approximately $5.5 million, after deducting the placement agentâ€™s fees and offering expenses paid by the Company. Each ADS (or 2024 Pre-Funded Warrant to purchase one ADS in lieu thereof) was sold together with a Series D Warrant to purchase one ADS and a Series E Warrant to purchase one ADS. The ADSs and accompanying 2024 Warrants were sold at a combined public offering price of $1.60 and the 2024 Pre-Funded Warrants and accompanying 2024 Warrants were sold at a combined public offering price of $1.5999, which is equal to the combined purchase price per ADS and accompanying 2024 Warrants, minus the exercise price of each 2024 Pre-Funded Warrant of $0.0001. The Series D and Series E warrants have an exercise price of $1.60 per share, were exercisable immediately following the 2024 Closing Date and expire in two years and five years, respectively, from the closing of the 2024 Offering. As of June 30, 2024, 2,181,500 2024 Pre-Funded Warrants have been exercised and are included in issued and outstanding ADSs. In connection with the 2024 Offering, the Company entered into a Securities Purchase Agreement (the â€œ2024 Purchase Agreementâ€) dated March 4, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the ADSs, 2024 Pre-Funded Warrants and 2024 Warrants sold in the 2024 Offering. Pursuant to the terms of the 2024 Purchase Agreement, the Company agreed, subject to certain exceptions, (i) to not enter into variable rate financings for a period of 180 days following the closing of the 2024 Offering, and (ii) to not enter into any equity financings for 90 days from closing of the 2024 Offering.On March 7, 2024, the Company also entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 638,834 ADSs, 207,499 of which were warrants issued in the Companyâ€™s 2022 public offering and 431,335 of which were warrants issued in the Companyâ€™s 2023 public offering (collectively, the â€œPrior Warrantsâ€) to, among other things, reduce the exercise price of such Prior Warrants to $1.60 and to extend the current expiration date of the Prior Warrants until March 7, 2029. The incremental fair value of the modified warrants was approximately $209,000, which was accounted for as an offering expense in connection with the 2024 Offering.WarrantsThe following table summarizes warrant activities during the six months ended June 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â WeightedÂ â€‹â€‹ADSsâ€‹AverageÂ â€‹â€‹UnderlyingâŠExerciseÂ PriceÂ â€‹â€‹Warrantsâ€‹Per ADSâ€‹Outstanding and exercisable at December 31, 2023â€‹ 864,081Â $ 16.13*Granted Common WarrantsÂ 8,125,000â€‹â€‹ 1.60â€‹Granted Pre-Funded WarrantsÂ 3,251,250â€‹Â â€”â€‹Exercised Pre-Funded Warrants Â (2,181,500)â€‹â€‹ â€”â€‹TerminatedÂ (735)â€‹Â 1,650.00â€‹Outstanding and exercisable at June 30, 2024â€‹ 10,058,096â€‹$ 1.87â€‹â€‹As of June 30, 2024, outstanding common warrants expire in 2026, 2027 and 2029, and the outstanding pre-funded warrants have an approximate intrinsic value of $620,000.* Note that the exercise price of certain existing outstanding warrants to purchase up to 638,834 ADSs was reduced from $12.00 and $13.20 to $1.60 on March 7, 2024, see above. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONTINGENCIES 6 Months Ended Jun. 30, 2024 CONTINGENCIES Â CONTINGENCIES NOTEÂ 14Â â€“ CONTINGENCIESFrom time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the unaudited condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450-20/tableOfContentReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450-30/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1 + Details Name: us-gaap_LossContingencyDisclosures Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LICENSE AGREEMENTS 6 Months Ended Jun. 30, 2024 LICENSE AGREEMENTS Â LICENSE AGREEMENTS NOTEÂ 15Â â€“ LICENSE AGREEMENTSAs of June 30, 2024, the Company had nine commercial license and supply agreements outstanding, whereby the Company will receive a royalty or other proceeds from the specified product revenues from the licensor, if and when the underlying products are approved and commercialized or sold via compassionate use or early access programs. No royalty revenues have been received through June 30, 2024 from any of these agreements. X - ReferencesNo definition available. + Details Name: qnrx_LicenseAgreementsAbstract Namespace Prefix: qnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for license agreements. + ReferencesNo definition available. + Details Name: qnrx_LicenseAgreementsDisclosureTextBlock Namespace Prefix: qnrx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Net Income (Loss) $ (1,974,033) $ (2,327,280) $ (2,106,947) $ (2,603,069) $ (4,301,313) $ (4,710,016) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 6 Months Ended Jun. 30, 2024 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Basis of Presentation: Basis of Presentation:The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2023 and for the year then ended which are included in the Companyâ€™s Annual Report on Form 10- K, filed with the SEC on March 14, 2024. The Company operates in one segment.Effective July 18, 2023, the ratio of American Depositary Shares (â€œADSsâ€) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. Except as specifically provided, ADSs and related option and warrant information presented in these unaudited condensed consolidated financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes. Use of estimates: Use of estimates:The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations. Cash and cash equivalents: Cash and cash equivalents:The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Warrants: Warrants:The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Companyâ€™s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Companyâ€™s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated its warrants outstanding to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. Investments: Investments:Investments as of June 30, 2024 and December 31, 2023 consist of U.S. Treasury Bills and Notes, which are classified as trading securities, totaling $9.7 million and $8.3 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Companyâ€™s U.S. Treasury Bills and Notes held on June 30, 2024 have maturities within one year from the balance sheet date. As of June 30, 2024, the carrying value of the Companyâ€™s U.S. Treasury Bills and Notes approximates their fair value due to their short-term maturities. Long-lived assets: Long-lived assets:Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10Â years.The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:â—Significant changes in the manner of the Companyâ€™s use of the acquired assets or the strategy for its overall business,â—Significant underperformance relative to expected historical or projected development milestones,â—Significant negative regulatory or economic trends, andâ—Significant technological changes which could render the platform technology obsolete.The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2024 and 2023, there were no impairment indicators which required an impairment loss measurement. Research and development: Research and development:Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered. Stock based compensation: Stock based compensation:The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.Since the Company has a limited history of trading as a public company, the Companyâ€™s expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future. Fair value of financial instruments: Fair value of financial instruments:The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (â€œASC Topic 820â€). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Earnings (loss) per share: Earnings (loss) per share:The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, other than unexercised prefunded warrants as described below, potential common shares are excluded if their effect is anti-dilutive.For the three and six months ended June 30, 2024, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 8,988,346 ADS and outstanding stock options to purchase 278,011 ADS, and for the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS, respectively, as their inclusion in the denominator would be anti-dilutive. For the three and six months ended June 30, 2024 basic and diluted net earnings (loss) per share included 1,069,750 ADS issuable with respect to unexercised prefunded warrants (See NoteÂ 13). X - DefinitionDisclosure of accounting policy for warrants. + ReferencesNo definition available. + Details Name: qnrx_WarrantsPolicyPolicyTextBlock Namespace Prefix: qnrx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-

gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) 6 Months Ended Jun. 30, 2024 FAIR VALUE OF FINANCIAL INSTRUMENTS Â Schedule of assets and liabilities measured at fair value on a recurring basis â€‹â€‹â€‹

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ in Millions 6 Months Ended Nov. 08, 2023 shares Jul. 18, 2023 shares Jun. 30, 2024 USD ($) segment Dec. 31, 2023 USD ($) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Number of operating segments | segment Â Â 1 Â Number of shares represented for one ADS Â 60,000 Â Â Shares owned (as a percent) Â 0.083% Â Â Reverse stock split 1.67 Â Â Â Number of ordinary shares for ADS 60,000 Â Â Â U.S. Treasury Bills | $ Â Â $ 9.7 $ 8.3 Maturity term Â Â 1 year Â Minimum Â Â Â Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Number of shares represented for one ADS Â 5,000 Â Â ADSs Â Â Â Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Number of ordinary shares for ADS 1 Â Â Â Â X - DefinitionDuration of investments maturity term. + ReferencesNo definition available. + Details Name: qnrx_InvestmentsMaturityTerm Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of ordinary shares for each American Depositary Shares. + ReferencesNo definition available. + Details Name: qnrx_NumberOfOrdinarySharesForAmericanDepositaryShares Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the number of shares represented for one American depositary share. + ReferencesNo definition available. + Details Name: qnrx_NumberOfSharesRepresentedForOneAmericanDepositaryShare Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage of entity's shares owned. + ReferencesNo definition available. + Details Name: qnrx_SharesOwnedPercentage Namespace Prefix: qnrx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_TradingSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Intangible assets, useful life 10 years Â 10 years Â Impairment loss measurement $ 0.0 $ 0.0 $ 0.0 $ 0.0 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) - ADSs - shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pre-Funded Warrants Â Â Â Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Unexercised prefunded warrants Â Â 1,069,750 Â Employee Stock Option Â Â Â Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Antidilutive securities 278,011 25,595 278,011 25,595 Outstanding warrants Â Â Â Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Antidilutive securities 8,988,346 864,068 8,988,346 864,068 X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of prefunded warrants. + ReferencesNo definition available. + Details Name: qnrx_IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrants Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance

Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qnrx_OutstandingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED INTEREST AND FINANCING EXPENSE (Details) 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) item Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) item Dec. 31, 2022 item Dec. 31, 2021 shares ACCRUED INTEREST AND FINANCING EXPENSE Â Â Â Â Â Â Â Number of notes holders who received consideration | item Â Â Â Â Â 2 Â Accrued interest and financing expense | $ $ 1,146,251 Â $ 1,146,251 Â $ 1,146,251 Â Â Convertible notes 2020 Â Â Â Â Â Â Â Â ACCRUED INTEREST AND FINANCING EXPENSE Â Â Â Â Â Â Â Â Total number of notes holders | item Â Â Â Â Â Â 5 Â Number of remaining noteholders | item Â Â 3 Â 3 Â Â Accrued interest and financing expense | $ 1,146,000 Â $ 1,146,000 Â $ 1,146,000 Â Â Interest expense | $ $ 0 $ 0 $ 0 $ 0 Â Â Â Convertible notes 2020 | Convertible Notes Warrants, Common Stock Â Â Â Â Â Â Â ACCRUED INTEREST AND FINANCING EXPENSE Â Â Â Â Â Â Â Shares issued upon conversion | shares Â Â Â Â Â Â Â 432 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: qnrx_AccruedInterestAndFinancingExpenseLineItems Namespace Prefix: qnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the number of noteholders. + ReferencesNo definition available. + Details Name: qnrx_ConvertibleNotesPayableNumberOfNoteholders Namespace Prefix: qnrx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the number of noteholders who received consideration. + ReferencesNo definition available. + Details Name: qnrx_ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration Namespace Prefix: qnrx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the number of remaining noteholders who received consideration. + ReferencesNo definition available. + Details Name: qnrx_ConvertibleNotesPayableNumberOfRemainingNoteholdersReceiveConsideration Namespace Prefix: qnrx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShortTermDebtTypeAxis=qnrx_Convertiblenotes2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_ConvertibleNotesWarrantsCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) - Recurring - USD ($) Jun. 30, 2024 Dec. 31, 2023 FAIR VALUE OF FINANCIAL INSTRUMENTS Â Â Warrant liability $ 9,725,463 $ 8,293,663 US Treasury Bills Â Â FAIR VALUE OF FINANCIAL INSTRUMENTS Â Â Warrant liability 9,725,463 8,293,663 Level 1 Â Â FAIR VALUE OF FINANCIAL INSTRUMENTS Â Â Warrant liability 9,725,463 8,293,663 Level 1 | US Treasury Bills Â Â FAIR VALUE OF FINANCIAL INSTRUMENTS Â Â Warrant liability $ 9,725,463 $ 8,293,663 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK BASED COMPENSATION (Details) - Amended plan 6 Months Ended Jun. 30, 2024 shares STOCK BASED COMPENSATION Â Percentage of ordinary shares reserved for issuance 15.00% Number of ordinary shares reserved for future issuance 2,147,412 Number of shares available for issuance 1,869,401 ADSs Â STOCK BASED COMPENSATION Â Number of ordinary shares reserved for future issuance 2,147,412 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-

types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=qnrx_AmendedAndRestatedEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK BASED COMPENSATION - Stock-based activities (Details) - $ / shares 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Weighted Average Exercise Price Â Â Outstanding at beginning of the period $ 16.13 Â Forfeited/Cancelled (in dollars per share) 1,650.00 Â Outstanding at the end of the period $ 1.87 $ 16.13 ADSs Â Â ADS Underlying Options Â Â Number of options outstanding at beginning of period 864,081 Â Forfeited/Cancelled (in shares) (735) Â Number of Options outstanding at end of period 10,058,096 864,081 Amended plan | ADSs Â Â ADS Underlying Options Â Â Number of options outstanding at beginning of period 278,011 Â Number of Options outstanding at end of period 278,011 278,011 Exercisable options (in shares) 14,228 Â Weighted Average Exercise Price Â Â Outstanding at beginning of the period $ 25.34 Â Outstanding at the end of the period 25.34 $ 25.34 Exercisable options (in dollars per share) $ 210.00 Â Weighted Average Contractual Terms Â Â Contractual term (in years) 9 years 2 months 4 days 9 years 8 months 4 days Exercisable options (in years) 7 years 9 months 29 days Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=qnrx_AmendedAndRestatedEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK BASED COMPENSATION - Stock based compensation expense (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 STOCK BASED COMPENSATION Â Â Â Â Intrinsic value of outstanding options $ 0 Â $ 0 Â Stock-based compensation expense 313,000 $ 264,000 619,000 $ 526,000 Unrecognized stock compensation expense 2,400,000 Â $ 2,400,000 Â Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period Â Â 3 years 3 months Â Research and Development Expense Â Â Â Â STOCK BASED COMPENSATION Â Â Â Â Stock-based compensation expense 68,000 34,000 $ 118,000 69,000 General and Administrative Expense Â Â Â Â STOCK BASED COMPENSATION Â Â Â Â Stock-based compensation expense $ 245,000 $ 230,000 $ 501,000 $ 457,000 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PREPAID EXPENSES (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 PREPAID EXPENSES Â Â Prepaid R&D costs $ 649,241 $ 447,979 Prepaid insurance 159,746 401,972 Prepaid expense 33,605 8,500 Deferred offering costs 108,104 32,583 Total 950,696 891,034 Less: Short-term portion (650,696) (591,034) Long-term portion $ 300,000 $ 300,000 X - DefinitionAmount of asset related to research and development costs paid in advance that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: qnrx_PrepaidResearchAndDevelopmentCosts Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSpecific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1 + Details Name: us-gaap_DeferredOfferingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED EXPENSES (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 ACCRUED EXPENSES Â Â Research contract expenses $ 550,391 $ 358,287 Payroll 611,843 804,156 Payroll taxes 90,781 93,989 Professional fees 97,622 50,534 Other expenses 35,988 1,740 Total $ 1,386,625 $ 1,308,706 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for research contract expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: qnrx_AccruedResearchContractExpenseCurrent Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and

utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedPayrollTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 IN-LICENSED TECHNOLOGY - Skinvisible (Details) - Skinvisible Licensing agreement $ in Millions 1 Months Ended Oct. 31, 2019 USD ($) IN-LICENSED TECHNOLOGY Â License Fee $ 1 Percentage of revenues to be paid 25.00% Amount of payment to be made $ 5 X - DefinitionRepresents the percentage of revenues to be paid under asset acquisition. + ReferencesNo definition available. + Details Name: qnrx_AssetAcquisitionPercentageOfRevenuesToBePaid Namespace Prefix: qnrx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=qnrx_SkinvisibleLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INTANGIBLE ASSETS (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 INTANGIBLE ASSETS Â Â Total cost $ 1,000,000 $ 1,000,000 Accumulated amortization (466,666) (416,666) Net book value 533,334 583,334 Technology license - Skinvisible Â Â INTANGIBLE ASSETS Â Â Total cost $ 1,000,000 $ 1,000,000 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INTANGIBLE ASSETS - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 INTANGIBLE ASSETS Â Â Â Â Amortization of intangibles $ 25,000 $ 26,000 $ 50,000 $ 52,022 Expected amortization expense Â Â Â Â 2024 50,000 Â 50,000 Â 2025 100,000 Â 100,000 Â 2026 100,000 Â 100,000 Â 2027 100,000 Â 100,000 Â Thereafter $ 183,000 Â $ 183,000 Â X - DefinitionFinite Lived Intangible Assets Amortization After Year Four + ReferencesNo definition available. + Details Name: qnrx_FiniteLivedIntangibleAssetsAmortizationAfterYearFour Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 RELATED PARTY TRANSACTIONS Â Â Â Â Â Non-bearing interest indebtedness Â Â $ 300,000 $ 175,000 Â Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember Â srt:OfficerMember Â srt:OfficerMember Dr. Myers Â Â Â Â Â Â RELATED PARTY TRANSACTIONS Â Â Â Â Â Â Non-bearing interest indebtedness $ 75,000 $ 75,000 $ 150,000 150,000 Â Other Liability, Related Party, Type [Extensible Enumeration] us-gaap:RelatedPartyMember Â us-gaap:RelatedPartyMember Â Â Outstanding indebtedness $ 1,800,000 Â $ 1,800,000 Â Â Monthly payment amount Â Â 25,000 Â Â Ms. Carter Â Â Â Â Â Â RELATED PARTY TRANSACTIONS Â Â Â Â Â Â Non-bearing interest indebtedness $ 75,000 $ 0 $ 150,000 $ 25,000 Â Other Liability, Related Party, Type [Extensible Enumeration] us-

gaap:RelatedPartyMember Â us-gaap:RelatedPartyMember Â Â Outstanding indebtedness $ 1,400,000 Â $ 1,400,000 Â Â Monthly payment amount Â Â $ 25,000 Â Â X - DefinitionThe amount of monthly payment to related party. + ReferencesNo definition available. + Details Name: qnrx_PaymentToRelatedPartyPerMonth Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates status and type of related party for liability classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount due from parties in nontrade transactions, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=qnrx_Dr.MyersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=qnrx_Ms.CarterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 RELATED PARTY TRANSACTIONS Â Â Total $ 3,223,733 $ 3,523,733 Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember Less: Short-term portion $ (600,000) $ (600,000) Other Liability, Current, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember Long-term portion $ 2,623,733 $ 2,923,733 Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember Salaries and other compensation Â Â RELATED PARTY TRANSACTIONS Â Â Total $ 3,223,733 $ 3,523,733 Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other and noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=qnrx_SalaryAndOtherCompensationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) 1 Months Ended 3 Months Ended 6 Months Ended Jun. 10, 2024 USD ($) Jun. 10, 2024 EUR (â‚¬) Nov. 30, 2020 Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2022 USD ($) Jun. 30, 2022 USD ($) May 31, 2022 USD ($) Nov. 30, 2021 USD ($) RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â Â $ 519,349 $ 625,104 $ 1,362,181 $ 1,716,837 Â Â Â Â Research and consulting agreement | Therapeutics Inc. Â Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â Â 162,000 360,000 650,000 959,000 Â Â Â Â Research and consulting agreement | Scleroderma Â Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total amount of agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 610,000 Â Research and development Â Â Â 0 $ 138,000 0 $ 276,000 Â Â Â Â Research and consulting agreement | The School of Pharmacy at UCC Â Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â Â $ 0 Â $ 0 Â Â Â Â Â Maximum funding amount $ 608,000 â‚¬ 567,000 Â Â Â Â Â Â Â Â Â Commitment period 2 years 6 months 2 years 6 months Â Â Â Â Â Â Â Â Â Â Consulting agreements | Netherton Syndrome Â Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total amount of agreement Â Â Â Â Â Â Â Â Â Â Â Â $ 250,000 Consulting agreements | Therapeutics Inc. Â Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial term Â Â 3 years Â Â Â Â Â Â Â Â Written termination notice period Â Â 90 days Â Â Â Â Â Â Â Â Total amount of agreement Â Â Â Â Â Â Â $ 830,000 $ 4,400,000 Â Â X - DefinitionPeriod of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: qnrx_AgreementInitialTerm Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: qnrx_AgreementWrittenTerminationNotice Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of fee per consulting or service agreement. + ReferencesNo definition available. + Details Name: qnrx_ConsultingOrServiceAgreementAgreedAmount Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum liability for the entity in relation to the funding for the research agreement entered into. + ReferencesNo definition available. + Details Name: qnrx_ResearchAgreementMaximumFundingAmount Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_LongtermPurchaseCommitmentPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=qnrx_TherapeuticsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=qnrx_SclerodermaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=qnrx_SchoolOfPharmacyAtUccMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=qnrx_ConsultingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=qnrx_NethertonSyndromeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHAREHOLDERS' EQUITY (Details) - USD ($) 3 Months Ended Mar. 07, 2024 Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2024 Jan. 25, 2024 Dec. 31, 2023 Nov. 08, 2023 SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Ordinary shares, shares authorized Â Â Â 100,000,000 Â 100,000,000 Â Number of ordinary shares for ADS Â Â Â Â Â Â Â Â 60,000 Accrued expenses Â Â Â $ 1,386,625 Â $ 1,308,706 Â Warrant Amendments Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Incremental fair value $ 209,000 Â Â Â Â Â Â Â Â Prior Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Warrants, exercise price of warrants (in dollars per share) $ 1.60 Â Â Â Â Â Â Â Â Shares warrants may purchase 638,834 Â Â Â Â Â Â Â Â Minimum | Prior Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Warrants, exercise price of warrants (in dollars per share) Â Â Â Â $ 12.00 Â Â Â Â Maximum | Prior Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Warrants, exercise price of warrants (in dollars per share) Â Â Â Â $ 13.20 Â Â Â Â Public Offering 2022 | Prior Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Warrants issued (in shares) 207,499 Â Â Â Â Â Â Â Â Public Offering 2023 | Prior Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Warrants issued (in shares) 431,335 Â Â Â Â Â Â Â Â Public Offering 2024 Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Net proceeds from offering $ 5,500,000 Â Â Â Â Â Â Â Â Aggregate gross proceeds $ 6,500,000 Â Â Â Â Â Â Â Â Threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering 180 days Â Â Â Â Â Â Â Â Threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering 90 days Â Â Â Â Â Â Â Â Public Offering 2024 | Series D Warrants Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Â Shares warrants may purchase 4,062,500 Â Â Â Â Â Â Â Â Warrants issued (in shares) 4,062,500 Â Â Â Â Â Â Â Â Number of ordinary shares for

each ADS 1 Â Â Â Â Â Â Public Offering 2024 | Series E Warrants Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Shares warrants may purchase 4,062,500 Â Â Â Â Â Â Warrants issued (in shares) 4,062,500 Â Â Â Â Â Â Number of ordinary shares for each ADS 1 Â Â Â Â Â Â Public Offering 2024 | 2024 Pre-Funded Warrants Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Warrants, exercise price of warrants (in dollars per share) $ 0.0001 Â Â Â Â Â Â Shares warrants may purchase 3,251,250 Â Â Â Â Â Â Warrants issued (in shares) 3,251,250 Â Â Â Â Â Â Number of ordinary shares for each ADS 1 Â Â Â Â Â Â Combined public offering price $ 1.60 Â Â Â Â Â Â Warrant maturity term 2 years Â Â Â Â Â Â Public Offering 2024 | 2024 Warrants Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Warrants, exercise price of warrants (in dollars per share) $ 1.60 Â Â Â Â Â Â Combined public offering price $ 1.5999 Â Â Â Â Â Â Warrant maturity term 5 years Â Â Â Â Â Â Alumni Purchase Agreement Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Commitment amount Â Â Â Â $ 8,000,000 Â Â Minimum commitment amount Â Â Â Â $ 4,000,000 Â Â Floor price Â Â Â Â $ 1.00 Â Â Maximum commitment securities value Â Â Â Â $ 240,000 Â Â ADSs Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Number of ordinary shares for ADS Â Â Â Â Â Â 1 Issuance of ADS's, pre-funded warrants and warrants, net (in shares) Â 2,808,750 583,333 Â Â Â ADSs | Pre-Funded Warrants Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Number of warrants or rights exercised Â Â Â 2,181,500 Â Â Â ADSs | Public Offering 2024 Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY Â Â Â Â Â Â Â Issuance of ADS's, pre-funded warrants and warrants, net (in shares) 811,250 Â Â Â Â Â Â Â X - DefinitionThe amount of cash inflow associated with aggregate gross proceeds from offering. + ReferencesNo definition available. + Details Name: qnrx_AggregateGrossProceedsFromIssuanceOffering Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of warrants or rights exercised as of reporting date. + ReferencesNo definition available. + Details Name: qnrx_ClassOfWarrantOrRightExercised Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants issued during the period. + ReferencesNo definition available. + Details Name: qnrx_ClassOfWarrantOrRightIssued Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionMaturity term of class of warrants or rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: qnrx_ClassOfWarrantOrRightMaturityTerm Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe combined public offering price. + ReferencesNo definition available. + Details Name: qnrx_CombinedPublicOfferingPrice Namespace Prefix: qnrx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe floor price per share. + ReferencesNo definition available. + Details Name: qnrx_FloorPrice Namespace Prefix: qnrx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum commitment amount related to right to sell newly issued ordinary shares that are represented by ADS. + ReferencesNo definition available. + Details Name: qnrx_MaximumCommitmentAmount Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum value of commitment securities that can be issued at the times set forth under the agreement. + ReferencesNo definition available. + Details Name: qnrx_MaximumCommitmentSecuritiesValueAtTimesSetForthUnderAgreement Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe minimum commitment amount for which purchase notices agreed to be issued. + ReferencesNo definition available. + Details Name: qnrx_MinimumCommitmentAmountForWhichPurchaseNoticesAgreedToBeIssued Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's offering of stock to the public net of issuance costs. + ReferencesNo definition available. + Details Name: qnrx_NetProceedsFromIssuancePublicOfferingAfterIssuanceCosts Namespace Prefix: qnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of ordinary shares for each American Depositary Shares. + ReferencesNo definition available. + Details Name: qnrx_NumberOfOrdinarySharesForAmericanDepositaryShares Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of ordinary shares for each American Depositary Shares. + ReferencesNo definition available. + Details Name: qnrx_NumberOfOrdinarySharesForEachAmericanDepositaryShares Namespace Prefix: qnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering. + ReferencesNo definition available. + Details Name: qnrx_ThresholdPeriodForNotToEnterIntoAgreementToEffectVariableRateTransactionAfterClosingDateOfOffering Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering + ReferencesNo definition available. + Details Name: qnrx_ThresholdPeriodForNotToIssueEnterIntoAnyAgreementToIssueOrAnnounceIssuanceOrProposedIssuanceOfAnyAdssAfterClosingDateOfOffering Namespace Prefix: qnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EquityClassOfTreasuryStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of warrants not settleable in cash classified as equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_WarrantAmendmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PriorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=qnrx_PublicOffering2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=qnrx_PublicOffering2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=qnrx_PublicOffering2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesDWarrantsAmericanDepositarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesEWarrantsAmericanDepositarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesWarrantsAmericanDepositaryShares2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=qnrx_AlumniPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHAREHOLDERS' EQUITY - Warrants (Details) - USD ($) 6 Months Ended Jun. 30, 2024 Mar. 07, 2024 Weighted Average Exercise Price Per Share Â Â Outstanding at beginning of the period $ 16.13 Â Terminated (in dollars per share) 1,650.00 Â Outstanding at the end of the period $ 1.87 Â Intrinsic value of outstanding options $ 0 Â Common Warrants Â Â Weighted Average Exercise Price Per Share Â Â Granted $ 1.60 Â Prior Warrants Â Â Weighted Average Exercise Price Per Share Â Â Shares warrants may purchase Â 638,834 Warrants, exercise price of warrants (in dollars per share) Â $ 1.60 Prior Warrants | Minimum Â Â Weighted Average Exercise Price Per Share Â Â Warrants, exercise price of warrants (in dollars per share) 12.00 Â Prior Warrants | Maximum Â Â Weighted Average Exercise Price Per Share Â Â Warrants, exercise price of warrants (in dollars per share) $ 13.20 Â ADSs Â Â ADSs Underlying Warrants Â Â Number of options outstanding at beginning of period 864,081 Â Terminated (in shares) (735) Â Number of Options outstanding at end of period 10,058,096 Â Weighted Average Exercise Price Per Share Â Â Intrinsic value of outstanding options $ 620,000 Â ADSs | Common Warrants Â Â ADSs Underlying Warrants Â Â Granted 8,125,000 Â ADSs | Pre-Funded Warrants Â Â ADSs Underlying Warrants Â Â Granted 3,251,250 Â Exercised (2,181,500) Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PriorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=qnrx_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LICENSE AGREEMENTS (Details) 6 Months Ended Jun. 30, 2024 USD ($) agreement LICENSE AGREEMENTS Â Number of license and supply agreements entered | agreement 9 Royalty revenues | $ $ 0 X - ReferencesNo definition available. + Details Name: qnrx_LicenseAgreementsAbstract Namespace Prefix: qnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new license and supply agreements entered during the period. + ReferencesNo definition available. + Details Name: qnrx_NumberOfLicenseAndSupplyAgreementsEntered Namespace Prefix: qnrx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAncillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyIncomeNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|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{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ŸG+0 MX]!2TB M4P2.$/8\/#>7#_0+VYS2,B3;.HME=D."R(L":?8&Q5Z@:@FH6FK:) PJ[+@3 M#'0,&].Q/[G5!F5DH&HQ5G"TF:VVBJ/-;+5!.1J6H:!VJTT&CD9><+S+=JM- M#%&:ODS6C\Z HC10M=2P1=ARNK&_ R0C>DBFVVKKL]H.2E"U&%0M 55+0=48 MD3':1Z4N(FCFQC09.!HQYFB:FQK*B[5>V;IO@+(U(G,I+XA"$T?=DH4*2\\ MUW.I/WW,(04M(B,JYQR#\/R2,O;T[$%'FV- =AC<^U!;+_(E$022OQ_0ELG8/ M]E%'V&<=#9N$&20<^SL@-&\)#&SQ#)#:5E!N!JH6$P5R4N^D%"GG=E*@162] MVOG(U>ZDR$#%R M.=]ENIHC,?=2;*7VAK T$16&@;JEIDS"HL.-^,* PHD=A MVB49*/H"58M!U1(B0Z@+% 74E: _,H/#+).[8V % _$3W^2K[Q>ILW1^RMX-U* MOT&Q%ZA:3&2FA,+I- WZT"*H&M.7?^SQ@,.('H+QT!X,HGM$+J72V9Z,O MA;63H @,5"TU;!$&%77L^7# B)Z ?>2/O&ZRHO,JVV[K ^_V4W>\[B[B_%MW M/T/YTIX;O:[U" K]%+6 M[Q@!A6-4!DL$$7F]#1HU!55CRW48FSS ,6I\@LR6C^B5K3T'96=4<3!+S4<4 M*>? X"&@1F2*PEH_0@7E1&^;U$CY"97BDYB/Z$EF[!WIR#%0M-6T29I#PV=_ U MV2O[NG<^BHVOV!HW3L'O1$[W;2 DZN??*#Y_::N'XUO\E=M6^V/^"]YMN-U MET^4$L#!!0 ("J "%DN[[K)GP4 +<5 8 M >&PO=V]R:W-H965T&ULK5A;]LV%/XKA#<4+=#4(G5/ M$P.-NV(=T"YHT.V9EFB;]"1Z)&4W_?4[!!S)EB@U!9R'6)?#H^\[=_+F(.0W MM65,H^]E4:G;V5;KW?%KK(M*ZEZ(W:L@C=&(4NJX59NYFHG&?.&;%9[T=>VP M!Z:_[NXEW,U;+3DO6:6XJ)!DZJO9.WR0)(%98"7^X>R@3JZ1H;(2XINY^9C? MSCR#B!4LTT8%A9\]6[*B,)H QW]'I;/VFV;AZ?63]@^6/)!94<66HOB7YWI[M.TMF*&=K6A?ZBSC\R8Z$0J,O$X6R_]&AD8V[&P$Y+B#]!<'(O^XP+=$V26UGNJZ>)&B@.21AJTF0MK&[L:V/#*N/%! M2WC+89U>+$65@U-8CN!*B8+G5,/-@X8?\)962*S1DJHM^@ >5^AE7=$ZYR#S M"EVAKP_OTJO0'_#Y_'S]"'BT/,@3 MCSLRJ?"ONGJ#?.\U(AX)''B6SU_N3\#Q6[/Z5I_9E9CL;6U6&V,RRL$F2>I MYM6F"5VN5/'&6BA++*HJ"DL+K"-IO $0X33P(]Z4(=B(0F3('$#C5]@T230 M=Z60FO^PX$PR\DK3:L-7!?,:-AJ"\."O!J4A!9%/W$CC%FD\B?1K!8VDX#_ MHAMH((A6.<1Z)FN; J!!A&D$)'BUARM;75P,X@&V*TRP1_KF=L@1WXO#T,TB M:5DDTZF[!?,R95*6*L6@ AH>!:9J$T/V-%'"@%WYE'VW>2,.PC3@6M\R-FX'X5#L3C")/"=#L1>U].\20[O MV9'#2WYD\\K0 6OM*.^0HQ>TW+U%0F^9//K:VB-U$'? M&T_W[LI,L9RA=92E#!TZEIR_?@<^,$ 5.+[Z; -.02Q[_GAJ>0Y M^*Z]X^G^/D@:5] YP0_;.%@4JM?0]@[)((S&+=^U?!P]-V=V4NPYS,AH]8C6 MO*5)IR\F1PI? CEO+J3MW!C=5(&GQXI[^F@BS<0=+9M^E-<,:0%/UCQCTNU& MQWC@>XY1R"6(XXD0[8)/-FH>_FC:&%3G_U7FRQ2+#/I!!Y\C2JFG122X906 MI#![ZQGT*#L$D@.(],B/C;AC T]- FT4_"T,G_F%_#[$3OT,PBH-1 *2;!,CT M)&#QVX'.E #+Q,PP]L(X8@].@8!R)A$9JO,@\%.2]- [Y'"2)J&'1]!WC9], M-_[E&%[8>]_8AE>5<0+$%,P#7.1.$L/&3@(/XW3 PB&81%Y$1L87T@T 9+*O M3K@)\'@:/W' "D(\V TX!(,X3#%)1 !W?9M,[^4?ZMVNL(D/IBXY'Z;]?F[-3X[2B8W]F10(;M_:4Z1 MVJ?MZ>,[>^;6>WZ'KY?-&6*GICG2_$0EI)Q"!5N#2N]-#+$FFU/"YD:+G3UH M6PFM16DOMXSF3!H!>+\60C_=F ^T9[6+_P%02P,$% @ *H (60CEIW[?)[DLA._94AJ\65E7B(!'E_5] MZ:1(HU.A^Z/!X*A?"&4Z%V=Q[<9=G-DJ:&7DC2-?%85PFXG4=GW>&7:V"[6E MU;^J-.3GG9,.I7(E*AUN[?I'V<3SD?$2JWW\2^O:=G34H:3RP1:-,Q@4RM3_MQ;*O@ M%RZN/W\8SV>_C^]FUW,:SZ+Q5D_)Z-^DD#-:FA1M^!.J(OUH3< MTY5)9?K4OP]:+;? 1EMMD]"K@3Y7IT<&@2Z/!Z/ 5O(,VUH.(=_!_Q%I#';X, MQ:WRR9<=](*7[E%V+MZ^&1X-3E\A>M@2/7P-_=\1?1UJ?GXU14-Z^^9D M-!R>TG>1Z6MEE:&;7$#JB:R"2H3V]'- (>_2.O4>#T]J$E[IQ!7C64<@E-0:7 MMBB%V30OWW>)AX9T>D,/QJ[1@IZX_]"0-%$VR"0W5MML\W2;QF2'HGS<)+[=9H#;;*;!UE MBH<=!F"^")? D])'5.3SIT;6AZR38I70T.HF2'7;;:)FRE@S"@2PKCRIYS\M+ M96I6:Q7RO>V[SQN0$@)B@-=+*A-Q^05J#Z:NE5JC!5R:[:7=_ME>:+ M=)ETNT!G12'A$"2*(U8!K!N.S 48[%K[[$61"Y-Q(H(G(PI)P=*37+ZDGJU2 M[@#8Z(,+*BB!5-F,?,#T)U_*1 D=-E0^06G+C9F"YYA#&^FE\A%G2HD3(I P M*1M"; RB_A1[<3A11BPJG4VK)+":1*" ,RR0XVJR-^J,\"A57F+(^ZBN=:Y0 M8H: #:NH<@Z[(67&DBB!]\AT&(A9>&X'V$C?VP\W]M[Q*:M)!; #- 8[)P$4 MGP<"REN:76*=9/Q<.B5#K&XL- -5YH-6"4Y'/*>NRH"B<;[!INTK)8$18TUL MI5/*I2Y)I*EC[<7 _8/:A? PRZ95R/I#&>;\EUJ6OM\-!@?=NI!EK%.VL:< M<[F<8E8(1=#269%^X.(&5Q6$20ICAL;3AY M;L,T;9BRW5$16_E!!GE^6KN5J&DUI- $/=I5WPSAM*2FWH<97C7WA_-/EEZ^7 M'R[O_B-N+F__<2MF5Q_$Y[M?/]Z(KU<7'V_N9I=7=Y#?&SL2AY.AF$ZF1R_(.^P\ M/V1YAW^]YU'PT6[!U$9O_5)FZFR /O&J?E"#\Q]_'@]>?>"V4>=V4? 1W=CL3?9K-K?CYXMS\4JU)G M):F#/4O#J^E!VT8R4KB"Y5VX:BDMM'LAQ<*14BS+5(TZO-OZ7DHR(6MJ\L," M1XWS'C+5@ZK78JTD,!#?%2V"&XQ%-N=MDF I:ZK&<+")CK3@0R0RV7M'C5@ M1R$ KXXGHV.TOS&\.P@T@^J:X7MSI#"ZXF@ O6O) 2LUP 0&MKCL\XXPD5# M72HTDI-V((F(0NV:10F[9H'WJ6\-I2Q&O926\H\ M*B4S^ =Y^" -E^E<&K@)'X(+TE ,7TU')YLT6"K;!^5#K&HR\>?1F_;[]UG) M55"H;PLK0XDD(M/TVC<%I1TR-K88#3MRBG5P0A4%9A@G9]Z@E)3W G4;@P Y M1DF/HH&77&P<.O)2>]^0 ZF@_1]L5P0QQR:XA-

==ZM&CAE1OW.%^0R#*?6P M-X//!KZR$82 LLZB6SEZPK@EB7W29=2=!V_>4JBIJTK5[T*L-!!SK5!3(=")%]R=(W';P+*-3Y5< M"^L".20?I#9R;A1%. (0/U$*/4N@]\:,Q&4?+C29$I8!Q$C(K0"BTSA\ M)>!/DRJ8"6.M0J5Y*)8H4\B1=[#A[S]J$@@(6?86J7H:ZC.&"!MWC-FY1I# MÜ71/G8>%J)@L)BE71D(74M9D:BBHG;@X(5=X6$1OX%ZK?-L>&+*H)44A+6@!
ME70QMDM!S5Y3Y&6.0*/T4A${NS/K;5V301Z$BKMIJ_W)KTUM4O%R/$?B,Y=$ MK?U]7-000%/,@U;^;1^=J-7FOY,5\#]NH1(ADUS/0=3^ @-*NV4IP?PRKD;6 M2Y(TCYS,-
)3'(4P/7#,MX@8W1#)7"&=66F?<@K=J:]U#==&8(74L"*VY-*^[5 M6L!3[ZQ59DC1#8FR(@9XPJ13Z(3U1B+RQCVFN;OCL'0(LV7K:[6@=1)5M46# MM6WQ8^;^E '.V"X&OO8A<,9
W:DD8X2&K3@>'03D0,?VTR;8:[(5K/Y>=S\J&D+!+Q\ MCBVP"34-($M=8AV&OF^B!H;J737;6+<1H1GM<<:PXO<&X<]U%CL#'V+[;;<]X9C1&0$\2<8AR&Q#R]_S-X(? M6Z[R88=!'4E+
8[5@#E%\&+)/\D?:L6KF5CU=-*KH@D-%G2A30:FYB0^4T.P M;0K 7<.A#8E$M?B<.1^Y"K<%FXFR(%1#C_$AEA1F:&Q"3$02K>TC_I$1G@9"
M/[/0C[>$SD5#7"DZIO+14W3AC+6]S5#G:*T.YZ?*+,(PY<&U W\ M*@T20'M1B#U:D0X(M_2F/1R0>935*^ES^0WHX+)[1LG?"@^?;KHCA5Q0;<- M T 7ZS9%K7E=*V4@PYP3G1-
(95R,8O;A]NE98X78S>FFI \@F,NZ:BJFF >C MR20R/Q*B74YO#P^8QZFLX51U-#&7:Y](0;^K!2@$CZV*;GZX7Y..C8T]>N45 MYPDUA:I-X;EI4*W'Q\>3/;F_-]V/#4&AP&9BML 5#?3-N?
WZ!,"D]%#?U9+ M^YE:191\QVOX@;LRG=B899$$'J5;J;N02Q ^DY(GZ'R33@SK:NY,F_TO5S?_ M'J4TBNNF)L;,_*#GXLG!9" ;WSO1L'[.@IO#M.E)+/!>;5YLIOPUJ]@<8HG"X-S$Y^8%=B4 M)L?
OQ;R.Q)8*FAH,Y,R?(X*" # "4:V99,K(273Q3T\)GD-$Q,*6<8VKTBGBK MMH.R+Y5Q'!%! S%SS,"M9NO%:+B9B02L;2:Y:F*?]ODZ$=S-VJ%Q$AD4Q@BA/?&,/7?<&K'2?/#LQ:=,@[
MH/DN?A$70+X:KMQE,P=CPG@O%4XQ'>@PG>/J1_ "L M*8$,K[>;!M7BB/EO$MF%NW>? XDYW7\D#D#LQR$.Z?*EU_ID K5Z9S45I2;4 MW1REW3)=+#T+7F$3QQV9\Z-=-
ZCCK>MO"Y"0++M-.SO();%(X.(^SWV S]>N _>J7 MQ@1U4U>-?[&W#&%U<7CHBZ6IM1^[E6GP9N[:6@?\;!>'?M4:7?*FNCH\GDS.
M#FMMF[V7S_G9Q_;E<]>%RC;F8ZM\5]>ZO7UE*K=^L7>TEQ\LHMEH >'+Y^O M],),3?BR^MCBUV%/I;2U:;QUC6K-_,7>Y='%JU-:SPM^L6;ML[\523)S[BO] M>%>^V)L00Z8R12
&O]=FRM3540(;/P6:>[U1]+& .]$_2W+#EEFVILK5_W; MEF'Y8N]\3Y5FKKLJ?'+K?Y@HSV.B5[C\[]J+6M/3_94T?G@ZK@9'-2VD?_U M3=1#MN%\6G_ZB?
WZKINQ\ O'0[[NKRPV=U>77U\Y22_\",=,[^9\(+[1/=].F8+KP*UV8%WN(%F_::[/W\H?O MCLXFSQ[@_ +3G_/0AZG^3\X=I?_CY\QMÜH@[4GS]$O=+>>N7FZB/)V@1-(7>A M/B\-XJYP]4HWM[99]*
[176F#*57AX!2-E[^\JVRIZ?'<-KHIK*Z4!Q&#\ ]> M+?6U43-C&@55KG2+=;9APFV)U08Q$Y;JRW@Z5C]>7GY4P"HL"*:U=4;0-H)A MX&RL+GDS6*IN1RHLS:TJG6I_ A7D^3ZI MSOI FG5-
=4MT&F*U F=%U[;T MJN_2.U7EH0A>Y8W[8TQ'9C"N,]P)AYUFJN M,:M6F0F3"OZ:W>+F*[& TOP$06SZ(([Z;'E=6+;&\!-O;U0MV($7C3($(&-V M)S 'P&5*R$PM<^D?)L&[M\^%(LC<20,6VK--
:0M-62)Q'D^ %M.QZ:!;HUM% M.H-<#@^@-KB;$R;]7U687[JN@C>1F]J=''M^[1K)8.SE='@BO9,&"=^:B@\I MK2\JYSMP'[7 &O+6,[!O+,]NF MZ<#')[-R;8 S*L]9ZFARH/XU
I\5$4OL3]]ROECJ9D&Z;AWD4=@&[<80H?5S MXB7 ;IX4N?]X-)E,'MVA$MRNO?#1<)MM/IOLW#V*=A ?C. '>F2UHV,EN]07 MSVYK O83 +),@#Y4JVEDISC3)U16<2=W\D'^*B\T-,;.DZ_ T@
MD' #'Q?*W*R@1F]L),CWW8)RX*-_%4+",XR(RTZ-H!!FS%/[UW."3D M<9@+E.3(--!+/V)BZZ5AG%LBX3B*KDJ%%C#A60\]E_ -AJ\ABPBL(A[$P 'QJ?:MNK8%U-6(:LA&!%9P
8<.6!CIZB#ZKV+)XTG.QZV2@TN H6SXQ=Q7Z M'E*GIJTC.H=0AE2)$/4FA$KX ?'2S (E%4DH;E;9A>0WF#:XXNL!J1\EUQ:P M-+\:43@81E*2+YJ/"9))X&Y4"KA%8V4URB*
(8HE_F!J-7Y*B)+;G7:4J&$R4 M91& MF5:M-9[]LT1E2%N3767%Z81=%1,!'TC-*/#%-HOU1Q+-QRM-0O-A9=: M./H7L5"8MNF#4@0>JRO:W9,A$+K6%9U_L9$HAEBFXFB)'@SN45DL)Q- DC!@
M"K)K&PX %[5HVC8^M)V\YZ" 6R\L1104TK706/(J*BIB,0'S5.2IXN?;S&UD ML5&$(C2QM)S_+[LVH8L4##[56Z8AKINO#('DDC-=B;+A4N8FAHF: M&U)6Q64+)?@24@._/<4I?-!W,\!)BA?2#;.*
(GU)<16]\TO#R#0-XL:Y8HD5 M*I#(BUJ+Y$@G.'(#VLP5:F1P:^,/,5-:0"W'@V$!G$B%P]"NG P=,[#PA>0&V ML:"U_BNVW0(?F:M8PN9OM^$+(8 4SZA)NI(*K1+?6=H56/JW;A&T=]RE B4[
MMU(/D>$8*MF/0HM$$-GN)X]2YE.KY:UGN,N#M47E& XX/V\]W[?8"SRCDF*C M_&7&-=#:V8*QA"BP538)9+^@:3*I6S>ID-C .!FYZ-DH1BHTV""IE76EN!+5W M575\,"!/^
$M2LQS8%@]HW3#+QY6ZB[9]_NL1[@O"U.]@?4J6_<)O+*S@G! MX72DBP*-3\2ON9PK+Z@_[8+?LDHO*A-SU:/>A LI[.B8CGI)I';RE6^UWU^Q MVZ:V!7NI%(UJ+_H2@^,].KJ4!9PYYL"K
PI_UB5P O 4!-:A#QL.#Z5,D [CL.)HW)"#[M)*[!D@A.-N"NE$J>;4:H)!(TU:M5A:>4V I -]6\:&* [JTD-SAZFY6UDBRC MR'E\],S4-!)E^R=R5&]'R;;8B'#Z;:...B.N*AW?^WN[X3L?&*7\E75!U2[.$
M/LU=Y#_^/$45YPBTG%7TF6J5#@W(*TN5$&WZX,+0B? 8(8$ 5<:HZS2;S=/< M@1T!+9D+NJ*'WZNGXR>J!JTT0OG^?'R2'FS+DSM*;R*?C PW:"D1;*KOGMC8 MJ #$FIR%J9SL4#.AG!)_C?
XHIVS12C&S>2#9$"W),"7:!I0'%2E9&,0WK<.# MKJSXB"4H=<#S.Y1CJUVS5:/?$:X4B@3K=G)XD9G36;2/M2NP<.@+=K"ZAB1K!-C11 M=D7(.T893DP)0+8K;!%J9CBMU82ZOQLVO49J;36Q?T
C6+IX.])SRR'IW0JWJCJ(!HVAHS@YE"Y(*NTZ@&V6E!B:7+^6G--ES=IQKG1-%VH M'[Y[>O;DZ3,UM6AA*'2I?Y=^-Z$N>KJ&VJ7=;MWYWN-[7QHJ%GI,5@AF(3-0 M+K>NN;+N&^[13BXKHR
E\6R88E$*T&N.A-YT6;?L.(G]*L_S1@TX")1"D-]S M4F,60AB]4$VBA9%VQD? M[W!\&%1"=SSFAI,$%?'M-74!L<%J-R3H^Y)>46[QF&X?AHTYK%:D^XR4SVC-;D7QBA3/%EF!6[9W
M@[:H2NW,MJ(YW(?:&Y%7HERSC*D$67=UN'7,T+5D[A^#L>CU,6@PB.@8Q9NI5*L=9E+&=HAMSOIOC@$:\MAR#@ M]+:VE"W,@(@<2UF@)*Q+
(Y^(2.F:II>3PE&PF$2=4N>M[L[\+NZ#X7Q1U+P, MR_FB(M6.UON.$Q9Y0C96U&A]2HXS VV[6T/F:5QST/^4" 8B2412[]_T8\:8 MC3=:G,V[P.R^+4EY G$>;5+NW]#1$ @ZASJ>?
UU)W=DFB]+M^20J,Z6TM4(MK70\AU0+:O(HX0P(KWN_XYX8?\NBH<=\56F<,BV6R(8^4CI KZR,:2-_=GO4V1') MWV/E[)%H*VEK:P,$X-E8@"7D*0[>[R
MOT$F7LND]Z7E:$R"14/U9+39PP]BH-.#$WKUXS;@2?6]5H@F%O-F]*3=M>:<5 M]UDO+IWX1A.>:R'"JL\Q26]^TW(YO5*?W0JA?7Z,0I85_0UZ>]JFG M!A3SDY-
GZHUN&PCFU3Z5K(_(.64>NIW!:!CII:[MU^SZQ(?X.3Z;'!R!F9[X M1^S@RWWZYN";BG(!JJ;C81AE0YG5HE&0;QWZE%G;Q@\O0S-@NX1:ÖA&(I]C MJO-$JE_3S.E\]/3\?'1R>L;?!'
)E&T1@'3IJCG;=_SD?#0YXB\)1G_\Z.GCT7JGHR>)/RPYEUX$7:DQ6O4W8N:&[K,H"Z+& MG'?R^4W2Y/X4;-(@3AV=/!KO^G[P,/L$M#;M@C]T]7)W(5^#]D_[;VDOY1/2
M8;E\B/M>MQ@*=]%.;9.QD\>[\F4+?T(;L4?E,Y<"*[F/Y<&R;:E!7A/W\>E M'W1 _X7QR_\"4$L#!!0 ("J "%D<-$ X8@, *\' 9 >&PO=V]R M:W-H965T[:1I? ,=VNUZ@ M3AJGN_M*2V.++46J)!7%_?
H.*5EQV]188/?!%B]SSIR9P0Q'M=)?3(THX:$0 MTHR#W-KR,@Q-FF/!3$^5*.EFJW3!+&WU+C2E1I9Y4""")(K.PX)Q&4Q&_NQ& M3T:JL[H)+O-%@JJ)@>G^%0M7C(X.!
[=\EUMW$$Y&)=OA&NVG\D;3+NQ8,EZ@ M-%Q)T+@=!]/X\FK@[+W!7QQK<[0&%\E&J2]NL\S&0>0$H<#4.@9&GWN-V-(Z]RSBR;C+2J
M03MK8G,+'ZI'DS@N75'65M,M)YR=3&>SVT^+.2Q7=XO;Q?H.IJLYO%NNIJO9 M%O_<+%;KQ2BTY,LAPK3EO6IXD]_PGL,')6UN8*$S'[$AZ2Q$YH[[^_QYXPSMXFM#4^H'G2J!Z?
8_X/JT[RKZ[L%.#.%LXLDCH?P[S M83KU*H-:DA\8:@\ M'RO%)2QEV@-N3(49E%H5M%1Z#U)9-/#2YNA=)='0@6#ECOU!/'P%5D&*VM) M 2[OD5I
$^9G^UR)#'6'ZL$=D3ZR08T:J5%DQ@C/Q1Y2163:\HU XB4G@WX" MT_G:G-%$VGRF*>$\L^PS-1U-'0N$;5A:)(5"DLA%W#ASV$.,A+3'_EMUD/', M!4W 5%09TA!*=>6)+#$;2TRU K7UZ"W-IU\I-
9(%YDSX1I8H2H2EU5(/\WE MSD/WR#2@:S68DWWA2M/?4T2'X@SFJFB9'+OB_QF:(#\/ O.-MPP>W^ M${Y&-]8;'QJ?T%:S1Q:?A W"_@L'IR?15$$=$O4U+G8=:X7\[/$OD\H9=KQ
M2=5E! "!'A_CA*1J)_FWI@0;97.OKU'E& U_@,(-'"A1&PO=V]R:W-H965T2X M;28O$DEA=\\Y>P&HP[DVMS8'<.RAD,H>=7+GROU^WZ8Y%-SV= D*?YEJ4W"'
MMV;6MZ4!G@6C0O:3P6"W7W"A.J/#\.RS&1UJ[Z10\-DPZXN"F\4Q2#T_ZFQU MZ@>78I8[>M ?'99\!E?@;LK/!N_ZC9=,%*"LT(H9F!YUQEO[Q]NT/BSX(F!N M6]>,F$RTOJ6;\^RH,R!
('%UY('CUSV<@)3D"&'<53X[34@R;%_7WL\"=^0R MX19.M/PJ,I7%\=]ÄT&HN7] MW'Z)'TF&YSNLH]:N=RR4Y5!MFK?1X -RJ1&>9P\Z_ OKWIL..BR9)!L/^-O MV+ >!G_#G\LZ.MU>
[Y3:9]^6/(6C#O:'I7,/G=']K5UN[@X-G(&\WD+>?_Y? M(3_O].+3]2G;86_8[RSZQS8B2Y*KA:,EZ448-F4\/NN?2 _95JKYQ0,X:S M@G$I&;<6GG&5<94P*/A%2.#)R.7>,&\"F3O5,B4?
(&%IDPJ926[S!GUN.A4(+ M8%.AN$H%E\PZ[@ ' [JFOB8WWA@*C/TI;(^=M8PM]2C21J\V^"F-2"%BF&LO M,S8)0 "'0\:F1A<,9X8D;UQ%!@2NY")C3C-GN+)30'X-I04AQ+7:9&#D(B[A
M<>A,P,T!%':LN45)3=.I (E)%E+#!P8;'@"$N@O M.;4L;-1ZD\[+A*4:YRCB:S10!$,2M4);3$=VCZ!P#&MO:[1(:YZ+-&>BE]JF M%D(%\&'E&YJ+&3/"WJZ"B]A\49(85>+721&]>QN230FJ63?Z-
V)W%*'SAT\2:5/B-$*;=Y-*0+N/,"(\9%5?5;Y+7@$PG=L Z?&H_*P -NHI; MD)2(!9$(W%(@BYH0U90;LPAE5Y G:C&C'Z15K>Q/(.6DE)X&,YMK0Z(Z;V+6
MX_,@94/B^Y98AO>60MYS(RCQ2P$+G8%$O+$ O$/M'Z&E3^FK@OO9^>V%.;,A M@*Y!L:Y_][36I M$6:#9;][Q;-ON/E"]D=H[G!TJ)BUYA>F%S DIGM3,[?;L\42\Q1YKD4XPV"Q
M3W,\4V"N")JI0DJ[*LA!6!_2]0;G4)BV31IMG7 LWEAQ9*PGM(GR M(&]H.IJG.,F,T1-M0OE.%C5?5)O78@SWV8UJ63]7KA3(^K+$+HK^D(U#&^2K M=.T\4"#]RKS01N7E4!Y--6\-
J/JO^C!7>UFKQHM1C@:[/_+#)_/G372(, M#;2ATEMZE61(D["]@RLN%X]5L!MU-9/ON$QFD"T8%<;-M8[SI=F=][@:VV' MHBNJ+P-(,_XA6K79!^"D9* <\>#X>BH\.EJ_0?;8ZU=
[R6!X$#4/C1_$"H41 MSFG*K6R5M'[K[8']H2A5E.^/*^N.)%17ZX>18WBVA>9L&Z*]Q]-(,<$-:[@5 MGF(YUR1^U?[O3O$ZR!ULHRZ[LER_4;O1>U]'KM_\3XU3H_276C\;_7=LEGKYN\&W9W
M6WQ>IL/2[J5:_\R8U;-U[TK]U@MN 6867N,M"T>N^[;/&W^*1C'%^3E\0@W MPT=N9K@1XFB9HNF@]W:G@P?! \.H>;YPNP^OR1#M\^0Z7.7#C?P!02P,$% @ *H (6= '#OA4!0 PPX !D
!X;"]W;W)K M&ŪLM5=M<]HX$/XK.URNT\Y0\!N$O#%#2*[7NTF3 M*>GUL[7K*DLN9(,X7[]K63CD)3DIFG[!21Y=_7L^^ITK?07DR-:N"N$-&>= MW-KRN-
\W:8X%,SU5H]0O"Z4+9FFKEWU3:F299RI$/PJ"8;]@7';&I_[L1H]/ M564%EWBCP51%P?3F'(5:GW7"SO;@(U_FUAWTQZ('2 M<"5!X^*L,PF/SQ-'[PG^X;@V.VMPFLR5^N(V[[.S3N
H<#4.@F,_E8X12&< M((+QM9'9::]TC+OKK?0_O.ZDRYP9G"KQF65<]-X+AT3IE935\Y\=GQ[/9Z^C><3V:7%S"]OKJY_#";W+Z_ M_G#:MR3=T?
331M)Y+2EZ0M(0KI2TN8%+F6'VD+]/[%IHT1;:>?2LP+\]V8,X MZ$(41,DS\N)6U=C+BW^"JK6D9+\DERC'IF0IGG4H$PSJ%7;&KWX+A\'),SB3 M%F?RG/3OPOF\I _7MY_C:(P/(&G!,-
["5=,I[FS=-0%FR.<*Z8S4 NX MX)H22&GC-N[+5!4EDQM@9:G5"C-_:*$\):\#DQE\1&.9IO.G".N>$9 MR<,3 Q,I*R;@'4K4']%F<'ET]&?[7+G*$@_"9-2VJ!T-K *PL'O
MCRS::D"UDRPH,P_[T86ND,&B$F+S-N.BN=2OF&;;SWXY)78=:[S4O=!#!1L TO-I 55NB)KG&;<&LBV M44.X%@N>HEMA40JU0:1E2K14-XF3-BQ;<>,,]2M'C[$GTX!S/G:=Z,/D67A?"
M[FAXU$V"\%Y%UX-<#*X8%VPN\(%3>G";NQ-!;<@9UGJ*NA?Q?XF?2FWZY>W< M.]WW"FXY'5=[S7#L(SB(3W[Z_V??1^B:=O% '),5!?H2G]RWYQ>SVJEBXPRP M/;Z\0YV2_=N#*95Q319P6?
18QG7CYNW^1CM?;7>WJ L#USOA2SEZ2GZ](E# M[[L8HL-1-PC#ENT HD$O3N"H-QS!.Q=.C=9AM%_KW7/JS0ODQ-&?.C<+\1V\ MCY ^B+!G4(:C' 9R8W0?@]O4^09!F'2C:+0+(
QZ00"'O5%\;W.*3$X.XS0G MI;!BHD)?J'9KR%,7N!)[$/1qYD(?ZM!/*;5IYF)^9L([M\;[6GS':1!"L8&# M.(R[8%Y?3 <^065.%&Y_.#2ET7?4%Q&9[BBV:^D[+&M0'=^$"6#;SB73=EV
M!"RC@8<;"D9?.1M>\\;1N82TN4:$HIXZZMQ\J)\7\A#V,#QJ8(?A2W$/@O"' M^N>3(64K:>LW1GO:OM F]F:@= 7U?*&6W&W=!^VX=_P=02P,$% @ *H (M69ZBN9O3 @ W08 !D
!X;"]W;W)K&ULI55M M3]LP$/XKIPPAD+#BO/:]$J6=Q@2L:MG+5S>YM!&)G=DN9?]^=A*RCD(UB2_Q MW?F?>Q_EXLMPQ\6#W" J>"IR)D?61JFR[S@RWF!!Y04OD>F=E(N"*NV*M2-+
M@32I0$7N>(1$3D$S9HV'56PNQD.^57G&<"Y ;HN"BM\3S/EN9+G6:Y(=(R?C6<5GND >[;S^R?JMIU+2LJ\8KG(]$ M;496UX($4[K-U8+O/F-33VCX8I[+Z@F[.M?M6!!OI>)%
]8*BHS5*WUJWL,> MH$O> '@-P*MTUP=5*J=4T?%0\!T(DZW9C%&56J&UN(R9IBR5T+N9QJGQ?#&; M7UY/8?9S/KM;SI9#1VE6L^?$#<.D9O#>8(C@EC.UD3!C"2;_XAVMII7D/4N:
M>$<)OVS9!?C$!H]XP1$^ORW1K_C\=Y18,P2O,YB+T9Z^WL^@ ZY>) @Z=J_3:Y$9DUM!68QMCAOV[$X0M7Y 7(WP7KZ,=M_W[8B$ MK=NU0T)T'2D*@0GP5!L96S?2SAA7"*Y_?E"
<2[JV2X*#N._98=>'>ZYHOE=' M+R1VU(OV(MV>:Q,_@!N4NC/+#1?JHT)10*DM,\A>,I]%-<>AEK.PYCJ'&\[6 MK[.R.G0+&N!]O4;V?+5+#U]VF@[NR_KD?4WO1]%MU2L M=?
L@QU1#R44GM$#4P[1V%"^K ;;B2H_#RMSH_P*DZ#W4ZZ;T3CF@/:/-OX# M4$L#!!0 ("J "%FF:35/O ('L& 9 >&PO=V]R:W-H965TG &#F]L:_C MZX ?.6[DT1QT)0O.'[7Q+1D8MA:$!<9*,S :GO
*BT(3D8S?.TZC3:F!Q_,] M^Y>Z=JIEP21+\>)GGJAL8>$0)))BR=:%F?/,5= 4$FB_FA:R-L&EBG8X!\5HJ M7N[!*_JV9DVJT'^ $B^PV NP.XM>XF4:WRFBDV[N^ :&CB4U/ZK)-G(+
M*WTH<&HZNKF8/DVN8_)I.;N>3>=]2Q*K7K'C',&X8W#<80KCAE8_4?I$CPT/ M9K2=3,09Q'2)!+W1@]2/%5<(CONI17R (+!-K^L<>;P@,MVH U/V+*BH/F@[JRN5-,;6F_;64=-0SF$-
VWYAHEE7DDH,"6H?=$) M#!!-JVL,Q5=U>UEP1&UL MI59I;LX$/TK [5;9 ''EF4G31/;0 ZWS2)-TAQ[?*2EL45$(E62LN-_WQGJ MB-VF!HKJ8I,4Y_&].3@C5/,A>WJ A5]F6N3 M"T=3L^C9PJ!
(O%&>]:(P/.SE0J@,O)KMV8RTJ7+I,); [;,"'"3Z_OIQ?P,#W_?'US=?/IOU'$3;OZ,4USEF%$_T"YQ"^:.52 M"U.58+)MWR-.+;&H(786[03\JU1=&(0=B,)HN -OT H=>+$! _Q9:X0Q?Q^$B
M.;:%B'$<4!58-$L,)N_>] _#DQTLARW+X2[TWV"Y&^?ZŸ$*^#=FZ.HWS^! MUV'A_DFJI;1REN$Q7"JXB9V>H2&7]SJTXÄNII:+EN NH'!I,0"JGP:4(T^!T81"I7AWL"0N"1I0),#BTRM]Z?H3
L+:MI&LR$XX7:#87125E?+RJANE3EG.Z9 MTB#H.7!^Q$86_GMBRD6SWU9 S$!#C,;1Y0D%+2CZE&*6P&R]2;^A#CB=JB3\Y MU0V1RO[KW;]A./#G^^&P"\;NG*1X)9X 5KAOH^(TFJ?
+D%RD_"G\#RF.$O' M\U;U'+VR]$L*/V']^\D$D$L*AS9UM-W.@/>]"K'_@Q5E$@T0N MI&M" 4:PG?4()C#!I3/[?^D0F M__KX>9^#X:O;ONRN\H8W_)2?V\ZE/-0[)$4'?
S!IWME2VW2&P1@IW:A8;*U7 MTH1R@3>Q@:.1<%LVMIS5/.VK$BT3$60B#:T)X]85Y9^45.0-?BNE\;Q^."@7 M3QR4MP=MU$F>-Z0#-E66A>_/+(435!3$9"FR1L=C][X+%(JI:>@I067VJ'Q6
M^+(DD09T'>&@B:-=1T?.[;STZVRH6Z[I%=$P1'R-PY=1J3.J;^7=%S!\"3W MQ2.$8M#'TKN BG+%/TJS(J36JI")-9FFR;$+P2EK(2E)NP-J0M@V(5]B%O5 MYSMRT/>K@ZZO@W#PZNW?
VVC,.9J%?WY8RL)2N:I'MZOM"^>T:NPOVZOGT1=A M%I*893@GT[#[_B"H\K:9.%WX-C_3CAX-?IC2*PT-;Z#O&ULI59M;R(W$/XKH[WHU$HT^P9 /WU'7MAV5P(JIH/BAR0HL
MF;E4%4JRK)0NF:6M7H>FTLAR'U2*,(FB85@R+H/)R.L>]62D:BNXQ$<-IBY+ MIG4^F!B47#8KV^[OH1-P%;T1D.P#$L^[.XA9 Y&\ 3&$KTK: MPL"=S#% &1\2G993F8AF.
_KV#>IG#"8?/\3#Z.8,P7Y+L\. ;\1/ _Q\/OB#N((?H)78' O M+9-KOA0(S!BT!IAV(JR4H$=IKN'CAZLD2F >O5+ET%?N,V98+E%#&O=>>;FR M=CB*'))W4+99F 3!G;
MFE\"#73+*O+6C*.+;!2:%P^&-'$^\U#]0X7=.!9R;J M+L5!FO;2M-_57+W4+ J$6U563.ZHOV5*Y]\3P&WE+T.M@%655EM.?0C%#BZ2 M@:?.9$[RT,M<@B5$6VA$*)LGB>Y)'LOB;]
[%N%OOT:&F0M\6Q>[R770&T9'. M(.G2,7S[?\DP*6NJXTD*;LU6RS51^/[#=V;':H=,FX8! MW9>JUX7;?.IY/N1 \VUE4?> F].I]N BCMZ4FHN(J=Y>_2*U4_TB[#3P$O7: MCRE#7W M;=/+6VT["?:+
#BZ-V/T*]-K+@T(7%%H=/EI$(!N1E.SL:KRXV"I M+ T7+Q8TS5$[!['OE+*'C3N@_7TP^1=02P,$% @ *H (6<[&ULK5;;CN,V#/T5PCM8 MM(W=NS,I=DD0.:&3C&W3M(6?
51L.A%6EEQ)WDS^OI3L>)W%3(JB?;$EBCP\ M)"5*DZW27\P&T<)K*:29!AMKJW$4F6R#)3,#5:&DE4+IDEF:ZG5D*HTL]T:E MB)(X/HM*QF4PFWC9LYY-5&T%E_BLP=1ER?3N$H7:3H-
AL!>\\/7&.D$TFU1L MC0NTOU7/FF91AY+S$J7A2H+&8AK,A^/+D=/W"K]SW)K>&%PD*Z6^N,E=/@UB M1P@%9M8A,/IJQ2L4P@$1C;]:S*!SZ0S[XSWZK8^=8EDQ@U=*_,%SNYD&%P'D
M6+!:V!>U_1G;>$X=7J:$\5_8-KK)>0!9;:PJ6V-B4'+9 -EKFX>>P47\CD'2 M&B2>=^/(L[QFELTF6FU!.VU"%#2;@S'7D MDCVYR^0HX"^U'$
:AY#*R>@(7MH%FWJ\']\)ML$:O8WE#LO85"S#:4"GP:#^ MBL'LXX?A6?SY"--1QW1T#/U?,CV.]?'#11*GG^'Q:7D#PR%\@O?1X::LA-K1 MJ;,P7VM$-S+ 9 [7-8)5\%04/$-MHEM54YFU&>]7[
9!\));S*&@-2[7H KX MM59-5/2=P)_.$G/R1Y0KU&'[7I)G46)!;*T'\+ CUE[IP0S@BFE+FCX6 MYY=KZC6F0M\M +^E@W7I"($9V%(C<7^-O%S5VO@E%P>^.MH'-%A)N:(T5HSG ML-J]S*GANN<-
+7EA$&I6>&&B>(PDR&YUPA2V0ZSE^8C<89^[HU9ENF:2D4Q M< I^1663:,PQZP'<*I=F5P9?[%,6^5^]7I45KAFDOK5%Z=6L5VSG4C_)#D- MXSB&BJ(N7==P?I%E&[=X+#\:"0;F'H3Z
W;]@4*K*JU>.6TI%#LX&0XNJ&,* MX9L_X9!@U G(VM3D[2#T>5NG=K.H=JL#LX>NFO. &98K(I4.O33U.YH;M_W; MA!3[(UA?PC_Z_^!:6+M7![X_U[-L^Q-4EBX8\,/MF7_A'7*)Y"&29*&YVGJ
MQZ?M>*DL$_^H=4]I',-BH[3]1 4KH:)1'_Z'LSAVA? Q#S)4NN,52 M+]JFU,13KU3D[3B*^NV""]DX._%[U_KL1%4V%Y*N-3-547"].J=<+4\;G<9F M8RP6F74;[;.3DB]H0O:VO-
98M6LKJ2A(&[$DTS0 ;0PZ[\][3MX+?!.T-%O/ MS$4R4^][6URFIXW(:*<$NLLX ;RQ_LG'CEAF MW-"%RO\4J',/3..BS*R5M9MA0II3NZK7O? RT!PT-OOP(W5>U/RA$X;F!M#^HX:9Z]^Z_2C#R_
[]7P M>R]9_Q7P7W8P^CH=LD[,7OUV%'9^!]E/$)U(>,ZX3%F]2.D.[%1N9& &?T51UQL:$12U M!7U,5C+5JJ"6T*X533\JX1+AMNF>DLKS&+P)F8H[D58 X#B/*9V2-JWM)!9\Y<$)R2V,
MRM66I(_,8'%#2QZ>,<12_D*6+0P6,6DLB[=IIK]#0)E*$6B#$HG9%+I@$JK M:I'57CS'(@CN2!$]E.Z\F1,U625S,BXUJ"\3!J)("&F7R!FPH$=FJST5'6QC M=[G=Z1!$#$H@UT=Q??
RYT,9N"EG7V=@J73%N@1,)+1$7C)"QPL%(?8 NO;PL MM5,FR*?1:/3!OGB,,8$&0:2I<3#0OWXOK(R5UCP=LG!E*%++T:Z =@0>C M*&JQ3^NX0]>Y,AAQSXK O.28-R1IPYM>! _=IE>
[4$7I&J(N+F>Z'EM(;@^(M0R<-H9@N;&@;VA[MIR [_=B!](8.^H=1O>CV'YX/C@^/_0)^7?0XJO-5ZS%1 M=';A/F(*_81I0FO?5 3$N7-S*V%8&V%7#NB4DDRJ7"U6[/7-[?3-ND3@B;=Ū
M86JCB&FA>5&WV"/2<&HJK<*H6'2SW4,>>[(3'ZY+B%"O,+2N55Z,;/W.&MN0[SC2Y#[W'!>P,L?!AEZP(OQ'L$WE9^>-:?",8>Y1)2^\P%U1JQSMX&GF.?+XP(;_H?.W4YN*
MU!%=Z'M/B8'D-.4;YX\;_*<]/C=BSP[8OT+8-V/=HX=1BM_U]XS2US5/=M:) MV(5EQ$(^FOLG!RVZ)5/X0H7[ZXRC91+/6+<7%^%0- GN"D]/0Y*N*;@Q9/9U MI<1\HW=4ZPZ.20F
MS*^L/%]X;1TJI'29@5E3@> <#B<8VC <1D[.UT5:I%.JD-^[PX)!75LUY$R+4@O3"7\0,U$ =X;92[]9WO4&XXCR(AXOB%=<+QSXYS:$:M=X= M-
I@.EZ^P0" Y"\],67QR^<<,]U723@#OYPJ!K1?.07T#/OL'4$L#!!0 (M "J "%G7W6^#O H (L@ 9 >&PO=V]R:W-H965TXLHZ+%F.CRK'=B9)92;>V-G4?H1(2,*$)!0"E.S] M]?NZP5.259J=V0^Q>
!]]^MN;)$[BU%X=S)U;O#DYL>%<)=)V MS$*E>#,U62(=;K/9B5UD2D:*8E/^MWNZ"21.CVXON1G#]GUIC9W].#D^G(A9^I1N:^+APQW)Q652"%_Q+JY5M7 O29&+,=
[KY$%T==$D@%:O0$06)GZ6Z57%,A"#& MCX+F0<62-C:O2^KO6'?H,I%6W9KXFX[<_.I@?" B-95Y[+Z8U7M5Z#,D>J&) M+?\5*[^V#XYA;IU)BLVX3W3J?^5S88?&AG'WE0W]8D.?
Y?:,6,H[Z>3U9696 M(]/5H$87K"KOAG Z):<\N@QO-?:YZ\?W-U_NWW_^=']? Y?%OXOZ?7S\\ ?OR MQ($RO3\)"RIO/97^*U1&XE>3NKD5]VFDHO;^$TA4B=4OQ7K;WTGP8YYVO* ; MB'ZW?
[J#WJ!2<\#T!G]234_E=#L52I W=B%#=76 #+ J6ZJ#ZY]_ZHVZ%SMD M/*UD/-U%?6\9=U[?[?/3O>@-Q,\C?N]WH5H4N5G9Q<%;7$3YTFJQ?V/7+L7 M%#0F$A$PC\9!GX1R!+FYFF5)(0"
<^I^*C3'-DK>@/O5,"X>9*W)ID(=,7@44J M4Y'0J3-"BD5)0E8DCF@Y"=#O7A2,-QGQ^][%,9+ S4OY;N5".QF+3P_BJ$6@ M7-TA2C:7X +NQ.=5!FVI\8[O,TI=V@NTB.FWV)\OZ.9P''2[7?
K74@)$%NU8 MMYO$Y WAS52D:A6_"&UM#J.8+-(IV<[.)<(&+*43N *H<1C!=I&8O(B;N\< MZ#CY'8A%C$.5.<"J"$T:-:A+I'9%$H/J.<+^@/N_L@,<36V('L M&/6#(1SP"%98>H<:G67H-
FQ+GNKMM^)MK5QHS M4UB;-3JG=8E;%97M^U?J0D(6Q&, #W@M8]8\I)7FT72&6X0&+WOE%,\6I MR>Y39AD2JU2:90:= :"<4H[[=H4A0S+CO +$\=A1=2)^4 MB^6K&X?-C1XLH$D>NG+
(6,2RP PY*T8XQLBI4GY>J:)?/:..6CQ=2!V5/6N1 M,!UQ+Y%Q4$T<0;-7#-=N9E)&V0H"*#B4F1YS"XKF;3UDY$; ;"7'C:58#\5M M2STL^=Z"-H6AUX5T;46?6%&E9Y%H*"%PF'!_O/#
(4UFH649'WJ5?RV, A]L MA^?GYV53C-Y$_][FE2.)XR:F^.DFW<+%V[5J3P)OHF(=EW.-(AAI' PU"E=>: (_MPQ9K\9$/;*6ZD?>,2PE32)\3E,>3G"&Y@XS:\H]@9\!/O"I0UH< MG5:
(VQ)QYPE075^W]22;&/GZ45#$[:TOR*>E'5BB\GQ1J9IEQ>#F$Z7RCH# M-U@]2R6N7CPT.!.T!NTM@]]:]T6V*<<7GN@JVD'%O#%A!+L3M9V;G)9%2[3F M^?73+#K&L:THV:^-

W'J81%W9HC@\HH8"KZA?8_=YYRUEICD5,HKQ*2I1&D(N MNS%'}\9=:B'M6I[L"NNRBFYES&'D#R/7N)Z7C"AU=J?-9O/6,DQL33M4 0U+ MG^VIFF'P7_.KS9!/GRM"Z'Q1R>^));3/L.OG].B M8C"DUVN$_)%B,R[.?2'A\QQR-(!C*G563#8%E<1$FH[\:O-1:['{6(6[YSQ_MEN:F%:B!.7=KG#*V-0,479#0>T!LIU;AJ345,$Y0_R5-_T?94D+_EG1$]TIM*XTWR)I?/"7&\![W^D ?
<=>DX=,N;2ZB5U_13U@X/ (&?DZ=]CKDSM(K\>H-/O MUGAH-HJ<55!J8I:JL^U+Y$GC W&BLAE_!J=S+J"4_U9.+/@S\T3XYQ)^'*N)#*;%N#]U,":Q0TQJ/[_MP?5_ 5!+ P04 " J@ A978AD/H@"
"2!0 &0 'AL+W=O(2P+^?[))F18).VDO.]OG[_#F)/6K/(-L"T<%KJ;0=1X5SU445:CY9D6F%(Y=LXYM95#D 52J.$'L2[@44D>348C=F\F(:]>DQGL#MBY+ M8=ZFJ*@'91_UH%WB0Z\+Y0#P956*-
C^A~5O>&O;ACR66)VDK28' UCJ[Z%].A MSP\)OR0V=L\&W\F2Z-D[-_DX2KP@5)@YSR#XV. ,E?)$+.-ERQEU)3UPW]ZQ M7X?>N9>EL#@C]5OFKAA'YQ'DN!*U<@_4?,=M/Z>>+R-EPQ.:-
K<_C""KK:-R M"V8%I=3M*5ZW[V$/<)Y\ DBW@#3H;@L%E5^%$Y.1H0:,SV8V;X16 YK%2>T'_MRJ,S?"L9YR:SN\73S>+;?#&[F3^.8L>4_B+.MO!I"T_@9_!+6E76)CK'//W
M^)BE='K2G9YI>I#P1ZU[,$A.($W2X0&^0=??/(-_K>_%C[\&.Y'XL)6(L-Q MQ/^\1;/!:')\U#]+++@^(&W;BAH?8_RWN,'QQ)S2' A".C\[3?O\2WM'!M:$2 M' \0. KG";@"849E)?0; T-OL,2,^%[J#:D-YFS
1AA)M06%:Z$XR3DT%CAH MI5[!,]!)I>:1Q@RJHUE?P7+FA/0VA[<'LW3S'/KO%JHM6B$"2EMU9;0X$LM MC:<4669]+L7[A:-*.-:AR%JTNVI,4>?2QS/BOTS;UK*D9![25RQ&9Y))K..
M+VU['WV>>&].2C3KL VL[T*[=F2Z:+=PKMHY^YO>;JM;8=92^ >T8FC2^W(: M@6DW0.LXJL+4+SX*6)QB?P_8K([1Q?H%O#DS]02P,$% @ *H (M69^5,R[= @ 9P8 !D !X;"]W;W)K&ULI551
M;]HP$/XKIU3]$R(AT*YK 0DZMG5:656Z[=DDE\2J8V>V0\I^ * &3[:8 M!!*D^FLAQZ3[*RFJR+Q>UB^; :AY9PG35,=ACS%B-^ ^,<;I6TA8&%9&>B\1\2GXY4O"H-!M/3
MD\%Y='6$X:AC.#J&_H\.CV*\SG#Y[6$!@S,X/;[!X,K^#L1S RH#*CFV-6\ M!['9 N%9EQ>06"I:"I&20J+)$G7 F0/"$.A.!R90:NJK$%EBN$:E?+>'5UE@R M<9GWH"E0XWK[
K+A0E!)/T@M"0RTVC)AMZ T*+34&F5(*8&,JU*'VDJ3'C& M,76VM$XLA6]0UQC@TY)2N@<\\\PHM?26FFZF%EOBLPWP#2EKFB[(5#G_2R/ M_Z8C(F.42&'#F3-
5S+A)Q"RAD7"R(M-.=I*@,0XVUZPT?5BJ3D!'L6"D'9O1_ MTSF7!@1F%!KUWYT%H-NQUFZLJOPH62M+@\DO" .H3LH'8.9_^4 MLON-21#]6Z9_%!+ P04 " J@ A9NN7QB_\YS/=_5=?
\WXD\@!)'JN2BH& M3B[ELN>Z(LVA(N*,+8&JG3GC%9%]RA>N6'(@F2%5I>MC'+D5*:B3],W:C"=] M5LNRH##C2-151?C+$$JV'CB>LUFX*Q;YU MNTE^2!=R#?%C.N)JYG4I65$!%
MP2CB.!\X5UYO&F]\ ?PJ8"VVQDA[\LC8DY[<9 ,'ZP-!":G4"D1]5G -9:F% MU#'^M)I.9U(3M\<;I8GO7?GR2 1$9D0D2?J2]U"\60R(RlH)= ,N.EJF@(:%2(MF:@YH%/T<#]"\)O\ ]UVIC&F*F[;" MPT;8?
T,X0+>,RER@,>#OV]@M]K>H8"_ 7YV \M MY[G>3[\E7-&]-^FCPZT'%OKX<.LV^N3_?)^^^_ [H0BZI N,7O">I+.E6B,7 MVN7T8]T32Y+"P%&OL0"^ B?Y],&+\%=;G(\I-CJFV/B88I-
CBDV/)+:3+6&7 M+>$^]>2GJL!#$ @P#[7>JS-.;<#8P]B+.F!SD^[6PU\! M7YB:+E#*:BJ:OV.WVK4-5Z9:OEH?>KVQ9UF?J#:CZ0K^R3<]BGJ1%@45J(2Y M.H7/8E7@>%/WFXED2U-
V'IE41GVO$)3X(^;O* (U>*L95XI5:UPO?SUD0)%58C40.W3W(A M*ZS-5!:"JB5@XI(JYH=!./,K3+F7QFYM(]-8-)I1#AN)5%-56+ZN@(E#XHV] MX*6%]6V"WX:U[B 1]_ZHTT.
[^G$%H!5U1P)"%/O.5XL9K;>!?PD\)!G8R1 MK60GQ+,=K$GB!58(&&3:$K"Y[>$.&+,@H_&[8WK]EC;Q='RD?W6UFUIV6,&= M8+\HT67B?? 0@1PW3&_%X1MT]4PM+O-
,N2LZM+'11P]EC=*BZI*-045Y>\$$R+_Y MOC'K]<*CWBH^?S>>!9\&E">]\F2(GFX;!F@<[*:WXU-M MM^2BUO\?0YBO"%]R& MF6^YS7NW^=4'-^PWS+WHYY_TAPIDX;]@0IEHN&Y;1;_:-
]IEVU_^AK==^@'+ M@G$"%,0F-1C-S>N4;>=K)UK4KMOLA#:]RPU+\[. :0/,\UP(?9S8#?K?3_H' M4$L#!!0 ("J "%0::8&PO=V]R:W-H965TD_I&%AS!3[I6_S1!H#.BE[G"\W_52M:>/3]06>L;5X;-
X*"TE?RK[X(BD@T7 MHQT;3L*&$^9;#F(NW^M&7[ZIW4K5M!K4Z \6E7>#.5N1529-C;<6^YK+R?=/ MGZZ^_J Z]:..W/SR^>;CS?75YV_JZOKZU^^?O]U\ D5]^??-
]\DV-.=AQSKCZYJEEX]:'*3;Z^_ Q@L=WR?1+[?G>PE M^*^V&JK3T4"=C$Z>[Z%WVNGAE.F=_FT];!->:#_?3IL"ZY5?ZLR\/4#D>%/? MFH/+GW\:GX]>[^'\>-)F]_M8W+I]!1WQ8&H9.Y MUO-55OI-
K>-R57F8,S*RU\>SI%K>CRSE:XRJPOE0<0@A!NO%OK6]*DQ ME8(*EKK&.ELQX3K':@,W;Q;]^W R5+]<77U1P!LL:$QMRX2@K02'P-E07?%F ML%3<#UZ3M,? JW:AT!1Z=:[#4>"#+
[ZTE=J:W&\>3 MS(5IS%:!ANJF8LJN:2NBBH-*70'(Z/4 *)8G"#[3!5_09WKFD5M##_ O]DZ5$O-X42E#@3]D=P)SP$RF MA.O2,Y=^/PG>O7DN%$'FCAJPT)ZM3@!6HS'QH/NC:X5Z0QR.3R
MVN!N3ICT3U687[BV@#>1F)J="'M^:RM)0NSE='@DO94&"5^;@@_)K<*YUMP M'[3_'O*64[!{.F9-G*Y9@*7J-9XX37!!YBFQZ<_79R,7[SVZJJJ6O#QU2Q= MW< 9%:4]-1X=J?\9@,_^"B$7V)Q^N:
<4G78/X^+E81*P;7444;\CUL=0H;^8D MW5!IF,T,YV+8$R8;7X@4',.*O8&DO"NC&@D"::JH'8'*%O=5GR=@-9")QN 'G#6)RA)*BWU#],? MQ9ZL/4K$I8!"L]"-TNPPXA[LG-"?+ET;S[3G.\-
H+74QXE/B:%K&5\&#C .6 MSJ]! !Z96QQ8B[O LCYA< B7[]B/*.PR 7]18;J:6K=)9U)W/V9? C. MUO>!N:'KYF^@D<0\^'BES-T26J1$UWJ8W LS'0!CG\0)?-53U8T(3/2HEL' M++(%__3>X9 F!8-
4H"A'HH%.^@$36RT,@^T"6<]1B!>JJ8%5GO70<0G?8 SM M4YE@^JQM@(5ABR!..(4M:P=)0,L;(" I;Y7]]: NAK MF(F!)-@-AE2P.B M/42?%JF-8KXLY$$\$2T-"G8,,"B$KE<29N!5\$QO:
S'.)93VO9/.FXV'8R MH+%WE V?F+D"#12I4]/6 9U#4&>J1(AZTS2%\/BN9DVE-DDJ[EI8>>29&': MQF4_CJB/R;G @:7YU8#"P3"8>KY7D"\IO,[1@C&;G5!$FP% MUZ?26LN=/;)0O;A 9PEG+2R6DT-
KTV/<"@XZN8(X%6*W6WEF[J5]QRB"+*Y MI?B&>=H:]HL^3G56]*_@+ 7%C43=)G-KB7T0@!&].2WG?_.VCE@G-92/):C) M!ZC]I?
X'\,C]!P,R!T@VSBKYE05$>8N5[Q3@Y;22H4L42*U0SDD_7%O4"G>#(*6DS%^V!P8V- M4U-80P[-86P;.L(@:/?.#DY('3K*:]D8!L+;NM_8-L]T]JY"E5]^G833!&0
MJ'H8PTE74K06XLD+N]SKS2\WZQUP/_JVN T [G_8M;ŨWVU@!AV9J4^):_A MK,%,W-3(B4%GA_99+ +4EU5/*O/OBOU*WR7[8%0"4 F5A++VP7B7KF=M(7MD9)3-X/.DB
M0R,:H'PFY\H+FA>TC=^P2BGM4,>0KC[7?4^RVKFU) M0]0:!+5G7;7%8!,<72HD3[G<0.4180_KB %;&PDPT$;FDM[*DWY+54-4'!N M")411%W-HT,-Q:7R^M%3TZQH/!
(SW[KA\QA8MI]8K(MD@-4M0\F:!&2?R#58 M$L')!CPEH.IODQ&J#@7*]7)9X"GE^_QY@\IC-)5(+;7D>3AZG53X4C<$D=/X MZ)@!:A@ M]F(O5M[T67HKTO[UW>HF3?A_52(5YDJTG$WTC1J_
MK/F[T&\((O#P4$CFK0DI#(^2&K,795^8O.S"Y.5>1_\WFI@CZA3R 'Q:@^6Q M--2#1V%J6L+1"#2@+YV%N6]CLD7E"C>77A>()\!2TWT.5\1H:))5@^USV"7J M-
!]I!/2D/"F@MTKZU!*MI1ZDM*0YKR4O&"/O,V:=(0@(L)P>AFRR5"30TG MIY)RSO^&'5"CP*@UL7]$NJ):*\K4MZ8.YNR[*Y5F[$/C4?EO\CSMW(<&P$I S8Z3*C,7PFBF6YSA@!*4D*%C
M5]HL#*%FD"]^VOW-U9B-J3\)#+$,$Q.VV!HB;(G<;0KK4X<*@X0^R1&]..7-&PL6U_TNC&NB(O0;"DFY^#NY7A>Y%4=2'D M.
(+"&#HZ[%K$D+!1,@:>/0@_'O4WS*.]^/QUOV!I*]0_E9;:]0:.Z)M^MLC0 MKGDP2J"+(GKGQK"\O[M#3'H'2"@BS8WV?><$C3\]"!54WY"A#JCS(^F!8M]% M)D*4A^CO* ZXX$5J0"%CJS
SM;KHAI$M#9)Z?.Z1<764N7>C2IEL+V)ZEE6 MM\:'FT[?]"JAFU!SQTF+6JOZEGJST/;6:Q)TW6(GN:OG&I$;K01XT!49EL*- M)I&.J,@(TE5KT. 4,"!DO,SLY*1PE-T#4?2B3?,#
[>TH\T1:N]4NBAX@MPN\?5BK/"M]RTG=/+,9 ZOT2#G'/<&UG?WAMRE MU\MZB_7^O(C> MK;Z8[MFFL5?.SCG*8IELTVN&0O >OSB86/*+-&AI4]UE^MU5>_OU2&S+^?VR
MG0*05!9'\]L*U:Y(8ENEEWE@*['VBK]@"S!#]R4F.D-(-7\M2R#V?7F6*X) =ZW"%!&KIPW!@SB MEJF%Y;,+>MTA7M]50?P$DHA[B' .:V3"(69)GUO^F"$/7*UD(MR6W;7H'Z9V
M$5LWKS88M@4OA(J':DENF9YD9ME]!94[(WOH2B6S2](K/VXAA3IIU[=-=9V'/_[9'=LEWW=(-T #7H+HM(M:;$LX+HJ39RNGWOF!IS8AQ1])%R)*VPT1@O=F^*?6Z_,$LQR?#'!GEI%.< M-
2T$O/ M^R'EY0==5U"*5X?4J3RCF)/+@.T>\E1B&UF>QOI>>]-NS:;/%TDQ)^>CHS&T MTA'_@AW\V1)]3?6HQD[O&IYK$L5@]QZH-F4K[BZLB*W1=OPEX TU=PA5/_U M5WHCT$WFJ>>
(T],+P2;BIN/N04!F6PL+/KG. *0ZI"0]_M4J M?BA(Z'O$,F\ \-&.P)5)%B# 48H90^J7@Q=G(Y:?\%;Z76T#Y5+UIVGWI?R7? MM_?+Y7\3^*3K.8]+=X,6T?#%V<',JF-
/QJWY*_=IZY17,E_+@P*DIH6X#U] M^1M_T '=__]P^7]02P,$% @ *H (60#R"ZRX @ U@< ! D !X;"]W M;W)K&ULO55M;]HP$/XKIVRJ=DU(:&4MA)VJ(Q MM:SBI?
MLD@.L.C:S'6C__6PG!#91U+VH7[#QG7I^RI98D;4J5@A-U_F0F9$&U,N?+622%('RI@?!D'3SPCE7MQVO@<9 MMT6N&>7X($'E64;D2P^9V'2\NK=UC.ABJ:W#C]LKLL QZNGJ01K+KUA2FB%7
M5'"0..]XW?IEKV'C7< CQ8W:VX-5,A/BR1]#M.,%MB!DF&C+0,RRQFMDS!*9 M,GZ4G%Z5T@+W]UOVOM-NM,R(PFO!OM-4+SM>RX,4YR1G>B0V7[#4
80E('1U%XE.S>36 _A6Q_Z@V%W>#WHWL%@.)Z, MIO>WP\D8/DW(C*'ZW/:UR6AQ?E*R]PKV\!7V)MP+KI<*;GF*Z:]XWU1:E1MN MR^V%1PF_YOP4HJ &81 VCO!%E?S(\45_+_^0ZH*T<9C4WJ-
+M2()=CQS413* M-7KQR8=Z,[@Z4G*C*KEQC#T>FWN9Y@Q!S($HA5H!X2DP2F:444U1089$Y1)3 M(!KFA$I8$Y8:@+D$YB(EN924+^R?F:I#ZH[G/_G0"H/H"MYK-4>.U9%7WCM<
M(X/Z;W98KA%,A"8,IF.82-,%^A1QHI6#84V3?H(%[7S\'S6:$9F;WGJX2[K M(<\N_E7V;,O>M2?S3SG>N\\WF& V0PE1W?4ZJGK\Y[W=Z6G5PHNHUMS3\[8^ M[']O[?7_S%GZ#MU6?^^MS5
NW$11D(BGYF0>RF"*%H<7*O=PSH&PO=V]R:W-H965T:=DT$;JVS8V02M:OFQX_Y]R=NQLN[N4:4<%CGC'9L]9*%>>.(Y,UYD3:O$"F MORRYR(G2IE@YLA!(T@]49XJONATG)Y19<;?
R347H;HNIT);3LJ0T1R8I9R!PV;/ZWOD@-/%5P ^* M&[FS!I/)@O[8URF/Y9D04I+FD9J1N^^8I-/J>&++^&9K)ZPJ6.#T(*DE(KG#5@K MR"FKW^2Q.8<=0.2^ O ;@% IKC>]5(Z((G%7\
T($ZW9S*)*M4)K<929GS)3 M0G^E&]?BV7PR_Z#_FP\@N'D:C]^GO7GEY-K>#\GBPSEAZZC]#8FV$:RD%- MZ;]"V8$KSM1:PIBEF/Z.=[2\5J_ U3CP#(Q)^*YD-@7L"ONN'!_B"-N>@X@O>
MF/.^5&NF<#^3Z9AS69 $>Y9N"8GB :WX^.CKN!<'=(:MSO 0>SRK&P7X$G0= M)/D.!- MO94T.09.4>12YB42BK" M4K,)43#"!/,%"@B\JNX"\.^B$]?S6M@[\$_M((1/=B>"+X*P;=:>OS_K7;^>
M*$ND&N$,"4OT3'H#|@^ENCNP[8X#*KWHG_]R<^AF, !OSO2% B\\?UH5X#G MVJX+9W84J[&L*9V=XY2A6U8B0D"2J7]_M=[V%NC7P^\YO+Y"KHA84:TIPZ6&
MNO;9J06B'LNUH7A1C<(%5WJP5LNUOLE0F #]?&PO=V]R:W-H965TO)CD@:F)GME.Z?[!S MDF9L4#1I7XCO?,^3Y_'ARV@GY)/: FCR4N1YXE$9.P3)N349U;BXG(U'I/.,PET151<'DSRGD8C>V
M7.LUL<@V6VT2SF14L@TL07\IYQ(CIV-)LP*XR@0G$M9CZ]H=3@-37Q=\S6"G M]M:$.%D)\62"NW1L42.((8;R'-#A#)^M)Q6]TH#W%^_LG^HO:.7 M%5-P(_)O6;JW8VM@D136K.KU0NP^0NLG-
'R]R%7]2W9-K1=:)*F4%D4+1@5% MOILG>VG/80\PH&\ O!:@U;J:%]4J;YEFDY$4.R)--:*916VU1J.XC)NF++7$ MW0QQ>C)?S.;7=[=D]GTP^CR<+4GOD:UR4!B<)/U7\DOC4)A[U@A-\?N?5K_G\?
_1ZS&++#$!QG M,#=DJ$J6P-C"*'Z! /H,U.7_G1O3JA+Z@TQ><8I\L\<:E50Y$K G2ERO+";$@ M]5.@CFD]S7;^;N!1_XK)L0 '47;B&!8@62^*Y]4&5:M!_X9-XZ6)RSHKRZ
M)8E06G4E9R0*8ML+W+U,$/3MN!]WR(RK2C*>0%?CAK'=#Z(N#]B+"*]#M*?5 M[?N^'=&P"P=V2"GZ6(.4D.(QXR+CFU9:CPL-Q/4O#LRY=&"[-#C(^YX=#GSR M*#3+]WS$(;6C.-
K+#&+7IGY [D&I(5ENA=3O:-Q=3.&?\ @ 508 !D !X;"]W;W)K&ULI55M;]HP$/XKIVRJ6BEJWD-H(1*T3-ND;@C::5]- M^Y[GG[-POVC+^+')$";N25F(LY%)N;BQ+ M)#F61%RS#5;J)&.\)%*92
&V)#4>2-J"26]YMAU9)BLJ(1XUOSN.1JR4M*IQS M'59$OXZ1!6W#N!UBW%K9G;7QO1M2'%1&H&HI87Q$-*-9&2\;OC-/J4 M&GB\W[-_:FI7M:R(P#M&?O:IS.=&9$"*&:FI7+#M9^SJ"31?PJAH?
F';QKI# M Y):2%9V8*6@+*IV);ON'HX D?T.P.T ;J.[3=2HO">2Q"/,ML!UM&+3FZ;4 M!JW$%95^E*7DZK10.!E/[NX63[-[F/V:S[XM9TNX?"0KBN]J9$E%KX.LI*.:
MME3N.U0A/+!*Y@)F58KI6[RE9/7:W+VVJ7N6\&M=78-GF^#:KG^&S^MK]1H^ M[Q]K/55BR^"?9M =+U7'I35% M8!E.DH37F),LI]I/H#BE]3S:O8?(M:U,^-]5O0(VKW"/"98KY. YYE]1^HF.
M#0\6ZGX(3W](U%?!5?]8B/$ 2VZ0V=(X\71*8;#6!.7CFC M=(]R#JC0<(NHU4ODZV:@"77'=27;KN^]_VTL%_MVTE#)DH:1\;^S[.\;FI]NG>Z%?))50 :/3/*U7BS&-M\E_""P58,[
MLI6LA'BRQFTO\P(K""CDVC)@<\N7"ZK<%VW;W#CP4-XH+5@'-@H8X>V) MG[O_80"8O >(.D#D=+K01ASAMBF9EB9*#$ZG MM_?+^?WGV\6W&S3/LIMEADZ6>$5!G4Y];?
AMEI]W7(N6*WJ'*T%W@NM*H1M> M0/$WWC>Z>G'13MPB.DCXM>%G* Y&*]B\0&^N"\V=GSQOQ:[K\;68KR?PL[(MA:IQ#C//(#($"N0$O/3X*D^#R@,!O+W!\B#W-
S,P5#04DUHAPC7E)3"\05@#T MVB?V,-WQT20*XDOTOZ?I [@^7$,,: 42Q>'H399MTM"(T1+RB@LJRA=$26XF M&5P\#"]1]D3XABA7W@I5 86C(CL;Z]O*32F*!=*]^&W@%?//\;UE"LH4"8
M";G):^PVP2[U9)PDHR1)3@>>L//?L/-V\%^36_7XQV6)>$*45@::'#V\=Q#LETYK:%% M[<9\);19&NY:F2T-TB:8^%H(O3/L _W>3_\ 4$L#!!0 ("J "%D?1^U$ MB@(L& 9 >&PO=V]R:W-
H965T>ZY6'?CK9!/*D?4\,(H5Q,OUIH<^;Y*)ZXDWI8]F YOO$KX4N%4=&VPG*R&>K'.73;S M"D**J;8,Q!S/>(V46B(CXWO#Z;4E+;!K[]C?N]Y-+RNB\%K0KT6F\XEWZ4&&
M:U)1O1#;#]CT[+N14WA!-XK$46Y VV[!9P[7JT$9

VC)%J:V\+@=+RXO9\N;V]@/ETL MO\%R,7U,IM?+NT^/"9PLR8JB.AWIVA2RZ7[:D,YJTO 5TB$\"*YS!;<\P^QW MO&\$MBK#G)#P8\7/(IZ$;AX !?U'8=.,:[HG[O>UVS-~=C/9:=FI$]2
MXL0S8Z%0/J.7'[_I#X.K TH'K=+!(?8X,5.8511!K($P47&M(*L0M#"1=9&B M5/LD'R8]?G,9!M$5 . Y0&2:0]3OP0VFR%8HG?-GFGVTKA-!0BB1!2H@/ .A M>-O12;T+]FW:-2(TAR(?5;C9)!::PN
M &PO M=V]R:W-H965T\]P]/)+GX5]J+WJ% M:."Y+"H]\E;&U.=!H+,5EESW9(T5K2RD*KDA4RT#72ODN0.511 OE@0E%Y4W M'KJY1H/96,*4>%4@6[*DJMO5UC(]
<@+O>W$G5BNC)T(QL,:+W&&YJ&>*K*" MCB47)59;R H4+D;>97A^U:?^SN$/@6N]-P;K9"[E%VM\S$<>LPEA@9FQ#)P^ M3WB-16&)*
(VO&TZO"VF!^^,M^P>GG;3,N<9K63R*W*Q&7NI!C@O>%.9.KF]Q MHV=@^3)9:/W5[>36X__WHSN9O])/?'S[> M_PFG]WQ>H'XW# R%L(Y!MJ&[:NFB[] E\$E69J5A4N68O\0'E%J77[3-[RHZ
M2OA+4_4@9CY$+.H?X8L[O;'CB_^#WD,R6Y;^819[4\YUS3,<>705-*HG],9O MWX0)NSB28[_+L7^,?3RCFYP]<@YOWZ01BR_^]?1W1_B M _^?"Y]S #698S@D3AVXKX@Z8)GV?I2&
<0)CTPAC>P\\V$DF[MEB5MY2YTZH?1P&>,OQ8,=(/23 >OMR?B7O7MQA'8LS&>#U&<_M)=T4;6$O/>O,] ";-$'CC!V6C<1MB6M78KHN&2I#G8A6A#8VNMS+9+T5;234 MC-
I'$NG[!WZ"D(]I[]$M72-20-F6PJTI[:W6S7\R[:IW[GWC9. MBKL4E88"%P1EO:.!!ZIM0JUA9,T>_KDTU$;<<$5]&Y5UH/6%I-W<]TM@ M_#=02P,$% @ *H (63!VIQCA P "1. !D
!X;"]W;W)K&ULK5AK:\'[8M9EO#!C:W32UDW;Z4<&R MS2P@%PE[^^\K :%^$$H:Y4,.XIYS[M4]MI F1UQ\)3N$*/B6I3F92CM*lV-9 M)O$.99#"W">2YHF M.7HL
"FS#!9_WZ,4'Z>2*KT.+)/MCO(!V9WLX1;M$'W>/Q;L3FY9UDF&'P5\'N"CN3D&O!*7C#^RF^B]512>$(H13'E#)!]'- + M<4]J_^!8QUJ*!.*24)PU8)9!EN3U)_S6S,,)@/%T [0&H%T"C#< >@/0AP*,
M!F .!9@-P!Q:@]4 K*$*=@.PAP*(K\%;CQ$(5)2CZ!6_"\\L#-]Y\F,F4)PI_+_ [HRH] 4S2C(Y]Y/_P++!A/"QVAJE?>\2 M(I+,$TGFBR0+K&OKZ(:A&B/SPCK6M75T71TQ0UY81U!Z9]:Q6^O8O=:9<]N\
MP!3F,>IRB'U5K>88]JI=V' >J_+>YHLD\T62!0.G8R%2+2OC*09BJI.G%;T MK/5.VWJGM_51?D"$LNT\[?QM<*Y41[9F&M;EKWBOR'L[+Y+,%TD6#)R.A4C1 M\%K4T4;Z=2):=UX^V4AGJ-
A6ARH$Q+C.::T7:4?;&PO=V]R:W-H965T^D2 U&3F&L;N)7VX66&8/[N&8OQ.W$>K-9]HVA98'D[!O MV#(B'.,%EP@D_G9XC.-8DD0<7PNH4?]4AJ?[! I-UGC1F"?$\)C$?T- MK@$A7]JMS._]G=<-
*@M>0L2L^P7]L6]M@&++>,D*8Q%$!$F4YO_H6R'B8'K MO&/@%@;N9PV\PL![9>"]%U*K,&B]]N"^8] N#++*F6WG;,^%\O-&@1\D>]+Q; MT.1.IGYF+?
2*4ME1YIR*JY&PXX/YXW0ZO/\';F]@/ODRF]Q,QL/9 PS'X]O' MV<-D]@7N;O^^'[EYE+-;]6PYZ5V$#5K@OB%F-8;I#AN#G'W]R M.O9O=5G1*2-UP@)-L$]"6F6"6BKZ8+9-GC %L@2Q6E Q
M/5H132MALX/6WWJK@F=Q7%VZ7B[4\]GH]][L4!F7E*.0Q#3() 4 MP]"O'1!*4NL]SM.F@NN$!9I@%<&O2L&OE((_FG,3'D3YQ+9"ZY%X+)4+Y%F=
MS$I0T[E#)\S/88Y]T@.NS,Y597NU5M:8=$W//MV.RVM%6<<^E@VV4MLIXEL: M\1?@F"9UBJKMFTJJE>9_T#8'7C"B=:U95QA5T4]J-4I1&R;9>;J5E8[EU MTGRMM$ 7K9H#]Y@#]P?
61P5<5YITTGRMM$ 7K9JF8Q7K*&NP[WIF5Z,;\)E[MLX2WWSZT:_49Z*)5Q3]6]ZUKT@&:G-&@NKM0352@MTT:H).!:L3OM' M3E):BU:M-%W&K+=!%]Z;I6-\ZZ@+W?U4$!5/QLF2L=MM8-
8?8RWSX>GG\3F2*ZBE(&,5X*4]N\% K3_#-# M?L#))GN/_D0X)TFVN\8HQ%3>(*XO">&' ^F@_-@S^]02P,$% @ *H (M69U9.BG? @ <@D !D !X;"]W;W)K&ULK59M
M3]LP$/XKIPPAD("D:VPJ;:0V+2P3A8K"IGUTTVMKX=B9[:3P[VYZ[>^SXW%D+>:^6B!H>8L95UUEJG;1=5T5+C(DZ$0ER\V4N9$RTF_4C0GECM_):&/I=T2J&>4XEJ#2.";RL8]K+M.S7DRW-#%
M4EN#ZW<2LL)ZKMD+,W,+5EF-$;NJ. @<=YU>K7VL&7],X>?%-=]8PRVDJD0 M]W82SKJ.9O-"AI&V#,2\5A@@8Y(I/&GX'3*D!:X.7YB\]J-[5.&) L%]T MII==+YYL#,YR3E.D;L:
Z.13U9@I%@*GO"NO#U'(A2I45(<@$T&,>7YFSP4,FP M#$\UH%X ZB\!S5< C0+0>&^$9@%HOC="]P!DI;MY[9EP Z*)WY%B#=)Z&S8[MR-3/T$8ORNT^F6AIOE*#T_[D;C3JW?
R&ZW.8A!=7X7D8]*YNH1<$UW=7M^'5 M!8RO+\,@'$[@&"X%7QPSL[S($JA5K!/XN0,0AZ)&&$3!U1P,$!-*%,'!G W M&<#!WB'L >4PHHR9O:$ZKC:)V .!N5"39SY.LOY)D T:"ZZ6"(9_AK (_V(X_
MW8)WC6"E:O4GU?KUK80_4GX"#>\(ZEZ]69%/\'YXHZJ_U$Z]LRK9=TDVV"79<$=D MSQ:H62Y0@RW>>15NAM-)$;YR+JW@DBD7.>'06DM+PB]K"^^L/=K[:!681^8
M"T7>___1Y[>1$9$+RA4PG)M0WLE7DZW,.WP^T2+)6MA4:-,0L^'27(I06@?S M?2Z$?IK8 ,4UR_\+4$L#!!0 ("J "%FV:V--E0, %82 9 >&PO M=V]R:W-
H965TM.]=,%)4,%FMFFZ _YL0UGH49;>O#<)-OY^?D_8LCT]$/K]@AQ M%3DF,V,/>?EA6FR9(*R,Y)B:!XLR6T@%PTZ2Y+PXVL#-5J;4GC\ $R_4L&+8.XA0R)OV0IW\^,P IVL(JY[?D M\!$U
7F2EY(PB%\2LD!4#E:T.2#RKY2BWQE6'XH&T[% MVTSH^'QS=WV]N/T'K*[9OGA9GFU#!O77,ES&&W & M8DAQAG<,O,L)8^]!B<0GMX<4@7<1XC#+1=\96$0;)O[4"S8UN?!2VC*3QJ/+
MVB/G%8]&X)I@OF<@QBE*> _31L-X?T)LB.VV*G.<473]#P$\5/@! M=,(BG:!8$ZQ3(*\MD#XP>D(TR9B8*P*_K6?-86#6#/+>6A2=L*B&>0HF M]QZ/<]OR)V//FIJ/Q_G69+23;[_-MS^8[[@H<_(-
(;#A)'D JU+N1/2(/AY M:YIUPB*=L@%3K%.+<5N+\2]6:7>G?M@SS/,F7G=4=!HL_A&L$,DC7DR&/.J MXHO#G(HM[. R/$AYZ^>G$Q;IA,6:8)U2V-:W(![JZ11EIID59:K(O6 M+=/\)=#6M4XTI.-
)&TR"8.3Z+U:*OH&^:_G!B[7B5&#\8V =O7ET3BX0W:D+ M"@824F%>'X;WO829*&._B_Z+^V+T.[IC^2EB3J7?\?7-R[7D.XRS$*.ML*4 M=3X6SM+Z$J-N<9*+,KQ[W"*:
(R@'B_980_MR0!MJKI/F_4$L#!!0 M ("J "%F_$"6/T@0 #$C 9 >&PO=V]R:W-H965T^&C UC*)*7G@2*S3 M%/- [DC"-D/#-CX*'N/%4NH"N#JS"PILS@E5.2,(D[F0^/6 MO@GMMA9D-?
Z,R4:L''/=E1?&7O7)_6OH6+I%)"&1U BL_KV1.4D235+M^+N M&F5.+=P]_J#[6>=59UZP(&_6_(AG)_*1:4)2=*BC>1%+1/87 M;?*ZW:Z!HK60+*W$J@5J3//_^T8B!V!XQP1.(7 .5?0*@2M?
4'OB*!="-KG M1N@4@LZY$;J%H+LGL*^//"!%H+"?C:[^71D<^EBB4<#SC:(Z]* MI@\R0V1J-84QU=Z=2]ZNQDHG1[?C\>.SYZ+[R9/WZ$V?T.W$1?[]Y'8RO\$ MR8IV/OKP9M,/?35)1+'B?
AM8$H556O-J(APET=PCD1HH>^,RJ5 'IV168W>;=9W M3^G]9KWM- !,-5SEF#D?8W;G-!+_6-,KU+*^(<=RVNAYZ]*O7^H&9GP^IM6 M<7^B-2B6)*UA>3!-\ILQ+HD4QJYBCC4I.)_E'&.$YS-
L));8$]'@@U9Y[0R M;.M_W3MU=TS.;==S]>OJ1JQP1(:&>A\PO^[.?XU%]MK_5[G,DB8"PGS(&$^_M)"R A(5 L(H'VZ4'VTWTT62=OA".V!Q1)HE 2Y:.'!=HLV0JM8B(2@QF*&(J
MUU#*%.$L7_CUV%]TUAKK4EI P%O+F0<)\2%B0PSH93&>=:R-G8+[M>@TH7,5K MG=)KG4:OW4817RL[Q50219<(TQF:QQ33**8+1-Y50BV(\M>7.G/E[.Y.WVR[MW74Z=K6'X\8V7.J;.X-
ZD$'],X,&D$%#(%C%&-W2&-U&8XP9?2-;BQ(F'M],.*MO10,.IQ_M,EP &2X$@E7<8EO;)3SK$ /R KX[5CI=M2QK+S%O;L6EABAH^UGR05@/-*Q_M;M@ -
&P(1:LZ9&>1UVYTR/V',TYYP3X8G0,7G*SBG][BG:[B-W?ITB<^*'V$ MHE6GT]E.I ,.3O[?4I.Y>F&07?F#.,,97BF[J6IHRBJ631:^W<-\:\].4!2G-! M:1XHS0>E!:"T$([I6]>EV?=S^K
5R&W2%)3F@M(\4)H/2@M :2$4K6K&[4*Y MW:Q2/LT^^Z!8"]TKK5?J61AECTN1+XK7?18JS BZ+@Y*VB^VYQ\K=[^HIX8MLCX50MEE3F7^B*4O+?1RWV>Z%O?([^V9LUY2[
M]HU75^[K_2#9]_UMV'PSR7?,%S$5*"%SU03KJJ=ZP//]&?F)9*OL;_\+DY*E MV>&28/6[45=0U^=,Y07%B0Y0[I(9_0=02P,$% @ *H (679KPG'S @ M^0P !D !X;"]W;W)K&ULM5=K3]LP%/TK5C9-
M(WRZI.UD4I+M4[0H9;"9S>];2\T[.N;Y) M;CH[ON_%&D"BAX"&HFNLI=R,!EFK*5Z;8<,"+&!10 MT[&LAAE@$AI>)]YVS;T.BR0E(5OS)*(@P/SQ'"C;=0W;>+HP(:NUU!=,K[/!
M*YB"GVNN9J9&O99WW8T((ZX); 3>V.DK3T:)K M6%H14/"ELJM(4^4*J9E(X_*:F1W5,#]\=/[./8O#(SQP+ZC-Z1A5QWC9:! M%K&#$$943MOL]J:&ZYO,9%?$1[=)8RT!^')"0+4K!2$) P.>,'-!%[
+OV"L!) M 2JU6B<-(:]D83 M=-N[G%V@WT,T'(U[X_ZH=XE&X^G-9'9U.;Z9HA,TO(2C+:.81()UZM7]^Q#D) M5SJ%1*"C 4A,J#A6L9-L[03-I@-T]/6X8THE5=_0]%-9YXDLYQ59OZ+P%+G6
M=^183JT WB^'#\!7<#N&NWFXJ1*49MRlVP_11Y+@BLIQ - /OEK%[=YAS'$!$"9X32N1CD=N$%A3 MZ+?'UFLWG7JMH39@NV_D95S+:,N:O;BW>D(K*[:F*+>]|K\&Q/Z-
"4]:J&ULO95M:]L P$,>_BA4D M!!(T#VW2=J21^C"T@;95ZX#7;G)IK#EVL)UV?'OL) U%9-E P)O$=N[^]SO' MYPL/7-S+#$"AAYPR.;,RI8HSVY9Q!

MU@"I49(8WQM-*TVI'$\'1_5WU>YZURV6,*2TR\D4=G,FE@H@127 M5-WRPP4T^?A&+^945D]TJ&U]WT)Q*17/&V=-D!-6O_%#LP\G#I[[B(/7.'@5 M=QVHHEQAA:-0\
,2QEJKF4&5:N6MX0@S/V6CA/Y*M)^*-G7*-7*U"84/D:O4S$_1<22%!!,0MMI<,:9SMN0BSJ$-XC(0)T MQ9G*)#HW(C_[VQJW92:,S NO5_!#R09HZ+Q!GN,-D,RP -DC.VRW8EC)#G]S M*
[HRKI5&W4JFD,YD@6.86;I2)(@]6-'+%V[@O.OA'+6 M(BX2PG0Y-?N FG@)T@6+B)0E9C%TI5 '<>N#86IW'SD#UP_M?0>;W[+YO6S7 M9;X%\2176JI20"]>'<< H?/MV 00L8/!.PX<)[?- OD MJLU!
[*]&(E',2Z;]6[==;7O6O+ZJ?YC7#>*BQUA$E%(M:LS&.OHHFXB]4QO MHKJXMUSI-E -,]UW01@#_3WE7!TG]D#;R:/O4$L#!!0 ("] "%D(I?R* MF@0 .H6 9 >&PO=V]R:W-H965TV!*5!"0S ?
&5;,=O&'6A[A>P M:.VC??:UZ\<:'1E_$EM")'B.(RK&UE;*W;5M"]+8BPZ;$>H>K)F/,92#?G& M%CM.<) 8Q9&-',>U8QO2:S)*[BWX9,3V,@HI67 @]G&,^WPABR) +Y;<#6RIJ@V3&7R$YBM(U
MT%16C#WIP==@;#G:(Q(17VH(K/X.9$:B2",I/ [.0*U\36U8OGY%_Y*05V16 M6) 9BWZ$@=R.+<\" 5GC?22_L>/O)"/4UW@^BT3R"X[IW$'7 OY>2!9GQL]# M.*3I/W[.
E$R0/TS!B@S0'6#WAF#;F:01,Y./4MHW6*))R/.CH#KV0I-7R2Q M2:P5FY#J-"XE5T]#92W8+9 'YQ]["VH0((&^YG9'B(#@*W"D,
<"O<;B!AD1]C3#N@ZOP+DH%Z30V;S6^(K>"7TRWTLA,0U"N@%8@A79A)3[M 5L#N25@1WC(FC;-38H[2'!U#SM,H-N!*A^',C?CZA=RZ^?<^D9NJOVL2:@2 M:\\P]54#4RG^%%
(0L"C"7&AN:5%];N*78OYIXCK>H$:L85(ENQ6/![G' Z/'T]ME8 ,\R6GVTFEH"]Q#TL9,H M@N"[:I(\>M%9F>_T&[21LM6A,;>:C1GEHZ77%EJ5]%-/ < M6.\Z9G_;)P-WRU[!^K>/V8,+
M$X,*S8+@QPIOQJCDV)=('(%'PN/&UR R"]&/UEY;:-40%(H'F15/F;%4C),,, MOQ"5W^:LFM&&J2E ($Z/>WH@P"]-49R]$)DS(54Y%XH'&:,7%V8UMH&T&'&3.
M#E^=1FCPJ6$T'DNV2L\D5DY+%R>668"4<]03U?,V8?!WH!?+C[&PO=V]R:W-H965TP%/ M:,N5!.3ZZRL)O[%CX8:KOH!>=I_=?59>O4P.A#ZQ+0!'SWE6L*FUY;R\LFT6 M;R"[(*44(B9-:$YY])+-
S8K*>!$>69[3E.8.!^W2SY7+ GDU*O(5\(?RCH]>7:,D:0X%2TF!**RG MUMRIBEQ?*BB)/U,XL$8;R5 >"7F2G>MD:CG2(\@@YA("B\]+"'+))+PX^'* MU*IM2L5F^P7]LPI>]/,(&2Q)]E>:\,W4NK10
FN\R_@\.?P&54!#B1>3C*E? M=*AD'0O%.\9)7BD+#_*T./[CYXJ(AH+ T2MXE8+W5F%P0L&O%/RW"],3"H-* M8?!>"\-*085N'V-7Q(68X]F$D@.B4E]@R89B7VD+OM)"+I05IV(V%7]\MOIZ
MN_P#+>:K*$3+VYN[Z,M]_O7Z]@OZA%:O1M M04;-B/?"R,+K!?Q]5UP@W_D9>8XWT/BS?+^ZKPOG_UF/OMMZBPR_7AZ^PO// M7!ZZ/!^1!GHD6?"N6(ECF%]BHC&@>[!F/_W@!LXO.I)-
@H4FP2)#8*UT#.IT M#/K09[<%IZDHTC':XVP'B*R1*Z,*Y20)BPTBI?P^F2XŸ1]O X$_%!1BLBG2?T:^0%=/SV9'0= M&GH=.'*^%:.R0.>_)X/ MZI@CYK"M1)$>ZRFO(
MG59^+^O\7O;Z=R\0,8VW2)1:%,)>G+!+<5[F*#K]L?0BGIL+DV"A2;#($%@K M+>,Z+6-CYI.QR728! M-@D6&P%KI<)W7ZX1C?&NM(%N[X65W3]&(^9JMM1)K
M;A>NVX6+=%;') _=6MW&ATV/9ZOB5%"FDF(2+32*%IE":R?E]9:[]MZ;OJ]J^)ICX5!3 M-C1R?O?T&&KDAHZKJ1M=N<%PU"T<=N-1)@>Z4:IA3(2W* CQ EZ/UB]N< 7.
M]&9\X5XM7>\&TXVX)[(,UL*4'R.'4Y*)23T M2#@GN6IN 2= I8"87O/"7SK20/UN.?L74$L#!!0 ("J "%FB=B0&U@(M *T(9 >&PO=V]R:W-H965TKJ D_(K64,DK"\I*(N24+4U>,R!9(RH+ MT\;8-
TN25T82-^>F+(GI6A1Y!5,&^+HL"?M["P7==#@W+>#DQRYW(_1Y/=T\GT^F:/S,0B2%_P"7:*'^1B=?[R(32%74O5FNG.];5WM-UR_MK*LKY.!/R,:VJY&/CLO'D$]YUZ>/)[%58IPOK"-
/I@QJDF=H=D;*^GJ,4LH% MUR5N;?S&1FWV3>*[D>U:L;G9S](O<]T@"]*N[!6EVU&Z)U'F%5\S4J6@(VPM MO+VE+2*7/^ L%_F8BL*;#VAUQ%Z)Q'"LWQC#UJT(/8SV< MW\Y1^'&L #&($-
T(0=YM7SL[.?Q)EXA#"[L'E/TRQ_9*1X\9=)C!4'3[9?%D86=EP]5=A1A4>IO@+G S1?428N!; 2U7(D>XH.-.P1 M7/HZ4OVE==P0UZE"CXZBT6K[+&/5VJ(/5[P#QW;*6T-QK)JJ1?R-
L*7J9#=JAFNY/<$,%4@KR\H%2\3U;*Z+Y3D'U!+ P04 M "]@ A9#"JJ3K$" #O!P &0 'AL+W=QTD:;V")" JF7 JY=^:;(Y<;'=R_X] M=I)%7>-5>^"E\>6<\YWC^C+
<<_$@]):TJ)OT6(_-1#KD6\6*"F8"R6U94O%X"XSO M1X[O/ W,BW6NS(";#C=T#0M0=YN9T#VW4UD6)52RX!42L!HY- [UF!A\#?A5 MP%X>M9%)AEGLOY%^P:+$P=E6ZEXV9*U
M@[*HFB\]M.MP1/##%PA!2PA>2\ M ==!&V=UE E5-!T*OD?"H+6:-=1K4[-U MF](R_^)'''3U:;)Y*:\;C=UT@]9_9M/OB^D"74Q T8+)2_0!W2TFZ.+MY=!5 NM+!NUFK>MNH!B^H?
MU65PA[[U'@!:&%/CY/GT"FZ7Y-Q\ IKL[7A0RZD$&M MAU\9TA:H40CM"N8L7S 2=^]\6/OHRW>?Q)[%A9W8?$Y]72 N M%:G(-;JC#X*SIC-5T..C@K&OD]"?.*K#R->Z$>QW5?
4^8I>XPLI>K"O6M0K M,_2D('=6]QYB\][$WP%TERBE*$5V/W% 7 M=/Z2L_Y^]!S$V2V7],KB;$#(B;D^RD]"S^Z-=-[(66_N:+6W49ZV]O')(Z# MZ,24#>>1Q#O=;^[1A6P>PV]4K(M*(@8KS?
2N$1U+-],TU%\4] 1]USI&=]I N MYOI-!F$ >G[%N7KJF&N_>73?U!+ P04 "]@ A9R*X_GT" #0!0 M&0 'AL+W=O X/*9)/5L@G MM4+4\%PRKH;>2NOJW/=5ML*2)ZHD)N;I9
ET<:4A:\[B21WH)+Y41#$?DDH M]]+$G&M,#]_8[]TN5N)P]R7)(UTP]B>X5- M/@/+EPFFW!>VC6_@0;966I0-V"@H*:]7\MS480\016\ H@80.=UU(*=R0C1)
M$RFV(*VW8:,;EZI#&W&4VT>9:VENJ<'I]/KN]_9Z/+V;3R?P;3J^NKN_N?_Z M$TYA_D3YABJZ8 C'$]2$.G7RZOR&9O9Y> &DD(CFK30< >5P2QDS-5>)KXU&
M&\G/&CVC6D_TAIX0:@77+P53GF/^-]XWN;4)1KL$1]%!POM,]Z ??H H"# _# MXWP"QT'ZCK?_7X7K2KCP>OFL4UWKBJ2K=_S7:50;M!+W[\+X^#+ M 95GKC*
7#;]5O*V2^*"2BU*LS>]H5%3DO?V9M8B2 MY)VEB\IQ6L! EZ7E2@+-TL49#9.W7#M:3NN+NHN_>->S[I;(@O*%3!<&FC0 M^VA*(.OY41M:5*YG%T*;">"V*S-R45H'<[\40N\,&Z
=XNEO4$L#!!0 (M "J "%D3[_O6FP(*\(9 >&PO=V]R:W-H965TL-U7J/WT-% _"J#!7M*MB?16XCE9LNF,>C4$K-R37;S&6 M7*T2A9/1U7PQF7^YNOA^B29Q?+F(T([5W4,I<';+Z
$);3$OH$MCI9^,>KUKP1%]' MV+ 5UI+7;^3U#[]F2-*<4;9Y0)0DZF %E;'Q'&ULK5=K;]HP%/TK5C9-G;0U+Q(H@T@\LHUIK;K2;I]=PD MI%#<-&SY0FSGGG-\CRI);F1+V0-? @CTF";$]XVE$*NN:?
+9$E+,S^D*B+PS MIRS%0D[9PN0K!CC*0&EB.I;EFRF,B1'TLK5K%O3H6B0Q@6N&^#I-,?L]A(1N M^X9M[!9NXL52J 4SZ*WP J8@[E;73,[.DB6*4R \[@0QF/>-@=T-;4L!LH@? M,6SYWABI5.XI?
5"32=0W++4C2& F% 66EPV,($D4D]S'KX+4*#45<'\^\8 ^< M)2>1<C3Y&4=BV3)N*;KU DY"F^&4UX]HNV>;SO&FBVYH*F M!5CN(((U)?L6A1%[,FC!SG#%P'D:,+T < N 6U>A50!:=16\
I"E;N:Y9\:- ML7 MSO^IA_^L?F"&6U:#F_&Y=:M!=\ Y14M/H1YL7;[",^@;\LG%@6W "-Z]L7WK MD\[=)LG&39*%#9$=G$.K/(=6%7LP2"D3\9 \?T?G*"8"DT5\GP#@7G4A.YF=D
MZLVP"1S/LJR>N=FW6A/E'T6-CZ,4U;.H4!,E2] IHPZRl\JLO7M-5F*39,.FR<*&R [.Q" /Q*^LQ!>>2\,F-4NS6J_9I:G,ZM!M'/:TKA527ZJ6_4TPX8T#^SJE'9U7K/+U!G5 MJ6=7)?
FI=M73#!O2/+#KHK3KXC6[VC]I+NK954E^]EWU-,&-_LLJVG3UNK MTK#:):)2Z ;!3K:-WF-UQCWVK%CG5N]IJ85.]N77F7H.0 EMDG1E',IHF M(O\Z+%?+[F^0]3S/UM=V=V1KUL>]6\P:DB?ZO-
6\Q&P1$XX2F$LIZ[PMBX;E MW5L^$725M2?W5,AF)QLN9<<+3 7(^W-*Q6ZB!,H>.O@+4$L#!!0 ("J M"%GZUQC/E@0 +8? 9 >&PO=V]R:W-H965T-E8^:8DPF-
_XQ"L1Y:/0N%9(FWL9C1W>^D:%!;\18TYME_M,MM M.ZZ%%ELN:%(XRQHD49K_XL>B(XX"0Z=PZ&1]GW=6UM,>%G@T8'2'F+*6-'61R95YRPZ.4C6R[@23 M3R/I)T8S_\OXWO?
0=#R[_PO=S\8W=^/)_>?;FSMT7@6XP8U@ICJY[1. HYA]D MZ=<<[#[U_lV%@"QE?4>Q%$>LJC^6^$*N)KFDJUASY:4A"C;IG]N\8_&W9[K+Q M[E/CKUPC\(]M>HF;C8_(:;@M37TFY[LW=),R' MA 5
L(JZK5+=EHD^NJ'IQ9Q@%J4K%*6"R A"7H1D+DB8$LYU(AN1=46&A'DY MK)/!U-K],&HVU- _?CB6[!3,Z;9/S *@JE6$:92"M(W"W(HU8>A+A.=1'{G] M1S0C,9::H"EFZO9^OR'H;]1J,W
/"9R[MPF1,WJ-/U')YHY'&>B?[M<1@O" MKDDR)TPGE1%15ZJWU\>'K$_PIOI4).Z4$G>,3(]=HNL]8=IWS.A:]QV#A'F0 M,!\2%@#!*F)V2S&[@,MD%U)=2)@'"?,A80$0K*)NKU2W!
[],]DY6&1W&H+Q'&[Q/2"H03N@V%5I9C*"ZZQSJA M^]!! Ra:53GWH)QK5HYZ?HHF<0+1SQY79N;9:D#0/E.:#T@(H6E740][%@4R\ M.*"9%U":!TKS06D!0*%]T]B'UP^/1?G-
'^AVUEJS)YO*S4FVGVEODXSJ0:F MQOYH9OY2)LY/SIF\$J_>WM(,J_U. 5:-!ZU: $6KCH)#5L4QIU5J[2\[I^._ MI=U?@J90S@WK@X8-H&A580X9$L?XB5YG?PF:'P&E>07ME:G0!PT:0-%RY>RC
M8T4Y_ZVR V",%DJ._&"H+"T/FJS\BNG/W$TY9[3]_,CY ,^/]&^QFP5 MI1S%9"E#-2Z[&ULK5=M;]HP$/XK5C9-K=0V;[RT#*)1Z+1.?4% -TW3/ICD M *M.G-D.M/]^=I*F9$U#,^
#V,D]S]UASW.7[IKQ>[$$D.@AI)'H&4LIXXYI M"G\)(18G+(9W0SD'F*IMGQABI@##E)02$W'LEIFB$ED>-WTVHA[799(2B(8 M<222,,3\\1PH6_<,VWBZ,':+I=073*\;XP5,0-[%(ZYV9L$2D!
B05B$,,Q[M1M_N#&Q' U*+[P368F.-M)098 =ZO)PNK="2X[M]G?^QK"&?"J.NU$ M4Q^L,JQKA/;S M8&+7#@#[;X5;_+WI;.[&D67"W!A;]3O#->8+$@E$8:Y(K9.V:E4\&\,SC61Q
M.LG.F%1S<;IC@N7H:\OU!+ P04 "]@ A9VL@] M:G\' @6 &0 'AL+W=O_?+ MKB_S7 /]70=]Y.0I3GZF2\8X^16NHO2TM^1\?=SOI_E"_WT*%ZS*+OG/DY" MGV=7DX=^NDZ8ORB*PE5?
EB2U' I(!U)N>%++==)=.3,-70<2N$!)NPM!/GL_9 M*GXZ[='>RPW7P<.2YS?TIR=K_X'=,'ZWODJR: V=L@A"%J5!)&$W9_VSNBQ M)P_R@F+$OP%[2OV8RM5KF4;<=
M)=K;S9D7[E]^T8UBY[.=^>&G;!:OO@<+OCSMC7MDP>[!S8I?QT\6*W=HF'OS M>)46_Y*G[5A5[9'Y)N5Q6!9G6Q &T?9__U?Y0.P5R/(;!7)9(!]:H)0%RJN" M;$O:"P9EP>#0&89EP?#0 K4L4
\M&)4%HT,+QF7!^-'"25DP.;2 2B_/G/2Z MA+Y5LGNR#WZVZ-<3]8I7^?]'DV?8[TY^54VG8J^8VI*+F(((Y,B1XMV**E7A?7*^_5 MF^)Z55#?SQZVW6,GOSQVY[(0=#:1$:'25R)+\H#.14,:.8U/88'[
MRON[9!S.* +&Q&R-A=D:6\OH)XQ MM&!D >,U,+1K*[L^*4K@*YL]*RX:?;R<8M$^0 M+TZ,TI4_9Z>];/61LN21];:?/U%5^M:60"2F(3$=B1E(S$1B%A*SD9B#Q%PD MYH&P6H 'NP
/1/KT.A/]9+XD?K3(5K6/V7)]G2V^>5M2A5+7I"(O#8GI6TPM ML/S@YG$ZI!-E,#GI/^YGL#E,E8=4&M2'F# _":W2Y;X:[;AP3PE M=C0 ;@N.
<)]N@4%B&A+3D9B!Q$PD9B$Q&XDY2,Q%8AX(]\58W<58 >BUJ8H, M,!+3D)B.Q PD9B(Q"XG92,Q!8BX2[T!8+<"C78!'L+6I4,J:5"2F(3%]BPWW M5XFJ+$G2J[5I)Y9#ZEQ/CYG^B^Y350LDC
MM7F0"-U'!ZJY4,U#:?50R%4H9,27&-GAXC*,5_D:V=72SXX9Y\ $Y^1N-FM- MCW#.SNE!:AI4TZ&: =5,J&9!-1NJ,5#-A6H>2JOGNV]H1_>>4,AK3=038-J M.E0SH)H\U2RH9D.U!ZJY4,U#:?
4T5UTX%->&(Z8ZQO;;B /5=-ILBFDL89$3 MFN]/:$$GM*&; 15*N[IN?!_!>$F)/>;:%$L@XO/:UKC-6P> M]$K-@Z)9,8[*>P.'ZJ@Q4!-O6>=.,0+MMH)H)U2RH9D.U!ZJY4,U#:?6D55TW M5-
@3,)W%81CPX@ASS9(@:OL%Q_D]ADR>L[?#E*@D+'[*T?K&[<>$)B8ZJO/: M1@/53*AF034;]CE0S85]'DJK]{-JIZ'B?II9RZ= *?E-+AE?LH3'$;EYCA9) M'++6RS);;*":!M5TJ&9 -1,J65#-AFH.5',AFH?
2ZD&NNH#H^,_ ^X'V 4$U M#:KI4,V :B94LZ":;#=4ZT,WS M4-HV;/V]DV^&+'DH3BF;DGF>I7R2O5MWIZT]*T[>^>KV^,E#$*5DQ>ZS39".1L,>2;:GH]U>X?&Z."7HCYCS."PN
M+IF_8$D^(+O /H[YRY5\@MU)@:?_ U!+ P04 "]@ A93(-M"R(- !^ MK &0 'AL+W=O^UA,KO--M4PS^:$@Y6:U2HJO M;^4R?IX9N(,7!SZECXNJ?F XN5XGC_)>5I_7'POUV7"GS-
*5S,HTST@AYS>&#GU@.8[IW*YW+O8U+ *_9[FO]R;O9S<"IGY%R>6R MEM3S^*U%![MMU@/W/WI16#/JO_FU2(2GE7;(\)3V5BYO!>$!F\R M3JID89G5V[ZM"2355XZK)O:C!1,6'?
\:TT UW MA/[K\[N?_T.^CV65I,OR! (C^7P?D^__^L/UL%);]\<,IZU\MY6]$[)/WN>9 MM2@)S69R9HX?]F>Y>ZK>RU-]ZUG!]TEQ29S1!?$<+^AZ/F<,]V3P^/SA_L= MPZE]^#\VF1KNG-
PZ>V5XHH9[X3!34R0FKD*MKE*K+F MZG8Z+39R1N07-0TI9=D5(ZO0-T9(+$9B=(M%^R\$_CB*O/#@U0>Y4=ZU46<\ MU WQTNH+F2WV3*HZ"&U M&*I1],:@&H=] J69T?-
T]+QS9@CEA9I'RE*!LBW0JZ_6*Y_9KY/LT([-\ MN4R*BQIOEL5V_Z%K1?]MN:;0_*[H\F!'=V9]2[^ A-0K5&%3C4$V@-#-X>@?7 MM2[73NZW:V"[C*V2KV2]*::+I.P\?&LY8O'%'X_]X#!-
X#KI(#]5B]$:A&H-J'*H)E&;&3Z_XNR'F M> ZZS _58JA&H1]#:ARJ"91F1D^7 JZ]%4 ?ST$;!*@60S7]=JSG>P?] 72+ M'*H)E&;F3A<-KKUI>)]\.7^"RTXR,7T.Z@60S7::L9:D7]WM,^%-A50 M3:
T\]VLNJOP7NDJ-@_+=$H^S.>R2+/^LV5WED[8+O;-V-0+89]%*HQJ,.A MFD!I9A9UA>%A*@P/6F% M1BJ4:C&H!]':@*EF='3%89W7H5!TK*LWQ!7[VNW
M[[#LW,&VVOY"LN>,@JNK@X5D^U9[9PO:4D U!M4X5!,HSTO1L8OU MS]O%0D\]@&HQ5*-0C4$U#M4$2C.S]$L-+\#L8J&%!E2+H1]%:@RJ<:@F4)H9 M/5UH>/9S&/KN8H_?\!
[XKN^'A[M8:&,!U2A48U"-0S6!TLQLZ<;"LS<6'\O8 MKA,4W]J9WB]KT"H"JE%RD]:AVH"I9G1TZ6%-\+L4:&%!52+H1]%:@RJ<:@F M4)H9/5U8>-95ZV<+ MVDA
-0;5.%03*,W,EFXD/'LCSSF0=GQ81=2<+VB1 M-0K5&%3C4$V@-/,]"[IQ\,V-P\\+I2[RY:PNL=)\UIS"G,45J7(BLTH6),W4 MATE&$A7!YKRIT5FI.42;-)6@N2#*OAU<+2:;+ MO*P/!&?
U]^3SYK$/EA?'5YZS.W84];K_7?VH7U#*=4H5&-0C4,U@=+,4.OJ MPK>N3UM#W!U!?4Z^\Z+]6T63\X M;YS;^+Z\.+HL@!IA/D3D;YOT*5G*IF7^$_]0['\5Y9_)]"">!:I1J,:@&H=] M
J69_TYTS^+:>Y:NB3KYG=RKSU1J8^MRN)WN.X.":C%4HU^-034.U01*,^.X M=PDHT#6@L!>!PEX%"GL9*.QUH+ 7@L)>">I;-#&^;F)\ZW)

[[W.76LY8#W**P_2>)ER=>R0'[6*@&H5J#*IQJ"90FGD]8MW%!/9>H^#Y=]LWW#!=4H5&-0C4,U@=+,<.E.)+!W 7]\FM#*"MFF"?=N]$P9M$Z : M@VH0#:K%4(U"-0;5.%03 M*.U,I2X5
DRI$$!+]:@0S4*U1A4XU!-H#0S>GLWF+"7"N#SR-NMN?[>CMBY M=!SG:&\,[1R@&H5J#*IQJ"90FAD^W3D$!LZA[OU."X=?"]TU73B,%W0T@&J M4:C&H!]'.@*EF>G2I4-
PWD6ISIVJ'C<-)\(%[1N@&H5J#*IQJ"90FADNW3<$ M]K[A3TQ51ZJ/5:$5 E2C4(U!-0[5!$HS$Z8KA,!^KL9=OGI0#\W4'K&9LJZ< MJ;$]/NM,UA:T7P;9OM7>V8)V!%"-034.U01*,
[.E.X+@K*M']0.N:E.DU5=2 MR6+5&2F[XY&O4DT*.F>7T+8 JE&HQJ :AVH"I9GWH--M0=C[6E&[Y3;;&IN= M[;O0 =5B]$:A&H-J'*H)E&9&47<+
(>9242'T4E%0+89]%*HQJ,:AFD!I9O1T MZ1#^7^]V$9YSMPO[4^H=/&BO -485.-03: T,WBZ5PCMUY]X5H06/]UKT, MKXZN4V;??#Z-.(5)SP]C;"/]O)TS:$\ MU1A4XU!-
H#0S9WOWLK:W1+?+S2I+R<>V&B"W+V?"=F8->Q=E]K&VLL?>QQM[(M&GLG:^RMK+]%DQ#]D&,,'Z,6BH%H,U2A48U"-0S6!TLSHZ9XAM/<,ZA!N ME5;-6?_)*M^<>,F#GL
U6*H1]$::[7]R]",G8[+T'#H9@5*,R.EBX707BR\ MW*9L>E:TH"Q_ EGESY9%3LTOH M72:@6@S5*%1CX?'ELMS#&$%K Y1FQ"C2M4%DKPU>;NNT]PI5RFD]Q:Q/YCMY
MKW6[VC=>4"V&:A2L58S;E(?=+Q40;]K('6&"+K+#]5B MJ$:A&H-J'*H)E&9&3;__1QYD^AA!SRR :C%4HU"-034.U01*,Z.G&X#(W@#8 MWZ9VXAUJ=K-W#]%- 52C4(U!-0[51'1\
(W-]"&F&2R__1_9E^W=[%Q944?]N MO%"'_O+'^?8JU=^+:-]L[?\'13^Z-G?'H\V]<<':,UM;\XZ+\^.]4X-=-T?JE&HQJ : MAVH"I9D!U.O^$6;=/X*N^T.U&*I1J,:@&H=]
J69T=/K_M&YYQ?LI]/]@*U(M'Q?JHY>W$X9O-8$='5_U:.QVG$EJ?WI]0PC5*%1C4(U#-8'2MB$,]X]2@HY5R%UW]QZ@^'1XW?NF]BM'Q[]
M9G*]3A[E^Z1X3+.2+.5\JK*5\V"'YG,9%%_ M@_KZ/,^KET_J#3SGQ:_-TY[\#U!+ P04 "]@ A9FB/GCU@% !8(0 M&0 'AL+W=O_&P@.!#JNT2F?Z1 ^#[VXZ^- M/]@9;PC]RE88<_
:1PF;6"O.TS;9O,5CA'KD10GXIL%H3'BXI0N;992C((\ M*(YLZ#B^:,,PL:;C_-H#G8Y)QJ,PP0\4L"R.$7V[P!'93"S7VEYX#),-VCH&T\D+(
M5WER&TPL1]8(1WC.I002_]:X$D>15!+U^*\4M:HR9>#N\5;]F'E!#%^2 MZ#D,^&IBC2P0X 7*(OY(-C>X-#20>G,2L?P3;(I[?<<"\XQQ$I?!H@9QF!3_ MT6O9$#L!0J<])8!L!G0?R?
*P.\W&A1L]S6%>)H.J9D ZB\6ZC)@[QM\FCA M)DQD&F>GLYOSQ^N;^S^OKA]GOX+KOY]NO_P+3L SHA0EG($/5YBC M,&(?Q<6GV17X\//'L%7!2%P'<*\<$=2?
B*@>]LDP$]WA85KFH- MM[6^@%K!/[*D!SS&$X_[+?4YU(??H=H#SC#MO!:=;RJ$;U<'UZ^8SD,&P0,-Y^(34S!;(8K;FJZ0IK=+RU%\QE(TQO-+#%,&Z!1; MTU[^9YQQE
1AL@2(@Q>\#)-$GI %X"L,4DQ# M$K0U0:$[S'7EZXWM]:XW;>E'>AM4W@9::U\P%8,/R1Q_"!,0D"A" ME$E+@,GS M@Z*0G)0LS5P&JZTY1[IRJ]<^*8=D3"8))\'W\^7OYZLW&C:,;8L^
MTMBP,C;4&KM-. W%5#,':Q1E6#HB.UY)*J<0UF:MT/5WK#43IBWY2%^CRM=(MZ^N2Q+&8^[9/YS8#6H%#'R>&Q&I>3RNOI[T[5$]-MH(AL5HKN(Z:H!UMSG^7
MJ6[.FN6LZ[0,1+_17_7RQU9_AR]<;?5%L@C5]EB]P*'),I56MPN57=A=KRVU M3;6$(;5Z2R@FK>:,@5*KM3KZ^-QIY_6IT MU&TIR"UE+/MR9\ WF8VS3,KYIC*ZX\S@KZT@UVWD-
3. Z%N6;&/JX>?^A & MW\!=F(1Q%K?Z,<0SI9\NZ,A5>.3Z'0YF0P!4MD07..4JGG+U0&6ZUP_WT1@V MYZTN0,M5I.7J46N_TZ/7=SN]4>@RI58WKK#+[9"[7*/@94JMOL:@R
OJR7Z=C/2M<@WI<.[^:M4*:/NS0Q)I2JYM4D :UD"9-@JRO[+X1?11^3I_:* MQ1M-WEJ6I!QG,').FV^-^JH<:U61%^R0O*!1\C*E5F\)15ZPJZ4LN+^6Y4-' M_#53W05H005:4
l:^L@^8@HU1E2JV^5:*H MRCMZ/:N,K$TK+ASL=UE]$<=:4)#D?1=]H/CD+&-75VM?C9PGF^6V^KVXC<'=X@* M>F4@P@L1ZO2&P@PMMO&++$T[2"?
\A7!.XOQPA9'HR_(&\?V*$X]D054/Z:8 M_@]02P,$% @ *H (63J!Z)!. @ ,@4 !D !X;"]W;W)K&ULC51K;],P%/TK5IO0]$F2Q_ 2"*M#\80FZJ6P66&^0QMZM(@$ MVH
\2&%*32:B@.+O^A"5M?+BO;QA?!;P:R,ZI!N](W$4]\C3?$PN+ZX(72D MO!GF#$.W/8"N8^C^]P$<:]MC](YC6./Z76T?A%OO@]=T_YH\4+5B0A,.2RR-.N^177F^L#(VKEB(0UZS$U+
M?-1 V03<7TII]H$E:) _)[ ]02P,$% @ *H (6?I;93Q4 P [A0 T M !X;"]S=`EL97_N>&ULW5A1;]HP$/XK4;I-K30U0-1 5D#:D"I-VJ9*[M*D,LGI[8Q2 M[2TR+H]!/L_Z_Q $Q61&,U*4)
4$93SHM%I1D!$F M_&%?S+/K3!?>1,Z%'OC=VN79R^=DX+>C"]^S=".9T(%_?_KNQUSJJS>>O9Z\ M/SEIW9]=;?M/2^#,#YRDEWN0GK=P7H-AU-$F]6IZZZTA.VTL++RI[(=PC#B
MGD-7HPG5$[OU_'[ZA12@07:6H-O:KP2[BU"5(:A::=A/I6@Z*O2MP^0G&?4> M"! X(\+96#&(2DG&^-*Z,^"82"Z5ITTK&T%M\!2/%FY;"[]\XLF8D*K,;3/8 MW^-]^A:PLD
@X[P6V/&M8]C/B=94B6MCE)-+YS/(]\9WR]PHG"]R;'4-K0+ MO5$T98O27]2U (R]C;.3/.?+CYQ-14;MXO=...R359PWDXH]FFS0*A/CH,KW M']C2;++N^:E(?
D<7>M5.BQ37W#E"S?]VGZ=44$7XNFC3^X>\RR]6"9?2W+Y M5D6[-18O=3E,8B,#E]D&!^^QNKL=>@B>\<@\AC*W7VU)_M.D4%U$EH[M;FT]-
YXQK)BIKQI*$BF=G+D.OR=C\,;?!;^8G-"5S MKN]J<. WXZ\T8?.LKF?=P$94LYKQ%UA>.ZI/U"87$PE=T&14F6HZ+H>>&9BL MU0<"MI'K\N-&L!B+N1' L#R8 BS&1F%Y_J?U]-#U6
S3UG,B/32FA\;8*!(;O[M *OIK@[!5HIW(K92?*\!<>\;1,2QN]I8'HC JH#U#N1WYX&>$(505TX;= MP3@2QQ@"O>CNT2A"=B>"K[L^V%T2AG'L1@!S*PA##&(&[$4-8?20$3;
M8T.P6BP^0"X99K>]9!:G1$$PP9B23=_?65<#PK$G*G+Z]?# ++APO2N;KF\W,C]V^: MYA][LZMJ-1O=M>W#V7BLBCN^8_]WYH'7^LBVD3O6ZEUY.U8/DK-2W7>[JJO
M/YF78WFE:7K2BJ76C:;@2_%G].&YVT9-0XD94HOTV&W7; M%1^AG:C%3GSGY6PT&2%UUSPO&RF^-W7+JJR0357-1M[^P!67K2C>-&<&,F I"G;B&3=(%C^A?.:1(C', _1^2:C,T C'.
<)1 ME&SBG%J0GP#(3VXA-4VZ(7-$XYRD),N[4%[0&,<1C1?V#.E-H'E\XA;S M,4 M7>'5AIAPOO#AE<:.\G1S:6."NG'LFRQ/HJ_H'&=8 M->N4K#&=(_*G02/V:/8@N7B.
[7)X"H>X0]XCH5"XY,5C0S2'.4D6L):*EE< MVW202#S')M%C%L<+>KXB"<&>9R7MA@^3A.;9'2E8XUR%;XU1/T7F%3"(S#CH M$4+^\!P+1$]U!*?1\E<]3.-LL\K-9(<7*2&7).X'$C*
(YUHA2YR29;*:DS3[M"1$MO;SW]$'B\]R;0P?.1(WHB;@W8'W($[YC3]R,UN%;Z4-J[\!VK8% MUEQV7S?+C[E01=6H1\EM2' EMV@M%:BY!+EDI5Z88FPE*R^-0E^]VQ&R!6^ M8U>
:54OR?\E[&@GW/6D?S A(SB.S;*Z\3E!4_] M8@-"0O$="^5U!C,("*G$=ZR2-\G"("$D%-^Q4-[/&CI4NPX"*29PK)@A)P_% M,H!L$SBV#;A [M>4(-\$CGT#S^5V+20
:U]'54YH8T+*"1PK!\:-X7^)RW3-B8D'X"URN9[S!/4-8VA8T) M.2M^ 0L_=LAI"#0L<.>IL.=3>[Z@DHA 04.A;0VWQHB!!R3^AZK3-8VS$W M^E[43_ :'2'WA[=,Y"W#442_-?%>97L-
>()PF4IS(FLLFD(>2=T+%W9/SR M!,7,QH2\$QZM>&;"NK,Q(>^$QZR@]6=*R#OA$2IHPR,(TD[HGCM#E"?H#\;]M+D!W2RQ32SO1_KZX-AG(*B6>Z?U?A\
()"R;>BYF6L^U>ZO6!5L9;(?.S_+ FG MILBY?:RJ2+%]A\.[&E_^!5!+ P04 "]@ A9H9?JE,D! "@ M'@ &@ 'AL+U]R96QS+W=O/@@*FC1NNWB\7%FU_;')EV6_#EVSW#7K&'0R
MF8;^YXSJ9?9SYFAQ(N)?)K:KU7897]OEYR$>\R^#PU?;[!(FOR~$DV_CGE> MA=/^?CJ%ZT'&E\G5Z.UC7O5O'U*%TD$*05H^R"#(@BQJK01Z
M*^JM!'HKZJT$>BOJK01Z^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z MVV"SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U
M;T>]G4!O1[V=0&\?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=H]XU M@=$XUZEW_]IXIG_UW7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5.>1N7&5#O'1+9C5V4HO
MB(G!8,0R4P>]0S\T-9+I^(GF>EV&WO,VOO:%J2>)HJGONL:N__CG:W--*%_4QG[5_H*>?M4$L! A0#% @ *H (60=!36*! L0 ! (! M &1O8U!R;W!S+V%P<"YX;6Q02P\'"% _4 "]@
A933P-S.X K @ M$0 @ &O 9&]C4'O>'<,O8V]R92YX;6Q02P$'"% ,4 M"]@ A9F5R<(Q & "<)P $P @ ', 0 >&PO=&AE;64O M=&AE;64Q+GAM;%! + 0(4 Q0 ("J "%DZF)RT, 8 *,C 8 M "
@0T(!X;"]W;W)K%P & @(%S#@ >&PO=V]R:W-H M965T&UL4$L! A0#% @ *H (6:&PO=V]R:W-H965T&UL M4$L! A0#% @ *H (62[ONLF?!0 MQ4 !@ ("!W24 M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (M6?A)1O#(#P ;2P !@ ("!53P 'AL+W=O&UL4$L! A0#% M @ *H (6;&PO=V]R:W-H965T&UL4$L! A0#% @ *H (6<[&PO=V]R

M;W-H965T&UL M4$L! A0#% @ *H (65V(9#Z(@ D@4 !D ("!&W\ M 'AL+W=O&PO=V]R:W-H965TZ$!X;"]W;W)K&UL4$L! A0#% @ M*H (61#"[$!$ @ B@8 !D ("!W(< 'AL+W=O&PO=V]R:W-H965TB: !X;"]W M;W)K&UL4$L! A0#% @ *H (6:ZI@Y7# @ M)P< !D ("!UYT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (6>]H%':, @ P8 !D M ("!S*8 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ *H (63!VIQCA P "1, !D ("!]Z\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (M6;9K8TV5 P 5A(!D ("!R+L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (624M)M"= @ U0< M !D ("!Q\< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (6:)V) ;6 @ K0@ !D M ("!O-, 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ *H (61/O^];; @ KP@ !D ("!9=P 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *H (6?$8 M]PTZ P & T !D ("!@^< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H (69HCYX]8!0 6"$!D M ("! P ! 'AL+W=O&PO M=V]R:W-H965T M : " 4 1 0!X;"]? 3 " 4$3 K 0!;0V]N=&5N=%]4>7!E&UL4$L%!@ [#L %! #45 0 $! end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 157 209 1 false 41 0 false 8 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995200300 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 995210101 - Disclosure - ORGANIZATION AND BUSINESS Sheet http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness ORGANIZATION AND BUSINESS Notes 7 false false R8.htm 995210201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES Sheet http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties LIQUIDITY RISKS AND OTHER UNCERTAINTIES Notes 8 false false R9.htm 995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 995210401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE Sheet http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense ACCRUED INTEREST AND FINANCING EXPENSE Notes 10 false false R11.htm 995210501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 11 false false R12.htm 995210601 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensation STOCK BASED COMPENSATION Notes 12 false false R13.htm 995210701 - Disclosure - PREPAID EXPENSES Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpenses PREPAID EXPENSES Notes 13 false false R14.htm 995210801 - Disclosure - ACCRUED EXPENSES Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 14 false false R15.htm 995210901 - Disclosure - IN-LICENSED TECHNOLOGY Sheet http://www.quoinpharma.com/role/DisclosureInLicensedTechnology IN-LICENSED TECHNOLOGY Notes 15 false false R16.htm 995211001 - Disclosure - INTANGIBLE ASSETS Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssets INTANGIBLE ASSETS Notes 16 false false R17.htm 995211101 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 995211201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Sheet http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Notes 18 false false R19.htm 995211301 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquity SHAREHOLDERS' EQUITY Notes 19 false false R20.htm 995211401 - Disclosure - CONTINGENCIES Sheet http://www.quoinpharma.com/role/DisclosureContingencies CONTINGENCIES Notes 20 false false R21.htm 995211501 - Disclosure - LICENSE AGREEMENTS Sheet http://www.quoinpharma.com/role/DisclosureLicenseAgreements LICENSE AGREEMENTS Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 99930503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments 25 false false R26.htm 99930603 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables STOCK BASED COMPENSATION (Tables) Tables http://www.quoinpharma.com/role/DisclosureStockBasedCompensation 26 false false R27.htm 99930703 - Disclosure - PREPAID EXPENSES (Tables) Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables PREPAID EXPENSES (Tables) Tables http://www.quoinpharma.com/role/DisclosurePrepaidExpenses 27 false false R28.htm 99930803 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://www.quoinpharma.com/role/DisclosureAccruedExpenses 28 false false R29.htm 99931003 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.quoinpharma.com/role/DisclosureIntangibleAssets 29 false false R30.htm 99931103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions 30 false false R31.htm 99931303 - Disclosure - SHAREHOLDERS' EQUITY (Tables) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables SHAREHOLDERS' EQUITY (Tables) Tables http://www.quoinpharma.com/role/DisclosureShareholdersEquity 31 false false R32.htm 99940201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) Sheet http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) Details http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties 32 false false R33.htm 99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 33 false false R34.htm 99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) Details 34 false false R35.htm 99940303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) Details 35 false false R36.htm 99940401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details) Sheet http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails ACCRUED INTEREST AND FINANCING EXPENSE (Details) Details http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense 36 false false R37.htm 99940501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) Details 37 false false R38.htm 99940601 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails STOCK BASED COMPENSATION (Details) Details http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables 38 false false R39.htm 99940602 - Disclosure - STOCK BASED COMPENSATION - Stock-based activities (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails STOCK BASED COMPENSATION - Stock-based activities (Details) Details 39 false false R40.htm 99940603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails STOCK BASED COMPENSATION - Stock based compensation expense (Details) Details 40 false false R41.htm 99940701 - Disclosure - PREPAID EXPENSES (Details) Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails PREPAID EXPENSES (Details) Details http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables 41 false false R42.htm 99940801 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables 42 false false R43.htm 99940901 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details) Sheet http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails IN-LICENSED TECHNOLOGY - Skinvisible (Details) Details 43 false false R44.htm 99941001 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables 44 false false R45.htm 99941002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails INTANGIBLE ASSETS - Additional Information (Details) Details 45 false false R46.htm 99941101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails RELATED PARTY TRANSACTIONS - Narrative (Details) Details 46 false false R47.htm 99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) Details 47 false false R48.htm 99941201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) Sheet http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) Details http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments 48 false false R49.htm 99941301 - Disclosure - SHAREHOLDERS' EQUITY (Details) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails SHAREHOLDERS' EQUITY (Details) Details http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables 49 false false R50.htm 99941302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails SHAREHOLDERS' EQUITY - Warrants (Details) Details 50 false false R51.htm 99941501 - Disclosure - LICENSE AGREEMENTS (Details) Sheet http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails LICENSE AGREEMENTS (Details) Details

http://www.quoinpharma.com/role/DisclosureLicenseAgreements 51 false false All Reports Book All Reports qnrx-20240630.xsd qnrx-20240630_cal.xml qnrx-20240630_def.xml qnrx-20240630_lab.xml qnrx-20240630_pre.xml qnrx-20240630x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "qnrx-20240630x10q.htm": { "nsprefix": "qnrx", "nsuri": "http://www.quoinpharma.com/20240630", "dts": { "schema": { "local": ["qnrx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["qnrx-20240630_cal.xml"] }, "definitionLink": { "local": ["qnrx-20240630_def.xml"] }, "labelLink": { "local": ["qnrx-20240630_lab.xml"] }, "presentationLink": { "local": ["qnrx-20240630_pre.xml"] }, "inline": { "local": ["qnrx-20240630x10q.htm"] } }, "keyStandard": 167, "keyCustom": 42, "axisStandard": 20, "axisCustom": 0, "memberStandard": 15, "memberCustom": 25, "hidden": { "total": 27, "http://fasb.org/us-gaap/2024": 20, "http://www.quoinpharma.com/20240630": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 157, "entityCount": 1, "segmentCount": 41, "elementCount": 456, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 380, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_MlyOUZyckk-xZShLxAT9zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_MlyOUZyckk-xZShLxAT9zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "longName": "995200300 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_Wc6ZvZ_q_kGOxbzQO9Zflw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wsf1Cd0zNkOL-KmOVDPEag", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R6": { "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness", "longName": "995210101 - Disclosure - ORGANIZATION AND BUSINESS", "shortName": "ORGANIZATION AND BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties", "longName": "995210201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES", "shortName": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense", "longName": "995210401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE", "shortName": "ACCRUED INTEREST AND FINANCING EXPENSE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments", "longName": "995210501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensation", "longName": "995210601 - Disclosure - STOCK BASED COMPENSATION", "shortName": "STOCK BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpenses", "longName": "995210701 - Disclosure - PREPAID EXPENSES", "shortName": "PREPAID EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:PrepaidExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:PrepaidExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpenses", "longName": "995210801 - Disclosure - ACCRUED EXPENSES", "shortName": "ACCRUED EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role":

"http://www.quoinpharma.com/role/DisclosureInLicensedTechnology", "longName": "995210901 - Disclosure - IN-LICENSED TECHNOLOGY", "shortName": "IN-LICENSED TECHNOLOGY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssets", "longName": "995211001 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions", "longName": "995211101 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments", "longName": "995211201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "shortName": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquity", "longName": "995211301 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.quoinpharma.com/role/DisclosureContingencies", "longName": "995211401 - Disclosure - CONTINGENCIES", "shortName": "CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.quoinpharma.com/role/DisclosureLicenseAgreements", "longName": "995211501 - Disclosure - LICENSE AGREEMENTS", "shortName": "LICENSE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:LicenseAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:LicenseAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "longName": "99930503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables", "longName": "99930603 - Disclosure - STOCK BASED COMPENSATION (Tables)", "shortName": "STOCK BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables", "longName": "99930703 - Disclosure - PREPAID EXPENSES (Tables)", "shortName": "PREPAID EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables", "longName": "99930803 - Disclosure - ACCRUED EXPENSES (Tables)", "shortName": "ACCRUED EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables", "longName": "99931003 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99931103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables", "longName": "99931303 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "longName": "99940201 - Disclosure - LIQUIDITY RISKS AND OTHER

{"UNCERTAINTIES (Details)", "shortName": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_dCiwnR1VQkijRJ-auvWIg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_dCiwnR1VQkijRJ-auvWIg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails", "longName": "99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:GoodwillAndIntangibleAssetImpairment", "us-gaap:GoodwillAndIntangibleAssetImpairment", "us-gaap:GoodwillAndIntangibleAssetImpairment", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R35": { "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "longName": "99940303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_qnrx_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wNzGwXaFAU2xuQnPwQtllA", "name": "qnrx:IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrants", "unitRef": "Unit_Standard_shares_A9tajvMn0EqFljDnlbm-bQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_qnrx_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wNzGwXaFAU2xuQnPwQtllA", "name": "qnrx:IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrants", "unitRef": "Unit_Standard_shares_A9tajvMn0EqFljDnlbm-bQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "longName": "99940401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details)", "shortName": "ACCRUED INTEREST AND FINANCING EXPENSE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_6EfqEYth4Uqm0NAnEIXZzg", "name": "qnrx:ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration", "unitRef": "Unit_Standard_item_H8j43MI-PEePTubStZI8tQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_6EfqEYth4Uqm0NAnEIXZzg", "name": "qnrx:ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration", "unitRef": "Unit_Standard_item_H8j43MI-PEePTubStZI8tQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails", "longName": "99940501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details)", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UrqcVZKJm0er4Q7oIQzHog", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UrqcVZKJm0er4Q7oIQzHog", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "longName": "99940601 - Disclosure - STOCK BASED COMPENSATION (Details)", "shortName": "STOCK BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_Z4Q8NK-nKkigk9-HxJNh8w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "Unit_Standard_pure_669VT4btD0qDtXUMv5L1EA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_Z4Q8NK-nKkigk9-HxJNh8w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "Unit_Standard_pure_669VT4btD0qDtXUMv5L1EA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails", "longName": "99940602 - Disclosure - STOCK BASED COMPENSATION - Stock-based activities (Details)", "shortName": "STOCK BASED COMPENSATION - Stock-based activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_04uRz2OWU0iCokUFMRlXnQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "Unit_Divide_USD_shares_MlyOUZyckk-xZShLxAT9zw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_1N-GFRkEqUiZFiJCUfGsTA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_A9tajvMn0EqFljDnlbm-bQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R40": { "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "longName": "99940603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details)", "shortName": "STOCK BASED COMPENSATION - Stock based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R41": { "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails", "longName": "99940701 - Disclosure - PREPAID EXPENSES (Details)", "shortName": "PREPAID EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "qnrx:PrepaidResearchAndDevelopmentCosts", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "qnrx:PrepaidResearchAndDevelopmentCosts", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails", "longName": "99940801 - Disclosure - ACCRUED EXPENSES (Details)", "shortName": "ACCRUED EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "qnrx:AccruedResearchContractExpenseCurrent", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "qnrx:AccruedResearchContractExpenseCurrent", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails", "longName": "99940901 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details)", "shortName": "IN-LICENSED TECHNOLOGY - Skinvisible (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_10_1_2019_To_10_31_2019_us-gaap_AssetAcquisitionAxis_qnrx_SkinvisibleLicenseAgreementMember_KinYtidKckSihVQK93r7Aw", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2019_To_10_31_2019_us-gaap_AssetAcquisitionAxis_qnrx_SkinvisibleLicenseAgreementMember_KinYtidKckSihVQK93r7Aw", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails", "longName": "99941001 - Disclosure - INTANGIBLE ASSETS (Details)", "shortName": "INTANGIBLE ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef":

```
"As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "longName": "99941002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)", "shortName": "INTANGIBLE ASSETS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "longName": "99941101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_qnrx_Dr.MyersMember_FzdSQIXD80ObedVaXbLf9Q", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R47": { "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "longName": "99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Amounts due to officers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:OtherLiabilities", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:OtherLiabilities", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "longName": "99941201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details)", "shortName": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_qA16INxfjk2RFUS_Xt_sOQ", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_CounterpartyNameAxis_qnrx_TherapeuticsInc.Member_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_BOZaHLg2vE-uLFaMxXCSrA", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R49": { "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "longName": "99941301 - Disclosure - SHAREHOLDERS' EQUITY (Details)", "shortName": "SHAREHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_6_30_2024_jrgYSdbvx0yXo1X2rlDo5g", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_A9tajvMn0EqFljDnlbm-bQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_7_2024_us-gaap_ClassOfWarrantOrRightAxis_qnrx_WarrantAmendmentsMember_5fQSBMRoyUaCE5kDxPqOVw", "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure", "unitRef": "Unit_Standard_USD_QZqVAQO27kWk5_o3v7GOuw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R50": { "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "longName": "99941302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details)", "shortName": "SHAREHOLDERS' EQUITY - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_12_31_2023_04uRz2OWU0iCokUFMRlXnQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "Unit_Divide_USD_shares_MlyOUZyckk-xZShLxAT9zw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_qnrx_CommonWarrantsMember_uPiu5MSamEe5Hux94gm8_A", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "Unit_Divide_USD_shares_MlyOUZyckk-xZShLxAT9zw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "unique": true } }, "R51": { "role": "http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails", "longName": "99941501 - Disclosure - LICENSE AGREEMENTS (Details)", "shortName": "LICENSE AGREEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:NumberOfLicenseAndSupplyAgreementsEntered", "unitRef": "Unit_Standard_agreement_YGYEZszNok6y0Y2NjE_l1w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "qnrx:LicenseAgreementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_dtkRx7SKYUSatyLjpjzF3g", "name": "qnrx:NumberOfLicenseAndSupplyAgreementsEntered", "unitRef": "Unit_Standard_agreement_YGYEZszNok6y0Y2NjE_l1w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "qnrx:LicenseAgreementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "qnrx-20240630x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r324" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36", "r609" ] }, "qnrx_AccruedInterestAndFinancingExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AccruedInterestAndFinancingExpenseLineItems", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "ACCRUED INTEREST AND FINANCING EXPENSE[Line Items]", "terseLabel": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "auth_ref": [] }, "qnrx_AccruedInterestAndFinancingExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AccruedInterestAndFinancingExpenseTextBlock", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure pertaining to accrued interest and financing expense.", "label": "Accrued Interest and Financing Expense[Text Block]", "terseLabel": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Payroll Taxes, Current", "terseLabel": "Payroll taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "qnrx_AccruedResearchContractExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AccruedResearchContractExpenseCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research contract expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research Contract Expense Current", "terseLabel": "Research contract expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Salaries, Current", "terseLabel": "Payroll", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r572" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties Details" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated deficit", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r8", "r9", "r51", "r101", "r439", "r457", "r458" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r662" ] }, "us-
```

gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r46", "r609", "r820"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r475", "r727", "r728", "r729", "r730", "r790", "r821"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r675"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r675"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r675"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r675"] }, "qnrx_AdjustmentsToAdditionalPaidInCapitalReversalOfAccruedOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalReversalOfAccruedOfferingCosts", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from reversal of the accrued offering expenses associated with the issuance of warrants.", "label": "Adjustments to Additional Paid in Capital, Reversal Of Accrued Offering Costs", "terseLabel": "Reversal of accrued offering expenses" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r28", "r29", "r281"] }, "qnrx_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsExercised", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the exercise of warrants.", "label": "Adjustments to Additional Paid in Capital, Warrants Exercised", "terseLabel": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "ADR [Member]", "terseLabel": "ADSs", "verboseLabel": "Loss per ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": ["r628"] }, "qnrx_AggregateGrossProceedsFromIssuanceOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AggregateGrossProceedsFromIssuanceOffering", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow associated with aggregate gross proceeds from offering.", "label": "Aggregate Gross Proceeds from Issuance Offering", "terseLabel": "Aggregate gross proceeds" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r708"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r634", "r644", "r654", "r686"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r709"] }, "qnrx_AgreementInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AgreementInitialTerm", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Period of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement, Initial Term", "terseLabel": "Initial term" } } }, "auth_ref": [] }, "qnrx_AgreementWrittenTerminationNotice": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AgreementWrittenTerminationNotice", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Period of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement Written Termination Notice", "terseLabel": "Written termination notice period" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r675"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r682"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r638", "r648", "r658", "r682", "r690", "r694", "r702"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r700"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r313", "r322"] }, "qnrx_AlumniPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AlumniPurchaseAgreementMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Alumni Purchase Agreement.", "label": "Alumni Purchase Agreement [Member]", "terseLabel": "Alumni Purchase Agreement" } } }, "auth_ref": [] }, "qnrx_AmendedAndRestatedEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AmendedAndRestatedEquityIncentivePlanMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the amended and restated equity incentive Plan (the \"Amended Plan\")." , "label": "Amended Plan [Member]", "terseLabel": "Amended plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangibles", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r3", "r198", "r205", "r583"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r141"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r13"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not

included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r13"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r337"] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r203", "r786"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "verboseLabel": "License Fee", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r595", "r787", "r788", "r789"] }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Amount of payment to be made", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition." } } }, "auth_ref": ["r786"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r203", "r786"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "IN-LICENSED TECHNOLOGY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r786"] }, "qnrx_AssetAcquisitionPercentageOfRevenuesToBePaid": { "xbrltype": "percentItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "AssetAcquisitionPercentageOfRevenuesToBePaid", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenues to be paid under asset acquisition.", "label": "Asset Acquisition, Percentage of Revenues to be Paid", "terseLabel": "Percentage of revenues to be paid" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r786"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureInLicensedTechnology"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "IN-LICENSED TECHNOLOGY", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": ["r786"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r76", "r83", "r95", "r115", "r144", "r148", "r149", "r150", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r339", "r343", "r376", "r434", "r511", "r578", "r579", "r609", "r624", "r755", "r756", "r803"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r91", "r103", "r115", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r339", "r343", "r376", "r609", "r755", "r756", "r803"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r697"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r698"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r693"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r693"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r693"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r693"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r693"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r693"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r309", "r310", "r311", "r312"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r696"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r695"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r694"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r694"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation:", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "IN-LICENSED TECHNOLOGY" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties Details", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r93", "r568"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents:", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r12"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r58", "r112"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents:", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r58"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r673"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair

Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r670"] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair
Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r668"] }, "dei_CityAreaCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" }
} }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain",
"presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails",
"http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Class of Stock
[Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable
preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r88", "r97", "r98", "r99", "r115", "r135", "r136", "r138", "r140", "r146", "r147",
"r182", "r226", "r228", "r229", "r230", "r233", "r234", "r253", "r254", "r257", "r260", "r267", "r376", "r466", "r467", "r468", "r469", "r475", "r476", "r477", "r478", "r479",
"r480", "r481", "r482", "r483", "r484", "r485", "r486", "r497", "r520", "r542", "r558", "r559", "r560", "r561", "r562", "r712", "r724", "r731"] }, "us-
gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "verboseLabel":
"SHAREHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r97", "r98", "r99", "r146", "r253", "r254", "r255", "r257", "r260", "r265",
"r267", "r466", "r467", "r468", "r469", "r589", "r712", "r724"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails",
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant
or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r25"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant
or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the
right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors
by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange
instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } },
"auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of
Warrants or Rights", "terseLabel": "Warrants, exercise price of warrants (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights
outstanding." } } }, "auth_ref": ["r268"] }, "qnrx_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630",
"localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": {
"documentation": "Number of warrants or rights exercised as of reporting date.", "label": "Class of Warrant or Right, Exercised", "terseLabel": "Number of warrants or rights
exercised" } } }, "auth_ref": [] }, "qnrx_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname":
"ClassOfWarrantOrRightIssued", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation":
"Number of warrants issued during the period.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Warrants issued (in shares)" } } }, "auth_ref": [] },
"qnrx_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname":
"ClassOfWarrantOrRightMaturityTerm", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": {
"documentation": "Maturity term of class of warrants or rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months,
and thirteen days.", "label": "Class of Warrant or Right, Maturity Term", "terseLabel": "Warrant maturity term" } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities
Called by Warrants or Rights", "verboseLabel": "Shares warrants may purchase", "documentation": "Number of securities into which the class of warrant or right may be
converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r268"] }, "ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r674"] },
"ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } },
"auth_ref": ["r674"] }, "qnrx_CombinedPublicOfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname":
"CombinedPublicOfferingPrice", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation":
"The combined public offering price.", "label": "Combined Public Offering Price", "terseLabel": "Combined public offering price" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":
"credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and
Contingencies", "terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has
entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or,
less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains
from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r42", "r79",
"r437", "r496"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "CONTINGENCIES" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock",
"presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments"], "lang": { "en-us": { "role": { "label": "Commitments
Disclosure [Text Block]", "terseLabel": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "documentation": "The entire disclosure for significant
arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services,
or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services,
period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": ["r64"] }, "us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-
us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of ordinary shares reserved for future issuance",
"documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r45"] }, "us-gaap_CommonStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock
[Member]", "verboseLabel": "Ordinary shares", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r614", "r615", "r616", "r618",
"r619", "r620", "r621", "r727", "r728", "r730", "r790", "r818", "r821"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value
Per Share", "terseLabel": "Ordinary shares, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r45"] }, "us-
gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized",
"terseLabel": "Ordinary shares, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } }
}, "auth_ref": ["r45", "r497"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": {
"role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, shares issued", "documentation": "Total number of common shares of an entity that have
been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the
firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the
treasury." } } }, "auth_ref": ["r45"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock,
Shares, Outstanding", "periodEndLabel": "Balance at ending of year (in shares)", "periodStartLabel": "Balance at beginning of year (in shares)", "terseLabel": "Ordinary
shares, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } },
"auth_ref": ["r4", "r45", "r497", "r517", "r821", "r822"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us":
{ "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized at June 30, 2024 and
December 31, 2023, respectively - 3,979,970 (3,979,970 ADS's) ordinary shares issued and outstanding at June 30, 2024 and 987,220 (987,220 ADS's) at December 31, 2023",
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes
treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within
stockholders' equity." } } }, "auth_ref": ["r45", "r438", "r609"] }, "qnrx_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.quoinpharma.com/20240630", "localname": "CommonWarrantsMember", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Common Warrants [Member]", "label":
"Common Warrants [Member]", "terseLabel": "Common Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r679"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r678"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r680"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r677"] }, "qnrx_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConsultingAgreementMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents consulting agreement.", "label": "Consulting Agreement [Member]", "terseLabel": "Consulting agreements" } } }, "auth_ref": [] }, "qnrx_ConsultingOrServiceAgreementAgreedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConsultingOrServiceAgreementAgreedAmount", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate amount of fee per consulting or service agreement.", "label": "Consulting or Service Agreement, Agreed Amount", "terseLabel": "Total amount of agreement" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Convertible Debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r65", "r235", "r236", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r584", "r585", "r586", "r587", "r588"] }, "qnrx_ConvertibleNotesPayableNumberOfNoteholders": { "xbrltype": "integerItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConvertibleNotesPayableNumberOfNoteholders", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of noteholders.", "label": "Convertible Notes Payable, Number of Noteholders", "terseLabel": "Total number of notes holders" } } }, "auth_ref": [] }, "qnrx_ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration": { "xbrltype": "integerItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of noteholders who received consideration.", "label": "Convertible Notes Payable, Number of Noteholders Who Received Consideration", "terseLabel": "Number of notes holders who received consideration" } } }, "auth_ref": [] }, "qnrx_ConvertibleNotesPayableNumberOfRemainingNoteholdersReceiveConsideration": { "xbrltype": "integerItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConvertibleNotesPayableNumberOfRemainingNoteholdersReceiveConsideration", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of remaining noteholders who received consideration.", "label": "Convertible Notes Payable, Number Of Remaining Noteholders Receive Consideration", "terseLabel": "Number of remaining noteholders" } } }, "auth_ref": [] }, "qnrx_ConvertibleNotesWarrantsCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ConvertibleNotesWarrantsCommonStockMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Warrants, Common Stock.", "label": "Convertible Notes Warrants, Common Stock" } } }, "auth_ref": [] }, "qnrx_Convertiblenotes2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "Convertiblenotes2020Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Convertible Notes issued in 2020.", "label": "Convertible notes 2020" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r116", "r117", "r238", "r255", "r391", "r409", "r432", "r573", "r575"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r7", "r20", "r23", "r33", "r68", "r69", "r118", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r584", "r585", "r586", "r587", "r588", "r608", "r725", "r800", "r801"] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": ["r739"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r279", "r283", "r314", "r315", "r317", "r594"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "STOCK BASED COMPENSATION" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r629"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r661"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "qnrx_Dr.MyersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "Dr.MyersMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Dr. Myers.", "label": "Dr. Myers [Member]", "terseLabel": "Dr. Myers" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r672"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Loss per ADS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r109", "r124", "r125", "r126", "r127", "r128", "r129", "r133", "r135", "r138", "r139", "r140", "r143", "r333", "r336", "r354", "r355", "r430", "r447", "r576"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Fully-diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r109", "r124", "r125", "r126", "r127", "r128", "r129", "r135", "r138", "r139", "r140", "r143", "r333", "r336", "r354", "r355", "r430", "r447", "r576"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (loss) per share:", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r13", "r14", "r142"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "STOCK BASED COMPENSATION", "documentation": "Line items represent financial

concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r316"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r784"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "terseLabel": "Document and Entity Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r625"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r625"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r625"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r625"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r711"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r625"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r625"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r625"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r625"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r666"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r707"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r707"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r707"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "SHAREHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r4", "r89", "r106", "r107", "r108", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r145", "r183", "r184", "r212", "r269", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r445", "r453", "r454", "r455", "r475", "r542"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r676"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r634", "r644", "r654", "r686"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r631", "r641", "r651", "r683"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r682"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r357", "r358", "r368", "r598"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype":

"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r357", "r358", "r368", "r598"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r243", "r271", "r272", "r273", "r274", "r275", "r276", "r356", "r358", "r359", "r360", "r361", "r367", "r368", "r370", "r396", "r397", "r398", "r585", "r586", "r590", "r591", "r592", "r598", "r601"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r357", "r358", "r359", "r361", "r598", "r795", "r798"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r363", "r365", "r366", "r367", "r370", "r371", "r372", "r373", "r374", "r429", "r598", "r602"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r243", "r271", "r276", "r358", "r368", "r396", "r590", "r591", "r592", "r598"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r357", "r358", "r359", "r361", "r598", "r795", "r798"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments:", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r243", "r271", "r272", "r273", "r274", "r275", "r276", "r356", "r358", "r359", "r360", "r361", "r367", "r368", "r370", "r396", "r397", "r398", "r585", "r586", "r590", "r591", "r592", "r598", "r601"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r598", "r792", "r793", "r794", "r795", "r796", "r798"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r251", "r265", "r351", "r375", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r446", "r581", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r733", "r734", "r735", "r736", "r791", "r794", "r795", "r796", "r797", "r798"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets, useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization, negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r94", "r195", "r204", "r583"] }, "qnrx_FiniteLivedIntangibleAssetsAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "FiniteLivedIntangibleAssetsAmortizationAfterYearFour", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Finite Lived Intangible Assets Amortization After Year Four", "label": "Finite Lived Intangible Assets Amortization After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r206", "r567", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r206", "r567", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r206", "r567", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r206", "r567", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r197", "r199", "r200", "r201", "r203", "r204", "r207", "r208", "r427", "r428", "r567"] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected amortization expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Total cost", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r195", "r204", "r428", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "INTANGIBLE ASSETS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r197", "r204", "r207", "r208", "r210", "r427", "r567", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r197", "r199", "r200", "r201", "r203", "r204", "r207", "r208", "r567"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net",

"totalLabel": "Net book value", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r427", "r747"] }, "qnrx_FloorPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "FloorPrice", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The floor price per share.", "label": "Floor Price", "terseLabel": "Floor price" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r638", "r648", "r658", "r690"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r638", "r648", "r658", "r690"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r638", "r648", "r658", "r690"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r638", "r648", "r658", "r690"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r638", "r648", "r658", "r690"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r671"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r53"] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Impairment loss measurement", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived assets:", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r63"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r213", "r214", "r215", "r362", "r364", "r369", "r450", "r452", "r527", "r567", "r600", "r817"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r214", "r215", "r362", "r364", "r369", "r450", "r452", "r527", "r567", "r600", "r817"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Expenses", "terseLabel": "Increase in accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease (increase) in prepaid expenses & other assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r2"] }, "qnrx_IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrants", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of prefunded warrants.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Pre Funded Warrants", "terseLabel": "Unexercised prefunded warrants" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r638", "r648", "r658", "r682", "r690", "r694", "r702"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r700"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r630", "r706"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r630", "r706"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r630", "r706"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r196", "r209", "r211", "r566", "r567"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r197", "r747", "r748"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r55", "r249", "r587", "r588"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Accrued interest and financing expense", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r77", "r814"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments:", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r448", "r462", "r463", "r464", "r465", "r551", "r552"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties Details", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Investments", "terseLabel": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r432", "r433", "r612", "r613"] }, "qnrx_InvestmentsMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "InvestmentsMaturityTerm", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Duration of investments maturity term.", "label": "Investments Maturity Term", "terseLabel": "Maturity term" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r7", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r115", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r340", "r343", "r344", "r376", "r495", "r577", "r624", "r755", "r803", "r804"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r50", "r80", "r441", "r609", "r726", "r737", "r799"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current

liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r39", "r92", "r115", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r340", "r343", "r344", "r376", "r609", "r755", "r803", "r804"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "qnrx_LicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "LicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "qnrx_LicenseAgreementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "LicenseAgreementsDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureLicenseAgreements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for license agreements.", "label": "License Agreements [Disclosure Text Block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "terseLabel": "Technology license - Skinvisible", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r30", "r327", "r740", "r741", "r742", "r743", "r744", "r745", "r747", "r748", "r749", "r750", "r785"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract", "lang": { "en-us": { "role": { "label": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Commitment period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingencyDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDisclosures", "presentation": ["http://www.quoinpharma.com/role/DisclosureContingencies"], "lang": { "en-us": { "role": { "label": "Contingencies Disclosure [Text Block]", "terseLabel": "CONTINGENCIES", "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made." } } }, "auth_ref": ["r216", "r217", "r218", "r220", "r222", "r223", "r224", "r225", "r323"] }, "qnrx_MaximumCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "MaximumCommitmentAmount", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum commitment amount related to right to sell newly issued ordinary shares that are represented by ADS.", "label": "Maximum Commitment Amount", "terseLabel": "Commitment amount" } } }, "auth_ref": [] }, "qnrx_MaximumCommitmentSecuritiesValueAtTimesSetForthUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "MaximumCommitmentSecuritiesValueAtTimesSetForthUnderAgreement", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum value of commitment securities that can be issued at the times set forth under the agreement.", "label": "Maximum Commitment Securities Value At Times Set Forth Under The Agreement", "terseLabel": "Maximum commitment securities value" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r219", "r221", "r222", "r223", "r278", "r323", "r361", "r425", "r449", "r451", "r459", "r487", "r488", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r580", "r589", "r593", "r601", "r602", "r606", "r607", "r611", "r757", "r805", "r806", "r807", "r808", "r809", "r810"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r674"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r674"] }, "qnrx_MinimumCommitmentAmountForWhichPurchaseNoticesAgreedToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "MinimumCommitmentAmountForWhichPurchaseNoticesAgreedToBeIssued", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The minimum commitment amount for which purchase notices agreed to be issued.", "label": "Minimum Commitment Amount For Which Purchase Notices Agreed To Be Issued", "terseLabel": "Minimum commitment amount" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r219", "r221", "r222", "r223", "r278", "r323", "r361", "r425", "r449", "r451", "r459", "r487", "r488", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r580", "r589", "r593", "r601", "r602", "r606", "r611", "r757", "r805", "r806", "r807", "r808", "r809", "r810"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r693"] }, "qnrx_Ms.CarterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "Ms.CarterMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Ms. Carter.", "label": "Ms. Carter [Member]", "terseLabel": "Ms. Carter" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r701"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r675"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r111"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r111"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties Details", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r58", "r59", "r60"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties Details", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or

loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r52", "r60", "r82", "r90", "r104", "r105", "r108", "r115", "r122", "r124", "r125", "r126", "r127", "r128", "r131", "r132", "r137", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r333", "r336", "r355", "r376", "r444", "r519", "r540", "r541", "r622", "r755"] }, "qnrx_NetProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NetProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "The net cash inflow from the additional capital contribution to the entity.", "label": "Net Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of equity securities, net" } } }, "auth_ref": [] }, "qnrx_NetProceedsFromIssuancePublicOfferingAfterIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NetProceedsFromIssuancePublicOfferingAfterIssuanceCosts", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's offering of stock to the public net of issuance costs.", "label": "Net Proceeds From Issuance Public Offering After Issuance Costs", "terseLabel": "Net proceeds from offering" } } }, "auth_ref": [] }, "qnrx_NethertonSyndromeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NethertonSyndromeMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Netherton Syndrome.", "label": "Netherton Syndrome [Member]", "terseLabel": "Netherton Syndrome" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r674"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r638", "r648", "r658", "r682", "r690"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r665"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r664"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r682"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r701"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r701"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r54"] }, "qnrx_NumberOfLicenseAndSupplyAgreementsEntered": { "xbrltype": "integerItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NumberOfLicenseAndSupplyAgreementsEntered", "presentation": ["http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of new license and supply agreements entered during the period.", "label": "Number Of License And Supply Agreements Entered", "terseLabel": "Number of license and supply agreements entered" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r579", "r732"] }, "qnrx_NumberOfOrdinarySharesForAmericanDepositaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NumberOfOrdinarySharesForAmericanDepositaryShares", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares for each American Depositary Shares.", "label": "Number of Ordinary Shares for American Depositary Shares", "terseLabel": "Number of ordinary shares for ADS" } } }, "auth_ref": [] }, "qnrx_NumberOfOrdinarySharesForEachAmericanDepositaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NumberOfOrdinarySharesForEachAmericanDepositaryShares", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares for each American Depositary Shares.", "label": "Number Of Ordinary Shares For Each American Depositary Shares", "terseLabel": "Number of ordinary shares for each ADS" } } }, "auth_ref": [] }, "qnrx_NumberOfSharesRepresentedForOneAmericanDepositaryShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "NumberOfSharesRepresentedForOneAmericanDepositaryShare", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares represented for one American depositary share.", "label": "Number of Shares Represented for One American Depositary Share", "terseLabel": "Number of shares represented for one ADS" } } }, "auth_ref": [] }, "qnrx_OfferingExpensesAssociatedWithWarrantModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "OfferingExpensesAssociatedWithWarrantModification", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amount of offering expenses associated with warrant modification.", "label": "Offering Expenses Associated with Warrant Modification", "terseLabel": "Offering expenses associated with warrant modification" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "ORGANIZATION AND BUSINESS" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND BUSINESS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r34", "r74", "r460", "r461"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r38"] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities", "terseLabel": "Total", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": ["r78", "r435", "r491", "r492", "r624", "r815", "r819"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "negatedLabel": "Less: Short-term portion", "terseLabel": "Due to officers - short term", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r38", "r609"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Long-term portion", "verboseLabel": "Due to officers - long term", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r41"] }, "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]", "terseLabel": "Other liability, current, related party, type extensible enumeration", "documentation": "Indicates status and type of related party for liability classified as other and current." } } }, "auth_ref": ["r802"] }, "us-gaap_OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration]", "terseLabel": "Other liability, noncurrent, related party, type extensible enumeration", "documentation": "Indicates status and type of related party for liability classified as other and noncurrent." } } }, "auth_ref": ["r802"] }, "us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityRelatedPartyTypeExtensibleEnumeration", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Other Liability, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for liability classified as other." } } }, "auth_ref": ["r802", "r815"] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Other (income) and expenses" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r674"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expense", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r721", "r738"] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Due from (to) Related Party (Deprecated 2023)", "terseLabel": "Outstanding indebtedness", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": ["r100", "r505", "r579", "r816"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r636", "r646", "r656", "r688"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r639", "r649", "r659", "r691"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r639", "r649", "r659", "r691"] }, "qnrx_OutstandingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "OutstandingWarrantsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "This member represents outstanding warrants.", "label": "Outstanding Warrants [Member]", "terseLabel": "Outstanding warrants" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r663"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "auth_ref": [] }, "qnrx_PaymentToRelatedPartyPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PaymentToRelatedPartyPerMonth", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of monthly payment to related party.", "label": "Payment to Related Party Per Month", "terseLabel": "Monthly payment amount" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Investments", "negatedLabel": "Purchase of investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": ["r56"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r673"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r673"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r665"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r682"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r675"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r664"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r666"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r710"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r665"] }, "qnrx_PreFundedWarrants2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PreFundedWarrants2024Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 pre-funded warrants.", "label": "Pre-Funded Warrants 2024 [Member]", "terseLabel": "2024 Pre-Funded Warrants" } } }, "auth_ref": [] }, "qnrx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r722"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "negatedLabel": "Less: Short-term portion", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r102", "r193", "r194", "r570"] }, "us-gaap_PrepaidExpenseCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAbstract", "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Expense", "totalLabel": "Total", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": ["r75", "r102", "r510", "r813"] }, "qnrx_PrepaidExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PrepaidExpenseDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpenses"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for current prepaid expenses.", "label": "Prepaid Expense Disclosure Text Block", "terseLabel": "PREPAID EXPENSES" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expenses - long term", "verboseLabel": "Long-term portion", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r720"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r571", "r582", "r738"] }, "qnrx_PrepaidResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PrepaidResearchAndDevelopmentCosts", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to research and development costs paid in advance that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research And Development Costs", "terseLabel": "Prepaid R&D costs" } } }, "auth_ref": [] }, "qnrx_PriorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PriorWarrantsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to prior warrants.", "label": "Prior Warrants [Member]", "terseLabel": "Prior Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from maturity of investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": ["r10"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r90", "r104", "r105", "r110", "r115", "r122", "r128", "r131", "r132", "r182", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r333", "r336", "r338", "r341", "r342", "r355", "r376", "r431", "r443", "r474", "r519", "r540", "r541", "r596", "r597", "r623", "r723", "r755"] }, "qnrx_PublicOffering2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PublicOffering2022Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to public offering 2022.", "label": "Public Offering 2022 [Member]", "terseLabel": "Public Offering 2022" } } }, "auth_ref": [] }, "qnrx_PublicOffering2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PublicOffering2023Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to public offering 2023.", "label": "Public Offering 2023 [Member]", "terseLabel": "Public Offering 2023" } } }, "auth_ref": [] }, "qnrx_PublicOffering2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "PublicOffering2024Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 public offering.", "label": "Public Offering 2024 [Member]", "terseLabel": "Public Offering 2024" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r663"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r663"] }, "srt_RangeAxis": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r219", "r221", "r222", "r223", "r270", "r278", "r309", "r310", "r311", "r323", "r361", "r399", "r408", "r425", "r449", "r451", "r459", "r487", "r488", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r580", "r589", "r593", "r601", "r602", "r606", "r607", "r611", "r616", "r754", "r757", "r795", "r806", "r807", "r808", "r809", "r810"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r219", "r221", "r222", "r223", "r270", "r278", "r309", "r310", "r311", "r323", "r361", "r399", "r408", "r425", "r449", "r451", "r459", "r487", "r488", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r580", "r589", "r593", "r601", "r602", "r606", "r607", "r611", "r616", "r754", "r757", "r795", "r806", "r807", "r808", "r809", "r810"] }, "qnrx_RealizedAndAccruedInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "RealizedAndAccruedInterestIncome", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amount of realized and accrued interest income from investment.", "label": "Realized and Accrued Interest Income", "negatedLabel": "Realized and accrued interest income" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r631", "r641", "r651", "r683"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r151", "r277", "r389", "r390", "r436", "r442", "r490", "r491", "r492", "r493", "r494", "r516", "r518", "r549"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r389", "r390", "r802"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r151", "r523", "r524", "r527"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r151", "r277", "r389", "r390", "r436", "r442", "r490", "r491", "r492", "r493", "r494", "r516", "r518", "r549", "r802"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r386", "r387", "r388", "r390", "r392", "r471", "r472", "r473", "r525", "r526", "r527", "r546", "r548"] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Repayments of Related Party Debt", "negatedLabel": "Payment of amounts due to officers", "terseLabel": "Non-bearing interest indebtedness", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": ["r57"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r116", "r117", "r238", "r255", "r391", "r409", "r432", "r574", "r575"] }, "qnrx_ResearchAgreementMaximumFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ResearchAgreementMaximumFundingAmount", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum liability for the entity in relation to the funding for the research agreement entered into.", "label": "Research Agreement, Maximum Funding Amount", "terseLabel": "Maximum funding amount" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement [Member]", "terseLabel": "Research and consulting agreement", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r326", "r567", "r578", "r811"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "verboseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development:", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r325"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r633", "r643", "r653", "r685"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r640", "r650", "r660", "r692"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r47", "r70", "r440", "r456", "r458", "r470", "r498", "r609"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r89", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r183", "r184", "r212", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r345", "r347", "r348", "r350", "r353", "r383", "r384", "r453", "r455", "r475", "r821"] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Royalty Income, Nonoperating", "terseLabel": "Royalty revenues", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": ["r54"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r701"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r701"] }, "qnrx_SalaryAndOtherCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SalaryAndOtherCompensationMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to salary and other compensation due to officers.", "label": "Salary And Other Compensation [Member]", "terseLabel": "Salaries and other compensation" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued

liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r27"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r792", "r793"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r197", "r204", "r207", "r208", "r210", "r427", "r567", "r583"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r583", "r746"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r31", "r32", "r523", "r524", "r527"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of amounts due to officers", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r280", "r282", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock-based activities", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r5", "r6", "r72"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r18", "r19", "r20", "r21", "r22", "r23", "r66", "r68", "r69", "r70", "r97", "r98", "r99", "r146", "r253", "r254", "r255", "r257", "r260", "r265", "r267", "r466", "r467", "r468", "r469", "r589", "r712", "r724"] }, "qnrx_SchoolOfPharmacyAtUccMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SchoolOfPharmacyAtUccMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the school of pharmacy at UCC.", "label": "The School Of Pharmacy At UCC [Member]", "terseLabel": "The School of Pharmacy at UCC" } } }, "auth_ref": [] }, "qnrx_SclerodermaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SclerodermaMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Scleroderma.", "label": "Scleroderma [Member]", "terseLabel": "Scleroderma" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r627"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r626"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r53"] }, "qnrx_SeriesDWarrantsAmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SeriesDWarrantsAmericanDepositarySharesMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Series D Warrants represented by American Depositary Shares.", "label": "Series D Warrants American Depositary Shares [Member]", "terseLabel": "Series D Warrants" } } }, "auth_ref": [] }, "qnrx_SeriesEWarrantsAmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SeriesEWarrantsAmericanDepositarySharesMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Series E Warrants represented by American Depositary Shares.", "label": "Series E Warrants American Depositary Shares [Member]", "terseLabel": "Series E Warrants" } } }, "auth_ref": [] }, "qnrx_SeriesWarrantsAmericanDepositaryShares2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SeriesWarrantsAmericanDepositaryShares2024Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 Series Warrants combined of Series D and Series E represented by American Depositary Shares.", "label": "Series Warrants American Depositary Shares 2024 [Member]", "terseLabel": "2024 Warrants" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "STOCK BASED COMPENSATION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r280", "r282", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r26"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Contractual Terms" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable options (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r290"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable options (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r290"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Terminated (in shares)", "negatedTerseLabel": "Forfeited/Cancelled (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r294"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r292"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value of outstanding options", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r26"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options outstanding at end of period", "periodStartLabel": "Number of options outstanding at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r288", "r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "ADSs Underlying Warrants", "verboseLabel": "ADS Underlying Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period", "periodStartLabel": "Outstanding at beginning of the period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r288", "r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share", "verboseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of ordinary shares reserved for issuance", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Terminated (in dollars per share)", "verboseLabel": "Forfeited/Cancelled (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r294"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r292"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock based compensation:", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r279", "r287", "r306", "r307", "r308", "r309", "r312", "r318", "r319", "r320", "r321"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable options (in years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r26"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual term (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r73"] }, "qnrx_SharesOwnedPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.quoinpharma.com/20240630", "localname": "SharesOwnedPercentage", "presentation": [
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Percentage of entity's shares owned.", "label": "Shares Owned, Percentage", "terseLabel": "Shares owned (as a percent)" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [
"http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r37", "r751", "r752", "r753"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [
"http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r36", "r751", "r752", "r753"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r61", "r113"] }, "qnrx_SkinvisibleLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SkinvisibleLicenseAgreementMember", "presentation": [
"http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for skinvisible license agreement.", "label": "Skinvisible License Agreement [Member]", "terseLabel": "Skinvisible Licensing agreement" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails",
"http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedActivitiesDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails",
"http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Class of Stock

[Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r88", "r97", "r98", "r99", "r115", "r135", "r136", "r138", "r140", "r146", "r147", "r182", "r226", "r228", "r229", "r230", "r233", "r234", "r253", "r254", "r257", "r260", "r267", "r376", "r466", "r467", "r468", "r469", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r497", "r520", "r542", "r558", "r559", "r560", "r561", "r562", "r712", "r724", "r731"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r4", "r45", "r48", "r49", "r89", "r106", "r107", "r108", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r145", "r183", "r184", "r212", "r269", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r445", "r453", "r454", "r455", "r475", "r542"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r119", "r120", "r121", "r145", "r384", "r426", "r462", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r500", "r501", "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r518", "r521", "r522", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r542", "r617"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (unaudited)" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r119", "r120", "r121", "r145", "r151", "r384", "r426", "r462", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r500", "r501", "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r518", "r521", "r522", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r542", "r617"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r635", "r645", "r655", "r687"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Shares issued upon conversion", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r4", "r20", "r45", "r48", "r70", "r245"] }, "qnrx_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Number of pre-funded warrants that are exercised during the current period.", "label": "Stock Issued During Period, Shares, Exercise of Warrants", "terseLabel": "Exercise of pre-funded warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of ADS's, pre-funded warrants and warrants, net (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r4", "r44", "r45", "r70", "r466", "r542", "r559"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r4", "r44", "r45", "r70", "r293"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of ADS's, pre-funded warrants and warrants, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r4", "r44", "r45", "r70", "r475", "r542", "r559", "r623"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r45", "r48", "r49", "r62", "r499", "r517", "r543", "r544", "r609", "r624", "r726", "r737", "r799", "r821"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r67", "r114", "r252", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r269", "r352", "r545", "r547", "r563"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r71"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [
"http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"qnrx_SubstantialDoubtAboutGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SubstantialDoubtAboutGoingConcernAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES" } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties"], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": ["r35"] }, "qnrx_SummaryOfWarrantActivitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "SummaryOfWarrantActivitiesTableTextBlock", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrant activities.", "label": "Summary Of Warrant Activities [Table Text Block]", "terseLabel": "Schedule of warrant activities" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental information - Non cash items:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r681"] }, "qnrx_TherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "TherapeuticsInc.Member", "presentation": ["http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Therapeutics Inc.", "label": "Therapeutics Inc. [Member]", "terseLabel": "Therapeutics Inc." } } }, "auth_ref": [] },
"qnrx_ThresholdPeriodForNotToEnterIntoAgreementToEffectVariableRateTransactionAfterClosingDateOfOffering": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ThresholdPeriodForNotToEnterIntoAgreementToEffectVariableRateTransactionAfterClosingDateOfOffering", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering.", "label": "Threshold Period for Not to Enter Into an Agreement to Effect a Variable Rate Transaction, After the Closing Date of the Offering", "terseLabel": "Threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering" } } }, "auth_ref": [] },
"qnrx_ThresholdPeriodForNotToIssueEnterIntoAnyAgreementToIssueOrAnnounceIssuanceOrProposedIssuanceOfAnyAdssAfterClosingDateOfOffering": { "xbrltype": "durationItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "ThresholdPeriodForNotToIssueEnterIntoAnyAgreementToIssueOrAnnounceIssuanceOrProposedIssuanceOfAnyAdssAfterClosingDateOfOffering", "presentation": [
"http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for not to issue,

enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering", "label": "Threshold Period for Not to Issue, Enter Into Any Agreement to Issue or Announce the Issuance or Proposed Issuance of Any ADSs, After the Closing Date of the Offering", "terseLabel": "Threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r673"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r680"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r700"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r702"] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecurities", "crdr": "debit", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "U.S. Treasury Bills", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r81", "r96", "r569"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r251", "r265", "r351", "r375", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r446", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r733", "r734", "r735", "r736", "r791", "r794", "r795", "r796", "r797", "r798"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r703"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r704"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r704"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r702"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r702"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r705"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r703"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Treasury Stock Common [Member]", "terseLabel": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r337"] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Bill Securities [Member]", "terseLabel": "US Treasury Bills", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": ["r812"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r699"] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Unrealized loss", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": ["r3", "r536", "r537", "r538", "r539", "r556"] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized gain and accrued interest on investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": ["r3"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates:", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r15", "r16", "r17", "r84", "r85", "r86", "r87"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r669"] }, "qnrx_WarrantAmendmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "WarrantAmendmentsMember", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to warrant amendments member.", "label": "Warrant Amendments [Member]", "terseLabel": "Warrant Amendments" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r794", "r795", "r796"] }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.quoinpharma.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Incremental fair value", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": ["r792", "r793", "r797"] }, "qnrx_WarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quoinpharma.com/20240630", "localname": "WarrantsPolicyPolicyTextBlock", "presentation": ["http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants Policy [Policy Text Block]", "terseLabel": "Warrants:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Fully-diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r134", "r140"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of ADS's outstanding" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r133", "r140"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r667"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":

"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r207": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450-20/tableOfContent" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450-30/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-

20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r456": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",

"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef",

"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r712": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 71 0001410578-24-001216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-24-001216-xbrl.zip M4$L#!!0 ("["%G II.^81$ "^O 1 <6YR>"TR,#(T,#8S,"YX M;HJY)\7UQ=
MMBX0<4S7HL[J_84GEHUW%W_]\#]_^/F/C<9O=],!LES3VQ!'(),1+(B%OE&Q M1G-WN\4.&A+&J&VC.T:M%4'HJG7YTV7K\@HU&A^4B#O,@<5UD)+5OKP*"SJ! M-->Y1>^:
[YKM5OLUNKIM_W3[^@I-AB'9$!JVI!JZ)V[=+: SG-\];*QJH8]L(GOAB'!2#)WJ\%MHR%&-WZXO7;:"BEI7S=^&@YE] M8TALD2TCINR$(YZG!;-
#KILF7%7"B7FYD1"R/+U&:];4+I7F5,I/7'ONB(P1,LH],A--*0%<;;Q':(@B.I-FB0H:$L M7L!XV+>:FLF 0,&Q>F++4BBA)-83*3VW+SIB((ZW;2>AUVXUR9,@#J<+FS0D M&6%8@-
/@C;9T&H%EN9XC6)IA^85'!3E$Z,P=2/;4F)H\6;@J.A)M$9I,"@5' MA$\QH(*!>G5S<]-4I7N9@IWTYU&CH;@IBZ7X=J-UW;B^.BBZRC.V [(]'$_F
M.ED)67*D10ZGM;>)1&LX[A-.]:ZK01TNL&.2Z."G&29_2O^[PYYR^N1]_V?T MH'48J,K3T$0W]-9W0_1D3#?((GUL_@6?2*F^ERBAU4G0@MT.R_0AYJ0NT2' MNM"K?
6U_J>$O"W\'_6][7XKCWZ"!"WXK\N!+ZM"JB[TRJO!3P&_2[EIN]QC M9,+(%E.K][257639J!5$"HY&$$D:M>8I6%FF';SB&Y#'C)F ML]Z\ABD=IB!%&/YO.%;/$53L^K"
4K9E@"I/)3:>*-U(^.-4$;T)W8LY M$_M$8DU7J77A!/,@&Y-! 7U"B\0C[ESK!;?E%DMHE='1=3#L_3R80:<9.W;%F&\ M][L'PZCT.B)+E-80KLLM**)U_AGYM=;KRCS3ZSVF[%=L>V2\O*
<.C"V*[:[# M!5-NE<\OS*BQR38?4_;4>]UZT[H^G7KOC?X4_6H,'GIH?(_N^R-CU.D; YB2 M9_/IP[WDI.Q+[[&-!73 84! (;_FU+^E<-,.P8/R1[;S((8V"23 UU"W#] MPM]V/+
:]/_VT._VYU_0M#_[98:,41>-YY]Z4_0PZO2F>!>.9M M-ICMP-O2E4.7,/M!2&6J;1?JK";@)DW RK LU3XY.O;RW.9 M2P\S!_[D Y?S"6%J4CW+6K($ZHTE-CL4,I:P;O0*^/E?
T)8PQ&4#:GO)G1B! M134!M>5B+9CGG560!LG.E>1@U,'_CU] M-$;]J;S=4$$@0) 'Z05:GQ/3QJ M.Q0J4R(/B0!\=YC3M+#A7'$Z6W@3MX4\D2)00]O#S)E7Z-5
JW/]SS.'4(C\&71J;9Y89@*3[FQM./QJC_=W^U(SWEW<.L/^K-9C5*9VQSEMC? MU*-7?F>SQO*#:IRNU!Z1,_:F*Q!+;^+5'S[2]FZ8VC&LB2VT4%MX/T$)); M[ZGQ*Y8.SI?JU:-58-
NFABCGZR.:5T;TH.1X5:0&(^=[(9H70O1@Y'@5I :C MR*9%GBT*/2RY=R1JS/.S^#7"^;/!^O2O'K&':P7/%,[6G!%HT$K(&02P7\5\U).>E8,]+Q>9+R=ZT6TG[6OE/ M_[*ZZGWN
KFA)+?]\NDS8;RNM OO_K=OH)YHF2\DHET0/T4!RI^NT@-4+'< M43) R40Z@-[% 8K?*%(#5#!ED8Q0"I4&HJM6'*$ZT1JC$JF,9*QTE#K,+N* M8Y9QD+$&K_C"-R6J2*/3
9;T:FCBD;4:JF>)^0>NLQK01V+YKK#O@"0RQT_I M+PX]D]AL0WA]YBH!EH?0@H8MFX"P:@/Z$]YL_P_Y34%"MJ4^+U=\2BUR[T A
M7HU!P/0,.XCX]%M?)/",>9O4BT12Z'0(YDKB_+<@)?^1;[Q-R1*IR\EOY97C M[R\XW6QM>;6V>K96-_;+"[8;X27;_P!5+Y\V=D@BQ6='!TB;ZZ0A\,U&4",<=?@^$GW[FXCGJ'
MQM7EU07R/R8S<$WU[.!V8K1QUDNH-K"XC!:D?T(@K>)$K]N M^1&;\B:?^+F67(,]@5/]S4N!(,Q-J#;V6IZM]? M#%U'$!,SVYW13> KAZY%["'9+ CS)TP9./O#2^D"OMO\MQ::K[K"
[*1TP.H MX"VXH,*3C!^9ZVW?7Z@OU-Q2(+E #K5MF0MZ?R&8)R,75081 W6MN2_:8\&A M: R2 %2)NFW4Q6B1U!L=UUO84P%JXG/D(4L>JX\H4BQP@$1?0LP.-K[#<4
MG@')#]7V>OI)3,R9.XLUWS:T3+'+2G>(JPZ#LKN<0VUVL9'K&"**M+'HGM M;OV;;WD8Y475S"2.HKAQ'5BULMTSJNA/@B)!0YJVX5^7#'U!%E2DZ]VQ,>?C M9?",Z)A-
Z6HM^IQ[X?6_2N%,JB-[E9E=_F.AA 'U*%<$(!?"0\+E=\UB?B>+ MJ(HN1_7K^)M#K EAI@S:5R3J7I++3S79^F65P67PPN&,J"2\=3 M0?02#FPF:9A&4VF-
QFQ&V",U#QD_]9<8&!)O8Z9*MRZG8%T44+L'[7>?#=,--U9[(-]T%>,F=8S%W M0V*N)Y6B@HYG#BW%6P)5FG+?\#*F3!I!!76);94DK!LR;"JV3@A'BC\,IB1(
M+A(+!LO8(2GC)6&H%150L?$V]H1DD1_7#J.4F)%FT%303L$_3)AKP@S-[\$] MR+A?3I#C923Z.G8G.:>=NMO3N,R)ZZL\!*L.0< M/-%NH/!P1=@/C@;@MT7DW@4L;^6G5BS_A
[X4B"BCV0"_18SZ$)<%33Q\7)) MV.&N"6YP[II4ZO&9BG4P1OT/TYN15^C]P5R<]Z48?^BH'MPKN H@?<8_:M)ZV@47?9Y7!'6'SZ.2VH8-N'_+*#&3C)>,;XM*2" MK9_@G?
QK[D8/J$Z@R:XCUM%$8C9=9=R$;B4\,VW"7 L6@S@^=.)E542,D7M/ M3F&I,5LJ106U20G!)MX"/',X7QE+&$1AT6F*N[2$RMBL9FK;GU0-X#Q<::_. M#B?-[FY".OJ*ZG&6-
PM;*_.#27SX(3Z!EIYBRFRD7N^1Q_ M>0T3CDGD\6>9E:7P[#2H?0YA+ZV'ID0Z;0!K$>T"U4IV4WZ)E>LK=2;;,&$5 MQI6!K<.VDE3KD3@>N#WWCDPPC2YlB[%5$4O2'-
(UP5R\"'8:G,Q:EX+39X4RDJ.'XC7X(Y#43C:TP];04UG*_!Q&14 M,%%BP+5 F#!W56X8#-#=ZP#/8,5EBE\QH((14RQ(Y'57M0SK0& .!MB%(O!9 MP0+M:%,L^U=6O:W?
%*W5T:6#ZLXNHKTJ&S/#<5P/)LS]]@6#]3 X>_ -^PT- MR6AQ?D[___^UI'K@&"O051XHAPHY3]XSBO5C$::7DHLP;&_CT(D'T2/.MK/Y=G18IRN?FJZSFO9*: MY^:KH.:QQ'?
R,_ZBJJ16U&49R?Z$T@IJ,<1/=.-M#E=_QHY=IE*\E'S$@#I) M"D]7E-S74X&_K'#[E_DE1FF&*'V,\5]%(Z[-YV70@1CP]N1A\F9-V4$_JA MB8J8G<[D%[O5[HKZHH0AYG1#^(Q(P,3Z
5P-VT= 6?9>3,Y+ 1GT6U!YVO\H M>CI%/9.JDF:0^*;)$ L)X>[D@'4.VNHM>]8$V_1?ZJC42:()OWLFHI^>M#(+ M'*U/DJ]]$W7G3^S:EPV,P_!;;G+]^H5@=N]ZT>FX''M5QK)F]1=;
%WKUTC7 M%8Y)8HUMZ_5I5UB?1#?3>R+,I%S_EER$L&); ^!$F/H;V\')7-4F0PA&%YY0 M1QK<+K4]>7[3SPF.E[$P/Z+_WO1G' M]G@9S.*AWSL]<_4N"&A-
U\XZY,\2#:28<'LR@JN!2O%#(W7_.B'_-HP/_P902P,$ M% @ *H (6?XP\!-@"0 %G0 !4 !Q;G)X+3(P,C0P-C,P7V-A;"YX M;6SE75MSXK@2?M^]\Q]TV)?9!^X)@50R6X20*:IRH2 Y-
6\IQ19!M49B)#D) M\^M7,H9@L&P9" C.RR2QU>W^^FNU6I:LN?C]8^2!-\0XIN0R5RZ4<@ 1A[J8 MO%[F?#'(UW-_?__'Q?_S>=_7O5N@4L=?X2(Y#4" 7O&,Q!(]T/(8$W"'&
ML.>!*X;=5P1 N50X*Y0*99#/?P]47$$N12@!@:Y*H3R[T0JU47(.ZL5ZL5*] MG(#R>>7L_*0,NG>S9G?2L %.:>=A\L^Y^N=%/@U(?(2??W!\F1L*,3XO%M_? MWPOOU0)EKU*\5"
[^O+OM.T,T@GE,N(#$03D@VY_SX.(M=: (G+,@_O'"O)F" M:G'^+&T+]5=^UBRO+N7+E7RU7/C@;BXT4=TV>,BLN;]+$]HO8)FV7]$?^]#< M;#2*P=W<]S\ N(STT
,&E'2RT+&BK58MBBR/W1*,AZ>=G#1[E4U\RT+=DD-3HRU'QOJJM<",;F/Y>U M3ZU=;'DK-8?ZE3G;'LX6P* /@:2$.[^*A7I>HW&JJIA2">3!7+?\?:X>+.H' MX0- Y@%3 5=$42=BE:?*
(\KB?1RH&D#^$NCS>?X5PG%0LQ61)_CL2A"I@;O# M"_3:)HI]> +\F0U&KGY7 [9V)E1T01U3XGC,R:=K3%3U_RY5JV?UL\JI9/3 M1JU2J]5/3CZ1+$16DT5!R8"?/2F,_?
6ZQH#149PSPV?1-1%0YB(F9Q YX'-I M&1VK!T,O![X1?AV*X,YN^5I.3O=(M#\UT83C=% M"S(VD='U/^CY2$.3D:R-]"51M$KK^C#MRZC1 4&B>A!#Q$SZI('DX5.]+DC[
MTFR'O"$N@GFT=H2LM^AH1$D /K$R7VIV)-P9P;)OJ%=FXVEQHN81E B931!QY$'3P)]& MPBXJUQLSL*SKQ\NX$XOU(Z!LC0X]O6Z!8N39[:K#:TE+-:P1+*2$%E8J#@. M]656Z,
()?/%0REO"V,:62+MY>D;Q=<<'[BAI.*Z8:3ST<".@"?#P7? MYH_]R]9M*/=(=(AT+;JE7#=36VJSVRXJXY!./4I>IU:$BT\Z8W7M[>J@L7Y?
M](_9<&RIQ%W=7J>N//<0]/!OY,ID'I9LL\%@:N,2*48R$4#54JU1VNT*]> M-44]Z9[V8(2)JR)W MWF6;CDRG2&,ZRFTP M*8Q18%<86#LI-/680.)L,.;$*+ K1JP=:0[-ON0:?
*>398C4"OP'F1GQV?/QN5*0ZDH]),#HVH3D,8+T5]9TFB/)C><(-97 M"YIFJ]5:A_2!'%[1P[LO&J9GC&9T?YD(;MZ9**O-2-> -FCVU3&A_6KG(^(\ ML.8&&0:E1NB@25T#FGVES
PG@W>8_PPY3058&C(-,0EGTK(B& /O0@,QT] MEAH? X$FD+:^UTY3G(8FS2HP=2@<@XY(G .:"QXD6QO"2]THMXOB5/__RYA5 MI^72:G7:N7]LWO_H7-
VV0:/?;S\>0'EZ@XD,AUO\%GPRO_Q_.6@23YK0;G-F M@C4_F/XCES2Q:.B>RM"M[[%GFO&TF$K7PF=?O9H 8^'8X\6O/++SK5%TQ!&0 M!;'Y9_@Q^?JB..4B3&[?_P502P,$% @ *H
(656G1!DR+ W+," !4 M !Q:G)X+3(P,C0P-C,P7V1E9BYX;6SM?=MRV[B6Z/M4G7_@9!YF3]5Q;"=] M2ZI[3]&RG%:-+7DD96?W>>FB24CB;HI00-*Q^NL/0(KB#0#!&P"Y5=75L<*
=;8$?&C8"5@@9]P@UUD#P[B^ M>OOCVZNWU\;%Q=_C+FZL #>!OA'W]>[M=?IA=.@-^A^-GRY_NGQW]>X]X_KC MNQ_?G=M/#ZD8 \8L95; ^>Y_A\?R?^>\&@&IL\//KX$[B]O-
F&X^WAY^>W; MM[??WK^%:(V;7UU?_O/A?F%OP-;ZQV)"D-\N4K +\]>+ZW<7[Z_?O@3.FP.*Y+/ ("GX2P7^0-/UAP\? M+N.O1U#'!%:/Z/VX,:I?^:OC/V0S?<3_P51-N8 MXV\,TO_G^:2
^M<(NOYN8V&@MS;<7A*82['N8N]$6'S9D;Q%B+69(#*"O@-\ MK/3XAP!ZKD.T_,R"+L7&P#"X-%"&&X#0M>VO 8DMQ]"%S8?XVP*@_+&.YX\AATZP:V!X,(@46T
MW5IHCS%SUSYV^K:%$=]V883MVE_8AIL%P2F@U'$XK2\G*7?@M!RO:")_^AU M6'W9-;:0CW\-[F$0/ (4"WUX;G%'5<$LC"**@#/Q0X! 0&:+.]?'_A(C.7[9
M$3OIPI0&O:L@_LYRT3\L+P*SU0$OHL5!B.*9,\@^^W-@1WA!YZ_QLLT-NK"D M\YA*3"]$]A_QBG4$MT1NW9T+OT=]B,S^:MJA^XQ]'>@D_Q:CZ,B,_%]
[+_YP_6&D\M1!;)SYTD*MZY3J2;6[)V"6XCL(2S M%5[0X.7P$%S@CJ.&(0&PD+TA\4'DD=6;N48@B0[P"@:[HJT;QK]U8T?C493, M Y5@]).;9_>F!W%?B$EVE*Q
KTV)C>E)*2ZCM+*"I[AI%%RL+6N7X . L[T< MOX1X)B$^=NSC]642[]^[01@4F41Z"M+\5]4_PKU+X(4!^0OI/(@9&C.3#/.& M*@0!S(46!I;O6,@A)A$%
(=R:+W@M#+>6BQ>+*PM;3M!D42/<&9,6;+,I.8CZX:7C;B\/.)>6Y]&[+HN!H@]III%D2[^/28I[ZXX4_IFH!_0OG)@) M/6)8!H'=..>+K9@^P10G[@6^^V.Z ;CA.SH"5P>U6&Q!:&T8:T
M;V&$2>\@P-X!1 CNR#]Q]Y=X_EP=D?_F8F]IX6,_"[^UU0T/H6-_9,"+PR^8 MC.N?+JZO+][%18K_*(^5HP13Y_INXF3]/PXCDCX&2?.3B9_=4,R MXHM L#>J00!%'K.83\
M)9M"#G_X/E9 \K D^B.XI>-XUA/P?GE3"__[=8D30BTNY5.<1^.VX(%+ MI%8!F33200O$95IJHB*96./3;E<(;IOQ&M8A$05X"+A+LL5ILX.1=?%/"0,R
M]CX*8&TLH<'"%B)LYK^\4:H9AX7C#,W=]2;DV (3ODY/Z"UTH5C$*&@MFE'= MGYF(B*%)BQLI-L+!WV*O;#05FHXIA^ZCNM%)*VR(GT.)4Z?K&|",^0=UA: M))48A7$D-
%NE]9BT%G.SIW? .;T!1V2]\PN>PB4>A^-4:*!,768!:T BUWCI MP,)D]F>H-=R&(CA(MRLZTGF#8".KU P(.EG%FV,$54"F;M!!E1-7.W^QP 4) M[7>^XO(;BN$@W0QH2.>-@(>L4C-X
!;)R1"L)CZ>_VIF!!8X4U-X#30AEVL: M[:-2.I// 0D $5QD6XF;.3SQL)'NG]S"5"8TQW\6Z8W^)-!MU5]$>9"@?&E]3L'8:+GM8@J MG1&.>_)N]CE#O$/@:P1\>\^9'
1:,IVF8%N5_*#AQ9T[!%K6\X/?MNMLTDQD ML#%^TF<8(8+RDXT@(;J8Y/''7UV R,Z=_3UX!IZ857(:BQAF37--;#.HHMG8 M2IE]-+)7;B\]6JZ86&N,EXNL2C/F4E=GR5RJU-
IT==L]SXCIT&QU9,,KH#7> M:+D"B&PI7 #T])*C%_23!V2M']_<:VXSR&87.U]D,X^H%8KX'#(R_<)+&KS M3J!O*M66$>%-JDS[TXE.& M7VTQH&$O;?
C%ZJ>'^;'%F&$GG%5,@^)$%M;'S8E3:O:LHSHW^_P7CM6+=\!4 MXF9=*&82UZRK@$)$]V>FF5G()6;XH8 /OM&CY? M.L!-I(E_R 2)?_G]'JPM+[FVCJ*$%(B*(!DP@V.>#$?
5O_)G*LYE@+::Q^<1 MI \F3?&HV!'5HV&E=G&1;B9)3O*3K>K0C^]H$##B82&M3?SB1U4H]254N&L+ M*BR36B9T;R<5:Y@/!7!1=V'1CGQ^\1-,9 KAU)R":-
$;]P1!R_ZTXB4#U]K#%BUZ:\'+VOJZ.*[132U@+W0H M.?+1BO#RJ9"6!$L/19:$%1@=WW&?72>R:+NMF'#4Q3T34A5%7]QP$^=72"H3 MK[>7D+.$;-&#&!?J^^@2 M6)!
[;&2FJHQ" C#9E:H"_=H$;DKC6 =B231W(. M#'NB@5$5B04HB9PYV!\U/'RM#)&3#L2;DLEO%'K+K93(PK8 AVI1D/'/[69
M1GA+MY:YY:]9)G+\3E/_%>9V#X4+L^BLC360.HH4C4QA]91 M_8KHJ,TT;" *EV+'PZFP[P""UH'*OGU"CJT.*4]YA5]6 Z%L)"?4:"C72A# ML-%57M>+3X.$XV?\OSJ3H$-
S:WH,>#UHY1L&"[X)O?V6[?C,AX*8**G545$O MF @/9:5&\NA9/F,A3P-AJD<92"$I7,4O M62TY^*,[@(>6-*5^8BDGD-KB(G ML9QWJ/(X#@)!$#\90WY@./3Z!IS"&:_)X&3FQF06
"LP5&*H4%U*@<(,A1P$ MI)8'ZS!.JX543)6Z9(+*;&62R_'6H.9T&166?0J*!:WB^$B&!3GQ.X6^E?TE MOSV3&I&V[(5]X*1Y/UTGA#K1P4[829\Z&.04#JDT)T/M(:YO%G)JPH8"#%N]
MRE!*(F=R&U]Y,9R\3&[V&$BW)A;B>;/B(:QV]6]JC!!PW"'$)_?]"]+8E#DK6!8\>Q7+;Z$+ MQ;5S9$VK9M3W.)B 0VPDC^.I1-0N',@7K4-9AGCKOZT@?4:R<;:HL:)\QL MHP_=
G,/HTU3VON>A>H$4IF*.!@IFH\8)%0G)0[J)6/Z^;+$U7O\:Y/7<#H] M798(CO'X3=;!1:11I M4G%XHHWZ\7?"C(?BF'7T>[$BEQ]_J_%Y=600YR>*?N;[=LB-5^R_O+E2?HJZ

MZ5=6XO>?:5N7>I\)U^9J\,T>?Q[@KK(&-0J1I.P_!X>]^,F9[* MRYT!JH#,12 ==&@5X(^NA2[P43PHQ3OU2E%:>)I/08@L.^2N#9C0_ @A@U:B M_,FCSZ;OW)*K-.$N/NR5/&C/M -.F]_?,4VBIE7/<5%%"+ !+@I6!A7$B^92 M@S#/G;*#HBZO@T([OA\Q_1=CEA3()_X*8DC2J5!<].'#]^^NKJX^Q ^#'CK+ M_VCYCI'T;!2[%GVQ.E6KX;>1+*TGKVPT;+#+UH@I?
8NO8WVA(L:FHV3D(_P*I: '"[A7Z,#W?51X$; MB/W%68//>I;Z%)A>Q;TWGHOL/],'4*5O,KGYK@TW2_A*Y&#)R>%)&I"#L (; M%'.@P_#7\KP&[KF">?'"C[(;+R^_XL?;/]HD)?
(2CKW8Z>"(%ZS)#IEW#P; M^>5-B*).TVN]7-+*E=0)%%\:-"_6XBB2+2V2]R&CG*X.S_1C@R!,C;S\$. MHG+_WW?E=P5\UZ^-]Q5,3U!^\[UP#1B+%2J(#)9_4/7F36/N%HNS\':)8F-
MY,E+)J?+8#*Y_6-7;I>15\MQDE="V*O%"9,X6(M/LJ/]"#IL =2TDBF/G[K* MHX86M>)96B\3!_M"=^4FNQI?! 37J9/(G05"9,*M<(XH'_XA]!PS10$%59] M3N"JIX"K2((6$HBM=
(8>$7QV?;LVFUH!ERJ'O@+?"A5:B&*$?YRA)?S&OC>4 M_BE5 !WB728!6O#^$0:AY?T_=\>=]^G 4B70(0+FT:!*"$013 0L!MN+GZ4R MND.T6\1:%6O)YDWO<0-
]=K!5!9'*X@Z!;15S6Q#9= #LBXUZ_6\?WOU'87 61 MRN8.06T5F;$)!]0.XS N+5"ZX D)V1#!Y=:?NH[&U(\.\ F M"C#* =OYE*"D\KMSX%E"7BV_QUN UMZ
4+P6[@AQ^HMGZWG#&BI_.\<=C*(M4*SW&^!Y=>PO DGE>H<8E(:[XJ5.MCDJOBXBF$5A$%H^6?^R%SS<1E*%T2%: M%:%%608FF?+OW !'U+\!"[%KX6Q0J8+H$,^R*5#%?
G,+?(>4Z.\\BV8&I>]2 M&=TAKBVAK=CS8#R0Y4U\![S\#V![^@J<5&YWKKY6T%>]MR8SLSO\%]K"D@DI ME?,= EHF 7KP/MGW(\;] JS437T=HE@."<42^/FRWR,ZV?
Y\B$W0CR_,\@/H MN0XY>G=C>99O [PB V'P:)%I: -"U\[..PD&H-3Z$S%%/DD-M$ %YLQ&$\R^.(MM-3@+):8)(6H&6;-VU%L2:KE<,GBG]FZBBVN:@N%1UQ:BZE*A<;BF01!)"Z:
M%%KAX9>.8DDIT%@DI.RL6!.%)V0Z"]=96E9N%'\BA4YH#'P'E,> \AQ0G@-*KG0.\Z>_ M/EPF%=1<=<:!/IZ^L$B08Q9TV/ Z%#X;RY]# MS]#YL.+A@SG8X?
_CD8%S!]',!^86!]4X%.XA#;4(3Y6[=3CWI4!(5EE@G M2@=/0R>%VF\^C9*VIHF(ZE 8;28)!B'Z)!BKVQNF, 1)67WGN>1L M#,F5DFP62;=YPAQ_532PZPG3.,G%H=:-&)#O73
M=DZQ 9'ZF&GZW'/R$K'++']3X'0HG#8V- H=0UM2LDB-5S4/5A@_^+P$:$NS M%R:H#C7/9E;!)$7[HD2Z]9WL/3I>"]"\)O&^4TTB1<+X&VX?_)>!U\=&0# Y
M@;*$O0%.1%3$Q'QUR+E<]QED%C=^L;T(L^T.JQ>I:D5A7&^9K;8,L-+([51,]Q51TI5UP!K4=42U\;C>X)"CQU&34ZQ"L_)\@IO9>_6\\>I9?
NXH;9B@!']'Y5X0N3S2#$]IWF9KOSX!XD&>19 MC 3WZ@(.O ;.=4A#*%R1P^:"#JN.P[IVAN;D!C2.^^; RW?EK'K7X*ZMNM.M)M:DFI:!CE2_O68!O7D#K8$Y>&K]G: M*-9?
RSO6P(/>F5 M1PI+S:678W#X<>?ZEF!GKW$U+BE_5SWF9HY&_C6V,R78[GX\72,*>WQMUD M:DY'I)X_N?C>+H8ZU\RO@5/X<0(\)10=Z\O%5)V6@:BD.QE(+C4)-(8L-H4
M3#F,+V9([&0HSHZ5<*I)<#&@]0B?N#K%E806Z;9D>V+H8O4A>-7I,OMNKOY9:'T_4-SUV M0OYV.#GT90/GP ;N<_ +BD.0$ARIA>2;LK5>%.:@N@N^-?GTDWTW"2@] 2I2D M-
<-*#'T@,+6MQ)NAS B_EPX&44800V;WU/HV\DO MC'E;]*7"\Y1]3,Y"-.HGS&._RE,ZB'D4<,MQ)K[)\W FS=7>/BR3[*6$ZJP MAG-
GN2B^27&V.A!'IBE,8X@@^^S/R7(0'=X:#1I7=KZO5G;NS,G<^(=Y_WE, MS@L>2CKFO3&9+I;SSP_CZ9*<$B0H&,\$!P/ZAF6@% _CB2"B?^'GR$,S"$ 8
M8#6Z=ZTGUXN7U@_OO7-1C_W(=R1'QF_T!3:)S=PA\C8!O M[SE)1Z&6VA2@>E> O)<18H72^>*((0T_;AI3]*4>Z6H^5R M0P]YYU6RBFYCK\OI0SO_*Z#HM5;,)E2KOCG*#U8
$6*3=P@P(?1(F>RE">B?N-ZV MWR$T<<9\S2_=5=4C^4J5Y?,B?7S[QO6\K'K&]<]UC31PT4,805X%ZEB@QXS; MP>E5LH0#)'#N-3C7,PBOJ'-
]]QGH]+9%I)MM,%'Q'AV!UTKY330XA3.XQO Y MH/*:OOBZ(_)Q[\99]1\HSP(M9Z/_,6[,Q?C6&,T>R.D([3Z]S_W)-/SW5SPD?BB#:I+Y[%VG>N(LT*UTF"%U HN?5(33EHG%YP.VV
MYC9V<,1)@X!2D3Q^02[_=9T!P8&^X;=1<@P4U^Y*.YN2<[WT;[-ZW 3S6 M^G%X:Y9F;YC, M5KDP-#DV8[V0][KZ5D&A(37(PRDIH.R39\-F;GC5_DGE0.\? 3H.7ZXZ"X* M(P3(1
+KR)9DWOS?C2XH6,8W$Q"WT4HC5+BF]?F<^6ZQ$WC8GI1-H?;NG MVN%T>+-*+I=4RS+M@]T#/"5 IBI:\-I#?&C=^J4=V!/>XQ\R MEN-??C<=^J4"I6\:% [9BD'86><)7J0I3W4:S5:X.R?
$L#%AM2E -O0J#'+57 M3&?8D&U54XQ#]I?\@0ENC;UQ+WKX([XN%NZ7;DK?$&D<+]KZ[F,Y@\M.1=)!5IJ(=GJ]6^@IP$R!KB:H7HR7/MV6J%8U=_C;^_8 LR-JP&;DQ<
MG](K%9CTR&#T^P:,?J^"T:SU5@^,?B^3T=\U8/1W*AC-C*5_7;SRHZ4."@,M5\P.S81ELF%TO? M56\OJTH\96,)4?F,3*H7;$86OZO>0,9A9!%1'=*+7^(H+)RAN;O>\/(S''CY
MSI51Q&P8LW!(TD\T(BE@>@\LHI1:?:N5S(#AR6$@$Y/DL!]^X8-J$)P(*,YO M#<>D8XBU,@*D] RF=& MX08B]T_FJ^<%AJLC5O*E4O6T+N'IQ&A;+::($V,MDFO,G7@I^'-
MMPGI^NA&BML4A@L0AAX@8*K'UG!YLYRT3\L+P+9P1^&*C3M1*;D/_0J^::4 M#GYBF3>1E.-3H1922V-7_;GF.KJ42")9I0N+(067*H-^DC_U1 TM@,.&C>SL M)?M$,1-
4*N/[R<[P"=)GHC%M&V$]$+Z2GP,O54K])&4$]!K2NC2"YT6$);P#;AW7M4:H<^\G!]$+WT)*^\R!$<11)DUK^]U0) M])@_R=,@?
5I)%OCQ[P5SEMGS#.3C&ERG2*7'"IHNDG4U%/E))X MZ,$*BBI TMDB7^&I";8)*"$;91O$19PC&Y:7+BA_#H M;?'?L++8X3\LY)(SQ]P*0?[M2U*8&'G8HOWU+?
Z$C9^3%I8QJM2B>H])"QF\ M4:15\6(W(\3?YVB)O\V0Z?MXW6R#8^X<+^G@CNSTR++II*$3!+VHG#R4I.IC MCPD>KL\Y79YVOSCI?G76"5V>=
M]/%,UI4,Y^.9Y^,9+1,O6^C7GW"CP^GC=X0.*M").) *)_*'(:M.II*?%U7 MP72[8>U\%D$=(\7]1 MO+9A)4P_7JEZL\] 'JU!O*7DFX6<64QE,(O"(+3BYR#FT//N("(?6:FK@0;3
M9_4HH#\#\4"?W70]4I@4\(?7IG0<#4*\80UR($U,^?=ZE//13'(-,*38%!^1 M&4@-J2-IX-%.1Q&I"P]JH@YMP)N&"%PI'$@5:2.I$$.X714D$@,>'A2E;$((R(
M!@Y/130AS)^_G)JJU0LW]Q.!UQ3U#JGJ?7'|% MZDY9@*O0^<9H:+#H>"6*WYCU)Z3]XA*8^"&,.@+7CL^O#;^"*8_WNH(]/=8L M91[KH[CG6WR83TEHH82OZ%*@\]UNFJM5#U?
%50_2_'R9R,|-CI?_?\#4$L# M!!0 ("J "%D6_$IEX%8 ,-O!0 5 <6YR>"TR,#(T,#8S,%]L86(N M>&UL[7WKD^/&D>?WC;C_H4X7L9J)8(\T&GN]TMK>P+#9(]ZRR3;)EE:KN'"@
M@6(3:Q"@ +!GZ+_^ZH%'@40!A6O_OW/_^N?_OB_;V[^\^-Z@6S?.AVP M%R$KP&:$;?39B?9HZQ^/IH?N<1 XKHL^!H[]C!%Z_^V[/[S[]MU[='/S9T;B
MHQF2+KZ'&*WOWKU/OIC&U'SO!_2OW_SK-l]]^]WOT/L?OOO##[]ICQ]NDV;W M1+"=4]'.=;R_4#_[XEP0T0_+_SA2^C\Z:M]%!U_^.:;SY_O_0X9T?/)/N
MWI[_YC_O%QMKCP_FC>.%D>E9^"M$VO\0L@\7OF5&S#A"]RI/@9L0^/!-RDO: M@O[K)FEV0S^Z>?_=S8?WI[Z$]E>QB/1K!29)<_JM':4=Q;._X9_F3:](AVK
M__[[[__AGW[U9__":$_!KZ+UWB'V$<_1.JY?^)/UZ83]C]"M&6C^NY5-_O<[3B3DP;)1-] M,Y0Z6S\RW48ZB3TA*D8@ 3=33.A95S$>NK3O@OR5TP]_B;!G8SO1D+(LHS=/&YJ
MR/SGVV20,ST;S;S(B3;-(_<\[$9A M\DGF@O$'?]U$!-!I(Q$=,PQ7NTWD6W\SOCCAA3%4VL-T2F5-]7=6-H;GINHB M-_571A#Y,\1(HE\I42W.*FIVZQ],QY/8HK A;/>4ZR;ZY74KN
Y9(FM7GLC) MZO%%_W#P/2;'/3X\X4!FA8)VP#U1IEG.$2\; ?9#J:B-W9!13)R0$[UTPDI4 M(AGODYI-M8;1;A78CF<&9Q3N32)T_ZFP80>%(73Y'CEY*&B M*=RXKM)/.J%-
V\&,^DIINYO84MJ($1\>%7I34_O:42+ EE L4/SB:[CA5:1' M$E+B=S##J%#"UCY%J0WG07\YF0$)(O>\QD<_*%K@EK>$[U<2[2Y=[*(9;&^3
M"=O:\5+"B%,>$,8"TPL="IV57EC0%+X;RO2[@KJ+<K =42IM>PA,*0_NB@\X M<'Q[YMFW9E0VM%ZV@^^$A9I=>F"N$6SW*Q:UM>]QLB2KLQ$E/-04ZLYQ\?(D M60,I:
+7WV3ZY*=*V?Y%2_,@WV*^:@;= MQ8KURKM9O@UD5Y-(VM+=,JJ(DAW*Y>:>Y0=DX&;38;8O.?5/7A2'),)8FR0'Z"8%:*\AG+IK?EE;I,$P=DY_+!H
MQ6@M;P_=C2LTS3NPI#%DUZT2N:73$O(H3W_@\3Y>\(S_0U<]WUZA M)1H6+LB+#2%[9IFXW2S)3Y(_$%N87WF#X6?,EV'X*G@(_!?'L^2Y@+3Y2'Q3
MHF>A>UZT'8&'RB3NQDGC@7X5H(3!P$XZ)7^N@JW_^?)X67G+D:CFM7:%7IDU M&X%#%@C;%6!2TC3IL0'IL,'XQ.I[^<8^FT2=)X)-Y8J&.A0^9:CL GB^7M MRBTY=43(#S0-
HG%@!-B4^.+%UW"]KTB/l!:,\!U,#RN4L/$Q1N91A-I +D3O M6;H/>]^3+W47-('K2C)]$G>Z_!ZF2TFE;'X$C1!$C.)@4]\-MDX!<>?WWSUO MG:CP)E5!$[BN)=,G<:W+
[V&ZEE3*IJ[%J-#S_^^_>_/\%B7T^_>O;6#2^_*; M\^')+]+T\GNXGE6H2>)6N2]A^E2QB(T=BE-#G-QP.#7[8NV)Q%BR)2=I!M>K MRO2ZQ"RQ#4P?*Y6TJ:LE1%%"== MN>DI"+
7\)?,T-'XB,SK)SVE+F\-U014] M\O/+XK8P75))XI:3RY@Z2LDC3G^X>,2,S%]=D#U+2'+J/ENMY MN4-5 KF)H1?O:#L]0&EZV@>V2A5MV7!/(SE8L;$MG
M8T110G4H9YL=#PCUVW2]GO&@$W1>+=+K 0:$%9,\KE+,M"E*:0[N94$UAPZH? MK$X1+1A)%XGDL[+R3M#=4$7GBXES20_(;]HD=]M)M% ;9((X&R3P&6"GEL^(M[IS0,MU?
L!G(KS.5-(7KM57ZI;NYDG8P/;12VL:[O/&]#J>,*.D!KS<9!^S9 M]&;5G6L6(>CE]W#=KE"3M,Z+^"5,!RL6L7&AE(0:HN0&&YX)P\!TYYZ-O_P' MEB>"U^W@^E6I9A?C;KX13#\K%
[7MZ,K)(D87$<+#70W.D/F.?%*T'"-O"=?[M*K2[O"!\T0RF!U8)V_J2L#B4,M)#>R&_I:SFA_FV8_'$ @V+?5%H. 9O+!*W M*W^,
[ZYWXI&M:@FO=G>.9WJ60_3U>24'20GUFEUA>F\3_0N+#9?T@^?;C:1O M7G&3#/@>?5F$_!7ZKF.SMT0^FBY]S(.N%>%(K\\7%7"7-AJ)'U\5;R]N,0+?
M[*9P>TH.1,7VA:3:8FG#D7C>E6Z%WK> 6V=10=8.O'"AJ;SB$-KIB"TC#,DX M4I&K7#6"'5/%.HGQE&\!-Y8DPF+DT*\)03TAU+52F\ULV[KR;_/8B5>; ME4+HNNT8(DFBX75
732$'E3)<(%!K1U R"L^,]_V2Z)]G$1+4O[+BL98'<(Q8J'>'&;3WQ&[LX M(<\]7;,_!$839$8HX848,RV1/; 9+/H'SACI>O=C.*V?^"J+#G";>R\XC.AT M0#;+S;> #50%VHAP)'P-
%W2*A&SJ70(M+<@QC"Z#!,I#@(^F8\^'.DR*0&& M5;3'02[ID1A!K2?LP*JAO1AP"MW@!F(>RXJM)3/BIF;>%&6Z7$'8U_$Y31!C#B]:!H.LS=(-)H|L5R3_2*P"??MS\[KGS6
MHM05-B#5T3_1Z[N!Q>H:DG??":;,$FS=,(O4DYH8356TVS[F&-8,9&\+#& M\>72K I\M.9UN,[\X4;^3'OAF$^.ZT0.#LE,G5V/V_NN
M3<""+E]'YXH=XQK=88=273N(P:;;%VXXUM:@<9*7,>+/M#+RNC>AAU-_;GR< M+^;;^6R#C.4MVOQHK&<_KA:WL_7F:S3[R^-\^XMF%% [*5+:8321KG!F1-YZ M%-'<]
<$*@328(R0][IMHZ&8LM!PF,2R+/JX4/IAG>L'Y8FE9UAXP7);KF$MN M"UO"C<<*>1LGOS%9-/5N^O3MY)'3E=*3] 4G;%_CC-P4TO;@8![CV[+%#[4G2! MP_'M-
G[052VQSL,&O6EY.T)H\A'_F[G6$0&=(-"JG#1;OWPN),5]7>I$SR8 M073>$N:S+Q'!1;HC-_-.!\Q?=58Q7%V"(T*O1K:2 EPM:B/!P&8Z=0.3YQ0D M)RCFCY@
$T1%0+]F0B!!"CV+D]JMYF96LQ*K!;'5CMQJ5'V2'Z5&PYD0,#8C ME!=^P<.,6GXTIM2HCV1AJ#64JD6&OE87TA.VPKZ"!@2!R%"YT%#: 7;D5>M: M-
D,9PVJ"@LP=SE,T!GM4=FJ@ZB=**APTK9%:IG*K)CQ1HF*IF>WZ)R4=S48TST+HTQP.OZ)/*V?X'GWC$GN6/'S*>\ .)P5M<[5P MY,WAAIN*T,U+SJ:T>?
D;D;]>0C<#:FN5;#M0F=,:-P1&?">@WBV ,9[[[_&H MNTCZZ^28KV?N#\GWA@TR%5KF#D47-X4+.54"-SZ.E])%E#!R/!23UG,FXV%
[9@8>P930L*S3X<36RFIQSK$<69:NU!%VD*KK+L9K M=2^XH5M#]J;NG;! "0_T1N"""8C9Z"E8,H+ZH]\UPIAT*\]DP(>M7+?RR37< ML"R1=8#)=!^A>&0OF,V\TJ/#/:B=Q"-
%LEU,L^4=.F,SZ$_#360&D3X=G_"S MXU$HZU/3ROV%'G3DVPQAP5H(Q)GU?LNLFZPD595[SJE3>"BL++DW98RT:TE MV(^N5_N$3&,H 2TL*1$QLB@JZP8W MN.L(W\W2*6&#_
!Q1GPAE3[LBA@OW4NIO=G@:G4U75K5'.=,O=!(UVVK;530 M8S1Q+=-6$L^7S4<1QU*ANXE?3AYE|'7';.?Z7L7JU>8&B)CEFT^]]DE;CRQ6 M\UJ6QBEO.J(8O1"XR_B$LC?
9J:*RP'2*5-43E*ML'U+5./DN(PO/ GU+8U1H M/Z) +9*ZVV@5,&A;=^Q5[?P*I+ TA]XX7AS(O>Q^*Y(#J7\U=)DW_K71^LN M-9=!MB_U]X$J1%G^ :=/<5>U>UAZV
M,U=]FKN$)VL,UZ&K16Z,P0GEY)D?[6_"#Z&KI*CB,,<,L.O2QSZP1Z1Q#<\V M[(/C.51'>M QUE]V;:C:&7:\UK-![HB"4D^XD5Q3_L9'&3B;"8H9L9VD/*LD
MX/5V,OM8T>NJ'[/)ADIA4)3 %[6&':Z6FA6GT M96.X85HMO*WJY'RQF$W[+0UNGSCUZ 39?N-'\R'6_AA^'*N\6! M\\+R6MF@5-T+MI6W__+A6Q:9[!.2#W.R="[+:^0GY?
@Y*EWH]!H'9E36TIC& MI%('O1%I^]:)3C&*RMW5$[_O/:@#?82)[B&D/LH6+BZ?7. C$:(_!?F;1 4K M7?*NCSRS"*:&,<9:-$'RZD3ZS 9G,C!&:5!
<\MOKR#NDB98$R9\2[/<"0C]9MU72X/Y7CZ3";(V@,3AS##\V8 M9#:X: ,\"(LTR@6>V$!OL%6NQA3+VCC*<%24O':BBD+%Y$&4&21JDCOMR4V.
MB@6CDN:P8ZE*3S&L9&WA#F>5$C=US;0:0WH%:8(^FJ%C\8T8QSW1TS^:CTOT MICV-;E;;R;C=0 A.9GE%(R1MQQ66.0W+8I(U'$] YL7M//!I!A%TW.A;IHR78 M8G!35#YK/:Z
N]"R+.3BIN,)NDN!NPR[F#:(P.M*$[N3ZYYO[$+-!@G!G['S MO">\#9*"F\[X>:)E!U>[JV/W%4E] S*P@[:I7<1HKDL#;I@6WU0J1I7"0,4W'5O4922"4:5P8 $4=1N#XI6(W7EWCWIM1)1-
G0O=R MTCS,&G!>P5O_8#JR=U]E;6'[;*F&N=7?HH9P?;1_[-HIOLS2*]L3JHUF@N>ZE) MRQ-&I4$K;0P[6LMU+'N>"'I\5LC;_.;!Y3-$6N.Q)RT+7E;2]MH0KWUZ>PJ(M?
@^L%B&K++[$G]DW\I4#M;ZPX[.6!:Z>*:KJ"#=ZZXG?N (0RX$Y&\3Y(,XH M?:&4,,.-!+SH/8P=*!E67S/9B9^@8X!O=B?)H;Y; :F3S[G?QC@CP,"1/X M1D)#4+CN/$I4D-A
18N>HX.%V3R]P$,2<5AF,C0M26:0D-)5=X6%\@-^[]/ M_"9ON/4E'5 =U6A&#B0GO;I?/&U$!?BF]G4[M;ZH[GD47
MHC!]DM>4OM*+WA@/\^E;^I[WR6670]GE]6B/$8Z%HL22*!OV*KLF$V9<)RAACE+N@Z*R1B/-!.S-"A',*G3:R>1I'\=0Z!?2!6L2?-A@628>VDTHJ M*T+
(S\6X,0!\#FV9"N#4E\&N\0LQE.FN=G'UE-5NAX.D3F'3D:>2*F"H['$LS,?:-:;\9X]186.$)2-7G%'?,!D(LIY9!7J#CCG/['SLA!;\X@/AS@\8FB)!$DU'.H!; MEL]@N$TM@;WFRQU3,]S?N?
[GJA>C*KK !CD5?24W.*[:PP47):E[O:!V2+& M%[TY:-VEL<01%>8A\%\<,AW^>'X,:?G.M%:^847."XGNRI?2&A&"'0W-;7-1 ME*\F%;B1TT*7-L7P6+@D3-
$3O=H4L@JP;U'VRD3&6W>E!0U68A;;,4 Y<=,(MSU&8*;\?=$,LEQ*Z (WB%4%;^K0\L>E!"Z M'I?J2?=GJGOA"R[$$H[4$H,$>;).?XOY?X79>KPF7K'\58L [-"O;PL1!=1[
MPP6$!CHT/G"?;!"]29BI!8LWPN.IR3U@O6M: YIDNJ>3E)"<'6$9!0,-US&? M'%??*M:U 0S+HN==0C*[HHL;V>M7BTQ496LJ$AL;+A0H2=W4G1/B[!(6)P@ MSZ=?E8G >Y-?L]6\J4.
R\+8#N^(6V],%]^;T2F@M?D]>^[]+K;H#G-(=[K MX(@1)=W5PZ%V<>ZY(!# 8ME&D<,#%/?OF5\PX\R,@_M]JM,2OF_6 &T?D6\D I:(+;.A0T3=?T5[>'BX<*$G=O,A)0ISF
MTC%YQ.@CRD#3^D2O.B=W86A=EP,_Z&&?V,TT?I=S+ (\FBK[]ZCSTO=NGK#) M:M>DAVX=SR:TL>WA1K?6) 7/"#"+,\2DGO!]QU_Z83=S+DQ0IQ].2*JM>5J6
M3*43\,)CM51HZL';69EIEF"[WAT&,[JY0H5QI+*8NR**;UV2E=-2&RSLKJ>MY$3G86N!#6('9^0^$EKP>U^4)RMF7N"(#^8-=K%B3W'*VVV'I M,M/@0L &++#V_B0AZPTH
%S@UV:'-@M&$PZ\@![ZVXFHC(OZ1[?)>?Y3IPT5'! MP6U:RSKIN))H@*@*B.N@!*I5"@L0]XXX]$S+$2%4K]UBO$*'2#L&>S!PZ8%OW99Q.9031."SWA M9\>CKZ=*[31,T:
[3\>BR4DRFFU0AG7L[/SBPE;;J*K/*O6'#=4TKY.I\]76% M"\%U%6A<#4O@DU6>10(KW;NY6BSA"/K?T&IH\>)RA ^-DCW)ADCR+$%RK=I(MWZSXV8GV\>LV][[M[!O+NL;>A
C,P&]GDW3?I#8%X)LHS?5I_UA+];LJ\3LJ_MZ" (,.P^RO#V2=] 25@BX\(J,5?C.7\ MOXSM?+5$QO(6?7SSS69TP7CKA);KAZ< ;_&7Z*-[?8]D1S:O.$1+[-I9
MM!;P>*6!6Z9IXQ@6!)J@G$ALA4,4BF9SJ5CBDR.98.A7*AIBLNF9[,&S<(VIUA0E4S&V0O)ZOV!#[) MJZ]'\P.?R,8[AS_+A3-W%_"^/\]OY]A>TGF_^8\.">+7] M<;9&C\OI;+TUYLOM?
*8EZZDT0E4^4XL S/!O;HO\>]]J;[C910,=F]]UIJP0 MXX5,R@PQ;BAFIS\;&- B@%$B+G))'T$GZ9!5?16PM -L%*C6-?

WQOK7]#]#FWFGY;SN_G46&Z1,9VN'HGW+C^AA]5B/M4UV#G/'EOP M\Z)K&U0.=*J=8;MW/1OD!CBEGG#=OJ;\C4,@8X,R/BAA!&!(&\@.H*$@+M<< M)O6:3;=J2"OO 3OH%;2]]0)0E:PXWO%6$;KP9.9VN'V>WB&1@L_5LLV6YV=U\ M;2RGU)%G__DP6VYFW:W'Q"7$D\<'B4KI58-X'TTV6C7H#M-UF]HA796IT1?X MNDP33=I<9*07$0.,
[&Q1]HB#R'38H;3(OWX?AZ[S9E=4XFW781=SAK11\A+! M7-0_NZL4\],VS@]OC[!0L?4H?V\+9NGS5,%_1!298UM%7'.C+VL,= MZ96D;NK,=\9\C7XR%H\SFKG&7FPLB'-
OMNO'^]ERJR5?+=*Y:L9:U6=\OEPZ M/RWM,"YO[@Z;*77$R N;K FH3UK#3.(,UU9?8'TW=^XH,K4#Z.0/3G,G@9. MRN!6#%BMB<*&@6YL)N)$.XIP@:0CO1]OlVQ7T_] 'XT-
R02GJWN:\[$C"Z # M[:-HBJKQM#W55Q)JY59K%&O%)%]!L%4HUCC:*.T;%LDH*1EFT%/-S^P@DOX! M7KN! ,%1_HVPZ2D(B*Y5R\T5?6!#B9+&^3+M)1W@PH":V(WK1JUG#\;\-
EE! MZ?# 7U[NZM/+RIU@NF4]G=,EY,H>P!>.U>7O=KEXYP?(XK%P]7+AL,O" 5O@ MXEU*\2AS-@0/O_X[@.+MP:FK&C##5BBU1-D#MG,J[XZL:F9:'7CL-XHK(C/5ML\.;>
MGY^DC\\+_"=LVY=))7XL) 3%$NF?S8.S< $/'C*71H;?&I?WARO.2&ET'? MTF;/SH6.0IV;VD1@(UHSFXB(58\"7$1J$?3@)@O;Q:S*8V%6[2=37]Q'1QJ%#.55<&*LK]RZ-
&"'<".+B&%=BP#<4&~F1O.(V!K+3_./ MBQDR-IN9GK,4^7?CROO #6AER9OZ\GJV,+8D;7LPUMM? MT'9M+#?&E!X" .74ZB-7/0KC='7%D:Q&]_$%0!^XGG\]4>0&:H@;U"2@X&'A
M>\|;'!SHPV,.>S(^?57BT2.!E;PA]T!LOB?RKYYV$S&F M/56XT-.A;LW#;S,SUM.?)VA*0NYQP>Z$&Y_6LQD[H,]ND4U7]_?SK;8#^YEU
M:HS2E9U@QY*:SKDG2$I[P(T!1;D;/_*0D0L9>WJP8-J\:P0[; M8IW$,,VW@!N6$CD;'P3_T5C/?EPM;F?KS==H]I?'^5;+ZCU[2G;ONS:)3Z[B MTH\4CMXVZ0_;56M;(E>%2+4S7
>OKT)CWQ ML4F4/ N7P:7SUI(.L%V\6M?\XH.L-5SG59"Y^61*B 10HU>2K<,3\GEKX5C MT4LAQG. 2Y^2]6P,,]I4=$PO>4E; K_<52WWJ*NS\IZ=>?)I+6)/H,:04KU8]
M]AM3P*EZB:/"9_W_5\I5R9Y@8U\P&N9L12CWA)O3IW]:1_QCLOX61L[!C*13\ZM&L",Y6"D(-WKKB=IX*8F^'4\O++, !$;@HGM@>UCT#YPQ:A+]DL6_^"K M4"5-5NH
,X#5=4WG_:6M@4_XU61OZI?"M):.,26;V?LR11R>=\\?/EP\\T^]7 M[X0Z%#0:4&4M^<;<>R$)#W5TM1RCK#U,6%+6-']!3M(8;OY0+7+SRW)97!) MPA!*:PK,P]%T
LI_%9#!X.B'IKO:T>/;"<%)PH4BO."AJ2 AW,+^^0BO0$= MP"#01U0&H9(R120K2=C2O(4ROF&;%(M<$D* MHX)#@,&-8F=^.L:UK>8D=,A4\P4_$&7#4AQH1@DV+K2P3NYX
M>GTR<'&CC3*]/6P !#ZTV(8>E$?<-I; 50NX%*+@0WRP@Q"IEWQ&ZQD#N9X812<[*UB MS,R OA8;/N" :4:)%3W@@T$BEKG+F66=X$;]*]"-_7LA#XB#!#C "[,!S/!
M&]1EAU:>O3\IQ '+_38^-P[GB+R M-0D?THOE*UOZ>15V=L<&-FCT9=?")*,C'G!AJ3=-VZ-O0KD^X2]\8&! O'P_,('V1'"GMB]0\#"%?V[0D44C[_$,!P MK2TT<*
2(B:BY@D0*&/#?!1Z8^VQ?7+Q:I=:C>\^&9ZM8#XV#E36#NF8!VP M[<6BN47>+AG A&%3DO3G2N"9\M"(%,]O: MKA@HFU(= $]VUJVGO:OXNSI\O6[T^%@!F>*=B'E%IO1Y-
P(VNE ML%N\PT$0OXX^-8].9+K.W[$=O^::/-)6]\6+#LC"1J^N["9B5UN:<)&K,\T: M7W*(!4!,@@D29)B@6 KQ><6BISA X)AV2XI)V^5+VWI3L.LG)FNF6@H$8(-2 M?
5L4ITY5O>$"30,=N@B$@L=:H0"&9HO,0$##'2TMA=DYZ\L7C>]N9M6@-!:P MJ&T=R6 /U"/[A%'DDT]VCD4$[JX: M0[S@L]K%]ZZ-
=*6G%!KJ]H6)!XTLD)9K4.T(O')#;34:EVLTGTZN&8BU&HF' MQV4:A"7&80LX#*9^LK2ZVJ&8%KQLGS=(\/ M3SB0:9M^"]R;\EKD_(E_!=BC+@3LW*=N_8/I>(-YU;WC.8?
30>I7E]_#]:Q" M31+?RGT)T[N*16SJ7S$U]"NG-^R20&_JZ$W4A>1G47'/JK(3S#BJIW-Q>ES4 M U[$U92[?0I[F:CV?:7H!0=/?L7V1,^Z/|[?&^M?Z-V@S?S3X8-/:P6UA!W.EIF(<2QO#
M#>%]D9MZ,*=,8S:EC1+B6M;*AE#53U4-BU5ML668R,\.J8=K?.3OL&#[S@]6 M'C8.." 9L7>+CW|H1!28:,.B#8?&E&#&:@?623<7FY$!OM784JGF]09C1B&*
M]AAY:92PLB$A"C)!6"5YGXSIB2S(3H7AS8?=G=1DL0(.&,TOC#12C11QITW M'W[G4KN9RCSIML.7-+F"]\>MA]P0(OIF<^%T"IK"!@Y2W7+3ET4M0*.>^4R M-
_6^C!1[J,F+G.C\=9BXHD^Y#7R4HA)IKY'9J4A\?0U]??WLFEI?3(P MH:FM77+K*S5IP)VN-=:D59'7F.'7R7X@Y3F)EV(8VPG*&/"&6<^1T:&ML\:4 M'N9W=E%(>70_WUL%MN,EN5-
(,BM)6G6Y^-*8"$Q :&>3]PF>,@7@.4YS?3I8 M[8AY)KD/3;VQ:>WE4Y2!#YGJ-$["_YG*4>/([:)O[@:%<9K-UUKG7=O M-E: MH'4*V#%8R=A2U XF4%9D]J9&5XW@YCYR49O?
_'^*4$9O@F(6_+9_G.R(W]_] M=+.<:TEMNE?^\=WF'5&8'9\XHX^.ZW:X5BV\6W9O1E3D\Q8'AR(%&5XJ M^]79AJ0=\)RB2NK&\78*>$E(=E$SY8$.,1-$PN P;(:0EZH"79001I3R\ -]
M7RK>B[^:EM*_TAO&CR'>G=R%LY/6]5;K"A.!FNB?*[6KT]N&E!+^L;56PP?SR*OT$G;C>[K7>@P3\))]^W/Y-$A;UHE%,[>T!18C'% MKK #0H[^8L"K]
(,;\+6D;^KL"1.6^5\&/,H8:0GW02P@O)I*'_A(RJL6*#UT M[2XO0(!3M=/V^D>(,JCS65!R:+WZA2%)#NGZ_1Q)9>P\&I@96.87]JF8[KT M+6T)?/&[6N[&A9CV#IU6L4W0(#L;
[6<,DZH\ V^3]Z>R0#FIOA3JN58YH*+) MCZACZ)RZ9ABFE:16P=IYWDY@PI*RI.$I*&\,='JM%;NJKC#*=]27U MT/P ,>H:4[Y";4NSO?(>(_1=>8Y7TGQD_MM19E?
BP9UG=0\!OCMY9)96G=/) MF\)T1Q7]TGQ.T@YX-E<8)=GW8,DS%Z/+DN\4/S9@NT>?@>_SRC!%%@?-$M*,%W?W:6(+9;H>M:+6[RMF"+TMS.*,/$JAZL)QS#
[X(L*ENQTHVCC#;=]B(IIO<[G*\&*<-W)K5.L8%8 M71 #<3F2>X>B)'11(I$%S5(:%DSG=5Q3 &'(1P]_P8'ET.>7KWU+SS/,3]'< M"Z. A7_9<<;BEC#A7D&
[_/O'5\W@IHUEPG9QQ&_A>\\W]-8-8C<8,U:ASE-[MF[T?1/1F$15]2QB5;#O*VL+VU5(-<\=@BQK"]==R<9L7V"%4,S>=($I9XQ;C ME9:EVXORUB/S4?
FVHJ3IB/RTH^U$B:=V74V^SG8XJU03T7L>5*+"+<>]MK#] MM%3#W.9W44.X/EHN;N,-[2UC =3E'+=*U MWA3X_%]!\"
[R!%&6VF7B_1QNR83%OC&2\M(Z84 M?)6=QQ&+:C8H"LWRGN.)5$4]N@OYY].6(OE![(:_=<)0WL$,:YS7Z H_T)IHT]75*"3F45':[M .TX.]-%\0^67XXW$5M8?8>V>]
(^:T,/2)SH$FCD)^]&8TJ5S)/8.K)XYLT, M0Y]PH$OXGYUHCVPV;8HO.H3LF5'/8Y2VUO3P'1_0$'CF_SG8BL>NQ]XPKE94#6Q.%B?+=VNRJ7'-CBG"7!CK2 MJU4I9\3Y(RX
XA),XKW"7!EG?X?$[&DC.RO1+SA!L5V\D\V-=SH2^U@IT_ZF MAP_FF0Z-2:E6^EE") M:8<*=OX\D)SOCO1:@;@'(KP9X!P%8]"@Z.%"AL3VE2=\>B[0 M*P;
P5!NC0_\;J2@6@SU;7/8&J3'BX]U[:<*GJITQXVLM;7L":#1((Q9KB# MF:\:N%<[E$J32WAC>8#GNH-93H66)/UY7A-F1YEX3> B&S&P2=&^WM1 M?#?
H#A/FF]I!7!Y5[0MW(;2V!BU*F#-&*.8TB<_WI=R0R$[+PN;PML"\X+3]LI;TX5;NLA+&BQ]+TC^^=$,G;#L M D27]&$#2.>6S#T0T15QN!#4O8J-GYH@DB
FR@2E[%@9>I&ASHL=]:T^GN^S_MHO!W ?IMA#WK7'+-0ZWG2"*M6OO^&))W&T%T* C?^/F@C#!**6N\'I+]7*1Q MZ541M9XC\?)]I0Nl7-YM!%ZN(S'7JIQ:DF1UF$Z\)3>-
%'L.CY/E^E?Y>]7 M_<;EZU+INTUEM!2&&U3OE)F[^S]\T<'!R0D]N<%?B&1I92@E7<>24PKV4"2 MII7T'$%(4]1N+\F%.Q*EAF=O ZOZ+K%HUT9_1AB/B"OK% \^5F
MNWZ\GRVW6IZ#2"]X$.79FU^A\:BQ*X576!CEX]^(A25M8>++$I2-_7D])$] M&OBS#-;2/EL!G;9:<\NZ<.&@,XMF2NWT15QN.#2O8I=E/%F?&[HYS82I4&B
M..CIG&L8BX283#I/A3X0"]"'U$M6K"^:P(ZQ(GW$,!&_A^OIA5(V=59*#%%] M&I>>$X5*%X^O&HW#U>0+N/D6\-VMHT54P>$Z?\?7(+!I8YNF6YCD61&V9[^=
M2&8T)S^71\4HNH#B@!44]-3XTK$/E(^FOY[6, MBD19EB=7+3QW0A@FOG9ON_QS'6VIUCS.M2M58F_BME8QL3[4]*_M0!^-S>P635?WM)*KL9VOEJ."L <<4$
WG_%J)ZS*\<+DYA?G<#IT_0NHL7RE ML%?#WIT H@*_5PB5=;36!J(3E(E)U\@$07FE?A2+.BZ '<+V>MDH?>9B:1R.<'=Z?H%.!Y+*3D MMVA"!S9^-
K9,_KFLFD3@(EUS59K7GLJ>!)F@F&GRD.Y:C"#.&,V+ VD8-!K> M/EE%J5)XV7'CZ$29QDB=5.F*7Q]^,1V7;K$06WZB.ZI=#PS5[&!C5M]V[B3? MJ^ %%P%[UUACGI=A2?)0>2(EPQ
FY[B2O+Z-GEDL!ETS9[%1PNWJ2!N*9U_6 MONL2D]$ON_Z!JIB]4JA5LG$G0%O*Z17"K)J^&D$V%G"T2FT?_2H5$L90C6ZGL MU<TU^+&[29$CYZ- _=,+96O#1B\X>/+':B712#&SD0\
[?'#M_X=(^?S###9Y MR_8TSG F_Q!#S(6]P$:7)+'O S*/L,VOF6%GQV-G:&0&',5 Q":(X=SCK]I]"ORP\^,3I9Q> M]V!48MTNAZ,"-
J]W0"I3%L*0Q.6CKPXG;UPR&4#;3M>TCIPTHQ36Q_Z7[$*Y;;JY1##6S+SBP MG#![QJFGGZ.(S^L>9J26[7*0N6+R>H<8N:H0!AA!NCX7B'K/Q+NWLD Q7>,8 M.6@*RT _8UK: -
O&"PI_9QPKBQ\"Q\)T2VCWU$:ONB"O&W:;_S8]+=PK2O%Z M;N%+2 @>V]I/U$ Q1HDN(\1TP']:CR%46!:T>AWG8?ZJ:HL2E)W_C.-?XL: MB$E?\8BK]S?\G[$U_RMH&%# _X4?
1T0Z=KV$[O=)M=?KG:]I: M'|*,N>UUJ2%AC)'2REV%NVA]C).=2C#RL;+[7Z/6>-D=^Q&/F3T8H<]QL[S6 M7>G>OH;1LXO)$: ?")/Y@"HS%6QFZ8#W^F*\,UP04^JYG=EO][@DHP
N?7\ M.E=X/JP8P%%>DS$@8'_Y68!4ARMXTS:N+U]O84+Y MK$=FPO<]_9C-)'G=(T2+7Z?+$:*!&*]WA&AC# @C1/E"SBL;(73\6+(%'HV#
M1/ILX>QP=/TSQALJ;A=PG,)LADD48ZE(\0M<<4UM*LD$&0?_1%IK?&]S M[EG^ 6_HLU-4V5$LL)+G-\M[P Y,!6W%"II#C=(5(1NZNJ<-D]HX2ZQ[<\ M)?]6ONQ9U6>47BQ_]
[.TP^@\N:-704M\N?DKH:V]F;ZR0%QA;WCV+7[!KG^D MLL4C2.$[HO5ZPO;L&MJ+_JW0#:Z7UQ&^^5NAG ?+0 0N26JBY_5+;1:P.RZ: M#J%!^-%UP-LG()'YMDO4-
NP#F7#3_3KZQ*D*P*GVA0UQM2P@@IQ21[@P5T_\ MQO<-.!?F\GD^.KV^F]GJHN()W.ZYP(ZDG]PJQES'+.!&9U^*:EQ366A^-A>< M25_#&]K76[US+PH<+W2LGTSW-$
MBBM^L$&R=TOW5&\BSPPN6>>%TF./# C5#WQ$]K$8PVVBXT7CZ@2@RMWA@V']6P@ M8IM:3[A 55/^OA,W+:@QE WHV[FQ#2P1>3'P*>C2]UYP2$]%4*@,MSY)JL7O
M:4:Z]*-?<)3EJDS9&%7;9,(=\(8-/8/^ K4GL6T9PP6^8=7O#3=3"?)V011 MTC/R8%I,SXP'7)C-"]H^)L7?&'#P;?_\N%;-B303_[Z$.^C MZ=C%V\9LH?CB5U+O!1-T:VI-
45*QBUY8LWWK1$5A3M?L-VO_TC+?(?%WR Q# M C !=LW8XP/),0D2*X0SHI+10DFF_4)+T9!H,"-T#/P7QR:10WY,_^!8)&P\ MO'-(\\].M*>MT>Y$R^7$4<&6Q#S,3L
CGX>4YP<'TT4^:4$L0R++.EOT1H*S M0ZY/<#)XUP?&%8TQ0_T(,0N4GM(P+DYI,#:#(OO@JO^S>3C^VRWW+1U9=BS(MW M/ ?5GR4A7T
PF:%;I)>:2EVW@9GM22=OZ7TI12_[4FUJ.1*U!0FI%7R#R(M)8G74Z>G("#8(3%#:0?885:MJQAP\M9P0T]!YL8EP2EIE/AL3)S,?#AY+1'9 MH[:)GAJ7E&[Q#A-E[-6._)?
==+R>-52UA1V/I1J*H5C8$&X4EHO;U"43]B@A MJR'C'$A#/]%0=Z:91Q626R^)5Y<.CTH=88>ENNX%^6E)+[@!6T/VM@-*G]OI M=+%.(8/M4TVV8 @F8.O889QAJ1R)
(PN^KN.MGT15_3GS?I1+">/R1?'T\6QY_.^SZ^# _:,PE6R)/^*375G6L%@QH M@+74U[2<'^8Z;T@T!<1MRW,B:6.8 *VF8^X\<&%+N&E1A;QM8S2AJW<%KR@CR@!&
MO/:D=4[;'=83MVR+U9TDDS1L'XI.2$[#5Q6<5;6%G:(EFJ8&U&+&L(-R'Q&X^?[-BJ M0%9G!=5+%4M*ITJ:CLLU9<52BIJ-QS$[*8]:X)?:RJ)>*EA:#U7:>%RN*;^ M6MQR/.
[94NKR-S[ZL7="=&"T$"N?$K+]MS!CC%S.&9D)ZV%WP?JW@< ! MQ2Q0RD-/T59MFM-=S_2'AC"B+BKJ,9:UAXEERIJ6#;T+^-4.JT7N<(!=:*Y# MV)^R\^7-8CZ=+6E%P>UL^N-
RM5A]^@5";$Y]@ARON,)ZTH-.HMR>F-?X(4$9IH*C]FBR0MN<--;K7(C@E>2/^ MB85(-OJ,:9G4%^R=<+CU/^('T[F,Z2;]809U8TMD9P=K= 8^WVBD2O-S5T=Z
MS,^+0G;XIICRHJ?W@IA;7"""G0H^>22TXMOT9B;DP(?RAC11 00^Y,RTSIN) M,M5P3&](DSQ4N0F0S(B>'V5W^841(=DV.JL)U5D8Q)6[M49$RE-$:5..EI
MTFT&%?(,)U,3=*/U#&+^U+]MTO(LQ[A8%(>0@VEKN3BYP0Z2)$DUCI'(NGLZ(_M4,2,H\;MZ!*;9!99F@=,Z^BN.8-=[E>#BN9;T/65YVO>8!S'" M?+DUEI_F'Q"+1,::"E%IL)!H 5-N
=UPLL2RZZ25G48+$X+.BI! >HPR_$6Y^PIU MPD-+7<>>U28TT)/O_XW7Z0(6M7?LI0H1K^*:3L93R$HPU;>9"LG11KRRO13Q MH)+>*-
%"7:L>L622RQ>R2I9W3FB1C/P76G7NWB2".M$9_9I(!FY!H7]:SI(G MH,3L0F?I]K(DZ]H.2_PEVG[&[@N^[]UHWV!)0HWH:#&KALU4)S;5%$>)6W7T
MZ@6Y^'O1UN5D9\+1:N7I>;I%L\4H/L"'(?H+;3_[G9@PH_6:0.?"0LVQ)B;T M6B#F4AT-R$+8CP!9NC(4B?3?CP10^&?9,=/FU%X=[(A6:@DKE-2K I:<0CJ@
MA0HP%G#IQ%@D[O]E'/!R1XS>F?%B8]\-7$0;M<,62NDU04M.'PW(0OF/!%@Z M,14)^#]T=^=840EC1\PAP8HV=&#"1&O+I'>1FQ !?B>YE4KM\ ')CH+EEG@9
MYWZQH0A! \3M5AHN\!1S3XEUQ%K M$8 =3?5M(8:0>F^X<=- A^954W(1H.VJH:A8Z6W"PH;C<6CYG<#K5N-PT(YN M]ETX8N<5;F^#=_=GDMK)RE>M8#I527:I/.V_-?
9V0283NJ ^5X,_H,(YL] M"0:^BM^TB'Q&^B#$>MN)3Q^JF6FBL+-N72MU%_WWX;DJ !0?R\+]N CC^ M)?JD '#Q/7
DG;.P00QHAS'A8#NE8XTT,C"O2GE.Z$5,C!%Q67@A6ZP825 MNGHKS+D6\"\"*TO>35HKL-!__I=_W6<+8SN[10_&>OL+VJZ-Y<;8;N>KI99+
MP.Q%K+3@6TYYPG7V):)5#YYPSM4;=/7(P 6'LHT MC1G^;EO*=))?HIP@RAG]FO%& G,M"S=,X#6VL/-"5T]EXV)!LQ$$1(%>5]XN MM 'NRD62=CZN3=#M"2-
J2_0F\M]>++&_N:6IN<4^(:[TX:V^MQ>[M,;]%+'7 M;NBTPO%L_$3T\ !5,8 6$]@'7E5TZXLP]$!R;7HZO2@;K^H , K4=4VGNJ6M M@4]\U6IOL6U,;T/%=6D/E*9[%NO3!G%L'BG;86?
_6K^D.F8QQ_" 3$6PT^/ M^]7X_N+7Y;\[H(ES_;W+,6]6UMR='.5V9 _[C[GY,8B]2$$BY6W)HCZC]&*U MS&ZH+'X'NR3R'9*028'(W ;Y;&G"$@1!-IGJD4;^;N=8@V^D]FX@S@ 1
M#H@ORX@\=#[D.8CB#@XE/[OVU5NG?)DIWPPFI%7I)5U4=< O,Q5)VLUR**&H M;[VH2[58.44M)B$+ X^!$;%Y:DO+P+ MW!!4%;QQP7)"_X9$S
$E'%#&0N<1:KGB\]3DI<_^\%YM:,[FTD+NV1-HCFU ML8:"DI740]24U!A#1TVAIB&5T*:KM)1Z&EFVQD40N3$DIBA='FE.;:SAI&0E MM7 3)Z^<%)3])
<1:H+*HDWC8S%K,A4GCK'+I*Z'(M3%Z^Z6Z]=II23Y_5D2_4EC6&&;]J.J9+L]*6P-=DJ^7N8#&VR!&'75GM3\V, ME<:5U$$437_$)L>!BO.*,(B$G(+*\LGR#^(6B>/*,Z.==!7\
KFN27- M8"),E5X46V1MX(WYE9(V]|N,:/P"8K=3R K7(S@6I]-I1%WJ63A1K-L7KI/6 MMD#BN7F*[Y1[ZW.7LV^6VQ/%N3-X7II"KZI9F;I!WP
M/*U*Z@ZRM)0%2G@,FZ/UI>*U7AKSL^&4[XY:+$F\XA/D6.%<\]Z)P<.:4O MN%&N70H;QLQ%Y(\!\4##I2?,KI31"R5]=GC$SW)QX-N8.$S)
MF;Z"1H#A0ZI3=FKOL@5PT)#+VRM>"&P'/G77N;X"19V'ZOK4JTM0V/N^N]H] M[$U"USH;T:-EE<%#67/00%&IIP 9TK;@P:-:\HYAA-WYBD&$%D<)F0AT,_08
M"X","#U.IT/#2G^6H/?@,'VTV]&$ S*8FEHA9Q"=?4%G_M/".D^RJ"BIHM83 M)I8UT%[M3,@"?FV5.L+W=!IQH;G$RA F6,\V,V,]_7&"IJOEYG&QG2_(>/3 M>C:[GRVW&V0L;\DW]_?
S+?MW=ZE(NLP]]YS(,5VJ:!',2=K!#-A*S=*LHZ@1 M\'2C5.3&=ZUQX(@V'66>+=^_=;KT?R7\V7R.>]4SH?QˆˆA82.+IZ@KQ_>__+]^_K%)D9FR)&L
MHG2'3V1ZT2Y1*;I6J0O0^CEPH@A[V\P_EW[D9%8IU*^DTQC@K$KG:VR3]1@+ MT%7*WQW]?>:LD,<8,+ 3L(_B#T&H4^S0_P.)_Q&V0FCF 42>"#.1"-8[J9W
MHJWH:+%7'IG;]G&L<15L*3ZL3]L@Q4B*3)$C;Z P;6N!0K.0)9W! ZU MM=5H5GA4UOSB'T^'NQ"]_R9%.M2-@F*NE>XIQ2KV M UP]'=]@VX$31FY2_9-E?
#2E(USI/YUD^9X,Z/'R_8Y+D;8,TBL-:?*#Z6$Y M @&.%_G#HN PIDMO<0BH%$~",2=M\#>,!1)M$V?05_R-+GA&A0N>?,)4LDY: MT0TF-
M;5^W)QOZP(]5])MOI5]NK!]T7BRUCJ,LX?[M-I%O_>WC>>]:8:CVL&-1#]C!JZ!M\2.-5\WAAJR*T,7NF0/+C+]]&E%1E]G M/1!:*7VU$RZ-EE3[D+6%
[;>E&HH>6]@0KJ^6B]L<6%W"QZ>E\E]P[JXS70@5 M_\V+3D5[TT/Y3OJ]<0CBA89G+WW/S#X1GX@LK1)0GPKL &AH%3$T:I* &S1- M%=$93IW?VC+8_J^N:[:C5]8:^_J,FNRl'K?
F(F2S$4// MLG*_EI JJ?&,I":-M4RZ3D^A8SMF<-Z8::)>DK26M8>)6\]:YJ9;LL9PQ^]] MD5M4YA6F6?KR44$O>@%[M5.MDZ_4$:CW*NN><^/?H#16SWVCAR[\SPX?3D
M.M9JM\!&=+)]]_)D*2MC]4TG#[,$D24/@66"EV+TF@$?&G5:Z9^SIXV7? M#?QB4E_Z<\)H):JF,>,;5,\> >9##8#Y,$J ^: *,!_&"3"78@\-,!\T TQ7 M^A<$W@=(-.GGCT"S.IJ
,SO1@DPOU,%F-^-$V NQ>X58"B_2Y31##!=Z5\0 M>+^#!#!]ZCE48; XC%$AYA1]#Q-G])HD1?AR7*;D(S)0E.C"> MPXZU?2D>TT4988T#[7!*=IC&!XX?Q Q*L*2X&6
<*=$KR]NOVP#'CS*)^UT. MH(P3,!GX9F8?2C.:*"&J,SGO7;D.BWUA^@KG;4*8P%'@6*9WBX]^Z$1T>W%O M$@N5E/^]20 POC2R158BK$YOX)C43)=>T0IQF=!M%N'II71LT^/
B90H$Q-Q M.0>N,S:H\:[-(K>#SD)D>HW2-6#.V@*F.@'P@%G3%A>]=A[%(!95Y=' ',V M$L [NI1W69:@4Z=YVR52%L2PUH $8JYI:Y")W M4R< '-4:]I, U,4C0/:^-)R)6F>9G@=
MW#1,WQ9 V_IP_^RWDQ/Q"^+TJ#:BW4/883-C\9ZIN-J<3M;;[Y&L[\\SK>_ M=/IHX4/@6QC;X1WQZ7D8GDSB[_GS2,..6"+Y:NJ'T64PMR0%,[J[L(_X*&(3
M.L#SK+9:M2E]9IGAGB9;KO\9D?CS+<>D&=)G)]KS KF\KE^ +>R\T-*V1,"X M*MK7879HFJ!*R, DKHX6'W?T,"L)Z,1BDS0M"I.JLNXA"]*&"/*&27TT>5I M0L8]^YKQU_+DHS9#'1-
#,?=*O$I"'A:/0G$6N K6SO,^FGW!@>6$^(%DH#C] M,HR_#=]+QK6FM& ">2<6$A.W1H3@IG+MU&E<#21)ZI*C4WZ &,7)2G@CQCOH M$Z:-AH49O99**$X03@QS3 R3+)>B-
XZ';%K)0A9;>.0SC'?=OD*0EQ'^5/@ MAV$1WB9(6P31M7K#1]&&5A >2%#M"CSI:Z(]P+>:7WFLHPO*_/]3*62C,M# M/U-2\(V-1 [$!:$;&7ZX2F05?>M300V)#6SB8A]2C
!9R&>K2=_-#'EU#&D#YL0%E. M$&&6*&%>4L=4R.QS8,G//"ECE.=-%.VJ$%\]@PX>:RB:[EV7YU7K C/$:VF9/ M,94V!SZ#4Q2^\;IH.NY_%H;X@ V6Z1*&3:9PM
E_>HXN)MLD91_XR:5^I:"P MPC7LBP1P?OR>48K.*6M 5-I\/B4UL0=]:#*"/[Q':SV/8? M>T # QUI#3'H%9&&0:L8@Q!G 1_.M+VYXL?EBZ*LX7LPL,.5\+A>1/;]BOP5 M-
WE3P$A3H5^*,I)VP!&F2NHV2]7):VQ6]B!/>@K!96O5D<^'0OI'B%T7>?BS M>T[,-+U[%I?*DXO?:%* M('%(I'Q_.#GO6/MDQ+E_(G@D^=N?
4_8GEVU)HB9%CKQ%H9^K4B!QTDNU&N M%99R$0JPE+Y;^9F*D2Z2QD]5A_P%2X:R3S@&U8&!4]_A8O;7>(KN:+4)9K3T MY8)8B.2YWZV//F)M62$0PUUY6W=H?>?Z?
L#.B!3IG_L6,(I>:Y$B8O85<'0K M$+0-4NTHN?A$3GKR9EC8Z5 C1HH?O!H>!3K7XUB@1Y=3OVQWD*WN&l'6.>!P M@REP1?
M'S\9!^D",4M99DR!I.C$5O+)9AUJP/&H&]VZF+BR'21VU"H;!\-L M[Y[-1^F-NS2[0N0#NFP640%)4Y:=17M$K_[RU\5-/<]>Z;5IP;Q6. +!-RN-
M"#$1Z*8F8D(@)@6B/XCL52D=$V$MEBMVP(YW.),S'JMXW84?Q"!JS4QK+[NV M662SIH0 PW^LW$:+BV!]:+;38>[LW%U@_Q=+.DLN+PY8+14T#/;G96W!8Y*I*WNM*9 MU,*X?
-F&3>,&WI3M4=>$]M5]2DW3[D%T+?O->SX'CB"?KZX?TOO[|__^CS=Y/-RUVR\GW M,#IC,R 4Z(OG!]^+]HO3+0D4[1W2%'O(-L\#YW3&[[IDM%SZFU!&0$ZL=*I[
MHO)!=+[NL'%+O@WWOFL_I---),E<^M'6GWGT2KP7^>GTG7Q&X-F*?C(#AQY> M7IL1%AYN97?HIRY)2;WG6_(5R5Y+[GP.PA4P.@[G]13>^V<)?'P8T =E(IC
M*Z>)O/'10S9N>#XI(40/_1DC"%_DDEKNI+*OF+2(Q.IQ]@@-YXC#(5R)#! MJG-0)A;7A!VQIA!+/UMIN1,[@A\H%1$]9+_(DO\B3$XTCW\10_Q%9LDODDB,
MJ,AH*_XB1OJ+Q*<CVX)?9/@1;E2_BJ8XZ7TX9D<9,I-[9\'J[+M58'B>?R*C M3GIG.G@(_*,?8CN[14T[VF'8R5@]HS$CC&\B'_KVJ1OFAYEG"C"X=0;(#]@> M["0/?
^<_K$F="IEQLHQHFE9,W9$@NLH?+AC=(S;#9EW7JX3DQ[YCQ#^[>2\ MF"YF%6H:8:F6E&,T#E&6C\RY!PAIB4% ,=$#YHD'&*('S 4/2)02/MQQ.LP# M1I:TC/!W?;V1W6[KZ.!
[U<\>2MH!SB?*-!-WB:X: 1]Y2T5N*(DH8%]8_&4EV\7-S66PS#E]7+ST$LV1X MZ_AC:O$;&K?LBC7/UA9%O;EZD@'DU!65:05=B1V]PV8EC7IP(WYEOHTJKR
MU@W]VZ9G=8_8"_G#+08=M)YYKOT4'Q*+VSV89WZQZK,9V!,4RY25] C9IC 3 MO5-0^9Y;T&.E#>TR4-%@2%D]DPX.YRXEX=+/I7,@F><476>MT MAHD3S6QP=?"VLB?
P.45]/=H?C?3P9^1ZR>NS81<@X9K/OD,_+11<,&=PXJQV*M>2&#/E'%#9.Q0S$_?<=IA_03)1_+]11N>Y9_D'O/0]GSBG&5UO_:BT
MAXF.RIJ*R9*T,=RF+_J@;X!7NGW&'_/WZ3B4+F M7W_[\S\EG\2]__S_ 5!+ P04 " J@ A9D^V\4G<[',P0 %0 '%N MT.6N8*:-KI MR9?K+R=?3K7/G_\6-G&G>ZB*ZVAA6V=?

3I,'_;@UU_E9N_EZ_7LY.Q"._WY M[/KGBU-M^I@4>T0?MK0*RMF6_O/^#_/Z&T:DL_Q?G[SK+]^>O']S<]?O_[X M\>/+/C_,O+ERAZB>G7__U.)H;+V"M?[8DV&?\I\^G9Y_/3[^\>>:G^!/Q8X:7),7Q4XM2_D"6 MJ'RF_5@'I[>WMU_#IY_^]F^:]A?HVF &EEKXIY_]I0;\]9-GK3.;_G;H;-TX3I4XR<-M_\T&Z8^ MY8_ M9S-BXX*?3'<]5=:ULF MINZ=;F-USU\ \#T,*;E:E5+8]0Y1N1?@6X9NUR/YT2MD4'FSW1\V$ MR7M-<^]XMSS#=KT @@E M[Q[ZG FR5/)&2_HZQ8:L4Y(9G:;4/@>;!>ZW"+NIRU,#"#P\'7FP'#1&H0\;O&UP'RPE,DNS;8C[MH%OPG[H=@,DR_B#=']))0PG8~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|/ MT)A_W45@F,2*,;EL9,96%G8:>7X8WU-=KJEBRF%#8-H,3Y7+>"#8Q4ALK=Q MF GJU7V\]0>W?= M&6/H;E] +I8P_@>+>5]TP#XLJQ1DK/+%<-VV!U=H$"9P"MU7*\]N147LJ+B* MH+&(F"RN3|H#KH]^G,"%^-X*%24D6X"]1+D&K6#Y+ZPJGK^;K|W!:&.B\) M*ZPB7L4")!E/2)/)U0H9YU(-)X!T^#C]l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l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|(>SCK.?%^C]PSOWX9W|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{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| "G'M[/N:-+:X'Y@#HA M/](21*2<+(^SC%)#ZH2^I$,6Z3S/(C6@#>DV=GFZ4S6EW&WS&Z $YM7X1MFX MV@#WLH1O6K_IL7^LKP$U6+"HFFP\);H2K*0LT%B+S"*XEB:!CX^18$=9!C& 'H$C"% M"[0LZ(P2RC*]J"4>O7T4&5'8PU>->^^'#LT%>@%M%7-81C90VUEW%&I$ M4#Q+.\?/)4Z>'*MGKQ3'Q)5.%JXLZ7B4;0XO)DC-+ M:$HOL@PYI?*2K3>VNP7@(.U^[]!46%XVQC2&?I9X?#KJ_/ 73PGB9=P$SJS5_MBT\9"HGEI;-0&\,BGW8$Q>2UN;9)2\JRR,FK(1MW^&!DI(&<8Q#!]S6%X"'M&Y+%GB|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||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|<) C[]Q6[]O)C]K>_0(F4_*1F#]:U64B2TI+]&RU*Y8@F[" M)>|>0<[V0$?ALPGL.0Y:31@MPF+UAPN&M^:N=^6Q15-SQ/"\Z8^Z7UU@E:UMFH0OUNNV;OHBA&0+K\2%"&=,%R)\UD)7]'DWPH4Z=R-O6)JV4M(FCQ* K"K6VH^4;M\3T)]R:,D((?C(PTD-.(DQWI:]2,ZCZ@/%*]G3-*!2S9)&P[9U1#^:FO+Y"X5QV=1!6+M)=W%(+7DIVX1Q&((DG81:7B8;]GYD[,! MT9R&I,JX)!./HTC.^BDE\;F\NKUI M]UAOI_G/JM^]+J[;B/].F)G'E* "T/+?A0]C!9&R3)1OZ(,_K'D(V=57=6TI M'3W5F*"_=W(WHEU!.>VB"?K R:+_K./L_Q7@C3M@]EX!U%<@E300 [ILR@7# M^"&R]1])W#-5M/SC#"G5OW1*?V^-&!7K6\=B $!J:ZM>~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|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

(A*]#V^:>0E6<<6N9Y,I]GA.=564T':WSU%8\H<7VDX6* M!K(4SM(2]9*A@&49K/RYM&5A.:'ZV:4F%_"9R0EQ9\AT)HNF0 K$S6\.-P!?7K-E4>\#T6(-
)0>YLQWR3&W+*ML>UGAW7>67LP)+)-*,0*$A MQV($">WNSQQO+G +=P/.PR?V=KAXNMB5G-%,YU?K]AHXU;Q$M ="' T7O>+K MQMJ +S"5P]$V[&:KJ5<&8U;.K3/B-):7)6TA)-
!HFY^* P8.5/$&JXN#[?@& M=:.!&Y:48EVKONY/W9Z=KC=AQW!\]JC;X,U*Y*W&R9E49;U'L+RR;+;922T= M:]R3J=*TV[R8JOS8+#^B*9-JW 1V,C/FP3HQR\SJZMJ=?
W2B+UEV!E"T@"TP M-4< 5)=MV M@7) B$I.ID%5F]PKK\0*XVF/LGT(2&=#*=3N*;F6ZF](@E3W5B)\'(%'+ MZ])MUU5O'IZ-" 518)2 %*Y&G6&32Y6Q;7T]! L
M"QU%@K238NS"6I;#?W9Y_UQ>FC]"K!L=N9ZVL,!/O^G4)E MSR<(6+;0]XD#BJR4F;F6R2H^SE:;TH05@10A[NCD>XGQG)?WAA7K!9?* MSARX!3L/JVK?9>&3C4(3%KBP=
(E[I*2O'/?GM<32Z9^ "/\ $8-<85$LVWN M=P\!585#'QX0;Y&LQO@6/8FSI,46\XF6E6+@TOF;3.!/0^DU2\9[IYZS[]HK MR.M@YHD%5RTVZPN3+QC,O-
=JC:1>97%N7SZL!'5,@QA($NVJF^HX42W-*]H1E MOA]__L_^:SZ\PIX+*;PA6%-/%\M3@$S9>CSGMV=(RZ/S]V1%6*<_2]ZM[4,9C MR[2YYFO'2DB7BS1^5'1[1W@QUYE,N=S#
P1$>5:9Y9I:K1S6Z;W;_JY."EI\ M\1"C<9#BULUUJCI-%+^C_3VU5ATQ6-5$!G#-]:0#:,M#T]3K:L/;2I17C,/+"_8*1@;NN?R&&J0')@#W9RBWS(6U#4# MS_X-WJ>(D$64)&=X.L%
^TE)Y07[2/&BT3@G1^,[U@=<& N-^YEJLC&6G+3L M4=Y<5:@JY$*#[-/5(R+_.-OOL8 *(/-E8/_^!VUK,;2]'2M(=LZ&W08AH&]OLR=XM;04%DG\\ZM/[:)MP'NB3MU_X,^"L-P
M=$5$0*=NM;3!T-EQ-'B^]>.W9H#:Y#+5EKGBQ2R;&.>6C5F] M _5+\&+@Q:LVGS0%?58U8&'>I,')O=ALJ7P8KGK\XTUW-AB@H?@?%?@RN,9J
MLA8P'E.T"9(FT!AS7YZ;Y,UOSSQ[8I;_#CYAM^;H6T\N/4K*<>@+8T\#8F M'2!:,,I&)[<3C#X9O-Y\[L?!SQ\FJ7':W!>U*R,J+L@L]K^680$1&*$JB"A M.9"H;9N2,85NG=>
>"2U>UU6@6A#U\2+ZEA@YD+\K4[WM]?2;@&D_*"[^+AC MS1 -64-13=NQO,#606<\U[:\;E893=^C!L><>1*;[QG,4RP],9)G>'J&(9T&PVX8SZ/AABI5!&0PEA/:>XSK5'K<1PI,:)
M=D6YKRW3^6CA")>@70_.SP-*WIK)G8?R_00'5KR9-$O-==&,%&ZX<' B0^!?CMDFOY?J-+ MB^W0KL]/4N7FMY>8#4-W//:
("#78"]WYB%U5)HS8DF_5/M^:X]0^QZD/ZX4@4O$]O(*;4^ML ^6!A!P!8=$!U.L1 M07T5(E]2 5.'L4G&QXNTWB)"&R+^#ILG&
MRK/6KB0(2+G4ZY3$0=/W4^[%8SS/6@8MX(B: 116M SH4&W"QWRK2E'%1'V- MKT])-*]6%2+"*THO](\.#W7Z](@K?"]_&471D%R)>D/4E)*1%:>:(^H!F],/ M:RM1;^='+VF+_+#-
E^/9Z_="GQVRM?!['??Z^D](6GFAXE1M\I-E7&WDIP3O&IJ'!=^BSZ4TGP9;M>* MJ?MVC,DUQP6#JE"=WG UZEQV.(OI7; MFV0)SW'V?>B TX;0&_7[":/.SM0:&
U(-4:MKUVBGYSQn;A\$7?C3$]I9Q0Z M(K$]+L8%TVP4EUV\FFU<.XL_66F'@K_/Z^RZ8@CR6F[7V(ELC9GF:&84]6MG M\\?HI(NXD^?3V0]SH:0N"P#5*Q+U1+T6>Z":UQXX^ *=?
0DWXTPZ.R572Q8] M(-PQN&>*^53"M1KK:S? /EMGAX&_+]C9W:[4SLP6TCB;+CJIMAHS\&+X4P%" MJ;,OP^TQH&OE=KS?P;F.FE)6ZUE?T2\NB%\Z^:U/29YMQ>K*],/\09@)XT)]
M*:V;]?2#]E\[SC][Q2(O%#IX*YN?6+)6PYEHSKK)_I@F1VE\Q+*$3.S:[<]/ M7;+"PN#GUZPUWQX,X^,QSA> U%]/B\DN%=[_Q"O66=C]RNKY;V8](("V";1 M8I.3TM#<1)43)RQ(%-
UE.CZ8I,*;]?9R5LGQ%,_)W _D+>Y[G&?.5#U&0D,7 MC<.23U!-'* PAM(-A(9Q9>7DH&*96IS@'ZRS31]IFKEF%$;>:X-Q.E9& MJ= J@/VY!C!XPV2_-3]H@XPVZDSP>&LJI-5?:"G!R-
VCPQOC6?)*<5YA<:%7, MA>#T]O7L*E(QSY2?]N1>U^C1 MM0M85V\$H*&-[*4[;P@L<0I<1Y-MR)*[1S#] MK JUF?J#6*P,R#D;R0^"LV73H]/X+ G%$QD@6 MKE$6PE/(O-
(:@D7Q\K7R MSY@Y&^_6JIE.)\DVS%;H=@XC"^H*_8KW2,776U#W#;.[U*KS#-\=#$F9'Q/U MU?#ZUHK(@OH&LA >"XI(# <&7ID-60U7'UI]JE](AR^)*+*@KE4^XGN[HKL4
M_:NPH/"80M?B8B:!K]PF/:IEZQEEG6*#OO MV_B"S39BM%G@.2DE7>M+$5E0(9,%XGI7")#02FPYOUCA]8*:H#+EQ7(8K1#? M2"K>4!\M!%+Q]2L$6>_E]
(*Z+/$%37W@^TJ_%RM$*T0D"Q?8I=AA\V.W4.?B MM3PQRL<[O#A22OSX/MV9C.@/ MZZ79 Y\=ZTUY4!,6*A,ZN_D:-$<8/+8S:1 KMNSWYKI6&(O5P7U:9XMZ8_%] M /)Y&N33\?
%4L=N/]@Q(&CI)#J0"2Y/^SIEQ097QF2>,/BGUB MP56+S?K"Y L&,^^U6B.I%]YCX2$2^Q#P>"\N)^JBM6(.I>X,@85.RT/*>8M& MP.9BNEB>&GS"QNLQISU;6@:=O[\V-
N]'T%Z8\'5P^L31R(^S&N\.NHZ1'*5P MNK[&9UQ9Z&3'U[:0?SVKSW\0\?D0TH>*N"Q(NV 4U^D*3@_L1='MQV=],.;3Q M@= 4<0E/^.@X[4L,4X/<[39V?.!HP]A
MHVOD@5!=Q]>X.UV32K\ZR!9'H37QPXF-T 2-SES+LFNK1%;!U[5QO1(K3^]= MN[&9UQ9Z&3'U[:0?SVKSW\0\?D0TH>*N"Q(NV 4U^D*3@_L1='MQV=],.;3Q M@= 4<0E/^.@X[4L,4X/<[39V?.!HP]A
(*Z+/$%37W@^TJ_%RM$*T0D"Q?8I=AA\V.W4.?B MM3PQRL<[O#A22OSX/MV9C.@/ MZZ79 Y\=ZTUY4!,6*A,ZN_D:-$<8/+8S:1 KMNSWYKI6&(O5P7U:9XMZ8_%] M /)Y&N33\?
%4L=N/]@Q(&CI)#J0"2Y/^SIEQ097QF2>,/BGUB MP56+S?K"Y L&,^^U6B.I%]YCX2$2^Q#P>"\N)^JBM6(.I>X,@85.RT/*>8M& MP.9BNEB>&GS"QNLQISU:6@:=O[\V-
N]'T%Z8\'5P^L31R(^S&N\.NHZ1'*5P MNK[&9UQ9Z&3'U[:0?SVKSW\0\?D0TH>*N"Q(NV 4U^D*3@_L1='MQV=],.;3Q M@= 4<0E/^.@X[4L,4X/<[39V?.!HP]A
MHVOD@5!=QJ>X.UV32K\ZR!9'H37QPXF-T 2-SES+LFNK1%;!U[5QO1(K3^]= MN

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|F_JSR)XV0Z==8RN/OT\JK OJ68K'__^=8:W(IY ML&KVMLZO=P]M?F,!<%M=**03%(&39YW7.RO@;FZ5WHX2VPWS;EL#UY].DZ^7 M:HTB R>;9? EV*)O2]&IZVY/EVMX61/B.-')6]:* M$A-S3"=Q=TB.&@^ROA#B OZX99ENIEL=E3#'DW*\U2C?$WJ? M&0B)XY;5ZK2L- RS@XL-?K)*#*@Z-V0$^KCE/=L=K]-9E6;+^J#-/LQ!NKP8 MP)9'XRQTOQ,M7BRGZF^: KI MXY893@2DRN37;$'NF2[?:*[D%B,0Q''36IO4\$YW*([IFMQS'SJK*0%)3Y#' M326KRB\7K+W@:9>RQ!5=[R3BL%?]N&F<-)SR:AQOXB!1*UC9)%-,=0:HZ1%- M.Z6JS3.-SIROMP>QQ(JK=8IK|H+]8,PD>+>SSO!HM=%=GFM$%-Z0<:-CTA?WT#.*.WI MSK@ZYG"]Q,;3^,/8&:"F1Q20&LE4;Z1(0YP M;. (KW3:$[(K,SNR%0)[@5HU71W1\G71P#;O3+5)4EXD,[/64O##IOE50;_BX M8.8F(W:>DS(5J--,$*NK=G/:E-,J8Z#)$ #%+K/I?H-P7JA!C6AZ*H.'D^P4_6,:M<:#2[[G(A4"?4^E4PR77[3Y M25F8QEE0:B]EJ(%/,-92;3%MV$UZS G3C-A\Z(|[33B $RP83%AJ."92"9Z> M) ICJQ5/CV@&-3TB5K]#KL3TB,_PM*IP^3QT KF6U^N&6&^(_HK,K+F _\$ MF;FR;QYOW##/<1!=Q|P\-T&|\F!2 2!W:>NQ?*= MP*"7)'Y'I)Z|&FO/=M_K'QVR0D7C-@[IYG,,!7%_^IX8*A?_HA.T%]?>-A4E M:)2X#KBP/W1+ISOX]I.WD6W(_E3,F[RCZ(@1(6$<9>(^! &/A!W>,2),' B M4DTA842DFD+*!ZB:[(@3Y^/$RU?:OLUJ_;O9I]XPZXLJX4^9\]9;!FWGP4Z* M0)\#- O4H6C8L:->TV^G#W2HT,-_;\B;]\HG>9=X5E-^F%BIP]VND_<[/Q/*? QV5E3[<5+GR\HJN_34KL\N9__MD64 5/7B]#G8H$K>D1N2:2BIQ/D9\Q^]7@(8CF/W;NX^!_B_@"I/8^13]+47 M&/R";;]96#Y])0MV$2+:A$E:WD*;2'Z^7'ZH[TV;<#H(;UUGM_GUM#>*;"' M-K]VVPEN;0ZY87F\D)ZP(R^R\9CGV-GXUN$N?!C[G-ILE=C M[MLZ5%M%'QRDS:(;7+T3]^@/=%QM+NK^89SKW1=_&M=?9 \>3/O__R[NSV.9 MQ:B#HX#8/]H2CMK(6T']!53LY, M#&XP!N]U6AE,P^9 M)AKFS6_R-A5/W!(D_<^/0U)L]H?K80$X-6GQ*[I3(NNK0[9DJ-V<,*G:VBD1#'<>*62*>> M$>)OYFH&%DC)F /;F9S5YO@3E--WG^.7.Z17;6CL2=4)3=3,%MJ@F<93[,2< MR4F16277R8&01.9$^C9))F[C-'4Y<^*[0_EPR\/AGS^.KY?K4NO)2I$L@PZXLP=*S]2'X93VR#C:@3 M*M)0]^-F;<0!?-7M2*/;8L !NREDD E#)_!;.AW%0R(EHN>O565' Y-U6R$N:I)%E^/I 5[+CPMP0%:*6K!A@(;21O4%0MR1) MW)*I1!0S^3,%+PJ%O' E?TGR!NN8+"7$2A6O=U?<@$Z7*MH$21Y=[&'FKF8;\[" F>9IFN)1.BQ'!JBY# M+YC"\5L:*A$LQ]O\4,X$0^1;13&*4+A-)'G="''ZY)99F8/Y2'/]9;]+-[3"62UL.6QU=/[*OE]<+I"2<$M@/(U+0QL,3P6;9# MYV*+<7;J+I# HL0$\I:@T[6]UDK%5BJ>)"(+S29RDB?4LG+Y@&%(E> M2$4O5#G)U[9!]EK9$Q:TJFFV6<%C;,*>68V4-2][LH=2;TCZ-D%&1[84V261V9Y>'W(:[<;D*A5=A&;9RJ *4$4X@+]3%@4NN94=?B$X$1"*_D M&'%+I>A;FKQ@!9"OAG$DO=_0J;YZT^/5XBMIQ3:^7O!#G%S7XNI(K2OBPP") M+^V)+YZZ3>+/U0S\MF$&S]C0T"5IP':\"JJJ9HB&#+O=V"'1!Q16#^@:;5I> MM251"N3GT MB#.794YI$9<*W&W%G@,\X+;.N5U.L(D.;PB\K=DO$Z5LR040! MB3]3'*.HQ(>.! [U#'L>E00WTV9DZGA0+G8XJT9PO+)LMME)+1UKW).ITK3;?/S;#\W"_X@Z@OR R- / M[E$/'MW\SKD W\28>[WH#|]) MYDRGV@66<\B2:*V8*3? S1)|^C>A_LQC/R8KP>^F)D1_Y1_B145CGW4;'JY3. M4-:IR3(VXMD58>BB1'!5]D;?EF\VW2"O$TDHL)X?ZCT15&<|R_\KQ(_I;48 MML>]I,;.E(E*%H=R#R\-D/BA4G>WB11Q&T]|BV)W)Y9XZH14^LU\Z;U-$A[0TEHNKQ$?+_S%/4?7X-^]0)-6X">QD9LR#=6*6F=75M3L/R0[% M7J7[BVQO?')*9HO).(WE/ORCO5Q.4._NQ"5V)?Y WR0,+MDYR]*&RLFZ:FME3W&= M.A?;*;0?U&61'FNDVI!'Z_AR$&*(VD:1OR=0%S9.OQFPDJM\K'G+= MEL;SLCI8XXG"4&D5>9H;B&ME-KM">K>.*6),YO6GQS>? QSW*3O/L_OM@;;"UES,M&<"4 EFM"9260>P/Z (4Z:GZ>GI[O&"6AOQG>UQJK&J,C\? M,K.R,H$+<]W(F.!%OZYXNYP?OUW_!\.WXKFVM3TY.CM\ MRT]X)TGBG6A:T M'7=GC2W;8_9_25A>;95^.8*+4X+C8|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lGE5&5I!HH-K$I@56;72\KZD?';S3=_@*X=8:[] M< ?$O7*;M=LPU0!=]EM\6/?5H;)4FX+'RA@:'O\35)ZAT3Q#,J"Z" #O#;F$ MF3]_/A%Z5T89X?RQYUL*@2H8Q@:-"IN@EXS0B^1DLICV$-VS@T7H1WG0T8R MF]I&0#7X5:K-9[$ZT4_XSY!4/P(MH M*UKJ_WV!7N&O(57=,[W5J,$O((%RI47%IX2-C"655PDX3\!XGGRE%._)H! MFC-?4O5\:#Z;Z?%W<(8H3*UB;:P$*SNXWV?+I=&63. LK++@0=)Y W+!G MD6UV/Z_4$&),&C*6U&NE\CA% \$G ['L =-;K-D%KT+]\24QU=!98=*7+'] MF'YIQS)+,<9]'(S)DR2>AY';B\6 \UIP7GLW^097:T%W[\)]$ 6^>L+!I3O) MW:QG_;QI27*3\'C:5S"YL<@$U=QP8NO7L;G/V^[DZFN]MKU|@7XHK*.IR_C> M*?OM:C)&+0NR9WVU.9%4RHZ,;S)VNI'(\B;P/(F / 9 6?TN!^0 B[19^6] M'&#V4)5O;RP+7FSI[GJQ=\9D?/Q Q@XX@N81DLFCZ%L;$45-Z,SVGJ*[JB.:PBS0V$IH:,&X06U)>|$].SHS4 MP/"2E$KR+G37##3?3W2*"74S#CI(E*4:$'^X:+HC MZ)]PD7]/B)]Y_OZ?Z(^GWU-M7?%B?I@=' X#ZO&7'-D!AO]Q?D#'QNT/2 >P M0NS9G),__^OYU'^R%:2ZMNM]>Z*D9VN:'6YGHPD[&3HT\73%@1IIH'O?%'NC M[/SC&FGZ*XH_';9^^T%K\2[DB*\T_8_ NOZ'(5),(GF!%.RG!/ZCY&9>3(;_MW1.XUV[3'Q#WUH7X7DPV,82XF%L3/!SU47F/3OZZ]Z]MEY+0HSS!406G44*> M*BHFXQJERPR.:3*A*"BE30A-(Y@OAV\|(>,<5SN)F/L-PA$EH=K*M2MLI\ER MO-2KXB7-WK%K\DV');!/6.3'}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|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lLNNMG(5'OTBN81C,HC" W"LX + !?1@C\B3RE@61]2-?$ F|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|)(MH* [WLLA;4M?;/%3\S^279V[TV#6+9FIKT3_&WDQNJ7LYMMC]S_1.0*G&6R_5 M>/Z+&W Z!W0.Z!S0NJ98%;>FI!.27U^.^Q&L M?DE"0S^0A,8KGA/MLM_6O6Z\I 2C;R6CC<9E;KIIC7IP.2AXZXZSG*@4*R-4 M? <%_HJ!^GX \@#R;]\@^2CD5Y-R<=@KK686.L 'QI:?V8L+0KZPZ+/!7"YN MI+*[Q+ <:7BG84S&&?'SSY"O(.P>0!Y#_P[V1CT*^9E#!0J%M ^Z61;/0#(M< MC6(O!OFU)YC[HEZN6@KI[&?T=#U&I03RS)?OR%<4!I 'D >0?_.VR$09MIAH&L@KI?9N-[I..FN">@6(@O% |C>HB!]:5;E/< M6"MXL\5VO"TTEQ$%T1>(+0#L NR"$,'GL/L NP"[P&G_/'8' M(=K$JU:QR'/K6@|'"'NFN,E[]WQN^[4C5> *SV-%)]I6N_?AU@WT_+'6#?3\ ML=8-I/RQU@WT_+'6?>-ZGO53Q.B9@Z38A:[EE&AFBJ'G(HI>Y&PR3@MW M=^A0WG7%E1SV4VOCX[]WUG8_GOVQ3*#,UTT'YEUYT],D"FHA7SI?[2#GX M)\>2/?B5K<2MC+X\69[PTZE\2N1]>1# (U=RJP.ZTOK6H2$5V,*OLA1HKHTB< M/$?D89S)4Z^7B7Y(2]YF(]3QA TJXT$4=:<=5:+G445F2MP,QF^]F^+L:<$*<0T@B61^AT M8\G;.;4#=_] 7/&J<440V7B-GX(}S2F:>H6A1-+A=O4FNV%"T>A7ZGR?=4E# M1M$+Q38 N &XLP/N6PA1?#<.@+Q!;HKF?QB*F#EP LPM\C&X+Y$D) &T [M]"^H5C#!Z!-=G$=FA:=1@*D<9>6+]T#R?0ODRT 8 ;@#L]X+Z%H,$'P%WR M1[URS5UO)+1HS[2UBH]|<6*4?R!L\+^!,K'US.#Q--,X_#5^T#M>;Z3E%5=U%-(==M-&1!-W <8/H"R,1Y*(5F)%&&9YBY:*%\1YQL%, M]_5(/Y50,^-,Y$CGH@7YAY|\US8U)?YX:CJ*HYK1+_I/&N:?<)%_SWV:N?[^_MG^B/I|]3;5WQ8N*8'1_^H_%_"5'7H?A?YR?'E#\6=3HL$+\V9R3/__K^=1_ MQD,AU;5=[]M_P\G__OUL3;-#FT0TX3I#AR:>KEB0,@UT[YMB;Y2=?UPC37|% M\7_\>^)Z6O1\-.DXEW($5|I^A^YGS_&>Y':R(6RA9YMUY%9(5N?!M\.O_7T M4;+]I\|FL@=D<)??4.0K>2:1O$ *!E,"_U%R,R_F MU?_N"=P+E7N&.":=F0/OPV&-GRN-'$=ABLHDAQ,4TG>#AJ(_*>W3RUUU];;N4 MA!SE*8KI%(;@,H&HN(KB.B5/Z!6)MMP6 ;WC$U^O*1\]Q!8GD7?HGM^49^: MUUH)IX/WGL\TIW.JL:2?3S8F(83Z=XY?A1$YY?XI/5'HOTY-_N|:0"_2YYCB M(QO*W.86T2_.`)P>+4K+U4)'CY0_GXM-A6U,2NH'AC0I-B1RP&3JZRVRO^GL. 2"E7W/+AC3J>M/-|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|4<&>;SH|# <.LLD&I'2X0".JB$:F%F_C M:'MS24(&HPNFWM>-48$9&M'(E)0:8|K1,H,&S@\VU:Z^G>)UR(N?F5I\>V\I M_2)>V_/"P*&J(49&9GL\S|3B1WH9KDAL]VUUB^**T.PU+%3C;T\OGH@\LOX2 MV?7A%2]51%1PFFK7D)E7$-K?SI]+IJ-**WA4G31WBJ5YFVAD:J(5*9OIT_E: MX$VO/9V7BCN^VA"CD2F$ML(:O-_7J*:D;Z"-$BQ8'9K&WYY&:*VZ4;;D7I)Y MR$3<$=U>6N0Z&9K:TB9K:"L.FK?@KL5H4[71K,Y\4S3"!47O;7![3=#6!CM M2KACU,:+49&X/3ZH[$B7VF7>8GTL'"\&.SGE)\,34F?)/?;\999!O" 16;M MM81I18*-AZ9I7VL36[OI-:TNP;K)A51MEDM&/#2UK8A>Z\V:#E& R7I@T:6' MTO%H.1Z:4@"L9:5UZMI)I67K#FN@HVZSC?O+4-$[W)KHI6/H<>]N&/AE6&D[9 M":*Q2'H+3'N\+8QV.FIUP^E2W&MH/5PE0U-/[>S5HL!"/0I>R?4UMJKK^JJ; M#$UM0;LW(SF)W@^BU|K'AT.(K< ,&P|-;8'LR;K0G-H>+W#+-AN.O>:XECPU MM06:A->U?F=F2MWF4A9521<*K61H&@1K3AWIWLY=PU!!*';-3 @QM$,T%>(M6FZMFW6JJ\ *6XQTT6B^5(9FIKLNCO'H(*QU. !7AL5,%MO-ZK)T!0.FN*D M4^LYP[:U8/#)4EX$0FULQ$/30)!AB)\TQXK+ZU CW/+[966U)XQ-;6V=:YEM MK0ROI `&Z^Q1W?T46-7 M1SVX2$^N>.(*F'@/GUPU\"'"89] MQ=X*'3YSVWJ]WHT>.;7=S5-,XNGO4!R4_'9PQC?1-OW1#SX&)9(O?AJJ3"+_ M(PST,[O$+R,MSP9&__BAN,OQS[\,LI- $%D0!/F59H @,B (@(B," (+\"@"1 M!3E$@,"|(#(@" ";(,@! "(C@H"_,@ 161 $|15],U4'")0TV,) E!31@1! M?26 (+(@"$!-&1$$H*;"(+^"K^9^PL$;CIL00!]"DC@@!6TVD%\<'[!7\Z M'KW1X) <^2Q57="73OQ1Y,?OF2YQF@OY:5_+7$Y.04Z__3 M^=_)L^5?W0"@!%=6 J #?S+&@ Y<= DM|T0+?71!_\G8?0BT_^GDX-J;D%(+ MP(S? @H;JVO&F)#TT/QLE(${A)"_LX:*_94;!BZ:C>+O3V41 "VXM7G2GSM=:M[DK6PTIMQ;L5]^G*\C^%2XU2F5:&GJ52F!H@L $"$R 9(67(8AC68ICQA:R MW.:2,FZYI^J)&=Z? 0X746PE09%X;;EL9V&+W?TZH"P|];"KNM!7[% 'NG"& MH_PX[G##BI'4]0:*<:8+L<\E02^X2.UY6WX&0] M58Y.]<57<]4N*ZPO"].X\B66-%E!TWU5#N7>.7>Q=)VX+'S26^5I5/3QPG42 MV^S89P5W]JOQ0M8%6-@RO9&$./9L^4M_M&JK](%.*\^^X3UM509P12^T)'<@ M*9+9YUAF8+'5N+0V^N4[#F-Y^LVF*@)SYQ((0/-1A:$RNQ3A/84.(LK =K M4.B6?/9BBE\EYP;?V?3V4AU?!6M;Z:['I%(\?F[%QX'B7TI[QDR8@W) M9>\DX7"\=F7]_?],=ILG4[H;Z^L_W\G44K09#\Y$WE6+O?P$2 "3P MVK%XIDC@DY;;A?C@YP6R,,NIZAR#B4=.V$L]8X9;%BR5]4EG;U6H =8X+2>\ MI)"<\J:QP1EBZR-%\-.#X?%4=)Q)W9@]#Q-$'D"1>[%E -<<#8N.-QBRQ07 M9-@Z.B!8CJZQBN>^{V}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|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|OI/: M>"U7]W59[_&+EF(30@L:8^+?Y>^^NW>*OJH,-%'W'6E%5-$YK[5G:R*VRB[4 M220W02+8@=08:(;*^YFLW7SG/ =-L,)CT"]O-Q.*82D#WII #5\[;BRVH,*]W M]GB7#YDZ5PB8^KK(B1&9)%< L#Q#DGF42%_XOQDVN8G =9:A=G)Z.1[H9'G- M-V6E_*88$*TVJQYI(*&EU]A*B29"K[T_;5.HWYHF#V2E=&V-I!6]%*I" MI=^/392X(A .YQ&$R=-(.B?[=HP40"M9HQ5@M7R 82R=;-5[^*@/=_M36MOM M5R/-/F_',+B*.6-BC?4LLM >A,"1AN2$F]V9A2A RO0]V2%S*?CG[THS4/! M];5D^RP? 69PZ[/E@PGY<63]:3AF0]>|/(^K63^(>_AIK.4@;Z?Z?"!OK_KD25 M+.M_E, ;^?3*G.2]$ZK'L-S$WTY<88C0JQ^.I_V"O>W2_7::CEW%[+$[>WQ M<%]HN0*[D1'D6+$%SV,4J,\-J.O"P>F;H:Y;>W4#0-P8(,"[_'*AUBN\?RN! MXO>@"FU:]:]MO>KTERCO.3]2[_G_7N+&:OOK:E2"QT]A\%G**GRZ.6+E<3HF=L@Q:Y,DL1 MQ0Z@:=- MWHE,NW1BQ17 2? $GZKD#2#WH;(K33' PC!$2Y(^\6==&>N(^N)R M$!M6R^'*6[9(:[?93OFIO-N46V(,L4O470$0NS^(@1S ;!3RO+R2G*M62_96 M>I6[SY\UZWY?H<61A_/1B' $? C5MZ7,#G4+8WKC,]>>EY9O(LE@U^2[)5%E% M6*\J8?+KMBO; =SDVA>R61B/V$ZE12A)YKQ7$-NE^(N MLPFKQ+5;T,A9)O,4F:|/ *P60"O :CF_U8*5E$E+V33*_K%6")4S&'8/&IQ M.%X8S(06N=)@Q9A"\O2?.PC\;Z!$$CO_4HMMN>RJBL%EA M:C7"'LKCFB$GIQ8O'KKM6Z4U5%O#BC]MBVRSMMM'#T737U\8]\.I(]Y&EKES M1,Z;>6=F6F(I$HD-

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{=;^*AJ2TH;8>\ M,<8WJ-7%:U:[AAOI156,AZ:VP)GS5:[?#DT>@EFA%O)B=(D$TAM05-JUD8C MG*O ;$4(%WRE-:Z[R=#T%K %9DN,6l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|LA!UR$XWM ^_+@Y= M16[%SFZ*,S[G:5^^C? O MQ0"IK^C33IA.Y$X'WZ##1^_?BN?-AA4G5+Q=#GE1'OT4=MAUVTYD,3GB:*Q?M7(>WVSA7+U.$53&D-/T%T;W--%@O?Z2WXT'K1V\;_+MNGBQYJ=K<3EKDXPP M@4-K46HU*T"%(.+"YF=O+PP@!2#U3DC]H7^PT;&=+='IMZ1RT89W)F%.BM/+M08A!5SHC|S':JF\\1N$KQ14OQ! Z>_M@ *&;A-!L^P,#)?CM):C+*\$OFW"* MCE>/ILVOM_<"VHS=A3;_MG]9K3Y+-W9/NTNO-U4=E8S/::_$4*K);<=OL 6 M]K.J>-96:[LJ2Y96^FM0<, Z6UF]<& %>,^2'%/621/DU0>P\@SV3N `.Z9 M''[:,_9ZY/#OL[6$_30E_*8G++7DYF;9P >2 G4=>]"+EFI^B1!$ &JY1& R@(9N* -!PC2NYYT/#';<%M_0@9[N^#Q)I0#85MR*8"2@"4 "@!4()[RZN\A7UY-'" G(LLY5QD?%^RG_4)P ' <=6X6Z; <8ZL MQV+H*?%S9$1.,I-PN>?*V#%-"3]-#]0R$LW!?E$R)9-#+&96)-6.],E M5!W57>@-U_??2G_:)[55]|DCT*>*CF4Z%. M^/QSTN^VY4(0HXTJ2!6?BIV20?3?Y;XE0+*I*-[N5GS#FW0+@+,$=*4SNO*W MC-%6/$ 6[U* O_>AJ:\,6OEH=*K[>2L>],UK1.:C*G%QQH/Y9#I*RZD%KK,K(!*1V<24.W4|LA!UR$XWM ^_+@Y= M16[%SFZ*,S[G:5^^C? O MQ0"IK^C33IA.Y$X'WZ##1^_?BN?-AA4G5+Q=#GE1'OT4=MAUVTYD,3GB:*Q?M7(>WVSA7+U.$53&D-/T%T;W--%@O?Z2WXT'K1V\;_+MNGBQYJ=K<3EKDXPP M@4-K46HU*T"%(.+"YF=O+PP@!2#U3DC]H7^PT;&=+='IMZ1RT89W)F%.BM/+M08A!5SHC|S':JF\\1N$KQ14OQ! Z>_M@ *&;A-!L^P,#)?CM):C+*\$OFW"* MCE>/ILVOM_<"VHS=A3;_MG]9K3Y+-W9/NTNO-U4=E8S/::_$4*K);<=OL 6 M]K.J>-96:[LJ2Y96^FM0<, Z6UF]<& %>,^2'%/621/DU0>P\@SV3N `.Z9 M''[:,_9ZY/#OL[6$_30E_*8G++7DYF;9P >2 G4=>]"+EFI^B1!$ &JY1& R@(9N* -!PC2NYYT/#';<%M_0@9[N^#Q)I0#85MR*8"2@"4 "@!4()[RZN\A7UY-'" G(LLY5QD?%^RG_4)P ' <=6X6Z; <8ZL MQV+H*?%S9$1.,I-PN>?*V#%-"3]-#]0R$LW!?E$R)9-#+&96)-6.],E M5!W57>@-U_??2G_:)[55]|DCT*>*CF4Z%. M^/QSTN^VY4(0HXTJ2!6?BIV20?3?Y;XE0+*I*-[N5GS#FW0+@+,$=*4SNO*W MC-%6/$ 6[U* O_>AJ:\,6OEH=*K[>2L>],UK1.:C*G%QQH/Y9#I*RZD%KK,K(!*1V<24.W4|LA!UR$XWM ^_+@Y= M16[%SFZ*,S[G:5^^C? O MQ0"IK^C33IA.Y$X'WZ##1^_?BN?-AA4G5+Q=#GE1'OT4=MAUVTYD,3GB:*Q?M7(>WVSA7+U.$53&D-/T%T;W--%@O?Z2WXT'K1V\;_+MNGBQYJ=K<3EKDXPP M@4-K46HU*T"%(.+"YF=O+PP@!2#U3DC]H7^PT;&=+='IMZ1RT89W)F%.BM/+M08A!5SHC|S':JF\\1N$KQ14OQ! Z>_M@ *&;A-!L^P,#)?CM):C+*\$OFW"* MCE>/ILVOM_<"VHS=A3;_MG]9K3Y+-W9/NTNO-U4=E8S/::_$4*K);<=OL 6 M]K.J>-96:[LJ2Y96^FM0<, Z6UF]<& %>,^2'%/621/DU0>P\@SV3N `.Z9 M''[:,_9ZY/#OL[6$_30E_*8G++7DYF;9P >2 G4=>]"+EFI^B1!$ &JY1& R@(9N* -!PC2NYYT/#';<%M_0@9[N^#Q)I0#85MR*8"2@"4 "@!4()[RZN\A7UY-'" G(LLY5QD?%^RG_4)P ' <=6X6Z; <8ZL MQV+H*?%S9$1.,I-PN>?*V#%-"3]-#]0R$LW!?E$R)9-#+&96)-6.],E M5!W57>@-U_??2G_:)[55]|DCT*>*CF4Z%. MW0A,&P5)&>2W;((151K/Y?(4DW:N "%SCJJNA=@"3@H)Y'$:S>,4>KXZ @#W MMX'[LZ>E@OCL N.7P MZA5>K\,B60[MQ7AE#3IEV![NH9F|&/'KE7[/Z_5>\EK?VZ:LJ7CJ+(>=HTO9 M0Q'-;]V"L8A5-#>=+D56ZI:K4Z*R[$B#@K(7.I&MSVN7ZZ5D M+EE)Y2HSVE*00EU;.!-WBADR$R?&8GF*(?(L=9NI@@]MXB>/Z38UI1:OUDP MD!*_T_;]1G=0IOKCCW+="G:6G6:F_*"C=""[0\/%IN*&,W M>](^'DI<6=]_;.D)NXD]J!)?H+9?UI08N[ZT3Z[$QY. VU'BL_3X.$^@7YH1 M\T&SN]2L08-:(]+4-;O=T[81>FG$3%H8XM&;=A02]S51@P F7[1V674XXQS7WOR*.WQ31("BT9-.]Q),6-$R&37M+C]S3 M-@SZ]0WYRF3L381RE8*AS[%K3E"&.F+LSR2-Q.@\9<C^E%W80$("86O\&NZ:.!,PG#=LJ>Q?

:M0SEP"ZUS=CXT3C+V!_IK)2$72\VH^]NR7"V:3'BI>,@A-'(!%%$Q>6\MW!X9U3F4XF9G@I·M.2/US.#7O8,3=1^>+!FH1O4OA7<QK8!=+ V'>E@45>?
L>KMNI=4=P515!1X'AXL/^:1\2D^X1KFP:R·M?@P<@I^2SX,))VC+R+=&7O!KRN\.?'?BVQ&?WP@^T+<3[E:0J#+FT&(8IXOA·M?(;(BGZ3E$W2U'[C6P]*SC8·AE(RNTS=2L8·PM*
VK&'EXFN-.6$!8TQ@UV·M93;?73?H[!@]@YT3BKM;8G'>[*DT"F9O0^=HB5^NR%QL)S&=0+3==:D)ZA>Z\·M73=UTG,@P&^_L8/^6TFR%6E-"KE4$"B9XSBD>V_D-L"Q_!S.UQY-0B?
*@@NO2·M%W>AR@GOU/UKB5P^BW:WAGUN;%WYP;*3&O.\8?B4$[O#^N7 <:;1))<'!YMM=5NJ8#'TJ)RCK^·M7"PNPHE:ZH+@8)X$QY)CXH7*9C2=L8VV*\5+@F!C1MA@.:[PP*
M'Q?SI7XIGBWDQU]^Z,:)6\=W?Q·4W6Z@$<<-W>)>+'U"S%R<$8>M)UUTGB ^O·M_/%&%2(9G·M2+;_VMW*2QO"O;9WI1GX#B4PX>R!>O&+*
[O)=FR&_V[_WS(,WA<+$$1_P%%H·MKRVO:LIADKOGY0L"54,3.^*%^D\,X80I/%1CK^F_7\OA=7?E=·MT$%.LRA)B)HLMRFJ90>&O@VWZ.SX=@A2·LT5;@%+TC7-
*O1.!WE38VI[2H/KS=M4PUX"JG@,/0]P,;/?XK"1#_3;"'>V^&+PT #V@4=9@6<-M]2NKS+& MB#M:%=E#)G*1O.3i0T!CBW&748>,M\#\U15R·H8'K]GE(@8B8O^?OT^S0*
*M4&D/0&XJA·MU=E·YEYH2UN29S&'3K3X.AMJQ/QO·MX\&?4,*ERCLFP/2G·*YO?+<0P#5]O:)Q)RD=EK'=Y37&W132O"19X7*6VZXFY2·M3).>T,?54C=1Z!)PS8)*
[%H2TIGB9ER##!!O+8<08"+BY%&QPIJKV;L1[8$?0]IF_VQ1/8·M^_EU_\O@\UQI@X2M5I1-+?32/-#>T*E6WN5Q;·M3%79VW2&J8$/!9-R07Q,))..:OMAW"'!J' M@;;BT$R,%%F_" S"-
*@>Q34^'6N\[%MNBIY1(=9B@KP%+%TLKO^IHC1?^QZ·M209?X#65?-A_+T'@WCY#(,\1ZE5K@B?.CSVVO#G.&7C7$9U=A19??6U*MK·MQ^DV6"6X,15P3WF\5VS6!9Z/,*
[LW"$YHZ5VU$>KK"#6,"BL@XW+IFB24K_MW.8%>P8+V'NJ37JQA_9{C&%Y'FAIL-YUFW5'MB#"PF/11-V+O9M$8).!'KHU
MPM5A_K@^W)-0I_#5%E&MR#R2]@K%W,:ZV#\$&;[7N3THF<^=0_);Z0R6?2MD·MEY%C?'<-_?%]%X)PY)_#Y,:/G+W$T/?TI7OZT@72ER)?+FY,\;O1@·MB]P[^%L!U6X?=!
(;!\/,3S6X?V$1=++U&92UY_*ZX3@W0BMJDCL=%FC=5>?@·M4DNN&L7Q3O/?Z^<701T>7Q7[PX*IZ'A9_C#VPG?KYC$UL%·M.OJX)Y6"AP.XHY@Q?';#3-SIJH9;,#Y!5 'FYY X\816((8*
*,;1C6·M?NVS MUXG=ZR:+2=4(=8)@ST>_5]+N+#@L)?0!=/-?8QBG\]|KD$*^-%#[*UGM^[A·MP@4VAH/R$@VI!1+KGL+]8,6E 'SVQ^5%'+CQ3C1P-&5#;0' 3L*F2XPGEN1·M*
*Y7NX#=;DJD. 3TPE"T4,/P^?,E=B-.>W?N157[A#XRWL588)O%;*U6SGW#M' M%X0.FGQZ@/4.ZD<1WX8PO[%_D I]<,,=C5>5>/[FM#]1$5ZO6@[AR4/3KBJ4·M=P^<0^?*
-8(8EH>W1H[A1K!075W=]=BMO^]KWMME8=F;YC=,LC5^=·'//Z+>QO'IW#QOO]+KK9LE5:50>Q$3^/1U/T:)ML, FW·M9WW\"I9/7^U_0BPG"N,IQXU*Y5E8X[5J01L4VZU?*
Z#A_>2S7N\MTM%[KZ;RX·M;_·$M<7MBF$Y60HE4R&(M'X&W(Q5EG.ZPNE\H=M__J61·MN%B.'M)=C61<>?/A J#H3(R&FYR2"0Z,.(G#9%O[\/T2I.*$SE9J563\6"Z" MO);6^K@ZR\MO_&A*
AXC;35#;JQ+Y3=%^129; MSV+2],0SX.&D^".<_U- MN-BO.#.6697YNZUYZ&=TVI24O!FPZ4FI-4GKM5=0\6O!.,53;+*Z[.>15MN9:95@?F44$ M;^R?O<%!/&).R.G>%5Z0K.[+-!*
*{^%W/P.OTLK5.!%*TTJJ$2,';R=.>C4&_ MP\+P3'P721G2(A(9_!5#=_M%GD1$M]YIZQF[GQ'E',.N2.'G9%$_*;VY[?,U?:) 4@']MOXOFXS3CM)MUU8CHEV])<%9X M3GI:-*
*UR+I<;\,C4!9RZ\F4^D#C,1U)I262WRL6U]=L$&(-"[OQ2LV>A5LK4Y M;8]&5X*G+,4C@WB%[=-SO2/K$XO91MOU_7<|"KS#N8G/A//'1*H7XIU^U5U*
*MK_48NFX=6J!$Y(@VNR21A·MX473'YC*<84&U>9P· DJ5N(09VEF1·M*(M(N93?OPO7%[U41H1S2."0")>]7;26R*N!#9:@_$)'>ZAN0?3*0&$%TJL M"*Q?@O.IRD(7!CIL·[?*
(G$,]N"BOT;$L6(XEK=;=*RWN-L#E7<*<#OZF 6\8>0,O"\;9NGYFL2(C[A1=X8Y(/]WDX6C=,&>0?LR3#?JZ>[91" CAW):*]B&:>R711#/L ?0?:KD'?=RF7H8Z$+=EL?><%Z2Z*
MJA]C!K<;P"\A94:8/,·XB")ZD4^VED?@2$;LAI$80VCP@>^ZB6S3\91APS2· MH4F0ZWWGD1EL5K(R'RG1+TP*Y?$PMX.J:S@-HP<@X$19@!"N,S#>]0;ONO·MK:O6O\%>*
*[4:AYRIU^@SB^MT@=*8+3E!I[:$K'8_B.S(W@=+#=_C'?KH/F M5:(N:ENOU\C/++[S6·P.):OZB,UD)MY+SSKI,R%)BC$0:."0#D,]N5RX>PW·M',/)?M1K1,HWI\F==2=\-*EWN^H[-*
Y+)OE<==W.O:[!7M?]T#N$3Of@#]$!MEE28!#N(2/'A(.HF$H-A*B$.0QA]&!G24CR2B'TA;R7?:$D#TYCIG,)(U=FR·MM!K66#ZCI9_] V9 'ZYL.=M4NVA·MT(·^7
*BIJ:E\4U6ADY7"D7,IE95YLM·M!7$R'5=*AB!V)0ZMC!^NW#IU/2·FLP·$D;5)N#@1!KT%/#-YN++*PV+M3WA!GR#G[.)1ZD=94]Y"C=@CX\T2X1C2K?: M'-'5]F*;K-*
95,Z_!2O9PY6#3V2|8N+5X=

*M+GKFOWNCBW1Z!RL)QE&5&&H1H%+J!QWIZ!6ENK6SGP%@T[`M:8[7"GY3=$22T-Q(VLWD!B6@3;,:]MFF9RC(X*SZ54[JSZTGL:2HWC*

*M=O/QSGZT:A_O;AHX8JTW+\7G13C\M$92J5AJ]\DGKM*V^9%2GT:FX,5NTDU1D MQ($VR-DVC-)\&*4?M=.V,JW?/MZ(SNR(G-_DG*F?#AK[,P:KVV.H>9^NU1 MI9E|T1[&RFF26'6 42X;1KPKD@T,3801''1@"-RIXF*S(3QA HC4&A,%^4R; MA5NI[0OYO]\AR*>AQDJH9^,KVU-UF.OV6E8I7VK=/)7H_*3/)]H4)/E>3D\Z M7K / MV.*<-X2;2[^6^O)1ZI5U'?MU1=(L_E? AW3 IQ"=P; I&7E3+YFV_YAK9N#W# M9G[\E66P'P&'&TQ_@/.)NA_:#HPJ'0E!M;,,,&[L+FP3 6F%0K<*F6E.B3<@5 MQ5@DLQOEI?1!|ZEW)=9.^IE6W5+NTX/I4F9)? &N(W0,=M:9&)*!RM4FS,WP< MO8(&VQU6U&M9N7L$J9):$H?_ R"%=UDDK([EV<'X&/?L=E,ZKI9[QCC7NY[^ MR; Z-APS$E2%3+MDY2],K?:%]#N2?9IVEM7Z7__\]? XR97TN[-SS1A*YME3 M\UC7[_3L"M+YG.M\ ^"CC5_7A%T)+[*5D!L?G8G#$_WLON*<52YS33N=/2VB M@"JDES!=Z{IV7!9!\%G5QM9] MJE46+|J7.5+.W;GIH_[GM7!LL$[EU]BUES; (9@2TLI6CJ8OS',]7:\IT?JI M5LRD4JHT_?SFC*M;?D2X3'8!;&+%658TFDRYC28:EA^-$!"Z`L.6QJ:*I@EI%!C28L :\@#"A4%-D49.S:*>1*88 RZ/C<#M*%) M3I6M!&UA#!\^,@^$]QD C#YT91T(9>!?>-)KV*Z-0M (#XF9 \3"6P3"A;$ M1EN!$W74<4R+M>F&<[+D=?WF?!%Q&TQ_@/.)NA ;#HPJ'0E!M;,,,&[L+FP3 6F%0K<*F6E.B3<@5 MQ5@DLQOEI?1!|ZEW)=9. 9VR4CE^Z"PH:MQP%MM(A?9 R(WF(C_&,V=9V9RY$BG2W\&F9T#Z5HEE:N#W6M|&[_&E5PKADP6D;PP|?I9IU";3;M8*P|=A M^D64{ZI/6KEV.W5:FB[W/XZ!H*A3 E%*9&6_<%|%>]$K(6D1):F^))EL_W5* M__,XS5\EVXW<*%.1S,KI<;9A%DIR/_(Z^2U1_[8+WR1 3MY%0_]#B5#N&!.2 M[-(!)1T@;QS]H=(I+Y;MC3T)$OR\$Y$RU"?[MC=$GL>OW6;|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{+[=97BD8?8=U%-#WTN#*

M3N+\"=_T!L<_&4T'Y_;PQH8+2=_6&/_XC7)R\.RDF^7 M!T?ISK&LR?:Y.W&@!*_ZN7-,99 ICFTA#?.AL,L=BHOALET(0>YAY6Y>@_O' MUYQ:1WW1JH6.:^[*[+E^SD|> I6,VY?;@&[5BD0Y.RI?M&O7G0JQC*M[<[*M-M>-)(U9,|=UD|""?H+H\GB>M'BK[M*<\R+T_= ;,$ZD#C#H:D2'_HS(<|0P1P MA!0C8A\0(1ID8D3L 2)BT;0GB(A%TIX@(A9-&T?$.QMTO*FU?MZI/W&ZR&HA MO-V&M0%PIHK8^W>$M8%$)IC) DWUC+15B7:\KKK'_QC)NW.&.C\Y!BXOAVQ/%[X^XC-QI|=Y,HF.HUQ>/!?/9^2?D M0DR^%*

(W7IF5WLIW1+N(H3WC2-QL^??K0I27Q,C\<3KES5M[~'!=#C FCX^?%D\OQGH[:XFU MI-UZ?C'UW/YA]-'Z5=-X:4OB=7)R7G-N"L,^&ZR4 M3DA2.I%/I[OZI(.9JK^)S M\^+QICS|<K;&@+A>98;/PWZ^!$HW1F3|D@W|\P)GWB43F3?% A?S0Z.5N@Z M1S>C6VVERL(>)N M[<[3R5EV?-TNST35@4?/VKTIF[#T"3K/5U9P8F;:2V;:6F_9-;CIX65:$&OF*

*M_;&8'&A&=8]RTQ5(@%?>PK#K&@V'-72(]!&)\FID^)',B*311ZZ^%[W'VM+X+ M'>*26-8OH3DP3#MI$W.DC+%G3>P-^L.\09N["[Z@^?CWEYN_-"]!RXYI$CV[MH?7+/FX7NI. [7+OV4CI_;#U83W>%$ANRE%O2DVLS0Y,V@=W_,!_,#J1;S.Z[MT+66_O)4^<^+UW?IBKJ+'G:.RK(%:G)9R.MP>_?PT4S-FGPU+F<2>U5Y>&WO\,O>]HBQDF?G<]1V3] /?*

&)J@P^;KK@Z]OQ'ZCL4OS M0K=]Z,12N3L9I^N7]6[Z2KP8BZ=ZX[]1/^KSD4M2(K?4U/T^"3((F+(4"X58 M.Q:%5LI%7*CEZ|:.B,CD3S<-/)141F5NG4V3DE*%-*

>2"!%PA.FW,'_=]ZTMZ MQOOH"=?R# `W]5U\;=$M7H+"RG\T04$OO4-MJN1VO?E,MK\+2BPR"(.>]N,3@;_T"$F M/J_1)5OYEQXE.)8@"K7$&P=F81\]@4I!&4#"'"Y1H%^-A

<JTMZ-MQOOH"=?R# `W]5U\;=$M7H+"RG\T04$OO4*-MJN1VO?E,MK\+2BPR"(.>]N,3@;_T"$F M/J_1)5OYEQXE.)8@"K7$&P=F81\]@4I!&4#"'"Y1H%^-A TMZ-MQOOH"=?R# `W]5U\;=$M7H+"RG\T04$OO4-MJN1VO?E,MK\+2BPR"(.>]N,3@;_T"$F M/J_1)5OYEQXE.)8@"K7$&P=F81\]@4I!&4#"'"Y1H%^-A

*

*M9;/#5RQ#FU#.&*F*:6!Z@D8BZI`?AKF&{(Z3*KH!0# -B$K V(%C$*>1VPP`MURY?,02I>2N1Z .;^Z+:.5BC3GK@A+!IVMK)$Q<*X!,WX(4F,1MG,|O&|%$!L`MQ-Z=/Z+M*1L\U62."/VD)LQG"9(Y;|G!"9G[6A&&W)*!4TK)U"\E:}!PORO3`M%W!AA11=9`*7=EV,12B!A679&!#M$280\$'6TX2F:+jN=8f.4$+:`MSGCC_=?9M0/6j"+4>,K;{]^KN;Z/00O5<4Q(,SNM>!M_B`MZ^Y!O5!W;(>+^-^Y@RP*$8UF?OK)`2IF,-jK7LP&7Z0&#E9Z@VQQG;'4#<3NC7XP`M4$8%%;TA7.I'9I"MPQS+*CV(@!DN,BJO1TWAAV$*2^`5A,*07P>8\XJ<6@:`M9?1^4M\H[9@5IA1Y@4XBEV-^ZGD?C'J4"?:+A(6PF%6=X&U0+DL,;7+#X209DW#Q/#Z+P`M"HZB4D@9#P`M@Q>KUJ;!OE^@H(W'WDYI?CI$<2>05@$Q13?IMTI9E9&VPV"V8N@Z4<*^N!!@`M%JO.D8F]*`/:I5C?/%Z4SPO/>,*9I7.%@@$\8N;,$E!U.(7M>,X^5,TQGP"M`M6A;DXHUI$@*MMN$RQ2NFH"HA4^L1`[R>6*.\1_//O243WCUNP999*>'O/Q$L?}#'+&";'JL40-7%YD4O?H{]=FZE#$?=`MMGY=`[>FN2'47GFU15S7RVZ'UJ+!*_=';9WR!A`A`M5@"1-V%23"=]@Z93=(-],CV6&M#(E_4|0S+X,_=V+P9YC+:%C})\`$,C=$%XM52NTHN6-?%AR6U",:""]{F^:#UR9`X(75Z`\|OPH3RLRQ@1SMXG)N(594%81K`MD5TF_T#$,OD:R;_MP:7,4+QWK`045D3HN2!TOGI55(@$W)@.5>EHBTN-ZM^:%ZQA1S1S4#,SP#[CLQX+Y#2O>N4U8PAU_E`M?!'GO"MS<.2.!CW@2$<',&VU:=G"OS.>$L%QNZ_.A!M14.PM(.FX:6?2K&31`MXD3LZ2A[.LA7PJBO7@5RGA@*5>=5?^=!+GZ'C%~:$NT>E"8%?=38]\GN8$.Y& M5L+@77YP4U*9AN)HI:@.AL29N.!)[]2.#^P(`_N-M1:J#\!0R-@PF<8*?"= M^B2S1,%UTW?W(,**TIWEP/Q3E`RLD;+!&0++;Z\K/'`MFZSLV0>/%7)IAVBVRQJ:L"`,RTADVZ(.1`4"/Q\`:`V\B`L'$K:,.T-1F.K`MGT#8/1(2^^J*YI3+<4_O$SP|>`ML&6*I$T<Z@QO*

M4[$E^EL"2(DYW+>JQEC#!R$FIJYN5D6-1DF@2$E1:^4, M.H,P&/7[;FLT$+;,PNTZWUW)6\TB=KS%0(#X,4'>.,D0R?D=_E4FT.W,NY6_U_M5@FN1? BKAAB,^^7*D/92I4'L=L]Q?
J8Q**;]>MT7!':K=$X:(6P6_W!J-^" M_[5LM^\'W;#MV^[*:K7?BK&'AQ=?P14[%W&4I.6:1YU.K^L,=F:WVFC*,K@6 MPFLQP,8N[=:.,A)[?=@?
^@.2Z@\&HT^_T1KYPPU'/&?MVR_/JKC=>S<,&X2C. MO;'(%T9*_:C7ZKB[DY/0:.(,%Q;#:>;,^;WD'R^_[_59W92_<4Y3;[\LLWY'3;3D=9V?VP6U.:!*)EP+C5 M'7B[$G)429 @-SE0'&,
[#9VJ"U:/.A(5.G56MV7[6_0=C.WX8S$+$T)2P@#- M&1KM\":>DL{'N&3U^2 47?4;O&';T.[^_]C|_'OE\|9R=?ST;_S47;Z~8?% M:/KE1?0=,9F -1Z#29"}%^!ASP!5(A@2
X9&$W?)=>YBFPS"9@UX\F7H7+X@N M/GH.IK_-GSSN_U_BZ]?S|]>M*_>'?Z1?_SU\XN_>WSUWXXJ=I8!,_MNGTU01I\2$YL=_;5>7=X=OK]'Z,+IWO]XN^Z'\GJ@M (5-
D+5"T#+5BT=V"_MOJ2S.%]>X-GYR>^V?WH<7?|[_(YEUDE|/KZ]U*3K]_>'-Z M^:. .^>7QH;UPO5,1?OKC @@O33%2A ;D\FIT1DF]=@PM5'/75+S->(BZ"=.+ MR86@QCE1)=>8-
4&K?^"H%H[J.8:]XY3\?M*I3Y;:VLWT:%]=.CFZ\'(MYD.YR;;==!709.UT?=`UV(9N6//"W6Z8O)XG59G)/SQV/:I7K_?6I=E@>M]\8-1L;&NGV$D"\1++II9,$^%.2K[!3-%*^(@
M2>=)2H5@&%F!JZ@<U!1C^C=@/QBE;$/305B_-0'F#OJ3?/)Q"OUA[D 9 1) 4@M M 5.9$F?$?X>M9JO?&W0}5=;JNSQ)}MG"AY%,;QEFPW0Z3<[O9M& M1!B$;SP>
U!CP+$2Y^HS#?%XQ6+L&K!SJP21\IQ>K"[U_"R9%KE86JWNB04E:M;N/G2JGLW;+:?Z^;=<MCTJQ.LG\ DG[\E=ZV.NZ3L_K_#9=:1^*[O/&;;O;;LEUT%1.WLT*Y
M^[>)ZR>G\W;3WD'R?:)Y49M)X2>P@MBLE*\YS$1P"%=C8M K:0&]-M_]7YB? M\/I6"/BRUR^DC3W)\WGVZNCH^OJZ"6]H7B171\,TF(!>R(Y$>.&E1Z&7>T=V MMV>[+><(^-
(&BZ;K#L"?M9U^OWN4SQCT!=E.:(_$!\'@T&Y.\EF=W7Y)-UJ MY0IEWP_952DG(V(>RK/$H99E@21+]#GIJ]+K>BM#WG8Q#0+BL|0AR4//813 M+!WKH&)&FO8C'KT-
XUA\MX852U2)A\&@:>,U9)1VL6E3-)6M$'2K_,5\HTO MFRL,RP\@4YR]3-G+E-MD2MON=GLD4_J]5G\[,D5UWD<,?20AP]4-MO-4$H:+ M+'YH\=+^^<2+L1I/(UN>CR"Q6_9@X)
(@<;IMU_UA)8ENO-U^*EER+N#=W.O; M_I$%2F!W2)+I"W4_B%EB=VT_KS29.?TOOY%]??#S$EH=5MM[Z+[VT[M?#*,XQCQKXJVZ?QS36L\JG7R6)08GTW[TS*ML^.:UN[3A,
[C)O(EW6BWW=8/R81[S?GS M,N%N:\Z?A0GMUEX1{@8/&B4B,AT]5W%7FFJ*R8=O5',CW4K;^@#66H$E^@?_ M>G/VX>4KZR!Z2;,$>,(R_$7I,A24>>--]>;Q?"
($%C(>1.NO/5491'C7-MIK>=3[Q4+%5 /N9]PZ<<>]G$.IDFU[+CYP'<^#')N7'?FB>4W%T^]_G# M\&QGS[.[P;/'U#;]$[(?-;_G_DS66R_W@-*!80 ->S7P1AM6Y%N_C*1;G(;]:
M81(4(#4O#FM/6T! OURBVR/*1*ZD8]Y_EBNH[YS5LEK+V:.;3==AE,VG MWN)51!MZZ$^3X))D*A5,G8[]_>_]>@VM#X^:ME,/KGA,+KF.*.I/@D!4#& MA?
#CAJ)@1R32CH#QS(JCG'UOU+XX:M.Y!Z$[!O2Z?7OD>`-[U.FV@1^]M!V1 MVW%%X+A^K^M622'.W_ZL+9V=-9!">93ED3!BS\97BQ/#ZHV M:=YH7AJ!R 6C,R:RPP'!FV DN-&
<;R>XXJ> H=1T_ - E=LV@=BX6>VG%O9=I?6L^MT-RPNL!&W!'&^ZV3U90'I M/J2R[?K'RAJ.LB/K5P (]+RW11P_"JD3+RJ-M8O^1E,23[\#N(/E+E(-CO.Z(L ;C*AB[#Z/M/!C/+(S6?
L@PFNEW<@RKXGA6 MOD)!V&[5QMZNDBA<$WHK;7T_"1?PSR2?3?_^_U!+ P04 "_]@ A9(G6S M+Q4) Z,P & '%NU;;5/C.!+^ M*[lLW0U4Q7$28#?
G,%1EDLP.5;GM"'6[Q5;CG7(EE>2$W*__KHE)S&0&9A9 M&,(L5 &QK)=NJ1\]3\OQX3\\;Y@E- M91#Z-3TI(),,B99DAH6+40.F-IN<=`4)2`,:*1S +2\3M^N!G>)\U6 MT/XE@
\7IV3G:MS?M94'Y_WQ'Q=#-^K%U8>3XSZI>,[_G[V^[P_& W=CO|%L MD;&BF>;&RXP*WQ^>U4@M,28/?"\^GS?F>PVHOYXY"@:W#/L!OC4<>#G:VG7^:W"/X&^K M[3{@B)-;
(\Z9)6TB100WA5<)GW!#]EJ-U]$ @4G+G\'$$.*5]8J-#YG5'X[& MQO^/^[WQ\?D9!-_H\]HW-B;C\RVR<71U,KPDK3W]M?9WZ"!JG0U(ZR JKZ[. M:!L,1&7\;DLMA_VIT/#Z&RL/?
^^Y2#9]\,2:_)NO?>_OU[^C25X5&[^ T M!N<7X^&@N@<MBZ0Y8<;>]D8?>7+_]Y/A'TOGVLUF^_E\>V^A#8]\ M6?RT+,B<]+.AP@;8\>J#OUD Q#(1^
MWD4GU$"U&7P><9N/.^Q7K(XXMAF5S\Y[%;C4CNX"Y,4Q2W>W#+,#IL$9B%XK MP!Z&5AVU84@+_?@F*-(F#&!2CN1DGRP4= #<,^/;,AK48IGM!W/Q-1=6^=0=`MG
'N2MVWQDZ[Y%]\R8$7P18M!8_LZ:8N)I!'G"J.#G"G3BW#9]A3H5$QVFU*.M6WEI^4]]!@89X%MLE%-<(_$)0I&UPRQJO5I[0PNG8JOR&3Q.&%8%9H3V$]>MD
MTK\Y9B?;C=E'D!4]Z#>ZYAZ-8$#]C$<(3*IE9F.::@ UGR(5JJB)7(RYQ. MN.!F@4)UT[^XCUB06?RX++>!6U4K";&7#3>E07]@<*NML Y#"#UK@$T=IRP# MO2P
QG"'Y;@_8!5(BQU481_A.3#W&UA?(UC#;0/K<$9%85D(IYG%,>1U? 8Q MJ#?D9RO-_ A6=9>;4S:+36@(C*A=8CB!I?^\!8_A2;]JS3#KC1\'>"&393YM MMQOF9@+LZ6+GKQ-
>SYU5;C>ZHFU#U\ %[GT X$EGF8O9.QM1]A4$B))4AF&A M,,PK^F[#KZG4!LKQ.1OTI6'*R9_N>8$[^]_0) :\ C7=J5T:'@**['$MGM]F
MQ(VM%/PSZ" #+&7M3";SOCL8_0HB56ZVMB0)Z]XF7-$1CQ M7R%M[R6$*],H)(5&*KU2D[8 NDQ3;@QC7V#AB02]BORN\%Z05\-Q_W-)>36G='T!&0ZX X'2.$Q(1XX
MAIP!:DH9N#HKF3-ZC;K.93Y6V=FJ -/8P54 M4(<(9Y;] "/V47.)IKJ35SR;23%CJ+$R.BV?F*N2\%B:"[E@<'>>2,=R!]94 M-5I/(D ;GP_ZIV0#FU8#3W<<>(.$1Q'+H (ZT-Q;GY#D3N#9
'E?PR|0UI9H M^!3$G\T_P^")6R?\YB3."]E-M>A57XK$TL]&'E(%3HXEBT.5]!.:<5]^ M0^S\,?FL?^J_.,0JSLT]?^_6^I;=*$W^H5OI_&P^C,;%_/OB6FUL'^34MJ
M,XR77<\SFK+@:;5;TAUVM[^K8&+\V'!^PEE,AC"MIAGC7%,$[5B;0T>3Y4LL@@97*I@N9E6 M7G:X?;/D<U,85/;N:,!*WK9V5>8 MB>,DP&[6H-
\P2FH4L(N_"TY)),,B99DAH6+40.F+JW>G)WU2|WS_/WM]WQ^,!^[&?]/9(F-%,\T- MEQD5OC\\JY%:8DP>^/]\/F_,IQI23?WQR$],*O9](:5FC> MD7FPU\Q-%VKZZU&^[*"?
P*3ES^:B"/'*5,7'A]S[#T?CD^.3?F[\ MZO.]=C/AG_WWO[/Z-WO;/AI?^Y^GPK^?@VLWE,X;4?PMM>+SXQ.!.ZN1W
MJ2*9D4&19742.H4UB$FH":Q3ADX$Q.P8NIMK5D#$R'\+6!UK7.;+[_+.,@:.M7BB%H+EFP?)#IZL&5^%Y(L)$8F08XD&YE4!/#1W\101>R.$',:UBT:48]&Y!S M=!G,1L%O[\"0+,
<.Y#*DHN[9>@)?=><(-\W#*6)#)N:.+YTIT.U"JGMO2GU8!-.M;JZ=/O^(?;Y)-ZZ2VP(G%([%=UJN)=%$# DH3-&%)MQ-@>,. G7Y(^'*@"1 M6) 1RZ4RP)SD&&H
M7I_$!F#@>09N0#;2F'4A9T634Y-U"' {)F'DWS]UVNUF M5[$IUP9XTMB"5G>W>^BC&T=N%GQ<'=^N\(__?-G ;&];8+ZCVDHVDB[(-7@O M&(B[NHM/Y;(RDM!Q)D$50@;4
I)F"U)D1A4,/ 7)9R4CA"LE*5PI3@6):0A% MBL@4!("1SNZ>0<9"IC55"S1)Z34CG&-6K-C641> ,="G0:^P###4*N0*>"&2A7 M#9[0=!B_*^^#M YX G.XK2KW>19C>RCQX7,HB@C:
M:"!4(K(.(+('CG$,4(0H0D)@IC97CK.UT#C",,,]31HA!@ ,"2$/VV.VW] M',E.2"SD7"]1MV890K'0^0U>UBO@T4MG[GG[2O'3_-[AL[]M\!G?BC54-*U? MN[H$2"FT<0>7<S%-
@+&0RO(ZY#-M(74!]9#7E!0N\!,E0Q9!L28[$,<1 -^'X8![>A G-IHST@#)&A0 +FZ$=[+!= M6]5F:'CE+CEF2)D#'+9/D%W5%]ZJ.8.L)QWD4G6*#:##Z.N,V'
M&Y8K5H<;VXS*9V>U"EQJ1WY;8Z=> MY,"+X(N6@D?V7%,7$\TC3A7'-7"G3BW#9]A2H5$QVFU*6WEI^4]J!@X9X%NL ME%-<_$)0I&T8EG5BK3RAAM.Q5?D-
GR8,#8%9H3Z$]>MDTG\X9B?;C=E'D]4] MZ#Z>YAZ-8$#]C$<(3*IE9F.::@ U)GR(5JJB)7(RYQ.N.!F@4)U4[>%6:25AM++AIAQ07]@<*NML
Y#*#WK@$T=IRP#O2P QG"'Y;@_H FD MQ0ZJL(_P')C[!UA?(UC#;0/K<$9%85D(IYG%,>1U? 8QJ#?D9RO-_A6=9>;M4S:+3:@(C*A=8CB!I?^X!X_A?;JR9ICUQ@\)?
O)#),I^VVPUS,P'^=+'QUPFO MY\XJMQM=T;:A:^ "]SX *2SS,7LG8TH^PP"1$DJP[!0&.85_;>AU51J ^7X MG W:TC#EY&_WO,"=_6^H$@->@9KN6)>.AX
B>TB+Y[+=9L?)KUWF54+T2RTA[M%M\LLFOOYZ-DX@41_)]\L3VCGW][Z?H_4P_1]YZ%SM/$>%/I$SR$9Q\?XNH
M'1TT["/(3V/L13W\LC,>^P@M6F*UOB8&Y*DJ7M8<@1'_&=+V7D*X2-"K>#_BX)]M9_=0!:2GD53A/Z:FRZV_.5UP<-_"MOLA">R*[&ZP7]-5PW#[<0F[=&4U/0*8#P^$ *3PFQ /'D#/
0"D#5VYS,@!'[J+D$ M4]W)*Y[-I)@QU%@9G99/S%5)>"S-A5PPN#M/I&,Y>@NJ *TG$;"-CP?]4\]! M3:N!ISL.O$'"HXAE8(#:.ZM3TAR) .!L@+RMX5#D:?Q&#HSWW9,7Q)-
ZS#_IL6TN<7+KN0935GPM6OY MW:]3-QW8&+\D'I[^PEE.CE>;ZJE+47ZLRTL-.`!,&Y!>,06E0SIU@J\=?,>K ML21M=^"Q+>Y99]S?1*T8FX;74R6++$+6EBI8;J.55QMNWRBY&[-
'P3/FE=?+ MC;?Z2D594GVCXNZ[&CFH+6\"2<>U1V.020&=21Z5R]H--K[J^W>E36M\'7O M@-B72H[^#U!+ P04 "_J@ A9L"U]! \& "@%P & '%NU8^V_,-A#^5VXNMB:];*3U)6<_*
[CH;F2.(T5 M,/V1EBB+*RVP]!7'^^MWU,.1O6[KTE?0+8AMB3P>OR,_>Y##'RQKDJ4DBV@, MK\/+"XA%5"OHB&2E&AL73&=0BCRG&1P2:5DG,.KR>(%!?!<^\CV>H>V:UDG
M0]0U&@>)S(>],W\Z;N\ 7,_OO?#QX?H2[F!#\)?XI?#H=AV^O)6LU[>O+L[' MT+$\ M<5*]Y <.%T)1.]9QYV1H6O";DOADN*2:0)02];-@^[MR&9]8 }333G)X,G>:W MDIV+>'TRC-
D=*+WF]+BS)'+!,DN+W.^[N0YPI(/=.S+WUHK%.O4]U_TQR$D< MLVQA<9IH_] >#!Z:)%NDFS91F>9+RHEF=]3H;FF-."72GPN=!KL3?&ADWHQ+
M1*:MA"P97_O/0[.D"]JH"FI$DF3/NU4+_BHJ6?(**45^YVB:C1/TWMM$P#_%ZU8.9<;XUXXJ6MLT%C[%ST)GCHN5? &*$ M?*6RA?&?0(TG-^'YV?EX%)Y/KY'\-[/;T54(X?0)8?0&
<&O/+-$-L\FXQ.GU M#[TNG&8P.IU>AY/3;P3\?Q&@P?[2/8+I&82O)S ;W:P.74UFUO37B\E;&(U# MT]-SW=Z7,^*W0FF6K*LFEL5HD^\-|K_C]?D$D<@R&AD7JZ*@3BF*8C$]>!K
MN^&YD!I#'9P)N<18.+T!D:" 8!E<8YQ9DH@6FD6$*[C0L0U!1L%/SP:]GAN, MQ1(CZK[\X)I2(0L];^O] -%D#'\7&04^KCK)!V@2A(&& "LA&?T:B0& 5P M84@6P^0>
UR&H1G5+YE2!CK^&\D8 S.D5%+$V 92F='@Z.(Y1%2;Q>I"7DA5 M$,P%6L #'7]ZYAV!"&HV(B(2B]S$_+9T+6-V':TS6.(FUZ MS*YWL9_HKAEF!.=4E5W+-,S+Q JM75"_9(4F5
MDZAYKTE4C; BP3G)%?6;A^"3V%5G! S,6BQ]0YR@E21*_AF\%B=K46@_8?U&DM:X2HAH0K!*F::664_] MXT9(D@]_A[9!_1'[W OWM\0^,'3-EY6L]A[
MV:^*L=LIE,2XFGSV/UOTICW%&G,LL2\EMS$E*0)RS#< MLBJL-QPGS.2D7%)EZ-PUW00K=1R&TQ..9%H1AQO'V;24_!Z4X"R&9VIYUUZ9'5I^@95WE
.GTH9+AL&.PQG'H@^Z.VU,32;IR?5YB<_,^SHI_M;GU5 MPT)SX^##.&4TP9("RPMSAH=IDC"LP/_?EV!EV"FF3!|&Q0(K&QA41Z_O?#>;.M!%Y=;?V=NX[' 'X*UP*F(,-RC"
fPE+^HC\K(@K*"8@I/KZ8Y*63&5(I5&@9\ MBG49GFU)%%4%5+ML^Y@3-I9EJ#@3NE%>W@"8^P(G:[8G+)V^H[
ME9M"CT3O%E(466R*/2')N^VKE2W.^2?SYSE43FUZOO(Z0@P&=N]@4Q]4;6YY)}KNGLO+[),__%!+ P04 M"]@ A9\R9WV0<& "4%P & '%NU8^U;,-Q#^5[;-
($9W\,V$.=LF'&,:>@03/ Q:7Z4[W0^-?+IHM-AW+^^ MN_ZA[5K6R1!UC:M)*O&@[_2=KML[M +?C=9![W1YK5S.?67V4,,)(?C)TZO^E[%R%ZY-A*&XA,VO)
MCUM+IA=%*C%6Q)9"KKUGOECR M#"]Y"]I5DB7/VF4/_L^X%M&S02&=B=|\]JD;S#+\S%I-B@=;*ZYX8=MQF L#0.[=`3ISW+3T"'T ,D*]<-S#^$ZSQY-H_ M/SL?C_SSZ262[WIV.
[KTP9\(^HR=/MS8.WMLPVPR+G!V>H=N&T8S&)U.K_S) MZ3<"_]\(4&-_X1+|I S\5Q.8C:Y?CBXG,VOZZ\7D+8S&/HUT?<+,N2W/#,B M6I==(@G1)]_33_^.U^<)"]D)=$ N5D9!$W-
XDS.-^R'7<,U3I0V&.CA3>HFQ MT'H#*D(!)1*XPCBS9 '/C0B8S.#"A#;LD8*G3_K=KCL8JR5&U"71Z@SV(5*Z MT/^^U\<08;P:(L0FD-*/&T89S"+BFS6I#FNLL9Y@+C(}[.CY]TCEZ
M/JC8B(A8]%**^4WI2H9.'9\2M4)K%]PK6&'87.*XTB'7QRVWA4"EK$+]IVE+*C;%8G*&5:@I&1I MQKWZR^"3V%5E! S,1B1](LZ@D20*_A%>2[*URHT7B3L>?HB2C8!>]V#@]'X
M"6LC*K%^E7M,V!$U\S-NZ;B1I\6N B*:,%C%PG"+]I-]=!";I8,&B&K?#[[MG?U=3-L"0UKTL\ MFZ0(4;&/R4$S[%1=K1,?]51Y;)+=-< '4Z2GVQ\1_/W MN="K?
+W3VV|[@/|8.=P+|S<$OO>TC9=5+.Z\Z)7.R9:%VP[(%X<. MX;J.Rj'#= I"/&X>N_]M&GW= MJCWNH[HRQ/&$B\?E45#13;N.V[I=TKOW]*D*>NH^,&?R+]#T=+EJAF'&\?9
M)3T#C(E10A/W.*GN3,[M/P", ^]D#OR$@) 9IWF2%#N[XQL/M]3S_*|/;>O:IA/KPP>C&/!(SC;!.%I% FL MNO_EV!EV"FF20]&^0*K&>B?UZWO_#3JI%T^8WV=]XX'
'X,3P%4A&$)QA=X MLU14UV-D05$UB0QOK-0=Y3H168R5&89ZCK48WF=9$)1%4[-4^YA;-99BJ#A1
MIE9>W/KIC0!GIRKCVQ>6_@,N*5NK(0OY%9J!0NVZ>,*=K[$:C#@FZ8!&R!JT M X$0GNV2L VKF&-,8[D9T@V>-HLN4"RBIXR=UX%5:0V@5/L-R4
M#01DET3\.5O0\I#E05RM,I=,+GA;_HWUIKACP;N%5GD24H&GM%=GW.8SZO9 M5>;1_1V5![YO* MH.OSBWM0^=Y"TR,#(T,#8S,"YX"TR,#(T,#8S M,%]C86PN>&UL4$L! A0#%
@ *H (656G1!DR+ W+,"`!4 M ( !(QL `%N"TR,#(T,#8S,%]P&UL4$L! A0#% @ *H (M60Q1=;=B@P$ ^9(/ !4 (!1=H `%N&5X,S%D,2YH=&U02P$"% ,4 "`J M@ A9,682C P) H,P & @
$E9P(<6YR>"TR,#(T,#8S M,'AE>#,Q9#(N;'1M4$L! A0#% @ *H (6; M?00/!@ H!< !@ M (!9W `"%N&5X,S)D,BYH=&U02P4& H "@"F @ Z?P" end XML 72 qnrx-
20240630x10q_htm.xml IDEA: XBRL DOCUMENT 0001671502 qnrx:WarrantAmendmentsMember 2024-03-07 0001671502 us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001671502 us-gaap:FairValueMeasurementsRecurringMember us-
gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30
0001671502 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001671502 us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001671502 us-gaap:FairValueMeasurementsRecurringMember us-
gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31
0001671502 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001671502 dei:AdrMember qnrx:PublicOffering2024Member 2024-03-07 2024-03-07
0001671502 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001671502 dei:AdrMember 2024-01-01 2024-03-31 0001671502 us-gaap:CommonStockMember 2023-
01-01 2023-03-31 0001671502 dei:AdrMember 2023-01-01 2023-03-31 0001671502 qnrx:ConvertibleNotesWarrantsCommonStockMember qnrx:Convertiblenotes2020Member
2021-01-01 2021-12-31 0001671502 2023-11-08 2023-11-08 0001671502 us-gaap:RetainedEarningsMember 2024-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember
2024-06-30 0001671502 us-gaap:RetainedEarningsMember 2024-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001671502 2024-03-31
0001671502 us-gaap:RetainedEarningsMember 2023-12-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001671502 us-gaap:
TreasuryStockCommonMember 2023-06-30 0001671502 us-gaap:RetainedEarningsMember 2023-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-06-
30 0001671502 us-gaap:TreasuryStockCommonMember 2023-03-31 0001671502 us-gaap:RetainedEarningsMember 2023-03-31 0001671502 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31 0001671502 2023-03-31 0001671502 us-gaap:TreasuryStockCommonMember 2022-12-31 0001671502 us-
gaap:RetainedEarningsMember 2022-12-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001671502 qnrx:CommonWarrantsMember 2024-01-01 2024-
06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember 2024-01-01 2024-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember
dei:AdrMember 2023-01-01 2023-12-31 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2023-12-31 0001671502
qnrx:CommonWarrantsMember dei:AdrMember 2024-01-01 2024-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2024-01-01 2024-
06-30 0001671502 qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2024-04-01 2024-06-30 0001671502 qnrx:SclerodermaMember us-
gaap:ResearchAndDevelopmentArrangementMember 2024-04-01 2024-06-30 0001671502 qnrx:SchoolOfPharmacyAtUccMember us-
gaap:ResearchAndDevelopmentArrangementMember 2024-04-01 2024-06-30 0001671502 qnrx:TherapeuticsInc.Member us-
gaap:ResearchAndDevelopmentArrangementMember 2024-01-01 2024-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember
2024-01-01 2024-06-30 0001671502 qnrx:SchoolOfPharmacyAtUccMember us-gaap:ResearchAndDevelopmentArrangementMember 2024-01-01 2024-06-30 0001671502
qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0001671502 qnrx:SclerodermaMember us-
gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0001671502 qnrx:TherapeuticsInc.Member us-
gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember
2023-01-01 2023-06-30 0001671502 qnrx:Ms.CarterMember 2024-04-01 2024-06-30 0001671502 qnrx:Dr.MyersMember 2024-04-01 2024-06-30 0001671502
qnrx:Ms.CarterMember 2023-04-01 2023-06-30 0001671502 qnrx:Dr.MyersMember 2023-04-01 2023-06-30 0001671502 qnrx:Ms.CarterMember 2023-01-01 2023-06-30
0001671502 qnrx:Dr.MyersMember 2023-01-01 2023-06-30 0001671502 qnrx:Ms.CarterMember 2024-06-30 0001671502 qnrx:Dr.MyersMember 2024-06-30 0001671502
qnrx:SalaryAndOtherCompensationMember 2024-06-30 0001671502 qnrx:SalaryAndOtherCompensationMember 2023-12-31 0001671502 us-gaap:RetainedEarningsMember
2024-04-01 2024-06-30 0001671502 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001671502 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30
0001671502 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001671502 qnrx:Convertiblenotes2020Member 2024-06-30 0001671502
qnrx:Convertiblenotes2020Member 2023-12-31 0001671502 qnrx:Convertiblenotes2020Member 2024-04-01 2024-06-30 0001671502 qnrx:Convertiblenotes2020Member
2023-04-01 2023-06-30 0001671502 qnrx:Convertiblenotes2020Member 2023-01-01 2023-06-30 0001671502 us-gaap:LicensingAgreementsMember 2024-06-30 0001671502
us-gaap:LicensingAgreementsMember 2023-12-31 0001671502 dei:AdrMember 2024-01-01 2024-06-30 0001671502 dei:AdrMember 2023-04-01 2023-06-30 0001671502

dei:AdrMember 2023-01-01 2023-06-30 0001671502 us-gaap:CommonStockMember 2024-06-30 0001671502 us-gaap:CommonStockMember 2024-03-31 0001671502 dei:AdrMember 2024-03-31 0001671502 us-gaap:CommonStockMember 2023-12-31 0001671502 us-gaap:CommonStockMember 2023-06-30 0001671502 dei:AdrMember 2023-06-30 0001671502 us-gaap:CommonStockMember 2023-03-31 0001671502 dei:AdrMember 2023-03-31 0001671502 us-gaap:CommonStockMember 2022-12-31 0001671502 dei:AdrMember 2022-12-31 0001671502 dei:AdrMember 2024-06-30 0001671502 dei:AdrMember 2023-12-31 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2024-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember 2024-06-30 0001671502 srt:MinimumMember qnrx:PriorWarrantsMember 2024-06-30 0001671502 srt:MaximumMember qnrx:PriorWarrantsMember 2024-06-30 0001671502 qnrx:PriorWarrantsMember 2024-03-07 0001671502 2023-06-30 0001671502 2022-12-31 0001671502 qnrx:SkinvisibleLicenseAgreementMember 2019-10-31 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2024-04-01 2024-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2024-04-01 2024-06-30 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2024-01-01 2024-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2024-01-01 2024-06-30 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2023-04-01 2023-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2023-04-01 2023-06-30 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001671502 2024-01-01 2024-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001671502 2023-01-01 2023-03-31 0001671502 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001671502 dei:AdrMember 2024-04-01 2024-06-30 0001671502 2023-07-18 2023-07-18 0001671502 qnrx:SchoolOfPharmacyAtUccMember us-gaap:ResearchAndDevelopmentArrangementMember 2024-06-10 2024-06-10 0001671502 2023-04-01 2023-06-30 0001671502 qnrx:Ms.CarterMember 2024-01-01 2024-06-30 0001671502 qnrx:Dr.MyersMember 2024-01-01 2024-06-30 0001671502 srt:MinimumMember 2023-07-18 0001671502 2023-07-18 0001671502 qnrx:SeriesEWarrantsAmericanDepositarySharesMember qnrx:PublicOffering2024Member 2024-03-07 0001671502 qnrx:SeriesDWarrantsAmericanDepositarySharesMember qnrx:PublicOffering2024Member 2024-03-07 0001671502 dei:AdrMember 2023-11-08 0001671502 2023-11-08 0001671502 2023-01-01 2023-06-30 0001671502 qnrx:PreFundedWarrantsMember dei:AdrMember 2024-01-01 2024-06-30 0001671502 qnrx:AlumniPurchaseAgreementMember 2024-01-25 0001671502 qnrx:Convertiblenotes2020Member 2024-01-01 2024-06-30 0001671502 qnrx:Convertiblenotes2020Member 2023-01-01 2023-12-31 0001671502 2022-01-01 2022-12-31 0001671502 qnrx:Convertiblenotes2020Member 2022-01-01 2022-12-31 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2022-12-31 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2022-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-05-31 0001671502 qnrx:NethertonSyndromeMember qnrx:ConsultingAgreementMember 2021-11-30 0001671502 qnrx:SeriesWarrantsAmericanDepositaryShares2024Member qnrx:PublicOffering2024Member 2024-03-07 0001671502 qnrx:PreFundedWarrants2024Member qnrx:PublicOffering2024Member 2024-03-07 0001671502 qnrx:SeriesWarrantsAmericanDepositaryShares2024Member qnrx:PublicOffering2024Member 2024-03-07 2024-03-07 0001671502 qnrx:SeriesEWarrantsAmericanDepositarySharesMember qnrx:PublicOffering2024Member 2024-03-07 2024-03-07 0001671502 qnrx:SeriesDWarrantsAmericanDepositarySharesMember qnrx:PublicOffering2024Member 2024-03-07 2024-03-07 0001671502 qnrx:PriorWarrantsMember qnrx:PublicOffering2023Member 2024-03-07 2024-03-07 0001671502 qnrx:PriorWarrantsMember qnrx:PublicOffering2022Member 2024-03-07 2024-03-07 0001671502 qnrx:PreFundedWarrants2024Member qnrx:PublicOffering2024Member 2024-03-07 2024-03-07 0001671502 qnrx:PreFundedWarrantsMember dei:AdrMember 2024-06-30 0001671502 qnrx:SkinvisibleLicenseAgreementMember 2019-10-01 2019-10-31 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2020-11-01 2020-11-30 0001671502 qnrx:PublicOffering2024Member 2024-03-07 2024-03-07 0001671502 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001671502 2023-12-31 0001671502 2024-04-01 2024-06-30 0001671502 us-gaap:CommonStockMember 2024-08-07 0001671502 dei:AdrMember 2024-08-07 0001671502 2024-01-01 2024-06-30 shares iso4217:USD pure iso4217:USD shares qnrx:item qnrx:agreement iso4217:EUR qnrx:segment http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember 0001671502 --12-31 2024 Q2 false http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember 3979970 3979970 0.0008300 1.67 25000 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember P2Y6M 10-Q true 2024-06-30 false 001-37846 QUOIN PHARMACEUTICALS LTD. L3 92-2593104 42127 Pleasant Forest Court Ashburn VA 20148 703 980-4182 American Depositary Shares QNRX NASDAQ Yes Yes Non-accelerated Filer true false false 3979970 3979970 2845126 2401198 9725463 8293663 650696 591034 13221285 11285895 300000 300000 533334 583334 14054619 12169229 819674 526523 1386625 1308706 1146251 1146251 600000 600000 3952550 3581480 2623733 2923733 6576283 6505213 0 0 100000000 100000000 0 0 3979970 3979970 987220 987220 987220 987220 57982969 51867336 -50504633 -46203320 7478336 5664016 14054619 12169229 1617769 1634960 3233221 3318777 519349 625104 1362181 1716837 2137118 2260064 4595402 5035614 -2177 -34472 -8686 -14045 165262 187589 302775 339643 163085 153117 294089 325598 -1974033 -2106947 -4301313 -4710016 -0.39 -2.13 -1.20 -5.79 -0.39 -2.13 -1.20 -5.79 5049720 987220 3576506 813187 5049720 987220 3576506 813187 403887 403887 -2932000 47855521 -37516747 7406774 -2603069 -2603069 583333 583333 5849266 5849266 261472 261472 987220 987220 -2932000 53966259 -40119816 10914443 -2106947 -2106947 264376 264376 987220 987220 -2932000 54230635 -42226763 9071872 987220 987220 51867336 -46203320 5664016 -2327280 -2327280 2808750 2808750 5482472 5482472 306314 306314 3795970 3795970 57656122 -48530600 9125522 -1974033 -1974033 184000 184000 18 18 13707 13707 313122 313122 3979970 3979970 57982969 -50504633 7478336 -4301313 -4710016 619436 525848 50000 52022 121026 230755 371070 761283 59662 -282358 -3441495 -3319260 9649774 13491505 8339000 13035000 -1310774 -456505 300000 175000 5496197 5849266 5196197 5674266 443928 1898501 2401198 2860628 2845126 4759129 209225 238231 NOTE 1 – ORGANIZATION AND BUSINESS Quoin Pharmaceuticals Ltd. (“Quoin Ltd.,” or the “Company”), formerly known as Cellect Biotechnology Ltd. (“Cellect”), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin Inc.”). Quoin Inc. was incorporated in Delaware on March 5, 2018. On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the “Merger”). Immediately after completion of the Merger, Cellect changed its name to “Quoin Pharmaceuticals Ltd.” The Company is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Company’s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Company’s first lead product, QRX003, is a topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (“QUT”), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma , and with University College Cork (“UCC”) for the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. To date, no products have been commercialized and no revenue has been generated. NOTE 2 - LIQUIDITY RISKS AND OTHER UNCERTAINTIES The unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which contemplates continuation of the Company as a going concern. The Company has incurred net losses every year since inception and has an accumulated deficit of approximately $50.5 million at June 30, 2024. The Company has a limited operating history and has historically funded its operations through debt and equity financings. The Company incurred net losses of approximately $4.3 million, and negative cash flows from operations of $3.4 million for the six months ended June 30, 2024. At June 30, 2024, the Company had cash and cash equivalents balances totaling $2.8 million and investments of $9.7 million. The Company has determined that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these unaudited condensed consolidated financial statements. Additional financing will still be required to complete the research and development of the Company’s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Company’s business, results of operations and financial condition. Other risks and uncertainties: The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements. The Company’s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Company’s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products. There can be no assurance that the Company’s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company’s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug product for clinical development. On April 29, 2024, the Company received a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per ADS of the Company was below the required minimum of $1.00 for a period of 31 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s ADSs and the ADSs will continue to trade on The Nasdaq Capital Market under the symbol “QNRX.” Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until October 28, 2024 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. Compliance may be achieved without further action if the closing bid price of the Company’s ADS is at or above $1.00 for a minimum of ten consecutive business days at any time during the Compliance Period, in which case Nasdaq will notify the Company if it determines it is in compliance and the matter will be closed; however Nasdaq may require the closing bid price to equal or to exceed the $1.00 minimum bid price requirement for more than 10 consecutive business days before determining that a company complies. In the event the Company does not regain compliance by October 28, 2024, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held ADSs and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. The Company intends to actively monitor the bid price of its ADS and will consider available options to regain compliance with the Nasdaq listing requirements. 50500000 -4300000 -3400000 2800000 9700000 NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction

with the audited financial statements and related disclosures as of December 31, 2023 and for the year then ended which are included in the Company's Annual Report on Form 10-K, filed with the SEC on March 14, 2024. The Company operates in one segment. Effective July 18, 2023, the ratio of American Depositary Shares ("ADSs") evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. Except as specifically provided, ADSs and related option and warrant information presented in these unaudited condensed consolidated financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations. Cash and cash equivalents: The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Warrants: The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company's control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated its warrants outstanding to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. Investments: Investments as of June 30, 2024 and December 31, 2023 consist of U.S. Treasury Bills and Notes, which are classified as trading securities, totaling $9.7 million and $8.3 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company's U.S. Treasury Bills and Notes held on June 30, 2024 have maturities within one year from the balance sheet date. As of June 30, 2024, the carrying value of the Company's U.S. Treasury Bills and Notes approximates their fair value due to their short-term maturities. Long-lived assets: Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years. The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant changes in the manner of the Company's use of the acquired assets or the strategy for its overall business,</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant underperformance relative to expected historical or projected development milestones,</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant negative regulatory or economic trends, and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant technological changes which could render the platform technology obsolete.</td></tr></table> The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2024 and 2023, there were no impairment indicators which required an impairment loss measurement. Research and development: Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered. Stock based compensation: The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Since the Company has a limited history of trading as a public company, the Company's expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future. Fair value of financial instruments: The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities. The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Earnings (loss) per share: The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, other than unexercised prefunded warrants as described below, potential common shares are excluded if their effect is anti-dilutive. For the three and six months ended June 30, 2024, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 8,988,346 ADS and outstanding stock options to purchase 278,011 ADS, and for the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS, respectively, as their inclusion in the denominator would be anti-dilutive. For the three and six months ended June 30, 2024 basic and diluted net earnings (loss) per share included 1,069,750 ADS issuable with respect to unexercised prefunded warrants (See Note 13). Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2023 and for the year then ended which are included in the Company's Annual Report on Form 10-K, filed with the SEC on March 14, 2024. The Company operates in one segment. Effective July 18, 2023, the ratio of American Depositary Shares ("ADSs") evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for <span style="font-family:'Times New

Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. Except as specifically provided, ADSs and related option and warrant information presented in these unaudited condensed consolidated financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes. 1 5000 60000 60000 1 Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations. Cash and cash equivalents: The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Warrants: The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company's control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated its warrants outstanding to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. Investments: Investments as of June 30, 2024 and December 31, 2023 consist of U.S. Treasury Bills and Notes, which are classified as trading securities, totaling $9.7 million and $8.3 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company's U.S. Treasury Bills and Notes held on June 30, 2024 have maturities within one year from the balance sheet date. As of June 30, 2024, the carrying value of the Company's U.S. Treasury Bills and Notes approximates their fair value due to their short-term maturities. 9700000 8300000 P1Y Long-lived assets: Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years. The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant changes in the manner of the Company's use of the acquired assets or the strategy for its overall business,</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant underperformance relative to expected historical or projected development milestones,</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant negative regulatory or economic trends, and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Significant technological changes which could render the platform technology obsolete.</td></tr></table> The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2024 and 2023, there were no impairment indicators which required an impairment loss measurement. P10Y 0 0 0 0 Research and development: Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered. Stock based compensation: The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Since the Company has a limited history of trading as a public company, the Company's expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future. Fair value of financial instruments: The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities. The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Earnings (loss) per share: The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, other than unexercised prefunded warrants as described below, potential common shares are excluded if their effect is anti-dilutive. For the three and six months ended June 30, 2024, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 8,988,346 ADS and outstanding stock options to purchase 278,011 ADS, and for the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS, respectively, as their inclusion in the denominator would be anti-dilutive. For the three and six months ended June 30, 2024 basic and diluted net earnings (loss) per share included 1,069,750 ADS issuable with respect to unexercised prefunded warrants (See Note 13). 8988346 8988346 278011 278011 864068 864068 25595 25595 1069750 NOTE 4 - ACCRUED INTEREST AND FINANCING EXPENSE On October 2, 2020, Quoin Inc. issued promissory notes (the "2020 Notes") to certain investors ("2020 Noteholders"). The 2020 Notes were mandatorily convertible into 432 ADSs, subject to adjustment and were converted in 2021. The ADSs issued to the 2020 Noteholders did not include accrued interest. Two of the five 2020 Noteholders received their amount due during the year ended December 31, 2022 and the Company's estimate of the liability to the remaining three 2020 Noteholders was estimated to be $1,146,000 as of June 30, 2024 and December 31, 2023. There was no interest expense recognized in both the three and six month periods ended June 30, 2024 and 2023. 432 2 5 3 3 1146000 1146000 0 0 0 0 NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are

classified in the fair value hierarchy as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data. Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. . The following table presents the Company's assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2024 and December 31, 2023: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:48.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.7%;background:#cceeff;margin:0pt;padding:0pt;"> US Treasury Bills and Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,725,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,725,463 </td></tr><tr><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> Total US Treasury Bills amd Notes Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,725,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,725,463 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.7%;background:#cceeff;margin:0pt;padding:0pt;"> US Treasury Bills and Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,293,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,293,663 </td></tr><tr><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> Total US Treasury Bills amd Notes Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,293,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,293,663 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.7%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.7%;background:#cceeff;margin:0pt;padding:0pt;"> US Treasury Bills and Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,725,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,725,463 </td></tr><tr><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> Total US Treasury Bills amd Notes Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,725,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,725,463 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:48.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.7%;background:#cceeff;margin:0pt;padding:0pt;"> US Treasury Bills and Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,293,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,293,663</p></td></tr><tr><td style="vertical-align:bottom;width:48.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total US Treasury Bills amd Notes Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,293,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,293,663 </td></tr></table> 9725463 9725463 9725463 9725463 8293663 8293663 8293663 8293663 NOTE 6 – STOCK BASED COMPENSATION In March 2022, the Board of Directors of the Company approved the Amended and Restated Equity Incentive Plan (the "Amended Plan"), which was approved by the shareholders at the Company's Annual General Meeting of Shareholders held on April 12, 2022, which increased the number of ordinary shares reserved for issuance under such equity incentive plan to 15% of the Company's outstanding ordinary shares on a fully-diluted basis, or 2,147,412 ordinary shares represented by 2,147,412 ADSs as of June 30, 2024. Under the Amended Plan, the Company may grant options to its directors, officers, employees, consultants, advisers and service providers. As of June 30, 2024, 1,869,401 shares remained available for issuance. The following table summarizes stock-based activities under the Amended Plan: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> ADS Underlying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Terms </td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> 278,011 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 25.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 9.68 </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited/Cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> Outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 278,011 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9.18</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Exercisable options at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 210.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 7.83 </td></tr></table> . The intrinsic value of outstanding options at June 30, 2024 was $0. Stock based compensation expense was approximately $313,000 ($68,000 included in research and development expense and $245,000 included in general and administrative expenses) in the three months ended June 30, 2024 and approximately $619,000 ($118,000 included in research and development expense and $501,000 included in general and administrative expenses) in the six months ended June 30, 2024 Stock based compensation expense was approximately 264,000 ($34,000 included in research and development expense and $230,000 included in general and administrative expenses) in the three months ended June 30, 2023 and approximately $526,000 ($69,000 included in research and development expense and $457,000 included in general and administrative expenses) in the six months ended June 30, 2023 At June 30, 2024, the total unrecognized compensation expense related to non-vested options was approximately $2.4 million and is expected to be recognized over the remaining weighted average service period of approximately 3.25 years. 0.15 2147412 2147412 1869401 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> ADS Underlying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Terms </td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> 278,011 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9.68</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 278,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9.18 </td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"> Exercisable options at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> 14,228 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 210.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 7.83 </td></tr></table> 278011 25.34 P9Y8M4D 278011 25.34 P9Y2M4D 14228 210.00 P7Y9M29D 0 313000 68000 245000 619000 118000 501000 264000 34000 230000 526000 69000 457000 2400000 P3Y3M NOTE 7 - PREPAID EXPENSES Prepaid expenses are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid R&D costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 649,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 447,979 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 159,746 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 401,972 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 33,605 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 8,500 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Deferred offering costs (note 13) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 108,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,583 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 950,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 891,034 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Less: Short-term portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (650,696) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (591,034) </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 300,000 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid R&D costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 649,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 447,979 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 159,746 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 401,972 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 33,605 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 8,500 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Deferred offering costs (note 13) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 108,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,583 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 950,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 891,034 </td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"> Less: Short-term portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (650,696) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (591,034) </td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 300,000 </td></tr></table> 649241 447979 159746 401972 33605 8500 108104 32583 950696 891034 650696 591034 300000 300000 NOTE 8 - ACCRUED EXPENSES Accrued expenses are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Research contract expenses (note 12) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 550,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 358,287 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Payroll (note 11) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 611,843 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 804,156 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Payroll taxes (note 11) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 90,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 93,989 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 97,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 50,534 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Other expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,988 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,740 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,386,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,308,706 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Research contract expenses (note 12) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 550,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 358,287 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Payroll (note 11) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 611,843 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 804,156 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Payroll taxes (note 11) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 90,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 93,989 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 97,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 50,534 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"> Other expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,988 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,740 </td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,386,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,308,706 </td></tr></table> 550391 358287 611843 804156 90781 93989 97622 50534 35988 1740 1386625 1308706 NOTE 9 – IN-LICENSED TECHNOLOGY Skinvisible: In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the "License Agreement") with Skinvisible Pharmaceuticals, Inc. ("Skinvisible"), under which Skinvisible granted the Company an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. The Company made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the "License Fee"). In addition, the Company agreed to pay Skinvisible a single digit royalty percentage of the Company's net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. The Company also agreed to pay Skinvisible 25% of any revenues the Company receives as royalties in the event that the Company sublicenses any licensed products to a third party. The License Agreement also requires that the Company make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder. There were no milestone or royalty obligations due at June 30, 2024 and December 31, 2023. 1000000 0.25 5000000 NOTE 10 - INTANGIBLE ASSETS Intangible assets are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.75%;background:#cceeff;margin:0pt;padding:0pt;"> Technology license – Skinvisible </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000,000 </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> Total cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> 1,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> 1,000,000 </td></tr><tr><td style="vertical-align:bottom;width:68.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (466,666) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (416,666) </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> Net book value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 533,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 583,334 </td></tr></table> The Company recorded amortization expense of approximately $25,000 and $26,000 in the three months ended June 30, 2024 and 2023, respectively. The Company recorded amortization expense of approximately $50,000 and $52,000 in the six months ended June 30, 2024 and 2023, respectively. The annual amortization expense expected to be recorded for existing intangible assets for the years 2024 through 2027, and thereafter, is approximately $50,000, $100,000, $100,000, $100,000 and $183,000, respectively.</p> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:68.75%;background:#cceeff;margin:0pt;padding:0pt;">Technology license – Skinvisible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000,000 </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;">Total cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> 1,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> 1,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"> 1,000,000 </td></tr><tr><td style="vertical-align:bottom;width:68.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (466,666) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (416,666) </td></tr><tr><td style="vertical-align:bottom;width:68.75%;margin:0pt;padding:0pt;"> Net book value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">533,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 583,334 </td></tr></table> 1000000 1000000 1000000 1000000 466666 416666 533334 583334 25000 26000 50000 52000 50000 100000 100000 100000 100000 183000   NOTE 11 - RELATED PARTY TRANSACTIONS Employment Agreements and Due to Officers/Founders: Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid by Dr. Myers and Ms. Carter to third parties on behalf of Quoin Inc., were not paid by Quoin Inc. to Dr. Myers and Ms. Carter, and were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to repay the above-described non-interest-bearing indebtedness. The Company repaid $75,000 and $75,000 of such indebtedness to Dr. Myers and $75,000 and $0 to Ms. Carter in the three months ended June 30, 2024 and 2023, respectively. The Company repaid $150,000 and $150,000 of such indebtedness to Dr. Myers and $150,000 and $25,000 to Ms. Carter in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, approximately $1.8 million and $1.4 million of such indebtedness was outstanding to Dr. Myers and Ms. Carter, respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Amounts due to officers at June 30, 2024 and December 31, 2023 consisted of the following:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Salaries and other compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,223,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,523,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 3,223,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,523,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Less: Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(600,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(600,000)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> 2,623,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,923,733</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Payable:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">See Note 4 for interest payable on the 2020 Notes.</p> 25000 75000 75000 75000 0 150000 150000 150000 25000 1800000 1400000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Salaries and other compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,223,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,523,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 3,223,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,523,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Less: Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (600,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (600,000)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,623,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,923,733 </td></tr></table> 3223733 3523733 3223733 3523733 600000 600000 2623733 2923733 NOTE 12 – RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Research agreements In November 2020, Quoin Inc. entered into a Master Service Agreement with Therapeutics Inc. for the management of the preclinical and clinical development of QRX003 for Netherton Syndrome. The initial term of the agreement was three years with automatic one year extensions, and the agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million. An additional work order was entered into in December 2022 for a second QRX003 clinical study at an expected estimated cost of approximately $830,000. For the three and six months ended June 30, 2024 and 2023, the Company incurred a research and development expense under these agreements of approximately $162,000 and $650,000 and 360,000 and $959,000 respectively. In November 2021, the Company entered into a research agreement with Queensland University of Technology (QUT) for a pre-clinical research program for the development of a product to treat Netherton Syndrome of approximately $250,000. In May 2022, the Company entered into a second research agreement with QUT for the development of a product to treat Scleroderma of approximately $610,000. Each agreement remains in place until the completion of the research program, which in each case was initially anticipated to be 18 months from execution. For the three and six months ended June 30, 2024 the Company did not incur any costs related to these agreements. For the three and six months ended June 30, 2023, the Company incurred research and development costs related to these agreements of approximately $138,000 and $276,000 respectively. On June 10, 2024, the Company signed a research agreement with The School of Pharmacy at UCC. The scope of the agreement encompasses the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. Under the terms of the agreement, based on the achievement of certain milestones, the Company will fund up to approximately €567,000 ($608,000) plus VAT over an anticipated 2-1/2 year period to support UCC research program to investigate the development of a number of topical rapamycin formulations for future development as potential treatments for several rare and orphan diseases. Following completion of the research program, the Company will have the option to advance the clinical development of rapamycin formulations developed by UCC. The Company incurred no costs related to this agreement in the three and six months ended June 30, 2024.

* Performance milestones and Royalties See Note 9 for asset and in-licensed technology commitments. P3Y P90D 4400000 830000 162000 650000 360000 959000 250000 610000 0 0 138000 276000 567000 608000 0 0 NOTE 13 – SHAREHOLDERS' EQUITY Alumni Equity Line and Purchase Agreement On January 25, 2024, the Company entered into a purchase agreement (the "Alumni Purchase Agreement") with Alumni Capital LP ("Alumni"). Pursuant to the Alumni Purchase Agreement, the Company has the right to sell to Alumni up to $8,000,000 (the "Commitment Amount") of newly issued ordinary shares that are represented by ADS, subject to certain conditions and limitations, from time to time during the term of the Alumni Purchase Agreement. The Company does not have the right to commence any sales of ordinary shares represented by ADSs to Alumni under the Alumni Purchase Agreement until the date, which the Company refers to as the Commencement Date, that all of the conditions set forth in the Alumni Purchase Agreement have been satisfied, including that the registration statement the Company agreed to file with the SEC pursuant to the Alumni Purchase Agreement is declared effective by the SEC, and the Company's shareholders have approved of the issuance of ADSs under the Alumni Purchase Agreement, which approval was obtained on April 5, 2024. From and after the Commencement Date, the Company may, from time to time and at the Company's sole discretion for a period of three months, which the Company at its sole discretion may increase by an additional three months (such period, including any extension, the "Commitment Period"), on any business day that the Company may select, direct Alumni to purchase ordinary shares represented by ADSs. The purchase price for the ordinary shares represented by ADSs the Company may sell to Alumni will be based upon formulas set forth in the Alumni Purchase Agreement based on the then current market price of the ADSs as computed under the Alumni Purchase Agreement and will depend on the type of purchase notice the Company submits to Alumni from time to time. There is no upper limit on the price per share that Alumni could be obligated to pay for the ADSs under the Alumni Purchase Agreement; provided, however at no time can the purchase price be below a floor price of $1.00 per share (subject to adjustment). The Company agreed to issue purchase notices for an aggregate of at least $4,000,000 of the Commitment Amount prior to the end of the Commitment Period. As consideration for Alumni's irrevocable commitment to purchase ADSs under the Alumni Purchase Agreement, the Company agreed to issue to Alumni, at the times set forth in the Alumni Purchase Agreement beginning with the trading day after the Commencement Date, a number of ADSs with a value at the time of issuance not to exceed $240,000 in the aggregate (the "Commitment Securities"). The Company may pay cash in lieu of issuing all or any portion of the Commitment Securities. Public Offering On March 7, 2024, (the "2024 Closing Date") the Company completed an offering (the "2024 Offering") of the following securities (i) 811,250 ordinary shares represented by ADSs, (ii) 4,062,500 Series D warrants (the "Series D Warrants") to purchase 4,062,500 ordinary shares represented by ADSs, (iii) 4,062,500 Series E warrants (the "Series E Warrants" and together with the Series D Warrants, the "2024 Warrants") to purchase 4,062,500 ordinary shares represented by ADSs, and (iv) 3,251,250 pre-funded warrants (the "2024 Pre-Funded Warrants") to purchase 3,251,250 ordinary shares represented by ADSs for aggregate gross proceeds of approximately $6.5 million, resulting in net proceeds of approximately $5.5 million, after deducting the placement agent's fees and offering expenses paid by the Company. Each ADS (or 2024 Pre-Funded Warrant to purchase one ADS in lieu thereof) was sold together with a Series D Warrant to purchase one ADS and a Series E Warrant to purchase one ADS. The ADSs and accompanying 2024 Warrants were sold at a combined public offering price of $1.60 and the 2024 Pre-Funded Warrants and accompanying 2024 Warrants were sold at a combined public offering price of $1.5999, which is equal to the combined purchase price per ADS and accompanying 2024 Warrants, minus the exercise price of each 2024 Pre-Funded Warrant of $0.0001. The Series D and Series E warrants have an exercise price of $1.60 per share, were exercisable immediately following the 2024 Closing Date and expire in two years and five years, respectively, from the closing of the 2024 Offering. As of June 30, 2024, 2,181,500 2024 Pre-Funded Warrants have been exercised and are included in issued and outstanding ADSs. In connection with the 2024 Offering, the Company entered into a Securities Purchase Agreement (the "2024 Purchase Agreement") dated March 4, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the ADSs, 2024 Pre-Funded Warrants and 2024 Warrants sold in the 2024 Offering. Pursuant to the terms of the 2024 Purchase Agreement, the Company agreed, subject to certain exceptions, (i) to not enter into variable rate financings for a period of 180 days following the closing of the 2024 Offering, and (ii) to not enter into any equity financings for 90 days from closing of the 2024 Offering. On March 7, 2024, the Company also entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 638,834 ADSs, 207,499 of which were warrants issued in the Company's 2022 public offering and 431,335 of which were warrants issued in the Company's 2023 public offering (collectively, the "Prior Warrants") to, among other things, reduce the exercise price of such Prior Warrants to $1.60 and to extend the current expiration date of the Prior Warrants until March 7, 2029. The incremental fair value of the modified warrants was approximately $209,000, which was accounted for as an offering expense in connection with the 2024 Offering.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes warrant activities during the six months ended June 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADSs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per ADS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Outstanding and exercisable at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> 16.13 </td><td style="vertical-align:bottom;white-*

space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> * </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> Granted Common Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 8,125,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 1.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"> Granted Pre-Funded Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 3,251,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> Exercised Pre-Funded Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> (2,181,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"> Terminated </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (735) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,650.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> Outstanding and exercisable at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 10,058,096 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 1.87 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr></table> As of June 30, 2024, outstanding common warrants expire in 2026, 2027 and 2029, and the outstanding pre-funded warrants have an approximate intrinsic value of $620,000. * Note that the exercise price of certain existing outstanding warrants to purchase up to 638,834 ADSs was reduced from $12.00 and $13.20 to $1.60 on March 7, 2024, see above. 8000000 1.00 4000000 240000 811250 4062500 4062500 4062500 4062500 3251250 3251250 6500000 5500000 1 1 1 1.60 1.5999 0.0001 1.60 P2Y P5Y 2181500 P180D P90D 638834 207499 431335 1.60 209000 The following table summarizes warrant activities during the six months ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> ADSs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> Underlying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per ADS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and exercisable at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 864,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,125,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,251,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,181,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Terminated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (735)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,650.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and exercisable at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,058,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 1.87 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td></tr></table> * Note that the exercise price of certain existing outstanding warrants to purchase up to 638,834 ADSs was reduced from $12.00 and $13.20 to $1.60 on March 7, 2024, see above. 864081 16.13 8125000 1.60 3251250 2181500 735 1650.00 10058096 1.87 620000 638834 12.00 13.20 1.60 NOTE 14 – CONTINGENCIES From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the unaudited condensed consolidated financial statements. NOTE 15 – LICENSE AGREEMENTS As of June 30, 2024, the Company had nine commercial license and supply agreements outstanding, whereby the Company will receive a royalty or other proceeds from the specified product revenues from the licensor, if and when the underlying products are approved and commercialized or sold via compassionate use or early access programs. No royalty revenues have been received through June 30, 2024 from any of these agreements. 9 0 false false false false "